WO1999065870A2 - Sulfonamide inhibitors of aspartyl protease - Google Patents

Sulfonamide inhibitors of aspartyl protease Download PDF

Info

Publication number
WO1999065870A2
WO1999065870A2 PCT/US1999/013744 US9913744W WO9965870A2 WO 1999065870 A2 WO1999065870 A2 WO 1999065870A2 US 9913744 W US9913744 W US 9913744W WO 9965870 A2 WO9965870 A2 WO 9965870A2
Authority
WO
WIPO (PCT)
Prior art keywords
amino
mmol
benzyl
cyclopentyloxy
furan
Prior art date
Application number
PCT/US1999/013744
Other languages
French (fr)
Other versions
WO1999065870A3 (en
Inventor
Ronald George Sherrill
Michael R. Hale
Andrew Spaltenstein
Eric Steven Furfine
Clarence Webster Andrews, Iii
Gregory Thomas Lowen
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99928769A priority Critical patent/EP1086076B1/en
Priority to BR9912169-7A priority patent/BR9912169A/en
Priority to AT99928769T priority patent/ATE285396T1/en
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to CA2335477A priority patent/CA2335477C/en
Priority to DE69922807T priority patent/DE69922807T2/en
Priority to AU45760/99A priority patent/AU767728B2/en
Priority to NZ508855A priority patent/NZ508855A/en
Priority to APAP/P/2000/002023A priority patent/AP1717A/en
Priority to DK99928769T priority patent/DK1086076T3/en
Publication of WO1999065870A2 publication Critical patent/WO1999065870A2/en
Priority to US09/731,129 priority patent/US6613743B2/en
Priority to NO20006405A priority patent/NO20006405L/en
Publication of WO1999065870A3 publication Critical patent/WO1999065870A3/en
Priority to HK01106764A priority patent/HK1037605A1/en
Priority to US10/600,937 priority patent/US20040097594A1/en
Priority to AU2004200636A priority patent/AU2004200636A1/en
Priority to US11/212,045 priority patent/US7419967B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors.
  • this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features.
  • This invention also relates to pharmaceutical compositions comprising these compounds.
  • the compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses.
  • This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
  • HIV human immunodeficiency virus
  • AIDS acquired immunodeficiency syndrome
  • ARC precursor AIDS-related complex
  • HIV encodes the production of a protease which carries out post- translational cleavage of precursor polypeptides in a process necessary for the formation of infectious virions (S. Crawford et al .
  • a number of synthetic anti-viral agents have been designed to target various stages in the replication cycle of HIV. These agents include compounds which block viral binding to CD ⁇ T T-lymphocytes (for example, soluble CD4), and compounds which interfere with viral replication by inhibiting viral reverse transcriptase (for example, didanosine and zidovudine (AZT) ) and inhibit integration of viral DNA into cellular DNA (M.S. Hirsh and-R.T. D'Aqulia, "Therapy for Human Immunodeficiency Virus Infection", New Eng. J. Med., 328, p. 1686 (1993) ) .
  • agents which are directed primarily to early stages of viral replication, do not prevent the production of infectious virions in chronically infected cells. Furthermore, administration of some of these agents in effective amounts has led to cell-toxicity and unwanted side effects, such as anemia and bone marrow suppression.
  • the present invention provides a novel class of compounds, and pharmaceutically acceptable derivatives thereof, that are useful as inhibitors of aspartyl proteases, in particular, HIV aspartyl protease.
  • these compounds can be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, antibiotics, im unomodulators or vaccines, for the treatment or prophylaxis of viral infection.
  • the compounds of this invention are capable of inhibiting HIV viral replication in human CD 4 T T-cells.
  • These compounds are useful as therapeutic and prophylactic agents to treat or prevent infection by HIV-1 and related viruses which may result in asymptomatic infection, AIDS-related complex ("ARC"), acquired immunodeficiency syndrome ("AIDS”), or similar disease of the immune system.
  • ARC AIDS-related complex
  • AIDS acquired immunodeficiency syndrome
  • the novel sulfonamides of this invention are those of formula I:
  • A is selected from H; Ht; alkyl, which is optionally substituted with one or more groups independently selected from hydroxy, C ⁇ C 4 alkoxy, Ht, -0- Ht, -NR 2 -CO-N(R 2 ); or -CO-N(R 2 ) 2 ; -R ⁇ C ⁇ -Ce alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C ⁇ -C 4 alkoxy, Ht, -O-Ht, -NR 2 -CO- N(R ; ) 2 or -CO-N(R 2 ) 2 ; or R 7 ; each R 1 is independently selected from -C(O)-, -S(0) 2 -, -C(0)-C(0)-, -O-C(O)-, -0-S(0) 2 , -NR 2 -S(0) 2 -, -NR 2 - C(0)- or -NR 2 -C(0)-C(0)-; each Ht is independently selected from C 3
  • D is selected from Q; C ⁇ -C 6 alkyl, which is optionally substituted with one or more groups selected from C 3 -C 6 cycloalkyl, -OR 2 , -S-Ht, -R 3 , -O-Q or Q; C 2 -C 4 alkenyl, which is optionally substituted with one or more groups selected from -OR 2 , -S-Ht, -R 3 , -O-Q or Q; C 3 -C 6 cycloalkyl, which is optionally substituted with or fused to Q; or C 5 -C 6 cycloalkenyl, which is optionally substituted with or fused to Q; each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from 0, N, S, S(0) r , or N(R 2 ) ; where
  • E is selected from Ht; O-Ht; Ht-Ht; -0-R 3 ; -N(R 2 ) (R 3 ) ; C ⁇ -C 6 alkyl, which is optionally substituted with one or more groups selected from R * " or Ht; C 2 -C 6 alkenyl, which is optionally substituted with one or more groups selected from R 4 or Ht; C 3 -C 6 saturated carbocycle, which is optionally substituted with one or more groups selected from R 4 or Ht; or C 5 -C e unsaturated carbocycle, which is optionally substituted with one or more groups selected from R 4 or Ht; each R 4 is independently selected from -OR 2 , -SR , -S0R 1 , -S0 2 R 2 , -C0 2 R 2 , -C(0)-NHR 2 , -C (0) -N (R 2 ) 2 , -C(O)- NR : (OR ), -S(0) 2
  • each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, -N(R 2 ) 4 , C ⁇ -C 12 -alkyl, C 2 -C 12 - alkenyl, or -R 6 ; wherein 1 to 4 -CH 2 radicals of the alkyl or alkenyl group, other than the -CH 2 that is bound to Z, is optionally replaced by a heteroatom group selected from 0, S, S (0) , S(0 2 ), or N(R 2 ); and wherein any hydrogen in said alkyl, alkenyl or R 6 is optionally replaced with a substituent selected from oxo, -OR 2 , -R 2 , N(R 2 ) 2 , N(R 2 ) 3 , ROH, -CN, -C0 2 R , -C(0)-N(R : ) 2 , S (O) 2 -N (R 2 ) 2 , N (R 2 ) -C (0)
  • Y is P or S
  • X is 0 or S
  • R 9 is C(R 2 ) 2 , 0 or N(R 2 ); and wherein when Y is S, Z is not S; and R 6 is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from 0, N, S, S(0) n or N(R 2 ); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH, C1-C 4 alkyl, -O-C 1 -C4 alkyl or -0-C(0)-C ⁇ -C 4 alkyl;
  • R is selected from C ⁇ -C 8 alkyl, C 2 -C 6 alkenyl, C 6 -C ⁇ 4 aryl or Ht, wherein R 10 optionally contains up to three substituents independently selected from -R 3 , -CN, -SR 5 , -S0R-, -S0 2 R 5 , -SR-NR 5 -C(0)R 6 , -NR 5 - (S0 2 ) R 5 , -C (0) N (R 5 ) 2 , -C(S)N(R 5 ) 2 , -S(0) 2 N(R 5 ) 2 , -C(0)R 6 , -C(S)R 6 , -N(R 5 ) 2 , -NR 5 - C(0)R 5 , -NR 5 -C(0)0R 5 , -NR 5 -C(0)N(R 5 ) 2 , -NR 5 -C(S)R 5 , -NR 5 - C(S)
  • the stereochemistry of OR 7 is defined relative to D on the adjacent carbon atom, when the molecule is drawn in an extended zig-zag representation (such as that drawn for compound of formula I) . If both OR 7 and D reside on the same side of the plane defined by the extended backbone of the compound, the stereochemistry of OR 7 will be referred to as "syn”. If OR 7 and D reside on opposite sides of that plane, the stereochemistry of OR 7 will be referred to as "anti”.
  • alkyl refers to a straight-chain or branch-chain saturated aliphatic hydrocarbon radical containing the specified number of carbon atoms, or where no number is specified, preferably from 1 to about 10 and more preferably from 1 to about 8 carbon atoms.
  • alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, n-hexyl and the like.
  • alkenyl alone or in combination with any other term, refers to a straight-chain or branched-chain mono- or poly-unsa ' turated aliphatic hydrocarbon radical containing the specified number of carbon atoms, or where no number is specified, preferably from 2 to about 18 carbon atoms and more preferably, from 2 to about 8 carbon atoms.
  • alkenyl radicals include, but are not limited to, ethenyl, propenyl, isopropenyl, 1, 4-butadienyl, pentenyl and the like.
  • alkoxy refers to an alkyl ether radical, wherein the term “alkyl” is defined above.
  • suitable alkyl ether radicals include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n- butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like.
  • aryl alone or in combination with any other term, refers to a carbocyclic aromatic radical (such as phenyl or naphthyl) containing the specified number of carbon atoms, preferably from 6-14 carbon atoms, and more preferably from 6-10 carbon atoms, optionally substituted with one or more substituents selected from Cl-6 alkoxy, (for example methoxy), nitro, halogen, (for example chloro) , amino, carboxylate and hydroxy.
  • substituents selected from Cl-6 alkoxy, (for example methoxy), nitro, halogen, (for example chloro) , amino, carboxylate and hydroxy.
  • aryl radicals include, but are not limited to phenyl, naphthyl, indenyl, indanyl, azulenyl, fluorenyl, anthracenyl and the like.
  • heterocyclyl refers to a stable 3-7 membered monocyclic heterocyclic ring or 8-11 membered bicyclic heterocyclcic ring which is either saturated or unsaturated, and which may be optionally benzofused if monocyclic.
  • Each heterocycle consists of one or more carbon atoms and from one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • nitrogen and sulfur heteroatoms include any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen.
  • a heterocyclyl radical may be attached at any endocyclic carbon or heteroatom which results in the creation of a stable structure.
  • Preferred heterocycles include 5-7 membered monocyclic heterocycles and 8-10 membered bicyclic heterocycles.
  • groups include imidazolyl, imidazolinoyl, imidazolidinyl, quinolyl, isoqinolyl, indolyl, indazolyl, indazolinolyl, perhydropyridazyl, pyridazyl, pyridyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazinyl, quinoxolyl, piperidinyl, pyranyl, pyrazolinyl, piperazinyl, pyrimidinyl, pyridazinyl, morpholinyl, thiamorpholinyl, furyl, thienyl, triazolyl, thiazolyl, carbolinyl, tetrazolyl, thiazolidinyl, benzo
  • pharmaceutically effective amount refers to an amount effective in treating a virus infection, for example an HIV infection, in a patient either as monotherapy or in combination with other agents.
  • treating refers to the alleviation of symptoms of a particular disorder in a patient or the improvement of an ascertainable measurement associated with a particular disorder.
  • prophylactically effective amount refers to an amount effective in preventing a virus infection, for example an HIV infection, in a patient.
  • patient refers to a mammal, including a human.
  • HIV protease and “HIV aspartyl protease” are used interchangeably and refer to the aspartyl protease encoded by the human immunodeficiency virus type 1 or 2. In a preferred embodiment of this invention, these terms refer to the human immunodeficiency virus type 1 aspartyl protease.
  • thiocarbamates refers to compounds containing the functional group N-S0 2 -0.
  • stable refers to compounds which possess stability sufficient to allow manufacture and administration to a mammal by methods known in the art. Typically, such compounds are stable at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein.
  • the basic nitrogen can be quaternized with any agents known to those of ordinary skill in the art including, for example, lower alkyl halides, such as methyl, ethyl, propyl and butyl chloride, bromides and iodides; dialkyl sulfates including dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides including benzyl and phenethyl bromides. Water or oil-soluble or dispersible products may be obtained by such quaternization.
  • novel sulfonamides of this invention are those of formula I:
  • A is selected from H; Ht; -R : -Ht; alkyl, which is optionally substituted with one or more groups independently selected from hydroxy, C ⁇ -C 4 alkoxy, Ht, -0- Ht, -NR 2 -C0-N(R 2 ) 2 or -C0-N(R 2 ) 2 ; -R ⁇ C ⁇ -Ce alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C ⁇ -C 4 alkoxy, Ht, -O-Ht, -NR 2 -C0- N(R ) : or -C0-N(R 2 ) 2 ; or R 7 ; each R 1 is independently selected from -C(0)-, -S(0) 2 -, -C(0)-C(0)-, -0-C(0)-, -0-S(0) 2 , -NR 2 -S(0) 2 -, -NR 2 - C(O)- or -NR 2 -C(0)-C(0)-; each
  • each R 2 is independently selected from H, or C ⁇ -C 6 alkyl optionally substituted with Q or R 1C ;
  • D is selected from Q; C ⁇ -C 6 alkyl, which is optionally substituted with one or more groups selected from C 3 -C 6 cycloalkyl, -OR 2 , -S-Ht, -R 3 , -O-Q or Q; C 2 -C 4 alkenyl, which is optionally substituted with one or more groups selected from -OR 2 , -S-Ht, -R 3 , -O-Q or Q, C 3 -C 6 cycloalkyl, which is optionally substituted with or fused to Q; or C 5 -C cycloalkenyl, which is optionally substituted with or fused to Q; each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from 0, N, S, S(0) n or N(R 2 ); wherein Q is optionally
  • D' is selected from -OR 10 , -N-R 10 or -N (R 10 ) -R 1 -R 3 ; E is selected from Ht; O-Ht; Ht-Ht; -O-R 3 ; -N(R 2 ) (R 3 ) ; C:-Ce alkyl, which is optionally substituted with one or more groups selected from R 4 or Ht; C 2 -C 6 alkenyl, which is optionally substituted with one or more groups selected from R 1* or Ht; C 3 -C 6 saturated carbocycle, which is optionally substituted with one or more groups selected from R 4 or Ht; or C 5 -C 6 unsaturated carbocycle, which is optionally substituted with one or more groups selected from R 4 or Ht; each R 4 is independently selected from -OR 2 ,
  • -SR , -SOR 2 , -S0 2 R 2 , -C0 2 R 2 , -C(0)-NHR 2 , -C (0) -N (R 2 ) 2 , -C(O)- NR 2 (OR 2 ), -S(0) 2 -NHR 2 , halo, -NR 2 -C (0) -R 2 , -N(R 2 ) 2 or -CN; each R 7 is independently selected from hydrogen,
  • each M is i ndepende :ntly selected from H, Li, Na, K, Mg, Ca, Ba, -N(R 2 ) 4 , C ⁇ -C ⁇ 2 -alkyl, C 2 -C ⁇ 2 - alkenyl, or -R 6 ; wherein 1 to 4 -CH 2 radicals of the alkyl or alkenyl group, other than the -CH 2 that is bound to Z, is optionally replaced by a heteroatom group selected from 0, S, S (O) , S(0 ), or N(R 2 ); and wherein any hydrogen in said alkyl, alkenyl or R 6 is optionally replaced with a substituent selected from oxo, -OR 2 , -R 2 , N(R 2 ) 2 , N(R 2 ) 3 , R 2 0H, -CN, -C0 2 R 2 , -C(0)-N(R 2 ) 2 , S (0) 2 -N (R 2 )
  • R 9 is C(R 2 ) 2 , 0 or N(R 2 ); and wherein when Y is S, Z is not S; and R 6 is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from 0, N, S, S(0) n or N(R 2 ); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH, C ⁇ -C 4 alkyl, -O-C 1 -C4 alkyl or -0-C(0)-C 1 -C 4 alkyl;
  • R is selected from C ⁇ _C 8 alkyl, C 2 _C 6 alkenyl, C 6 -C ⁇ 4 aryl or Ht, wherein R 10 optionally contains up to three substituents independently selected from -R 3 , -CN, -SR 5 , -SOR 5 , -S0 2 R 5 , -SR-NR 5 -C(0)R 6 , -NR 5 - (S0 2 ) R 5 , -C(0)N(R 5 ) 2 , -C(S)N(R 5 ) 2 , -S (0) 2 N(R 5 ) 2 , -C(0)R 6 , -C(S)R 6 , -N(R 5 ) 2 , -NR 5 - C(0)R 5 , -NR 5 -C(0)OR 5 , -NR 5 -C(0)N(R 5 ) 2 , -NR 5 -C(S)R 5 , -NR 5 - C(0)OR 5
  • At least one R ' is selected from:
  • P0 3 -spermine P0 3 - (spermidine) 2 or P0 5 - (meglamine) 2 .
  • component M or M' in the formulae set forth herein will have either a covalent, a covalent/ zwitterionic, or an ionic association with either Z or R 9 depending upon the actual choice for M or M' .
  • M or M' is hydrogen, alkyl, alkenyl, or R &
  • M or M' is covalently bound to R 9 or Z.
  • M is a mono- or bivalent metal or other charged species (i.e., NH 4 + ) , there is an ionic interaction between M and Z and the resulting compound is a salt.
  • Z When x is 0 in (M) x , Z may be a charged species. When that occurs, the other M may be oppositely charged to produce a 0 net charge on the molecule. Alternatively, the counter ion may located elsewhere in the molecule. Except where expressly provided to the contrary, as used herein, the definitions of variables A, R ⁇ R 4 , R 6 -R 9 , Ht, B, x, n, D, D', M, Q, X, Y, Z and E are to be taken as they are defined above for the compounds of formula I.
  • the compounds of this invention are those represented by formula II, formula III or formula IV: - II wherein A, R 3 , R 7 , Ht, D, D', x, E are as defined above for compounds of formula I.
  • R- 3 and R 3' the two R J moieties present in formula IV have been labeled R- 3 and R 3' .
  • more preferred compounds are those wherein: A is -C(0)Ht; D' is -O-R 10 ;
  • E is C 6 -C ⁇ o aryl optionally substituted with one or more substituents selected from oxo, -OR 2 , SR 2 , -R 2 , -N(R 2 ) 2 ,
  • E is a 5-membered heterocyclic ring containing one S and optionally containing N as an additional heteroatom, wherein said heterocyclic ring is optionally substituted with one to two groups independently selected from -CH 3 , R 4 , or Ht; and all other variables are as defined for formula I.
  • R 7 in -OR 7 is -PO(OM) 2 or C(0)CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 3 and both R 7 in -N(R 7 ) 2 are H, wherein M is H, Li, Na, K or C ⁇ -C 4 alkyl; or wherein R 7 in -OR 7 is C(0)CH 2 OCH 2 CH 2 OCH 3 , one R 7 in -N(R 7 ) 2 is C (0) CH 2 OCH 2 CH 2 OCH 3 and the other is H.
  • A is C 6 -Ci 4 aryl optionally substituted with one or more groups independently selected from the group consisting of C ⁇ -C 8 alkyl or hydroxy, or OR 4 , wherein R 4 is C ⁇ C 8 alkyl, C 3 -C- cycloalkyl, C ⁇ -C 8 alkyl substituted with C 6 -C ⁇ 4 , C 6 -C ⁇ 4 aryl optionally substituted with C ⁇ -C 8 alkyl, heterocyclyl or heterocyclylalkyl;
  • E is C6-C ⁇ 4 aryl, optionally substituted with one or more groups selected from nitro, oxo, alkoxy, amino, hydroxyamino; heterocyclcyl, optionally substituted with one or more groups selected from the group consisting of nitro, oxo, alkoxy, amino, hydroxyamino or N(CO)OCH 3 ;
  • R and R are as defined above; or a pharmaceutically acceptable derivative thereof.
  • R 7 and R 1C are as defined above for formula I;
  • E is C 6 -Ci4 aryl, optionally substituted with one or more groups selected from the group consisting of nitro, oxo, alkoxy, amino, hydroxyamino; heterocyclcyl, optionally substituted with one or more groups selected from the group consisting of nitro, oxo, alkoxy, amino, hydroxyamino or N(CO)OCH 3 ; or a pharmaceutically acceptable derivative thereof.
  • a compound of Formula (VII) there is provided a compound of Formula (VII) :
  • A, E, R and R are as defined in formula (I); or a pharmaceutically acceptable derivative thereof.
  • R i ⁇ is selected from isopropyl or cyclopentyl
  • R 11 is selected from NHR 7 or OR 7
  • x, R 7 and G are as defined above
  • X " is a pharmaceutically acceptable counterion.
  • the compounds according to the invention contain one or more asymmetric carbon atoms and thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers . All such isomeric forms of these compounds are expressly included in the present invention.
  • Each stereogenic carbon may be of the R or S configuration.
  • Most preferred compounds of the present invention include the following:
  • Path 1 Amine of formula (I) is reacted with a sulfonyl chloride of formula (A) to produce sulfonamide of formula (II' ) .
  • Step 2 Sulfonamide of formula (II') is reacted with intermediate of formula (B) , which bears an amine protecting group P, such as t-butoxycarbonyl, to produce compound of formula (III').
  • amine protecting group P such as t-butoxycarbonyl
  • Suitable amine protecting groups are described in numerous references, including T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2d Ed. , John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed. Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) .
  • amino protecting groups include, but are not limited to, Cbz or Alloc.
  • Step 3 Compound of formula (III') is then reacted with A-L, wherein L is a leaving group, to produce compound of formula (IV) .
  • a leaving group is an atom or group which is displaceable upon reaction with an appropriate amine or sulfonamide. Suitable leaving groups would be obvious to one of skill in the art and include but are not limited to hydroxyls, carboxylates and halides.
  • Step 4 Compound of formula (IV) is then converted to compound of formula (V) by functional transformation of the hydroxy group .
  • Path 2 differs from Path 1 only in the sequence of reagents employed to convert compound of formula (I) to compound of formula (IV) .
  • the novel compounds of the present invention are excellent ligands for aspartyl proteases, particularly HIV-1 and HIV-2 proteases. Accordingly, these compounds are capable of targeting and inhibiting late stage events in HIV replication, i.e., the processing of the viral polyproteins by HIV encoded proteases. Such compounds inhibit the proteolytic processing of viral polyprotein precursors by inhibiting aspartyl protease. Because aspartyl protease is essential for the production of mature virions, inhibition of that processing effectively blocks the spread of virus by inhibiting the production of infectious virions, particularly from chronically infected cells.
  • Compounds according to this invention advantageously inhibit the ability of the HIV-1 virus to infect immortalized human T cells over a period of days, as determined by an assay of extracellular p24 antigen -- a specific marker of viral replication. Other anti-viral assays have confirmed the potency of these compounds.
  • the compounds of this invention may be employed in a conventional manner for the treatment of viruses, such as HIV and HTLV, which depend on aspartyl proteases for obligatory events in their life cycle. Such methods of treatment, their dosage levels and requirements may be selected by those of ordinary skill in the art from available methods and techniques.
  • a compound of this invention may be combined with a pharmaceutically acceptable adjuvant for administration to a virally-infected patient in a pharmaceutically acceptable manner and in an amount effective to lessen the severity of the viral infection.
  • the compounds of this invention may be used in vaccines and methods for protecting individuals against viral infection over an extended period of time.
  • the compounds may be employed in such vaccines either alone or together with other compounds of this invention in a manner consistent with the conventional utilization of protease inhibitors in vaccines.
  • a compound of this invention may be combined with pharmaceutically acceptable adjuvants conventionally employed in vaccines and administered in prophylactically effective amounts to protect individuals over an extended period time against HIV infection.
  • the novel protease inhibitors of this invention can be administered as agents for treating or preventing HIV infection in a mammal.
  • the compounds of formula I may be readily absorbed by the bloodstream of mammals upon oral administration.
  • Compounds of formula I having a molecular weight of less than about 600 g/mole are most likely to demonstrate oral availability. This surprisingly spectacular oral availability makes such compounds excellent agents for orally-administered treatment and prevention regimens against HIV infection.
  • the compounds of this invention may be administered to a healthy or HIV-infected patient either as a single agent or in combination with other anti-viral agents which interfere with the replication cycle of HIV.
  • the compounds of this invention may be administered with other anti-viral agents which target different events in the viral life cycle, the therapeutic effect of these compounds is potentiated.
  • the co-administered anti-viral agent can be one which targets early events in the life cycle of the virus, such as cell entry, reverse transcription and viral DNA integration into cellular DNA.
  • Anti-HIV agents targeting such early life cycle events include, didanosine (ddl), alcitabine (ddC) , d4T, zidovudine (AZT), polysulfated polysaccharides, sT4 (soluble CD4), 3TC, 935U83, 1592U89, 524W91, ganciclovir, dideoxycytidine, trisodium phosphonoformate, eflornithine, ribavirin, acyclovir, alpha interferon and trimenotrexate .
  • Ribonucleotide reductase inhibitors such as hydroxyurea may also be used.
  • non-nucleoside inhibitors of reverse transcriptase such as TIBO, delavirine (U90) or nevirapine
  • TIBO delavirine
  • U90 delavirine
  • nevirapine may be used to potentiate the effect of the compounds of this invention, as may viral uncoating inhibitors, inhibitors of trans-activating proteins such as tat or rev, or inhibitors of the viral integrase.
  • Combination therapies according to this invention exert a synergistic effect in inhibiting HIV replication because each component agent of the combination acts on a different site of HIV replication.
  • the use of such combinations also advantageously reduces the dosage of a given conventional anti-retroviral agent which would be required for a desired therapeutic or prophylactic effect as compared to when that agent is administered as a monotherapy.
  • These combinations may reduce or eliminate the side effects of conventional single anti-retroviral agent therapies while not interfering with the anti-retroviral activity of those agents.
  • These combinations reduce potential of resistance to single agent therapies, while minimizing any associated toxicity.
  • These combinations may also increase the efficacy of the conventional agent without increasing the associated toxicity.
  • we have discovered that these compounds act synergistically in preventing the replication of HIV in human T cells.
  • Preferred combination therapies include the administration of a compound of this invention with AZT, ddl, ddC or d4T.
  • the compounds of this invention may also be co-administered with other HIV protease inhibitors such as Agenerase (VX-478, Vertex) , saquinavir, Ro 31-8959 (Roche), L-735,524 (Merck), XM 323 (Du-Pont Merck) A-80, 987 (Abbott), MK 639 (Merck), ABT 538 (A-80538, Abbott), AG 1343 (Agouron) , XM 412 (Du-Pont Merck), XM 450 (Du-Pont Merck), BMS 186318 (Bristol-Meyers Squibb), ABT 378 (Abbott) and CPG 53,437 (Ciba Geigy) to increase the effect of therapy or prophylaxis against various viral mutants or members of other HIV quasi species
  • AZT HIV aspartyl protease inhibitors
  • retroviral reverse transcriptase inhibitors or HIV aspartyl protease inhibitors may exert a substantial synergistic effect, thereby preventing, substantially reducing, or completely eliminating viral infectivity and its associated symptoms.
  • the compounds of this invention can also be administered in combination with immunomodulators (e.g., bropirimine, anti-human alpha interferon antibody, IL-2, GM- CSF, methionine enkephalin, interferon alpha, diethyldithiocarbamate, tumor necrosis factor, naltrexone, tuscarasol and rEPO) ; and antibiotics (e.g., pentamidine isethiorate) to prevent or combat infection and disease associated with HIV infections, such as AIDS and ARC.
  • immunomodulators e.g., bropirimine, anti-human alpha interferon antibody, IL-2, GM- CSF, methionine enkephalin, interferon alpha, diethyldithiocarbamate, tumor necrosis factor, naltrexone, tuscarasol and rEPO
  • antibiotics e.g., pentamidine isethiorate
  • compositions according to this invention may be comprised of a combination of an aspartyl protease inhibitor of this invention and another therapeutic or prophylactic agent.
  • this invention focuses on the use of the compounds disclosed herein for preventing and treating HIV infection, the compounds of this invention can also be used as inhibitory agents for other viruses which depend on similar aspartyl proteases for obligatory events in their life cycle. These viruses include, as well as other AIDS-like diseases caused by retroviruses, such as simian immunodeficiency viruses, but are not limited to, HTLV-I and HTLV-II.
  • compositions of this invention comprise any of the compounds of the present invention, and pharmaceutically acceptable salts thereof, with any pharmaceutically acceptable carrier, adjuvant or vehicle.
  • Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphate
  • compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. We prefer oral administration or administration by injection.
  • the pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques .
  • the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example, as a solution in 1, 3-butanediol .
  • suitable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides .
  • Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant such as Ph. Helv or a similar alcohol.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
  • compositions of this invention may also be administered in the form of suppositories for rectal administration.
  • These compositions can be prepared by mixing a compound of this invention with a suitable non- irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components.
  • suitable non- irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
  • Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application.
  • the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.
  • compositions of this invention may be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 50 mg/kg body weight per day of the active ingredient compound are useful in the prevention and treatment of viral infection, including HIV infection.
  • the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a typical preparation will contain from about 5% to about 95% active compound (w/w) .
  • such preparations contain from about 20% to about 80% active compound.
  • a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
  • the compounds of this invention are also useful as commercial reagents which effectively bind to aspartyl proteases, particularly HIV aspartyl protease.
  • aspartyl proteases particularly HIV aspartyl protease.
  • the compounds of this invention, and their derivatives may be used to block proteolysis of a target peptide or may be derivatized to bind to a stable resin as a tethered substrate for affinity chromatography applications.
  • the compounds according to the invention are defined to include pharmaceutically acceptable derivatives or prodrugs thereof.
  • a "pharmaceutically acceptable derivative” or “pharmaceutically acceptable prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
  • the compounds according to the invention may be used in the form of salts derived from inorganic or organic acids. Included among such acid salts, for example, are the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectianate, persulfate,
  • Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g., magnesium), ammonium and T NW4 (wherein W is C ⁇ _ 4 alkyl) .
  • Physiologically acceptable salts of a hydrogen atom or an amino group include salts or organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p- toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids.
  • organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids
  • organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p- toluenesulfonic acids
  • inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids.
  • Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as Na , NH 4 , and NW 4 (wherein W is a C : - 4 alkyl group) .
  • salts include salts of organic carboxylic acids such as ascorbic, acetic, citric, lactic, tartaric, malic, maleic, isothionic, lactobionic, p- aminobenzoic and succinic acids; organic sulphonic acids such as methanesulphonic, ethanesulphonic, benzenesulphonic and p-toluenesulphonic acids and inorganic acids such as hydrochloric, sulphuric, phosphoric, sulphamic and pyrophosphoric acids.
  • salts of the compounds according to the invention will be pharmaceutically acceptable.
  • salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
  • Preferred salts include salts formed from hydrochloric, sulfuric, acetic, succinic, citric and ascorbic acids .
  • esters of the compounds according to the invention are independently selected from the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non- carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl) , aryl (for example, phenyl optionally substituted by, for example, halogen, C ⁇ _ 4 alkyl, or C ⁇ _ 4 alkoxy or amino) ; (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl) ; (3) amino acid esters (for example, L-valyl or
  • any alkyl moiety present advantageously contains from 1 to 18 carbon atoms, particularly from 1 to 6 carbon atoms, more particularly from 1 to 4 carbon atoms, Any cycloalkyl moiety present in such esters advantageously contains from 3 to 6 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group.
  • any reference to any of the above compounds also includes a reference to a pharmaceutically acceptable salts thereof.
  • the compounds according to the invention are especially useful for the treatment of AIDS and related clinical conditions such as AIDS related complex (ARC) , progressive generalized lymphadenopathy (PGL) , Kaposi's sarcoma, thrombocytopenic purpura, AIDS-related neurological conditions such as AIDS dementia complex, multiple sclerosis or tropical paraperesis, and also anti-HIV antibody-positive and HIV-positive conditions, including such conditions in asymptomatic patients.
  • ARC AIDS related complex
  • PDL progressive generalized lymphadenopathy
  • Kaposi's sarcoma Kaposi's sarcoma
  • thrombocytopenic purpura AIDS-related neurological conditions
  • AIDS dementia complex such as AIDS dementia complex
  • multiple sclerosis or tropical paraperesis multiple sclerosis or tropical paraperesis
  • anti-HIV antibody-positive and HIV-positive conditions including such conditions in asymptomatic patients.
  • the present invention provides a method for the treatment or prevention of the symptoms or effects of a viral infection in an infected animal, for example, a mammal including a human, which comprises treating said animal with a therapeutically effective amount of a compound according to the invention.
  • the viral infection is an HIV infection.
  • a further aspect of the invention includes a method for the treatment or prevention of the symptoms or effects of an HBV infection.
  • the compounds according to the invention may also be used in adjuvant therapy in the treatment of HIV infections or HIV-associated symptoms or effects, for example Kaposi's sarcoma.
  • the present invention further provides a method for the treatment of a clinical condition in an animal, for example, a mammal including a human which clinical condition includes those which have been discussed in the introduction hereinbefore, which comprises treating said animal with a therapeutically effective amount of a compound according to the invention.
  • the present invention also includes a method for the treatment or prophylaxis of any of the aforementioned infections or conditions.
  • the present invention provides the use of a compound according to the invention in the manufacture of a medicament for the treatment or prophylaxis of any of the above mentioned viral infections or conditions. It will be appreciated that of compounds of Formlula (I), (II), (III), (IV), and (V) and one or more other HIV protease inhibitors, reverse transcriptase inhibitors, or non-nucleoside reverse transcriptase inhibitors may be used in the manufacture of the above medicament .
  • Reference herein to treatment extends to prophylaxis as well as the treatment of established infections or symptoms.
  • Combination therapies comprise the administration of at least one compound of the formula (I) or a pharmaceutically acceptable derivative thereof and at least one other pharmaceutically active ingredient.
  • the active ingredient (s) and pharmaceutically active agents may be administered simultaneously in either the same or different pharmaceutical formulations or sequentially in any order.
  • the amounts of the active ingredient (s) and pharmacuetically active agent (s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
  • the combination therapy involves the administration of one compound according to the invention and one of the agents mentioned herein below.
  • agents that are effective for the treatment of viral infections or associated conditions such as (1 alpha, 2 beta, 3 alpha) -9- [2, 3-bis (hydroxymethyl) cyclobutyl] guanine [(-)BHCG, SQ-34514], oxetanocin-G (3, 4-bis- (hydroxymethyl) - 2-oxetanosyl] guanine) , acyclic nucleosides (e.g. acyclovir, valaciclovir, famciclovir, ganciclovir, penciclovir) , acyclic nucleoside phosphonates (e.g.
  • the combination therapy involves the administration of one of the above mentioned agents and a compound within one of the preferred or particularly preferred sub-groups within formula (I) as described above. Most preferably the combination therapy involves the joint use of one of the above named agents together with one of the compounds of formula (I) specifically named herein.
  • the present invention further includes the use of a compound according to the invention in the manufacture of a medicament for simultaneous or sequential administration with at least one other therapeutic agent, such as those defined hereinbefore.
  • Preparative HPLC was also carried out using C i8 reversed- phase media. HPLC retention times were recorded in minutes. NMR spectral data was recorded using a Bruker AMX500, equipped with either a reverse or QNP probe, at 500 MHz, and was taken in the indicated solvent.
  • the compounds of this invention are able to inhibit the replication of the HIV virus in CD cells of human lineage, they are of evident clinical utility for the treatment of HIV infection. These tests are predictive of the compounds ability to inhibit HIV protease in vivo .
  • N-methanesulfonyl-2-aminobenzimidazole 2-amino- benzimidazole (1.0 g, 7.5 mmol) was dissolved in 15 mL of anhydrous CH2CI2 and 3 mL anhydrous DMF and cooled to ⁇ 0°C. Trethylamine (1.6 mL, 1.5 eq.) was added followed by an addition of methanesulfonylchloride (580 ⁇ L, 7.5 mmol) over
  • N 1 - (cyclopentyloxy) -4-methoxy-l-benzenesulfonamide A mixture of 2- (cyclopentyloxy) -lH-isoindole-1, 3 ⁇ 2H) -dione (3.00 g, 12.99 mmol) in anhydrous tetrahydrofuran (15 mL) at ambient temperature under an Argon atmosphere was treated with anhydrous hydrazine (0.448 mL, 14.29 mmol). After stirring vigorously for 1.5 hours, the resulting slurry was filtered and washed with approximately 15 mL of anhydrous tetrahydrofuran.
  • Example 54 the product was purified by silica gel flash chromatography using a gradient elution of chloroform: methanol: water (90:10:0 to 10:3:0.5) to yield a beige powder (1.75 g, 3.13 mmol, 77%).
  • l E NMR (d 6 -DMS0) ⁇ : 7.50- 6.64 (m, 9H) , 5.07 (d, J 6.0 Hz, IH) , 4.80 (bs, IH) , 3.56- 1.40 (m, 16H), 1.18 (s, 9H) .
  • Step 2 (300 mg, 0.536 mmol), 4-morpholine carbonyl chloride (0.08 mL, 0.643 mmol), and anhydrous diisopropylethylamine (0.11 L, 0.643 mmol), were combined in anhydrous tetrahydrofuran (8 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was refluxed for 18 hours, allowed to cool, and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using
  • o-nitroaniline-p-sulfonyl chloride A mixure of o- nitroaniline-p-sulfonic acid sodium salt (25.00 g, 104 mmol; and phosphoryl chloride (75 mL, 804 mmol) under Argon was heated to reflux and vigorously stirred for 4 hours. After cooling to ambient temperature, the reaction mixture was carefully added to a large excess of ice. The resulting slurry was stirred for 15 min., filtered and dried under vacuum to provide o-nitroaniline-p-sulfonyl chloride (21.43 g, 87%) as a yellow solid.
  • N 1 - (sec-butoxy) -4-methoxy-l-benzenesulfonamide O-sec- butoxy-N-hydroxylphthalimide (16.3 mmol, 3.57 g) was combined with hydrazine (17.9 mmol, 0.56 mL) in anhydrous THF (30 mL) under nitrogen. The reaction immediately formed a white suspension and was allowed to stir at room temperature for 5 hours. The suspension was filtered directly into a flask containing 4-methoxybenzenesulfonyl chloride (14.6 mmol, 3.03 g) and diisopropylethylamine (17.6 mmol, 3.1 mL) was added.
  • the reaction product was concentrated to an oil and partitioned between ethyl acetate and I HCl.
  • the organic layer was separated and washed with saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate and concentrated under vacuum to a clear oil.
  • the crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) providing 3.03 g
  • the reaction product was concentrated to an oil and partitioned between ethyl acetate and IN HCl.
  • the organic layer was separated and washed with saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate and concentrated under vacuum to a clear oil.
  • the crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) providing a white solid.
  • Step 2
  • Phosphazine base P ⁇ t/4>t-Bu (0.26 mmol, 0.26 mL, 1M in hexanes) was injected into the stirring solution. The reaction was allowed to stir for 48 hours at room temperature and was quenched by the addition of a few drops of glacial acetic acid. The reaction product was concentrated to a red oil and partitioned between ethyl acetate and IN HCl. The organic layer was separated and washed with saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate and concentrated under vacuum to a red oil. The crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and crystallization (hexanes/ethyl acetate) providing 300 mg
  • the suspension was filtered directly into a flask containing 4-methoxybenzenesulfonyl chloride (6.5 mmol, 1.34 g) and diisopropylethylamine (20.5 mmol, 3.6 mL) was added. After stirring at room temperature for 15 hours, the reaction was refluxed for 4 hours, then stirred at room temperature for 12 days and concentrated to a yellow solid. The resulting solid was partitioned between ethyl acetate and IN HCl, and the organic layer was separated and washed with a saturated aqueous solution of sodium bicarbonate and brine, and dried over magnesium sulfate.
  • the suspension was filtered directly into a flask containing 4-methoxybenzenesulfonyl chloride (6.8 mmol, 1.40 g) and diisopropylethylamine (8.1 mmol, 1.42 mL) was added. After stirring at room temperature for 24 hours, the reaction was concentrated to a yellow solid. The resulting solid was partitioned between ethyl acetate and IN HCl, and the organic layer was separated and washed with a saturated aqueous solution of sodium bicarbonate and brine, and dried over magnesium sulfate. The crude product was concentrated to a yellow solid and purified by silica gel chromatography (2:1 hexanes/ethyl acetate).
  • Phosphazine base P ⁇ t/4>t-Bu (0.08 mmol, 0.08 mL, 1M in hexanes) was injected into the stirring solution. The reaction was allowed to stir for 15 hours at room temperature, quenched by the addition of a few drops of glacial acetic acid and concentrated. The crude residue was partitioned between ethyl acetate and IN HCl, and the organic layer was separated and washed with saturated aqueous sodium bicarbonate solution and brine, and dried over magnesium sulfate. The crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate).
  • the purified product was then washed with IN NaOH to remove remaining sulfonamide starting material that coeluted, brine, and was again dried over magnesium sulfate.
  • the silica gel chromatography was repeated and yielded 130 mg (62%) of a white solid.
  • the resulting solid was partitioned between ethyl acetate and IN HCl, and the organic layer was separated and washed with a saturated aqueous solution of sodium bicarbonate and brine, and dried over magnesium sulfate.
  • the crude product was concentrated to a white solid and purified by silica gel chromatography (1:1 hexanes/ethyl acetate) .
  • the purified product was then combined with ether and filtered to remove the residual phthalimide-hydrazine biproduct.
  • the filtrate was then crystallized by adding hexanes providing 203 mg (48%) white crystals.
  • Phosphazine base P ⁇ t/4>t-Bu (0.21 mmol, 0.21 mL, 1M in hexanes) was injected into the stirring solution. The reaction was allowed to stir for 15 hours at room temperature, quenched by the addition of a few drops of glacial acetic acid and concentrated. The crude residue was partitioned between ethyl acetate and IN HCl, and the organic layer was separated and washed with saturated aqueous sodium bicarbonate solution and brine, and dried over magnesium sulfate.
  • Benzylhydroxylamine hydrochloride (31.3 mmol, 5.0 g) , 4- methoxybenzenesulfonyl chloride (34.5 mmol, 7.12 g) and anhydrous THF (50 mL) were combined under nitrogen. The reaction was cooled to 0°C and diisopropylethylamine (69.0 mmol, 12.0 mL) was injected. The reaction was allowed to warm to room temperature and continued to stir for 18 hours.
  • Lithium hexamethyldisilazide (0.6 mmol, 0.6 mL, 1M in THF) was injected into a stirring solution of N 1 - (benzyloxy) -4- methoxy-1-benzenesulfonamide (3.0 mmol, 1.0 g) , tert-butyl N- (IS) -l-[ (2S)oxiran-2-yl] -2-phenylethylcarbamate (2.4 mmol, 0.64 g) , and anhydrous THF (8 mL) . The reaction was allowed to stir for 15 hours at room temperature under nitrogen. The reaction was quenched with a few drops of glacial acetic acid and concentrated to a thick oil.
  • the crude was partitioned between ethyl acetate and IN HCl, washed with saturated sodium bicarbonate solution and brine, dried over magnesium sulfate and concentrated.
  • the crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and crystallized from ethyl acetate with hexanes, providing 400 mg (22%) of a white crystal.
  • tert-butyl N- (IS,21?) -l-benzyl-2-hydroxy-3-isobutoxy [ (4- methoxyphenyl) sulfonyl] aminopropyl) carbamate. Synthesized under the same conditions as outlined for tert-butyl N-
  • Step 3
  • Phenylmethyl N- ( (1S,2S) -l-benz ⁇ l-3- (cyclopentyloxy) [ (4- methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate A mixture of phenylmethyl N- (IS) -1- [ (2S) oxiran-2-yl] -2- phenylethylcarbamate [250 mg, 0.842 mmol, Tetrahedron (1994), 50(21), 6333-46] and N 1 - (cyclopentyloxy) -4-methoxy- l-benzenesulfonamide (285 mg, 1.05 mmol) in anhydrous tetrahydrofuran (3 mL) under an Argon atmosphere was treated with phosphazene base P ⁇ t/4>t-Bu (0.168 mL, 0.168 mmoL, 1.0 M in hexane) .
  • Trifluoroacetic acid was removed in vacuo and the residue was partitioned between dichloromethane and IN NaOH. After separating the phases, the aqueous layer was extracted twice with dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate, filtered, evaporated in vacuo and dried under high vacuum to provide 3-amino- N 1 - [ (2iP, 35) -3-amino-2-hydroxy-4-phenylbutyl] -N 1 -
  • Step 2
  • N, N-diisopropylethylamine (40 ⁇ L, 0.224 mmol) was added and the reaction mixture was heated at 60°C for 1.5 hours. The reaction was cooled and evaporated in vacuo . The residue was dissolved in ethyl acetate and washed three times with 5% w/v potassium carbonate, saturated aqueous brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude product was purified on a preparative TLC plate (20x20 cm, 500 ⁇ M) eluting with 95 : 5/methylene chloride :methanol .
  • reaction mixture was evaporated in vacuo and the residue was purified on a preparative TLC plate (20x20 cm, 500 ⁇ M) eluting with l:l/ethyl acetate :hexane .
  • the product band was removed, eluted with 3 : 1/methylene chloride: ethanol, filtered, and evaporated in vacuo .
  • the product was lyophilized from acetonitrile and water to provide (3.R, 3aS, ⁇ aR) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 2R) -3- [ [ (3- aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (1) as a white lyophile (18 mg, 13%) .
  • the fraction containing the diastereomer possessing a longer retention time was evaporated in vacuo to a residue and then purified again by preparative TLC as above.
  • the reaction was concentrated under vacuum, dissolved in ethyl acetate, washed with distilled water and brine, and dried over magnesium sulfate.
  • the crude material was concentrated under vacuum and the resulting clear oil was purified by silica gel flash chromatography (2:1 hexanes/ethyl acetate) to yield 60 mg (63%) of a clear oil.
  • the resulting silyl ether was then stirred in a 3:1 (CH 3 C ⁇ /HF (49%) ) solution for 1 hour and quenched with a saturated aqueous solution of sodium bicarbonate.
  • the reaction was concentrated under vacuum, dissolved in ethyl acetate, washed with distilled water and brine, and dried over magnesium sulfate.
  • this material can also be obtained according to the following method: In a dried flask was introduced 1 eq. of (32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl- ⁇ - (IS, 22?) -l-benzyl-3- [ (cyclopentyloxy) [ (3- (N- (methyl- ert-Butoxycarbonyl) )phenyl) sulfonyl] amino-2-hydroxy propylcarbamate (21.5 mg, 0.031 mmol) in 2 mL dichloromethane. To this solution was added 1 L of trifluoroacetic acid. The reaction was continued at room temperature for 45 min. The solvant was evaporated in vacuo to an oil. The crude material was purified on flash grade silica gel eluting with 50% ethyl acetate in hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide
  • the aqueous phase was diluted with saturated aqueous brine and extracted three times with dichloromethane followed by two extractions with ethyl acetate.
  • the organic layers were combined, dried over anhydrous sodium sulfate, filtered, evaporated in vacuo and dried under high vacuum to provide N- [ (22?, 3S) -3-amino-2- hydroxy-4-phenylbutyl] -N- (cyclopentyloxy) -122-benzimidazole- 6-sulfonamide (0.423 g, 104%).
  • the residue was purified on a preparative TLC plate (20X20 cm, 1000 ⁇ M) eluting with 95:5 methylene chloride : methanol.
  • the product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, and evaporated in vacuo .
  • the residue was purified again on a preparative TLC plate (20X20 cm, 500 ⁇ M) eluting with 95:5 methylene chloride : methanol.
  • the product band was removed, eluted with 3:1 methylene chloride: methanol, filtered, and evaporated in vacuo .
  • Example 48 (73 mg, 0.168), 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (34 mg, 0.18 mmol), N- hydroxybenzotriazole (24 mg, 0.18 mmol), and (25) -4-amino-4- oxo-2- [ (2-quinolinylcarbonyl) amino ]butanoic acid hydrochloride (57 mg, 0.18 mmol, Eur. Pat. Appl . EP 432694) was combined under an Argon atmosphere at ambient temperature in anhydrous dimethylformamide (2 mL) .
  • Example 54 the residue was dissolved in anhydrous DMF (5 mL) followed by (2S) -4-amino-4-oxo-2- [ (2-quinolinylcarbonyl) amino] butanoic acid hydrochloride (320 mg, 1.13 mmol), anhydrous diisopropylethylamine (0.4 mL, 2.26 mmol), l-(3- dimethyl-aminopropyl) -3-ethylcarbodiimide hydrochloride (220 mg, 1.13 mmol), and 1-hydroxy-benzotriazole (150 mg, 1.13 mmol) . The reaction was stirred for 18 h and concentrated in vacuo.
  • Example 54 the residue was dissolved in anhydrous acetonitrile (15 mL) , followed by 1- ( [ (3S) tetrahydro-3-furanyloxy] -carbonyloxy) dihydro-122- pyrrole-2, 5-dione (660 mg, 2.88 mmol), anhydrous diisopropylethylamine (0.50 mL, 2.88 mmol), and N,N- dimethylaminopyridine (105 mg, 0.86 mmol). The reaction was heated at 50°C for 2 hours, allowed to cool, and concentrated in vacuo.
  • aqueous layer was extracted with ethyl acetate (25 mL) and the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to a sticky white solid.
  • Anhydrous acetonitrile (20 mL) was added, followed by racemic (3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl 4-nitrophenyl carbonate (1.21 g, 4.12 mmol), anhydrous diisopropylethylamine (0.72 mL, 4.12 mmol), and N,N- dimethylaminopyridine (150 mg, 1.23 mmol).
  • Example 54 After the workup described in Step 2, Example 54, the residue was dissolved in anhydrous acetonitrile (20 mL) , followed by 1, 3-dioxan-5- yl 4-nitrophenyl carbonate (1.02 g, 3.79 mmol), anhydrous diisopropylethylamine (0.65 mL, 3.8 mmol), and N,N- dimethylaminopyridine (140 mg, 1.14 mmol). The reaction was heated at 50°C for 2 hours, allowed to cool, and concentrated in vacuo.
  • Example 54 the residue was purified by flush chromatography over a bed of silica gel using a gradient elution of hexane: ethyl acetate (1:2 to 1:4) to give the desired product as a white foam (600 mg, 1.52 mmol, 40%).
  • Example 54 the residue was purified by preparative silica gel TLC using 93:7 chloroform: methanol as an eluent to provide the desired product as a colorless glass (40 mg, 0.0618 mmol, 24%) .
  • Example 54 the residue was purified by preparative silica gel TLC using 1:1 hexane: ethyl acetate as an eluent to give the tritylated product as a colorless film.
  • the compound was deprotected as described in Example 57 and purified by preparative silica gel TLC using 3:1 ethyl acetate: hexane as an eluent to provide the desired product as a colorless film (6 mg, 0.01 mmol, 5%) . (no HNMR data available). MS(ES): 559 (M+l), 557 (M-l).
  • Example 57 the residue was purified by preparative silica gel TLC using 1:1 hexane: ethyl acetate as an eluent to give the tritylated product as a colorless film.
  • the compound was deprotected as described in Example 57 and purified by preparative silica gel TLC using 3:1 ethyl a
  • Example 54 the residue was purified by preparative silica gel TLC using 1:1 hexane: ethyl acetate as an eluent to give the tritylated product as a colorless film (100 mg, 0.125 mmol) .
  • the compound was deprotected as described in Example 57 and purified by preparative silica gel TLC using 3:1 ethyl acetate: hexane as an eluent to provide the desired product as a colorless glass (30 mg, 0.0537 mmol, 43%).
  • Example 54 the residue was purified by preparative silica gel TLC using 1:1 hexane: ethyl acetate as an eluent to give the tritylated product as a colorless film (117 mg, 0.139 mmol, 58%) .
  • the compound was deprotected as described in Example 57 and purified by preparative silica gel TLC using 3:1 ethyl acetate: hexane as an eluent to provide the desired product as a colorless film (60 mg, 0.100 mmol, 72%).
  • Example 54 the residue was purified by preparative silica gel TLC using 1:1 hexane: ethyl acetate as an eluent to give the tritylated product as a beige foam.
  • the compound was deprotected as described in Example 57 and purified by preparative silica gel TLC using 3:1 ethyl acetate: hexane as an eluent to provide the desired product as a colorless glass (53 mg, 0.0922 mmol, 36%).
  • reaction solution was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated under vacuum.
  • the crude residue was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and crystallization from ether and hexanes to yield 10 mg (19%) of white solid.
  • the crude reaction mixture was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine and dried over magnesium sulfate.
  • the solution was concentrated to a residue, purified by silica gel chromatography (ethyl acetate) , and lyophylized providing a fluffy white solid.
  • the reaction was concentrated to a yellow oil, dissolved in ethyl acetate, washed with IN HCl, saturated aq. sodium bicarbonate solution, brine and dried over magnesium sulfate.
  • the crude product was purified by silica gel chromatgraphy (1:1 hexanes/ethyl acetate) and crystallization from an ether/hexanes solution to yield 30 mg (43%) of white crystals.
  • the crude reaction mixture was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine and dried over magnesium sulfate.
  • the solution was concentrated to a residue, purified by RPHPLC (water/acetonitrile) and lyophylized providing 20 mg (30%) of a white solid.
  • the crude reaction mixture was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine and dried over magnesium sulfate.
  • the solution was concentrated to a residue, purified by silica gel chromatography (1:1 hexanes/ethyl acetate) and crystallization from ether and hexanes, providing 20 mg (25%) of a pink solid.
  • reaction solution was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated under vacuum.
  • the crude residue was purified by silica gel chromatography (1:1 hexanes/ethyl acetate) and crystallization from ether and hexanes to yield 20 mg (36%) of white crystals.
  • reaction solution was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated under vacuum.
  • the crude residue was purified by crystallization from ether to yield 15 mg (27%) of white crystals.
  • reaction solvent was removed in vacuo and the residue was partitioned between dichloromethane and IN ⁇ aOH. After separating the layers, the aqueous phase was extracted with dichloromethane. The combined organic layers were combined, dried over anhydrous magnesium sulfated, filtered and evaporated in vacuo . The residue was purified on three preparative silica gel TLC plates (20x20 cm, 1000 ⁇ M) eluting with 65:35 ethyl acetate : hexane. The product band was removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo .
  • tert-butyl 27- [ (IS, 22?) -l-benzyl-3-hydrazino-2- hydroxypropyl ] carbamate A mixture of tert-butyl N- ( 1S) -1- [ (2S) oxiran-2-yl] -2-phenylethylcarbamate (2.50 g, 9.51 mmol) and anhydrous hydrazine (3.00 mL, 95.0 mmol) in 15 mL of isopropanol was heated at reflux under an Argon atmosphere for 18 hours.
  • reaction solvent was removed in vacuo and the residue was purified on flash grade silica gel eluting with 2:3 ethyl acetate : hexane. Fractions containing the product were combined, evaporated in vacuo to a residue and triturated with hexane and diethyl ether. The solvents were removed in vacuo and the residual solid was dried under high vacuum to provide tert-butyl N- ( (IS, 22?) -l-benzyl-3-2- cyclopentyliden-1- [ (4-methoxyphenyl ) sulfonyl ] hydrazino-2- hydroxypropyl) carbamate (26 mg, 23%) as a solid.
  • tert-butyl 27- (IS, 22?) -1-benzyl-2-hydroxy-3-1- [ (4- methoxyphenyl) sulfonyl] -2- [ (Z) -2-methylprop ⁇ lidene] hydrazinopropyl) carbamate.
  • Step 1 Example 80
  • (100 mg, 0.339 mmol) in approximately 2 mL of dichloromethane under Argon was treated with isobutyraldehyde (46.2 ⁇ L, 0.508 mmol).
  • 4- methoxyphenylsulphonylchloride (77 mg, 0.372 mmol) and ⁇ , ⁇ - diisopropylethyla ine (88.6 ⁇ L, 0.508 mmol) were added and the reaction was maintained for an additional 18 hours.
  • the reaction mixture was evaporated in vacuo and purified on flash grade silica gel eluting with 3:7 ethyl acetate : hexane.
  • tert-butyl 27- (IS,22?) -3- [ (lH-benzimidazol-6-ylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate .
  • Example 88 step 1

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Description

SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE
TECHNICAL FIELD OF THE INVENTION The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
BACKGROUND OF THE INVENTION The human immunodeficiency virus ("HIV") is the causative agent for acquired immunodeficiency syndrome ("AIDS") — a disease characterized by the destruction of the immune system, particularly of CD4+ T-cells, with attendant susceptibility to opportunistic infections — and its precursor AIDS-related complex ("ARC") — a syndrome characterized by symptoms such as persistent generalized lymphadenopathy, fever and weight loss. As in the case of several other retroviruses, HIV encodes the production of a protease which carries out post- translational cleavage of precursor polypeptides in a process necessary for the formation of infectious virions (S. Crawford et al . , "A Deletion Mutation in the 5' Part of the pol Gene of Moloney Murine Leukemia Virus Blocks Proteolytic Processing of the gag and pol Polyproteins" , J. Virol . , 53, p. 899 (1985) ) . These gene products include pol, which encodes the virion RNA-dependent DNA polymerase (reverse transcriptase) , an endonuclease, HIV protease, and gag, which encodes the core-proteins of the virion (H. Toh et al., "Close Structural Resemblance Between Putative Polymerase of a Drosophila Transposable Genetic Element 17.6 and pol gene product of Moloney Murine Leukemia Virus", EMBO J . , 4, p. 1267 (1985); L.H. Pearl et al . , "A Structural Model for the Retroviral Proteases", Nature, pp. 329-351 (1987); M.D. Power et al . , "Nucleotide Sequence of SRV-1, a Type D Simian Acquired Immune Deficiency Syndrome Retrovirus", Science, 231, p. 1567 (1986)). A number of synthetic anti-viral agents have been designed to target various stages in the replication cycle of HIV. These agents include compounds which block viral binding to CD<T T-lymphocytes (for example, soluble CD4), and compounds which interfere with viral replication by inhibiting viral reverse transcriptase (for example, didanosine and zidovudine (AZT) ) and inhibit integration of viral DNA into cellular DNA (M.S. Hirsh and-R.T. D'Aqulia, "Therapy for Human Immunodeficiency Virus Infection", New Eng. J. Med., 328, p. 1686 (1993) ) . However, such agents, which are directed primarily to early stages of viral replication, do not prevent the production of infectious virions in chronically infected cells. Furthermore, administration of some of these agents in effective amounts has led to cell-toxicity and unwanted side effects, such as anemia and bone marrow suppression.
More recently, the focus of anti-viral drug design has been to create compounds which inhibit the formation of infectious virions by interfering with the processing of viral polyprotein precursors. Processing of these precursor proteins requires the action of virus-encoded proteases which are essential for replication (Kohl, N.E. et al . "Active HIV Protease is Required for Viral Infectivity" Proc. Natl. Acad. Sci. USA, 85, p. 4686 (1988)). The antiviral potential of HIV protease inhibition has been demonstrated using peptidal inhibitors. Such peptidal compounds, however, are typically large and complex molecules that tend to exhibit poor bioavailability and are not generally consistent with oral administration.
Accordingly, the need still exists for compounds that can effectively inhibit the action of viral proteases, for use as agents for preventing and treating chronic and acute viral infections.
SUMMARY OF THE INVENTION
The present invention provides a novel class of compounds, and pharmaceutically acceptable derivatives thereof, that are useful as inhibitors of aspartyl proteases, in particular, HIV aspartyl protease. These compounds can be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, antibiotics, im unomodulators or vaccines, for the treatment or prophylaxis of viral infection. According to a preferred embodiment, the compounds of this invention are capable of inhibiting HIV viral replication in human CD4 T T-cells. These compounds are useful as therapeutic and prophylactic agents to treat or prevent infection by HIV-1 and related viruses which may result in asymptomatic infection, AIDS-related complex ("ARC"), acquired immunodeficiency syndrome ("AIDS"), or similar disease of the immune system.
It is a principal object of this invention to provide a novel class of sulfonamides which are aspartyl protease inhibitors, and particularly, HIV aspartyl protease inhibitors. The novel sulfonamides of this invention are those of formula I:
Figure imgf000006_0001
wherein:
A is selected from H; Ht;
Figure imgf000006_0002
alkyl, which is optionally substituted with one or more groups independently selected from hydroxy, Cι~C4 alkoxy, Ht, -0- Ht, -NR2-CO-N(R2); or -CO-N(R2)2; -R^C∑-Ce alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, Cι-C4 alkoxy, Ht, -O-Ht, -NR2-CO- N(R;)2 or -CO-N(R2)2; or R7; each R1 is independently selected from -C(O)-, -S(0)2-, -C(0)-C(0)-, -O-C(O)-, -0-S(0)2, -NR2-S(0)2-, -NR2- C(0)- or -NR2-C(0)-C(0)-; each Ht is independently selected from C3-C-> cycloalkyl; C5-C7 cycloalkenyl; C6-Cι4 aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R2), 0, S and S(0)n; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR2, SR2, -R2, -N(R2) (R2), -R2-0H, -CN,
-CO R- -C(0)-N(R- -S (0) '- (R*- -N(R^)-C(0)-R2, -C(0)-R% -S(0)r,-R2, -OCF3, -S(0)n-Q, methylenedioxy, -N (R2) -S (0) 2 (R2) , halo, -CF3, -N02, Q, -0Q, -OR7, -SR7, -R7, -N(R2) (R7) or -N(R )2; each R2 is independently selected from H, or Ci-Ce alkyl optionally substituted with Q or R10;
B, when present, is -N (R2) -C (R3) 2-C (0) -; each x is independently 0 or 1; each R3 is independently selected from H, Ht, Cι-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl or C5-C6 cycloalkenyl; wherein any member of said R3, except H, is optionally substituted with one or more substituents selected from -OR2, -C(0)-NH-R2, -S(0)n-N(R2) (R2) , Ht, -CN, -SR2, -C02R2, NR2-C(0)-R2; each n is independently 1 or 2; G, when present, is selected from H, R7 or C1-C4 alkyl, or, when G is Cι-C4 alkyl, G and R7 are bound to one another either directly or through a C1-C3 linker to form a heterocyclic ring; or when G is not present (i.e., when x in (G)x is 0), then the nitrogen to which G is attached is bound directly to the R7 group in -OR7 with the concomitant displacement of one -ZM group from R7;
D is selected from Q; Cι-C6 alkyl, which is optionally substituted with one or more groups selected from C3-C6 cycloalkyl, -OR2, -S-Ht, -R3, -O-Q or Q; C2-C4 alkenyl, which is optionally substituted with one or more groups selected from -OR2, -S-Ht, -R3, -O-Q or Q; C3-C6 cycloalkyl, which is optionally substituted with or fused to Q; or C5-C6 cycloalkenyl, which is optionally substituted with or fused to Q; each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from 0, N, S, S(0)r, or N(R2) ; wherein Q is optionally substituted with one or more groups selected from oxo, -OR", -R -S02R2, -S02-N(R2)2, -N(R2)2, -N(R2)-C(0)-R2, -R2-OH, -CN, -C02R:, -C(0)-N(R')2, halo or -CF3;
D' is selected from -OR10, -N=R10 or -N (R10) -R^R3;
E is selected from Ht; O-Ht; Ht-Ht; -0-R3; -N(R2) (R3) ; Cι-C6 alkyl, which is optionally substituted with one or more groups selected from R*" or Ht; C2-C6 alkenyl, which is optionally substituted with one or more groups selected from R4 or Ht; C3-C6 saturated carbocycle, which is optionally substituted with one or more groups selected from R4 or Ht; or C5-Ce unsaturated carbocycle, which is optionally substituted with one or more groups selected from R4 or Ht; each R4 is independently selected from -OR2, -SR , -S0R1, -S02R2, -C02R2, -C(0)-NHR2, -C (0) -N (R2) 2, -C(O)- NR:(OR ), -S(0)2-NHR2, halo, -NR -C (0) -R2, -N(R2)2 or -CN; each R7 is independently selected from hydrogen,
Figure imgf000008_0001
wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, -N(R2)4, Cι-C12-alkyl, C2-C12- alkenyl, or -R6; wherein 1 to 4 -CH2 radicals of the alkyl or alkenyl group, other than the -CH2 that is bound to Z, is optionally replaced by a heteroatom group selected from 0, S, S (0) , S(02), or N(R2); and wherein any hydrogen in said alkyl, alkenyl or R6 is optionally replaced with a substituent selected from oxo, -OR2, -R2, N(R2)2, N(R2)3, ROH, -CN, -C02R , -C(0)-N(R:)2, S (O) 2-N (R2) 2, N (R2) -C (0) -R2, C(0)R, -S(0)r,-R2, 0CF5, -S(0)rι-R6, N(R2)-S(0)2(R2), halo, -CF3, or -N02; M' is H, Cι-Ci2-alkyl, C2-Cι2-alkenyl, or -R6; wherein 1 to 4 -CH2 radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from 0, S, S(0), S (02) , or N(R2); and wherein any hydrogen in said alkyl, alkenyl or R6 is optionally replaced with a substituent selected from oxo, -OR2, -R2, -N(R2)2, N(R2)3, -R--0H, -CN, -C02R2, '-C(0)-N(R2)2, -S (0) 2-N (R2) 2, -N(R2)-C(0)-R2, -C(0)R2, -S(0)n-R2, -0CF3, -S(0)n-R6, -N(R2)-S (0)2(R2) , halo, -CF3, or -N02; Z is 0, S, N(R2)2, or, when M is not present, H.
Y is P or S;
X is 0 or S; and
R9 is C(R2)2, 0 or N(R2); and wherein when Y is S, Z is not S; and R6 is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from 0, N, S, S(0)n or N(R2); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH, C1-C4 alkyl, -O-C1-C4 alkyl or -0-C(0)-Cι-C4 alkyl;
10 R is selected from Cι-C8 alkyl, C2-C6 alkenyl, C6-Cι4 aryl or Ht, wherein R10 optionally contains up to three substituents independently selected from -R3, -CN, -SR5, -S0R-, -S02R5, -SR-NR5-C(0)R6, -NR5- (S02) R5, -C (0) N (R5) 2, -C(S)N(R5)2, -S(0)2N(R5)2, -C(0)R6, -C(S)R6, -N(R5)2, -NR5- C(0)R5, -NR5-C(0)0R5, -NR5-C(0)N(R5)2, -NR5-C(S)R5, -NR5- C(S)0R5, -NR5-C(S)N(R5)2, -NR5-C [=N (R5) ] -N (R5) 2, -NH-C [=N-N02J - NH2, -NH-C[=N-N02]-0R5, -N (R8) 2-C (0) R8, -0C(0)R6, -0C(0)N(R5)2, -0C(S)N(R5)2, wherein any one of the -CH2 groups of said alkyl or alkenyl chains of R1C may be optionally replaced by 0, S, SO, S02, C(0) or NR5; wherein each R5 is independently selected from hydrogen, Ci- C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or Ht, wherein each R5, except for hydrogen, is optionally substituted with -CF3, -PO3R3, azido or halo. It is also an object of this invention to provide pharmaceutical compositions comprising the sulfonamides of formula (I) and methods for their use as inhibitors of HIV aspartyl protease.
DETAILED DESCRIPTION OF THE INVENTION
In order that the invention herein described may be more fully understood, the following detailed description is set forth. In the description, the following terms are employed herein: Unless expressly stated to the contrary, the terms
"-S02-" and "-S(0)2-" as used herein refer to a sulfone or sulfone derivative (i.e., both appended groups linked to the S) , and not a sulfinate ester.
For the compounds of formula I, and intermediates thereof, the stereochemistry of OR7 is defined relative to D on the adjacent carbon atom, when the molecule is drawn in an extended zig-zag representation (such as that drawn for compound of formula I) . If both OR7 and D reside on the same side of the plane defined by the extended backbone of the compound, the stereochemistry of OR7 will be referred to as "syn". If OR7 and D reside on opposite sides of that plane, the stereochemistry of OR7 will be referred to as "anti".
The term "alkyl", alone or in combination with any other term, refers to a straight-chain or branch-chain saturated aliphatic hydrocarbon radical containing the specified number of carbon atoms, or where no number is specified, preferably from 1 to about 10 and more preferably from 1 to about 8 carbon atoms. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, n-hexyl and the like.
The term "alkenyl" alone or in combination with any other term, refers to a straight-chain or branched-chain mono- or poly-unsa'turated aliphatic hydrocarbon radical containing the specified number of carbon atoms, or where no number is specified, preferably from 2 to about 18 carbon atoms and more preferably, from 2 to about 8 carbon atoms. Examples of alkenyl radicals include, but are not limited to, ethenyl, propenyl, isopropenyl, 1, 4-butadienyl, pentenyl and the like.
The term "alkoxy" refers to an alkyl ether radical, wherein the term "alkyl" is defined above. Examples of suitable alkyl ether radicals include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n- butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like.
The term "aryl" alone or in combination with any other term, refers to a carbocyclic aromatic radical (such as phenyl or naphthyl) containing the specified number of carbon atoms, preferably from 6-14 carbon atoms, and more preferably from 6-10 carbon atoms, optionally substituted with one or more substituents selected from Cl-6 alkoxy, (for example methoxy), nitro, halogen, (for example chloro) , amino, carboxylate and hydroxy. Examples of aryl radicals include, but are not limited to phenyl, naphthyl, indenyl, indanyl, azulenyl, fluorenyl, anthracenyl and the like.
The term "heterocyclyl" or "heterocycle" refers to a stable 3-7 membered monocyclic heterocyclic ring or 8-11 membered bicyclic heterocyclcic ring which is either saturated or unsaturated, and which may be optionally benzofused if monocyclic. Each heterocycle consists of one or more carbon atoms and from one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. As used herein, the terms "nitrogen and sulfur heteroatoms" include any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. A heterocyclyl radical may be attached at any endocyclic carbon or heteroatom which results in the creation of a stable structure. Preferred heterocycles include 5-7 membered monocyclic heterocycles and 8-10 membered bicyclic heterocycles. Examples of such groups include imidazolyl, imidazolinoyl, imidazolidinyl, quinolyl, isoqinolyl, indolyl, indazolyl, indazolinolyl, perhydropyridazyl, pyridazyl, pyridyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazinyl, quinoxolyl, piperidinyl, pyranyl, pyrazolinyl, piperazinyl, pyrimidinyl, pyridazinyl, morpholinyl, thiamorpholinyl, furyl, thienyl, triazolyl, thiazolyl, carbolinyl, tetrazolyl, thiazolidinyl, benzofuranoyl, thiamorpholinyl sulfone, oxazolyl, benzoxazolyl, oxopiperidinyl, oxopyrrolidinyl, oxoazepinyl, azepinyl, isoxozolyl, isothiazolyl, furazanyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolyl, thiadiazoyl, dioxolyl, dioxinyl, oxathiolyl, benzodioxolyl, dithiolyl, thiophenyl, tetrahydrothiophenyl, sulfolanyl, dioxanyl, dioxolanyl, tetahydrofurodihydrofuranyl, tetrahydropyranodihydrofuranyl, dihydropyranyl, tetradyrofurofuranyl and tetrahydropyranofuranyl .
The term "pharmaceutically effective amount" refers to an amount effective in treating a virus infection, for example an HIV infection, in a patient either as monotherapy or in combination with other agents. The term "treating" as used herein refers to the alleviation of symptoms of a particular disorder in a patient or the improvement of an ascertainable measurement associated with a particular disorder. The term "prophylactically effective amount" refers to an amount effective in preventing a virus infection, for example an HIV infection, in a patient. As used herein, the term "patient" refers to a mammal, including a human.
The terms "HIV protease" and "HIV aspartyl protease" are used interchangeably and refer to the aspartyl protease encoded by the human immunodeficiency virus type 1 or 2. In a preferred embodiment of this invention, these terms refer to the human immunodeficiency virus type 1 aspartyl protease.
The term "thiocarbamates" refers to compounds containing the functional group N-S02-0.
Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and administration to a mammal by methods known in the art. Typically, such compounds are stable at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. The basic nitrogen can be quaternized with any agents known to those of ordinary skill in the art including, for example, lower alkyl halides, such as methyl, ethyl, propyl and butyl chloride, bromides and iodides; dialkyl sulfates including dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides including benzyl and phenethyl bromides. Water or oil-soluble or dispersible products may be obtained by such quaternization.
The novel sulfonamides of this invention are those of formula I:
Figure imgf000014_0001
wherein:
A is selected from H; Ht; -R:-Ht;
Figure imgf000014_0002
alkyl, which is optionally substituted with one or more groups independently selected from hydroxy, Cι-C4 alkoxy, Ht, -0- Ht, -NR2-C0-N(R2)2 or -C0-N(R2)2; -R^C∑-Ce alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, Cι-C4 alkoxy, Ht, -O-Ht, -NR2-C0- N(R ): or -C0-N(R2)2; or R7; each R1 is independently selected from -C(0)-, -S(0)2-, -C(0)-C(0)-, -0-C(0)-, -0-S(0)2, -NR2-S(0)2-, -NR2- C(O)- or -NR2-C(0)-C(0)-; each Ht is independently selected from C3-Cτ cycloalkyl; C5-Cτ cycloalkenyl; C6-Cι4 aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R2), 0, S and S(0)n; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR2, SR2, -R2, -N(R2) (R2), -R2-OH, -CN,
-C02R-, -C(0)-N(R' -S (0) --N(R2 -N(R' -C(0)-R2, -C(0)-R2, -S(0)n-R2,' -OCF3, -S(0)n-Q, methylenedioxy, -N (R2) -S (0) 2 (R2) , halo, -CF3, -N02, Q, -0Q, -OR7, -SR7, -R7, -N(R2) (R7) or -N(R7)2; each R2 is independently selected from H, or Cι-C6 alkyl optionally substituted with Q or R1C;
B, when present, is -N (R2) -C (R3) 2-C (0) -; each x is' independently 0 or 1; each R3 is independently selected from H, Ht, Cι-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl or C5-C6 cycloalkenyl; wherein any member of said R3, except H, is optionally substituted with one or more substituents selected from -OR2, -C(0)-NH-R2, -S (0)n-N(R2) (R2) , Ht, -CN, -SR2, -C02R2, NR2-C(0) -R2; each n is independently 1 or 2; G, when present, is selected from H, R7 or C1-C4 alkyl, or, when G is C1-C4 alkyl, G and R7 are bound to one another either directly or through a C1-C3 linker to form a heterocyclic ring; or when G is not present (i.e., when x in (G)x is 0), then the nitrogen to which G is attached is bound directly to the R7 group in -OR7 with the concomitant displacement of one -ZM group from R7;
D is selected from Q; Cι-C6 alkyl, which is optionally substituted with one or more groups selected from C3-C6 cycloalkyl, -OR2, -S-Ht, -R3, -O-Q or Q; C2-C4 alkenyl, which is optionally substituted with one or more groups selected from -OR2, -S-Ht, -R3, -O-Q or Q, C3-C6 cycloalkyl, which is optionally substituted with or fused to Q; or C5-C cycloalkenyl, which is optionally substituted with or fused to Q; each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from 0, N, S, S(0)n or N(R2); wherein Q is optionally substituted with one or more groups selected from oxo, -OR", -RJ, -S02R2, -S0:-N(R2L, -N(R-)2, -N(R2) -C(0)-R2, -R2-0H, -CN, -C02R:, -C(0)-N(R2)2, halo or -CF3;
D' is selected from -OR10, -N-R10 or -N (R10) -R1-R3; E is selected from Ht; O-Ht; Ht-Ht; -O-R3; -N(R2) (R3) ; C:-Ce alkyl, which is optionally substituted with one or more groups selected from R4 or Ht; C2-C6 alkenyl, which is optionally substituted with one or more groups selected from R1* or Ht; C3-C6 saturated carbocycle, which is optionally substituted with one or more groups selected from R4 or Ht; or C5-C6 unsaturated carbocycle, which is optionally substituted with one or more groups selected from R4 or Ht; each R4 is independently selected from -OR2,
-SR:, -SOR2, -S02R2, -C02R2, -C(0)-NHR2, -C (0) -N (R2) 2, -C(O)- NR2(OR2), -S(0)2-NHR2, halo, -NR2-C (0) -R2, -N(R2)2 or -CN; each R7 is independently selected from hydrogen,
Figure imgf000016_0001
wherein each M is i ndepende :ntly selected from H, Li, Na, K, Mg, Ca, Ba, -N(R2)4, Cι-Cι2-alkyl, C2-Cι2- alkenyl, or -R6; wherein 1 to 4 -CH2 radicals of the alkyl or alkenyl group, other than the -CH2 that is bound to Z, is optionally replaced by a heteroatom group selected from 0, S, S (O) , S(0 ), or N(R2); and wherein any hydrogen in said alkyl, alkenyl or R6 is optionally replaced with a substituent selected from oxo, -OR2, -R2, N(R2)2, N(R2)3, R20H, -CN, -C02R2, -C(0)-N(R2)2, S (0) 2-N (R2) 2, N (R2) -C (0) -R2, C(0)R:, -S(0)r,-R2, 0CF3, -S(0)n-R6, N(R2)-S(0)2(R2) , halo, -CF3, or -N02; M' is H, Cι-CI2-alkyl, C2-Cι2-alkenyl, or -R6; wherein 1 to 4 -CH2 radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from 0, S, S (0) , S(02), or N(R2); and wherein any hydrogen in said alkyl, alkenyl or R6 is optionally replaced with a substituent selected from oxo, -OR2, -R?, -N(R2)2, N(R2)3/ -R2OH, -CN, -C02R2, -C(0)-N(R2)2, -S (0) 2-N (R2) 2, -N(R2)-C(0)-R2, -C(0)R2, -S(0)n-R2, -0CF3, -S(0)n-R6, -N(R2) -S (0)2(R2) , halo, -CF3, or -N02; Z is 0, S, N(R2)2, or, when M is not present, H.
Y is P or S; X is 0 or S; and
R9 is C(R2)2, 0 or N(R2); and wherein when Y is S, Z is not S; and R6 is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from 0, N, S, S(0)n or N(R2); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH, Cι-C4 alkyl, -O-C1-C4 alkyl or -0-C(0)-C1-C4 alkyl;
R is selected from Cι_C8 alkyl, C2_C6 alkenyl, C6-Cι4 aryl or Ht, wherein R10 optionally contains up to three substituents independently selected from -R3, -CN, -SR5, -SOR5, -S02R5, -SR-NR5-C(0)R6, -NR5- (S02) R5, -C(0)N(R5)2, -C(S)N(R5)2, -S (0)2N(R5)2, -C(0)R6, -C(S)R6, -N(R5)2, -NR5- C(0)R5, -NR5-C(0)OR5, -NR5-C(0)N(R5)2, -NR5-C(S)R5, -NR5- C(S)0R5, -NR5-C(S)N(R5)2, -NR5-C [=N (R5) ] -N (R5) 2, -NH-C [=N-N02- - NH2, -NH-C[-N-N02]-OR5, -N (R8) 2-C (0) R8, -0C(0)R6, -0C(0)N(R5)2, -0C(S)N(R5)2, wherein any one of the -CH2 groups of said alkyl or alkenyl chains of R10 may be optionally replaced by 0, S, SO, S02, C (0) or NR5; wherein each R5 is independently selected from hydrogen, Cι-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or Ht, wherein each R5, except for hydrogen, is optionally substituted with -CF3, -P03R3, azido or halo;
Preferably, at least one R' is selected from:
Figure imgf000018_0001
*P03 (NH4 -CH2-0P03Na2,
Figure imgf000018_0002
- (L) -serine,
-S03Na, 2, -S03Mg, -S03(NH4)2,
Figure imgf000018_0003
O
.NH,
-CH-0S03Na2, -CH2-0S03(NH4)2, f ■Q NH2 '
Figure imgf000018_0004
Figure imgf000018_0005
' - (L) -valine, - (L) -glutamic acid, - (L) -aspartic acid,
- (L) -γ-t-butyl-aspartic acid, X0-« r—°/>'
- (L) - (L) -3-pyridylalanine, - (L) -histidine, -CHO, ^ CF3
Figure imgf000019_0001
P03-spermine, P03- (spermidine) 2 or P05- (meglamine) 2.
It will be understood by those of skill in the art that component M or M' in the formulae set forth herein will have either a covalent, a covalent/ zwitterionic, or an ionic association with either Z or R9 depending upon the actual choice for M or M' . When M or M' is hydrogen, alkyl, alkenyl, or R&, M or M' is covalently bound to R9 or Z. If M is a mono- or bivalent metal or other charged species (i.e., NH4 +) , there is an ionic interaction between M and Z and the resulting compound is a salt.
When x is 0 in (M)x, Z may be a charged species. When that occurs, the other M may be oppositely charged to produce a 0 net charge on the molecule. Alternatively, the counter ion may located elsewhere in the molecule. Except where expressly provided to the contrary, as used herein, the definitions of variables A, R^R4, R6-R9, Ht, B, x, n, D, D', M, Q, X, Y, Z and E are to be taken as they are defined above for the compounds of formula I.
According to a preferred embodiment, the compounds of this invention are those represented by formula II, formula III or formula IV: - II
Figure imgf000020_0001
Figure imgf000020_0002
Figure imgf000020_0003
wherein A, R3, R7, Ht, D, D', x, E are as defined above for compounds of formula I. For ease of reference, the two RJ moieties present in formula IV have been labeled R-3 and R3' . For compounds of formula II, more preferred compounds are those wherein: A is -C(0)Ht; D' is -O-R10;
E is C6-Cιo aryl optionally substituted with one or more substituents selected from oxo, -OR2, SR2, -R2, -N(R2)2,
-R2-0H, -CN, -C02R2, -C(0)-N(R2)2, -S (0) 2-N (R2) 2, -N(R2)-C(0)- R2, -C(0)-R2, -S(0)n-R2, -0CF3, -S(0)n-Q, ethylenedioxy, -N(R2)-S (0)2 (R2) , halo, -CF3, -N02, Q, -0Q, -OR7, -SR7, -R7, -N(R2) (R7) or -N(R7)2; or a 5-membered heterocyclic ring containing one S and optionally containing N as an additional heteroatom, wherein said heterocyclic ring is optionally substituted with one to two groups independently selected from -CH3, R4, or Ht . all other variables are as defined for formula I.
-Another preferred embodiment for the formula II compounds are those wherein:
E is a 5-membered heterocyclic ring containing one S and optionally containing N as an additional heteroatom, wherein said heterocyclic ring is optionally substituted with one to two groups independently selected from -CH3, R4, or Ht; and all other variables are as defined for formula I.
More preferred are any of the formula II compounds set forth above, wherein R7 in -OR7 is -PO(OM)2 or C(0)CH2OCH2CH2OCH2CH2OCH3 and both R7 in -N(R7)2 are H, wherein M is H, Li, Na, K or Cι-C4 alkyl; or wherein R7 in -OR7 is C(0)CH2OCH2CH2OCH3, one R7 in -N(R7)2 is C (0) CH2OCH2CH2OCH3 and the other is H.
According to another preferred embodiment of the present invention, there is provided compounds of formula (V) :
Figure imgf000021_0001
wherein: A is C6-Ci4 aryl optionally substituted with one or more groups independently selected from the group consisting of Cι-C8 alkyl or hydroxy, or OR4, wherein R4 is Cι~C8 alkyl, C3-C- cycloalkyl, Cι-C8 alkyl substituted with C6-Cι4, C6-Cι4 aryl optionally substituted with Cι-C8 alkyl, heterocyclyl or heterocyclylalkyl;
E is C6-Cι4 aryl, optionally substituted with one or more groups selected from nitro, oxo, alkoxy, amino, hydroxyamino; heterocyclcyl, optionally substituted with one or more groups selected from the group consisting of nitro, oxo, alkoxy, amino, hydroxyamino or N(CO)OCH3;
R and R are as defined above; or a pharmaceutically acceptable derivative thereof.
According to yet another preferred embodiment, there is provided compounds of Formula (VI) :
Figure imgf000022_0001
wherein:
R7 and R1C are as defined above for formula I; E is C6-Ci4 aryl, optionally substituted with one or more groups selected from the group consisting of nitro, oxo, alkoxy, amino, hydroxyamino; heterocyclcyl, optionally substituted with one or more groups selected from the group consisting of nitro, oxo, alkoxy, amino, hydroxyamino or N(CO)OCH3; or a pharmaceutically acceptable derivative thereof. According to yet another preferred embodiment, there is provided a compound of Formula (VII) :
Figure imgf000023_0001
wherein:
A, E, R and R are as defined in formula (I); or a pharmaceutically acceptable derivative thereof.
According to yet another preferred embodiment, there is provided a compound of formula (VIII) :
Figure imgf000023_0002
wherein A, R1, R3, R7 and E are as defined in formula
According to yet another embodiment of the present invention, there are provided compounds of the formula:
Figure imgf000024_0001
wherein X is a pharmaceutically suitable counterion;
Figure imgf000024_0002
Figure imgf000024_0003
Figure imgf000024_0004
Figure imgf000025_0001
Figure imgf000025_0002
Figure imgf000025_0003
wherein Riυ is selected from isopropyl or cyclopentyl; R11 is selected from NHR7 or OR7; x, R7 and G are as defined above; and X" is a pharmaceutically acceptable counterion.
The compounds according to the invention contain one or more asymmetric carbon atoms and thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers . All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be of the R or S configuration. Although the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral center or mixtures thereof are also envisioned.
More preferred compounds of formula (I) of the present invention are set forth below in Table 1.
Table 1
Figure imgf000026_0001
Figure imgf000026_0002
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000046_0002
Figure imgf000046_0003
Figure imgf000046_0004
Figure imgf000047_0001
Most preferred compounds of the present invention include the following:
( 3R, 3aS, 6ai?)hexahydrofuro[2, 3-j ] furan-3-yl N- ( (IS, 21?)- l-benzyl-3- (cyclopentyloxy) [ (3- [ 2- (dimethylamino) ethyl] aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate;
(3S, 3aR, 6aS)hexahydrofuro[2,3-i>]furan-3-yl N- ( ( 1S, 2R) - l-benzyl-3- (cyclopentyloxy) [ (3- [2- (dimethylamino) ethyl] aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate;
( 3R, 3aS, 6ai?)Hexahydrofuro[2,3-b]furan-3-yl-N- ( ( 1S, 2R) - l-benzyl-3- (cyclopentyloxy) (2- [ (methylsulfonyl) amino] benzimidazol-5-ylsulfonyl) amino-2-hydroxypropyl) carbamate;
( 3R, 3aS, 6ai?)hexahydrofuro[2, 3-b] furan-3-yl N- ( 1S, 2R) -3- [ [ (3-Ν-methylaminophenyl) sulfonyl] (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate; 1, 3-Dioxan-5-yl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2- { (methoxycarbonyl) amino] -lH-benzimidazol-5-ylsulfonyl) amino] -2-hydroxypropylcarbamate;
( 3R, 3aS, 6ai) hexahydrofuro [2, 3-J] furan-3-yl N- ( 1 S, 2R) - 1- benzyl-2-hydroxy-3- [ [ (4-methoxyphenyl) sulfonyl] (tetrahydro- 2Jϊ-pyran-4-yloxy) amino] propylcarbamate;
( 3R, 3aS, 6aΛ) hexahydrofuro [2, 3-i>] furan-3-yl N- (IS, 2i?)-3- [ [ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate; ( 3R, 3aS, 6ai) hexahydrofuro [2, 3-jb] furan-3-yl N- [ ( 1S, 2R) - l-benzyl-3- ( (cyclopentyloxy) [3- (2- [methoxy (methyl) amino] -2- oxoethylamino) phenyl] sulfonylamino) -2-hydroxypropyl] carbamate;
( 3R, 3aS, 6aΛ) hexahydrofuro [2, 3-.] furan-3-yl N- [ ( 1 S, 2R) - l-benzyl-4- (cyclopentyloxy) -2-hydroxy-4- ( 6-quinoxalinyl sulfonyl) butyl] carbamate;
( 3R, 3aS, 6a/P) hexahydrofuro [2, 3- ] furan-3-yl N- ( ( 1 S, 2R) - l-benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino- 2-hydroxypropyl) carbamate; ( 3R, 3aS, 6ai) hexahydrofuro [2, 3-ip] furan-3-yl N- [ ( 1S, 2R) - l-benzyl-3- ( (cyclopentyloxy) [3- (2- [ (methylsulfonyl) amino] ethylamino) phenyl] sulfonylamino) -2-hydroxypropyl] carbamate;
( 3R, 3aS, 6ai?)hexahydrofuro[2,3-iι] furan-3-yl N- ( lS, 2R) -3- [ [ (3-Ν-methylaminophenyl) sulfonyl] (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate phosphate ester;
( 3R, 3aS, 6a/)hexahydrofuro[2,3-i>] furan-3-yl N- ( l S, 2R) -3- [ [ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate phosphate ester;
(3R,3aS,6aR) hexahydrofuro [2, 3-b] furan-3-yl Ν- (IS, 2R) - 3- [ [ (4-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -1-benzyl- 2-hydroxypropyl carbamate;
(3R,3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (1S,2R)-1- benzyl-3-{ (1-ethylpropoxy) [ (4-hydroxyphenyl) sulfonyl] amino}- 2-hydroxypropylcarbamate; (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (lS,2R)-3- t (1, 3-benzodioxol-5-ylsulfonyl) (1-ethylpropoxy) amino] -1- benzyl-2-hydroxypropylcarbamate;
( 3R, 3aS, 6aR) hexahydrofuro [2, 3-j] furan-3-yl N- [ (IS, 2R) - 3- [ (1, 3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2- (phosphonooxy) propyl ] carbamate;
( 3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (lS,2R)-3- [ (1, 3-benzodioxol-5-ylsulfonyl) (cyclohexyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate; ( 3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl 3- [(1,3- benzodioxol-5-ylsulfonyl) (tetrahydro-2H-pyran-4- yloxy) amino] -l-benzyl-2-hydroxypropylcarbamate;
( 3R, 3aS, 6aR) hexahydrofuro [2, 3-jb] furan-3-yl N- [ (IS, 2R) - 3- [ (1, 3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2- (phosphonooxy) propyl] carbamate; or a pharmaceutically acceptable derivative thereof.
The compounds of the present invention can be readily prepared by techniques known in the art. Scheme I illustrates a general synthetic route to compounds of formula (V), a preferred sub-genus of formula (I).
According to Scheme I, commercially available Ν- hydroxyphthalimide is reacted with R -Br or R -OH under displacement or Mitsonobu-type conditions respectively, followed by hydrazinolysis in ethanol to produce the amine of formula (I). Amine of formula (I) is further utilized in two synthetic routes, Path 1 and Path 2.
Path 1 Step 1: Amine of formula (I) is reacted with a sulfonyl chloride of formula (A) to produce sulfonamide of formula (II' ) .
Step 2: Sulfonamide of formula (II') is reacted with intermediate of formula (B) , which bears an amine protecting group P, such as t-butoxycarbonyl, to produce compound of formula (III'). Suitable amine protecting groups are described in numerous references, including T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2d Ed. , John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed. Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) . Examples of such amino protecting groups include, but are not limited to, Cbz or Alloc.
Step 3: Compound of formula (III') is then reacted with A-L, wherein L is a leaving group, to produce compound of formula (IV) . A leaving group is an atom or group which is displaceable upon reaction with an appropriate amine or sulfonamide. Suitable leaving groups would be obvious to one of skill in the art and include but are not limited to hydroxyls, carboxylates and halides.
SCHEME I
Figure imgf000051_0001
Figure imgf000051_0002
(V) Step 4: Compound of formula (IV) is then converted to compound of formula (V) by functional transformation of the hydroxy group .
Path 2 differs from Path 1 only in the sequence of reagents employed to convert compound of formula (I) to compound of formula (IV) .
The synthetic approach illustrated in Scheme I can be readily extended to produce other compounds of the present invention. The above synthetic scheme is not intended to comprise a comprehensive list of all means by which compounds described and claimed in this application may be synthesized. Further methods will be evident to those of ordinary skill in the art.
As discussed above, the novel compounds of the present invention are excellent ligands for aspartyl proteases, particularly HIV-1 and HIV-2 proteases. Accordingly, these compounds are capable of targeting and inhibiting late stage events in HIV replication, i.e., the processing of the viral polyproteins by HIV encoded proteases. Such compounds inhibit the proteolytic processing of viral polyprotein precursors by inhibiting aspartyl protease. Because aspartyl protease is essential for the production of mature virions, inhibition of that processing effectively blocks the spread of virus by inhibiting the production of infectious virions, particularly from chronically infected cells. Compounds according to this invention advantageously inhibit the ability of the HIV-1 virus to infect immortalized human T cells over a period of days, as determined by an assay of extracellular p24 antigen -- a specific marker of viral replication. Other anti-viral assays have confirmed the potency of these compounds. The compounds of this invention may be employed in a conventional manner for the treatment of viruses, such as HIV and HTLV, which depend on aspartyl proteases for obligatory events in their life cycle. Such methods of treatment, their dosage levels and requirements may be selected by those of ordinary skill in the art from available methods and techniques. For example, a compound of this invention may be combined with a pharmaceutically acceptable adjuvant for administration to a virally-infected patient in a pharmaceutically acceptable manner and in an amount effective to lessen the severity of the viral infection.
Alternatively, the compounds of this invention may be used in vaccines and methods for protecting individuals against viral infection over an extended period of time.
The compounds may be employed in such vaccines either alone or together with other compounds of this invention in a manner consistent with the conventional utilization of protease inhibitors in vaccines. For example, a compound of this invention may be combined with pharmaceutically acceptable adjuvants conventionally employed in vaccines and administered in prophylactically effective amounts to protect individuals over an extended period time against HIV infection. As such, the novel protease inhibitors of this invention can be administered as agents for treating or preventing HIV infection in a mammal.
The compounds of formula I, especially those having a molecular weight of less than about 700 g/mole, may be readily absorbed by the bloodstream of mammals upon oral administration. Compounds of formula I having a molecular weight of less than about 600 g/mole are most likely to demonstrate oral availability. This surprisingly impressive oral availability makes such compounds excellent agents for orally-administered treatment and prevention regimens against HIV infection.
The compounds of this invention may be administered to a healthy or HIV-infected patient either as a single agent or in combination with other anti-viral agents which interfere with the replication cycle of HIV. By administering the compounds of this invention with other anti-viral agents which target different events in the viral life cycle, the therapeutic effect of these compounds is potentiated. For instance, the co-administered anti-viral agent can be one which targets early events in the life cycle of the virus, such as cell entry, reverse transcription and viral DNA integration into cellular DNA. Anti-HIV agents targeting such early life cycle events include, didanosine (ddl), alcitabine (ddC) , d4T, zidovudine (AZT), polysulfated polysaccharides, sT4 (soluble CD4), 3TC, 935U83, 1592U89, 524W91, ganciclovir, dideoxycytidine, trisodium phosphonoformate, eflornithine, ribavirin, acyclovir, alpha interferon and trimenotrexate . Ribonucleotide reductase inhibitors such as hydroxyurea may also be used. Additionally, non-nucleoside inhibitors of reverse transcriptase, such as TIBO, delavirine (U90) or nevirapine, may be used to potentiate the effect of the compounds of this invention, as may viral uncoating inhibitors, inhibitors of trans-activating proteins such as tat or rev, or inhibitors of the viral integrase.
Combination therapies according to this invention exert a synergistic effect in inhibiting HIV replication because each component agent of the combination acts on a different site of HIV replication. The use of such combinations also advantageously reduces the dosage of a given conventional anti-retroviral agent which would be required for a desired therapeutic or prophylactic effect as compared to when that agent is administered as a monotherapy. These combinations may reduce or eliminate the side effects of conventional single anti-retroviral agent therapies while not interfering with the anti-retroviral activity of those agents. These combinations reduce potential of resistance to single agent therapies, while minimizing any associated toxicity. These combinations may also increase the efficacy of the conventional agent without increasing the associated toxicity. In particular, we have discovered that these compounds act synergistically in preventing the replication of HIV in human T cells.
Preferred combination therapies include the administration of a compound of this invention with AZT, ddl, ddC or d4T. Alternatively, the compounds of this invention may also be co-administered with other HIV protease inhibitors such as Agenerase (VX-478, Vertex) , saquinavir, Ro 31-8959 (Roche), L-735,524 (Merck), XM 323 (Du-Pont Merck) A-80, 987 (Abbott), MK 639 (Merck), ABT 538 (A-80538, Abbott), AG 1343 (Agouron) , XM 412 (Du-Pont Merck), XM 450 (Du-Pont Merck), BMS 186318 (Bristol-Meyers Squibb), ABT 378 (Abbott) and CPG 53,437 (Ciba Geigy) to increase the effect of therapy or prophylaxis against various viral mutants or members of other HIV quasi species.
We prefer administering the compounds of this invention as single agents or in combination with retroviral reverse transcriptase inhibitors, such as derivatives of
AZT, or other HIV aspartyl protease inhibitors. We believe that the co-administration of the compounds of this invention with retroviral reverse transcriptase inhibitors or HIV aspartyl protease inhibitors may exert a substantial synergistic effect, thereby preventing, substantially reducing, or completely eliminating viral infectivity and its associated symptoms.
The compounds of this invention can also be administered in combination with immunomodulators (e.g., bropirimine, anti-human alpha interferon antibody, IL-2, GM- CSF, methionine enkephalin, interferon alpha, diethyldithiocarbamate, tumor necrosis factor, naltrexone, tuscarasol and rEPO) ; and antibiotics (e.g., pentamidine isethiorate) to prevent or combat infection and disease associated with HIV infections, such as AIDS and ARC.
When the compounds of this invention are administered in combination therapies with other agents, they may be administered sequentially or concurrently to the patient. Alternatively, pharmaceutical or prophylactic compositions according to this invention may be comprised of a combination of an aspartyl protease inhibitor of this invention and another therapeutic or prophylactic agent. Although this invention focuses on the use of the compounds disclosed herein for preventing and treating HIV infection, the compounds of this invention can also be used as inhibitory agents for other viruses which depend on similar aspartyl proteases for obligatory events in their life cycle. These viruses include, as well as other AIDS-like diseases caused by retroviruses, such as simian immunodeficiency viruses, but are not limited to, HTLV-I and HTLV-II. In addition, the compounds of this invention may also be used to inhibit other aspartyl proteases, and in particular, other human aspartyl proteases, including renin and aspartyl proteases that process endothelin precursors. Pharmaceutical compositions of this invention comprise any of the compounds of the present invention, and pharmaceutically acceptable salts thereof, with any pharmaceutically acceptable carrier, adjuvant or vehicle. Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat.
The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. We prefer oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques .
The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example, as a solution in 1, 3-butanediol . Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides . Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant such as Ph. Helv or a similar alcohol.
The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non- irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.
The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 50 mg/kg body weight per day of the active ingredient compound are useful in the prevention and treatment of viral infection, including HIV infection. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w) . Preferably, such preparations contain from about 20% to about 80% active compound.
Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
As the skilled artisan will appreciate, lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the infection, the patient's disposition to the infection and the udgment of the treating physician.
The compounds of this invention are also useful as commercial reagents which effectively bind to aspartyl proteases, particularly HIV aspartyl protease. As commercial reagents, the compounds of this invention, and their derivatives, may be used to block proteolysis of a target peptide or may be derivatized to bind to a stable resin as a tethered substrate for affinity chromatography applications. These and other uses which characterize commercial aspartyl protease inhibitors will be evident to those of ordinary skill in the art.
As used herein, the compounds according to the invention are defined to include pharmaceutically acceptable derivatives or prodrugs thereof. A "pharmaceutically acceptable derivative" or "pharmaceutically acceptable prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
The compounds according to the invention may be used in the form of salts derived from inorganic or organic acids. Included among such acid salts, for example, are the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectianate, persulfate, phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate . Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g., magnesium), ammonium and TNW4 (wherein W is Cι_4 alkyl) .
Physiologically acceptable salts of a hydrogen atom or an amino group include salts or organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p- toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as Na , NH4 , and NW4 (wherein W is a C:-4 alkyl group) .
Pharmaceutically acceptable salts include salts of organic carboxylic acids such as ascorbic, acetic, citric, lactic, tartaric, malic, maleic, isothionic, lactobionic, p- aminobenzoic and succinic acids; organic sulphonic acids such as methanesulphonic, ethanesulphonic, benzenesulphonic and p-toluenesulphonic acids and inorganic acids such as hydrochloric, sulphuric, phosphoric, sulphamic and pyrophosphoric acids. For therapeutic use, salts of the compounds according to the invention will be pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
Preferred salts include salts formed from hydrochloric, sulfuric, acetic, succinic, citric and ascorbic acids .
Preferred esters of the compounds according to the invention are independently selected from the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non- carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl) , aryl (for example, phenyl optionally substituted by, for example, halogen, Cι_4alkyl, or Cι_4alkoxy or amino) ; (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl) ; (3) amino acid esters (for example, L-valyl or L-isoleucyl) ; (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a Ci_20 alcohol or reactive derivative thereof, or by a 2,3-di (C6-24)acyl glycerol.
In such esters, unless otherwise specified, any alkyl moiety present advantageously contains from 1 to 18 carbon atoms, particularly from 1 to 6 carbon atoms, more particularly from 1 to 4 carbon atoms, Any cycloalkyl moiety present in such esters advantageously contains from 3 to 6 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group.
Any reference to any of the above compounds also includes a reference to a pharmaceutically acceptable salts thereof. The compounds according to the invention are especially useful for the treatment of AIDS and related clinical conditions such as AIDS related complex (ARC) , progressive generalized lymphadenopathy (PGL) , Kaposi's sarcoma, thrombocytopenic purpura, AIDS-related neurological conditions such as AIDS dementia complex, multiple sclerosis or tropical paraperesis, and also anti-HIV antibody-positive and HIV-positive conditions, including such conditions in asymptomatic patients. In a further aspect of the invention there are provided the compounds according to the invention for use in medical therapy particularly for the treatment or prophylaxis of viral infections such as HIV infections.
According to another aspect, the present invention provides a method for the treatment or prevention of the symptoms or effects of a viral infection in an infected animal, for example, a mammal including a human, which comprises treating said animal with a therapeutically effective amount of a compound according to the invention. According to a particular embodiment of this aspect of the invention, the viral infection is an HIV infection. A further aspect of the invention includes a method for the treatment or prevention of the symptoms or effects of an HBV infection. The compounds according to the invention may also be used in adjuvant therapy in the treatment of HIV infections or HIV-associated symptoms or effects, for example Kaposi's sarcoma.
The present invention further provides a method for the treatment of a clinical condition in an animal, for example, a mammal including a human which clinical condition includes those which have been discussed in the introduction hereinbefore, which comprises treating said animal with a therapeutically effective amount of a compound according to the invention. The present invention also includes a method for the treatment or prophylaxis of any of the aforementioned infections or conditions.
In yet a further aspect, the present invention provides the use of a compound according to the invention in the manufacture of a medicament for the treatment or prophylaxis of any of the above mentioned viral infections or conditions. It will be appreciated that of compounds of Formlula (I), (II), (III), (IV), and (V) and one or more other HIV protease inhibitors, reverse transcriptase inhibitors, or non-nucleoside reverse transcriptase inhibitors may be used in the manufacture of the above medicament .
Reference herein to treatment extends to prophylaxis as well as the treatment of established infections or symptoms.
The above compounds according to the invention and their pharmaceutically acceptable derivatives may be employed in combination with other therapeutic agents for the treatment of the above infections or conditions.
Combination therapies according to the present invention comprise the administration of at least one compound of the formula (I) or a pharmaceutically acceptable derivative thereof and at least one other pharmaceutically active ingredient. The active ingredient (s) and pharmaceutically active agents may be administered simultaneously in either the same or different pharmaceutical formulations or sequentially in any order. The amounts of the active ingredient (s) and pharmacuetically active agent (s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect. Preferably the combination therapy involves the administration of one compound according to the invention and one of the agents mentioned herein below. Examples of such further therapeutic agents include agents that are effective for the treatment of viral infections or associated conditions such as (1 alpha, 2 beta, 3 alpha) -9- [2, 3-bis (hydroxymethyl) cyclobutyl] guanine [(-)BHCG, SQ-34514], oxetanocin-G (3, 4-bis- (hydroxymethyl) - 2-oxetanosyl] guanine) , acyclic nucleosides (e.g. acyclovir, valaciclovir, famciclovir, ganciclovir, penciclovir) , acyclic nucleoside phosphonates (e.g. (S) -1- (3-hydroxy-2- phosphonyl-methoxypropyl) cytosine (HPMPC) , ribonucleotide reductase inhibitors such as 2-acetylpyridine 5-[(2- chloroanilino) thiocarbonyl) thiocarbonohydrazone, 3'azido- 3' -deoxythymidine, hydroxyurea, other 2', 3'- dideoxynucleosides such as 2' , 3' -dideoxycytidine, 2', 3'- dideoxyadenosine, 2' , 3' -dideoxyinosine, 2', 3'- didehydrothymidine, protease inhibitors such as agenerase, indinavir, ritonavir, nelfinavir, [3S- [3R* (IR*, 2S*)]]- [3 [ [ (4-aminophenyl) sulfonyl] (2-methylpropyl) amino] -2- hydroxy-1- (phenylmethyl) propyl] -tetrahydro-3-furanyl ester (141W94), oxathiolane nucleoside analogues such as (-)-cis- 1- (2-hydroxymethyl) -1, 3-oxathiolane 5-yl) -cytosine
(lamivudine) or cis-1- (2- (hydroxymethyl) -1, 3-oxathiolan-5- yl) -5-fluorocytosine (FTC), 3' -deoxy-3' -fluorothymidine, 5- chloro-2' , 3' -dideoxy-3' -fluorouridine, (-) -cis-4- [2-amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopentene-l-methanol, ribavirin, 9- [4-hydroxy-2- (hydroxymethyl) but-l-yl] -guanine (H2G) , tat inhibitors such as 7-chloro-5- (2-pyrryl) -3H-1, 4- benzodiazepin-2- (H) one (Ro5-3335) , 7-chloro-l, 3-dihydro-5- (lH-pyrrol-2yl) -3H-1, -benzodiazepin-2-amine (Ro24-7429) , interferons such as α-interferon, renal excretion inhibitors such as probenecid, nucleoside transport inhibitors such as dipyridamole; pentoxifylline, N-acetylcysteine (NAC) , Procysteine, α-trichosanthin, phosphonoformic acid, as well as immunomodulators such as interleukin II or thymosin, granulocyte macrophage colony stimulating factors, erythropoetin, soluble CD4 and genetically engineered derivatives thereof, or non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as nevirapine (BI-RG-587), loviride (α -APA) and delavuridine (BHAP) , and phosphonoformic acid, and 1, 4-dihydro-2H-3, l-benzoxazin-2-ones NNRTIs such as (-)- 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1, 4-dihydro- 2H-3,l-benzoxazin-2-one (L-743,726 or DMP-266), and quinoxaline NNRTIs such as isopropyl (2S) -7-fluoro-3, 4- dihydro-2-ethyl-3-oxo-l (2H) -quinoxalinecarboxylate (HBY1293) .
More preferably the combination therapy involves the administration of one of the above mentioned agents and a compound within one of the preferred or particularly preferred sub-groups within formula (I) as described above. Most preferably the combination therapy involves the joint use of one of the above named agents together with one of the compounds of formula (I) specifically named herein.
The present invention further includes the use of a compound according to the invention in the manufacture of a medicament for simultaneous or sequential administration with at least one other therapeutic agent, such as those defined hereinbefore.
In order that this invention may be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way. EXAMPLES
General Methods and Conditions
All temperatures are recorded in degrees Celsius. Thin layer chromatography (TLC) was carried out using 0.25 mm thick E. Merck silica gel 60 F254 plates and elution with the indicated solvent system. Detection of the compounds was carried out by treating the plate with an appropriate visualizing agent, such as 10% solution of phosphomolybdic acid in ethanol or a 0.1% solution of ninhydrin in ethanol, followed by heating, and/or by exposure to UV light or iodine vapors when appropriate. Thick layer silica gel chromatography was also carried out using E. Merck 60 F254 plates ("prep plates") of 0.5, 1.0, or 2.0 mm thickness. Following development of the plate, the band of silica containing the desired compound was isolated and eluted with an appropriate solvent. Analytical HPLC was carried out using a Water's Delta Pak, 5 μM silica, C18 reversed-phase column, 3.9 mm ID x 15 cm L with a flow rate of 1.5 mL/min using the following table:
Mobile phase: A = 0.1% CF3C02H in H20
B = 0.1% CF3C02H in CH3CN Gradient: T = 0 min., A (95%), B (5%) T = 20 min., A (0%), B (100%)
T = 22.5 min., A (0%), B (100%)
Preparative HPLC was also carried out using Ci8 reversed- phase media. HPLC retention times were recorded in minutes. NMR spectral data was recorded using a Bruker AMX500, equipped with either a reverse or QNP probe, at 500 MHz, and was taken in the indicated solvent.
We have measured the inhibition constants of each compound against HIV-1 protease using the method described essentially by M.W. Pennington et al., Peptides 1990, Gimet, E. and D. Andrew, Eds., Escom, Leiden, Netherlands (1990); and the method described essentially by Partaledis et al . , J. Virol., 69, pp. 5228-35 (1995) . Compounds of invention were tested for their antiviral potency in several virological assays.
Insofar as the compounds of this invention are able to inhibit the replication of the HIV virus in CD cells of human lineage, they are of evident clinical utility for the treatment of HIV infection. These tests are predictive of the compounds ability to inhibit HIV protease in vivo .
Example 1
Figure imgf000069_0001
N1-isopropoxγ-3-nitro-l-benzenesulfonamide. To a cooled solution (0°C) of O-isopropyl hydroxyphthalimide (4.10 g, 0.02 mol) in anhydrous THF (45 mL) was added anhydrous hydrazine (0.69 mL, 0.022 mmol) with stirring. The solution was allowed to warm to RT and stir for 20. Oh, filtered and the ppt . was washed with anhydrous THF (20 mL) . To the filtrate was added 3-nitro-benzenesulfonylchloride (4.86 g, 0.022 mol) and diiosopropylethylamine (4.17 mL, 0.024 mol) at RT and the mixture was stirred at RT for 20h. The solution was evaporated and the reside was partioned between ethyl acetate (200 mL) and Aq. 1. ON HCl (30 mL) . The organic layer was washed with 1. ON HCl (2 x 50 L) , 5% Aq. NaHC03 (2 x 50 L) , brine (2 x 25 mL) , dried (MgS04), filtered, and evaporated to give a yellow oil. The oil was purified by column chromatography: hexane/ethyl acetate (80/20) to give 3.58g (69%) of the product as a white solid. lH NMR (CDC13) : 1.20 (d,6H); 4.27 (m, IH) ; 7.05(s,lH); 7.75(1, IH); 8.22 (d,lH); 8.48 (dd, IH) ; 8.74(t, IH) .
Step 2 -o-
Figure imgf000070_0001
3-amino-N1-isopropoxy-l-benzenesulfon.ιmide. To a Parr H2 vessel containing 5% Pd/BaS04 (0.350g) was added a methanolic solution (125 mL) of N1-isopropoxy-3-nitro-l- benzenesulfonamide (3.50 g, 0.0135 mol) at rt under Ar atm.
The solution was hydrogenated at 45psi for approx. 1.0 h.
The reaction mixtire was filtered (1/2" celite pad) and evaporated to give the product as yellow crystalline solid
2.90 g (96%) . 2H NMR (CDC13) 1.20 (d, 25H) ; 4.27(m,lH) ;
7.05(s,lH) ; 7.75(1,1H) ; 8.22 (d,lH) ; 8.48 (dd, IH) ; 8.74(t,
IH) .
Step 3
Figure imgf000070_0002
tert-butyl-N-(lS,2R) -3- [ [ (3-aminophenyl) sulfonyl] (isopropoxy) amino] -1-benzyl-2-hydroxypropylcarbamate. To a solution of 3-amino-N1-isopropoxy-l-benzenesulfonamide (2.20 g, 9.56 mmol) and tert-butyl N- (IS) -1- [ (2S) oxiran-2-yl] -2- phenylethylcarbamate (2.01 g, 7.65 mmol) in anhydrous THF (10.0 mL) was added phosphazene base P4 t-butyl solution (1.0 M in hexanes, 1.53 mL, 1.53 mmol) with stirring at rt . After 8. Oh at rt, the THF was evaporated to give a dark yellow residue that was dissloved in ethyl acetate (200 L) . This solution was washed with 0.50M HCl (3 x 20.0 mL) , sat. ΝaHC03 (3 x 20 mL) , brine (2 x 25 mL) , dried (MgS04), filtered, and evaporated to give a yellow foam. The crude product was purified by column chromatography: methylene chloride/ethyl acetate (95/5) to give the product as a light yellow foam (3.61g, 95%). MS: product: M+Na = 516 -*H NMR (CD30D) 0.90 (m, 15H); 2.50-3.10 (m, 4H) ; 3.60-3.85 ( , 2H) ; 4.70(m, IH) ; 6.90(d, IH) ; 7.05(d, IH) ; 7.10-7.30 ( , 6H) .
Example 2
Figure imgf000071_0001
4-amino-N1-isopropoxy-3-nitro-l-benzenesulfonamide.
Prepared using the procedure outlined in Example 1. The crude product was purified by column chromatography: 60/40 hexane/ethyl acetate to give the product as a yellow solid (63%). XH NMR (DMSO) 1.05(d, 6H) ; 4.00 ( , IH) ; 7.10(d, IH) ; 7.65(d, IH) ; 8.10(s, 2H) ; 8.40(s, IH) .
Step 2:
Figure imgf000072_0001
3 , -diamino-N1-isopropoxy-l-benzenesulfonamide . Prepared using the procedure outlined in Step 2, Example 1. XH NMR (DMSO) 1.05 (d, 6H) ; 3.95 (m, IH) ; 4.80(s,2H); 5.30 (s, 2H) ; 6.50(d, IH) ; 6.92(d, IH) ; 7.97(s, IH) ; 9.50(s, IH) .
Step 3
Figure imgf000072_0002
(2)
tert-b tyl-N- (1S,2R)-1-benzyl-3-[ [ (3,4- diaminophenyl) sulfonyl] (isopropoxy) amino] -2- hydroxypropylcarbamate. Prepared using the procedure outlined in Step 3, Example 1. The product was purified by column chromatography: to 40/60 hexane/ethyl acetate give the product as a dark orange solid (91%) . MS: M+Na = 531 **H NMR (CD3OD) 0.90(m, 15H) ; 2.50-3.10 (m, 4H) ; 3.60-3.85 (m, 2H) ; 4.45(m, IH) ; 6.40(d, IH) ; 6.70(d, IH) ; 7.00-7.30(m, 6H) . Example 3
Figure imgf000073_0001
( 3 )
tert-butyl-N-(lS,2R)-3-[ (1H-1 , 3-benzimidazol-5- ylsulfonyl) (isopropoxy) amino] -l-benzyl-2- hydroxypropylcarbamate. To a solution of tert-butyl N- ( 1 S, 2R) -l-benzyl-3- [ [ (3, 4-diaminophenyl) sulfonyl] (isopropoxy) amino] -2-hydroxy propylcarbamate (0.70 g, 1.38 mmol) in ethanol (10 mL) was added triethylorthoformate ( 0.64 mL, 3.86 mmol) and TFA (5.0 μl) with stirring at rt . After l.Oh., the reaction was neutralized with Aq. sat. ΝaHC03 (50 μl) and evaporated to give an orange residue. The residue was dissolved in ethyl acetate (100 mL) and washed with aq. sat. NaHC03 (1 x 20 mL) , water (2 x 20 mL) , brine (1 x 20 mL) , dried (MgS04) , filtered, and evaporated to give the crude product as a orange foam. The crude product was purified by column chromatography: 30/70 hexane/ethyl acetate give the product as a white solid (0.60g, 85%%). MS: M+H - 519 αH NMR (CD3OD) 1.00-1.40 (m, 15H) ; 2.50-3.10 (m, 4H) ; 3.60-3.85(m, 2H) ; 4.60 (m, IH) ; 7.20 (m, 5H) ; 7.80(s, 2H) 8.20(s, IH) ; 8.40(s, IH) . Example 4
Figure imgf000074_0001
( 4 )
tert-butyl-N- ( (1S,2R) -l-benzyl-2-hydroxy-3-isopropoxy [ (2- oxo-2 ,3-dihydro-lH-l , 3-benzimidazol-5- yl) sulfonyl ] aminopropyl) carbamate. To a solution of tert- butyl N- (IS, 2i) -l-benzyl-3- [ [ (3, 4-diaminophenyl) sulfonyl] (isopropoxy) amino] -2-hydroxypropyl carbamate (0.70 g, 1.38 mmol) and DIEA (0.24 mL, 1.38 mmol) in anhydrous THF (10 mL) was added triphosgene (0.136 g, 0.46 mmol) with stirring at rt . After 0.5h., the THF was removed in vacuo and the residue was dissolved in ethyl acetate (100 mL) . This solution was washed with 0.5M HCl (2 x 25 L) , aq. sat. NaHC03 (2 x 25 mL) , brine (1 x25 mL) , dried (MgS04), filtered and evaporated to give the crude product. The crude product was purified by column chromatography: 30/70 hexane/ethyl acetate give the product as a yellow solid (0.63g, 86%) MS: M+Na = 557 :H NMR (CD3OD) 1.00-1.40 (m, 15H) ; 2.50- 3.10(m, 4H) ; 3.60-3.85(m, 2H) ; 4.55 ( , IH) ; 7.20 (m, 6H) ; 7.50 (m, 2H) .
Example 5 Step 1:
Figure imgf000074_0002
N-methanesulfonyl-2-aminobenzimidazole. 2-amino- benzimidazole (1.0 g, 7.5 mmol) was dissolved in 15 mL of anhydrous CH2CI2 and 3 mL anhydrous DMF and cooled to ~ 0°C. Trethylamine (1.6 mL, 1.5 eq.) was added followed by an addition of methanesulfonylchloride (580 μL, 7.5 mmol) over
~ 1 minute. After 1 minute at ~ 0°C, the reaction was warmed to RT . After 1 hour the reaction was quenched with water, and partitioned between a saturated sodium bicarbonate solution and CH2CI2. The aqueous layer was extracted with CH2CI2 and the combined organic layers were washed with water (2 times), brine then dried over NaSθ4, filtered and the solvent was removed in vacuo to give 455 mg of N-methanesulfonyl-2-aminobenzimidazole. HPLC shows the material to be 91% pure, (ret. time = 3.70). LCMS : obs . M+H@ 212.1 amu. The material was carried on without purification.
Step 2:
Figure imgf000075_0001
N-methanesulfonyl-5-chlorosulfonyl-2-aminobenzimidazole. To
9.5 mL (20 eq., 142 mmol) of well stirred chlorosulfonic acid at ~25°C was added N-methanesulfonyl-2- aminobenzimidazole (1.5 g, 7.1 mmol) in small portions over 10 minutes with slight exotherming. The solution was stirred at ~25°C for 3.5 hours, then was added dropwise to a well stirred mixture of ice and water. The aqueous solution was slowly basified to pH ~ 7.5 with solid sodium bicarbonate and extracted with EtOAc. A precipitate formed in the organic phase which was filtered off and was washed with H20 and dried on the filter to yield 1.23 g of N- methanesulfonyl-5-chlorosulfonyl-2-aminobenzimidazole . HPLC, single peak, ret. time = 7.61 min. MS: Obs . M + H @ 310.0 amu .
Step 3:
Figure imgf000076_0001
tert-Butyl-N- ( ( 1S, 2R) -l-benzyl-3- (isopropyloxy) (2- [ (methylsulfonyl) amino]benzimidazol-5-ylsulfonyl) amino-2- hydroxypropyl) carbamate. tert-Butyl-N- ( ( IS, 2R) -l-benzyl-3- ( isopropyloxy) amino-2-hydroxypropyl) carbamate (86 mg, 0.25 mmol) was combined with 2- [ (methylsulfonyl) amino] benzimidazol-5-ylsulfonyl chloride (77 mg, 0.25 mmol) in anhydrous pyridine (1 ml) with a catalytic amount of N,N- dimethylaminopyridine. The reaction was stirred at room temperature overnight. The solvent was evaporated under vacuum. The crude mixture was diluted in EtOAc and washed with water and brine. Organic phase was dried with MgS04 and solvent was removed in vacuo . Purification by TLC prep (2% Me0H/CH2Cl2) . Recovered 56 mg (37%) of product as a white solid. HPLC showed the material to be 98% pure; Ret. time = 9.87 min. λE NMR (CDCI3) : 7.12-8.04 (m, 8H) , 6.5 (m, IH) , 4.47-4.51 ( , 2H) , 3.68 (m, 2H) , 3.22 (s, 3H) , 2.81- 2.88 (m, 3H) , 1.75 (m, 2H) , 1.22 (s, 9H) , 1.16 (d, 6H) . MS (ES+) : obs. M+H @ 612.1 amu. Example 6
Step 1
Figure imgf000077_0001
N1- (isopropoxy) -4-methoxy-l-benzenesulfonamide. A vigorously stirred solution of 2-isopropoxy-liY-isoindole-l, 3 [ 2H) -dione [2.50 g, 12.2 mmol, Synth. Comm., 22(10), 1427-1432 (1992)] in 35 mL of tetrahydrofuran under an Argon atmosphere at ambient temperature was treated with anhydrous hydrazine (0.421 mL, 13.41 mmol). After 1.5 hours, 4- methoxybenzenesulphonyl chloride (3.024 g, 14.63 mmol), dichloromethane (20 mL) and N,N-diisopropylethylamine (6.38 mL, 36.6 mmol) was added with continued stirring. After an additional 2 hours at ambient temperature, the reaction mixture was evaporated in vacuo to a residue and partitioned between ethyl acetate and IN hydrochloric acid. The layers were separated and the aqueous layer was extracted again with ethyl acetate. The combined organic layers were washed with 5% w/v potassium carbonate and brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified on flash grade silica gel eluting with 30% ethyl acetate in hexane. Fractions containing the product were combined, evaporated in vacuo, and dried under high vacuum to provide N1- (isopropoxy) -4-methoxy-l-benzenesulfonamide (2.061 g, 69%) as a white solid. Hl-NMR (chloroform-D3) : 1.22 (d, 6H) , 3.92 (s, 3H) , 4.27 (m, IH) , 6.70 (s, IH) , 7.05 (d, 2H) , 7.90 (d, 2H) . MS(ESI): 268 (M+Na) .
Step 2:
Figure imgf000078_0001
tert-butyl N- ( (IS,21?) -1-benzyl-3- (cyclopentyloxy) [ (4- methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate. A solution of N- (isopropoxy) -4-methoxy-l-benzenesulfonamide (0.147 g, 0.599 mmol) and tert-butyl N- ( IS) -1- [ (2S) oxiran-2- yl] -2-phenylethylcarbamate (75 mg, 0.285 mmol) in anhydrous tetrahydrofuran (1 mL) under an Argon atmosphere was treated with phosphazene base P<t/4>t-Bu (0.285 ml 0.285 mmol, 1.0 M in hexane) . After stirring for 30 minutes at ambient temperature, the reaction mixture was quenched with several drops of glacial acetic acid and evaporated in vacuo to a residue. The crude product was purified on a preparative TLC plate (20x20, 500 μM) eluting with 35:65 ethyl acetate : hexane. The product band was removed, eluted with ethyl acetate, and evaporated in vacuo to a residue. The crude product was purified again on a preparative TLC plate
(20x20, 1000 μM) eluting with 4:1 dichloromethane : ethyl acetate. The product band was removed, eluted with ethyl acetate, and evaporated in vacuo . The residue was triturated with water and the resulting slurry was stirred overnight, filtered, and dried under high vacuum to provide tert-butyl N- (( IS, 2R) -l-benzyl-3- (cyclopentyloxy) [(4- methoxyphenyl) sulfonyl] amino-2-hydroxypropyl ) carbamate (87 mg, 60%) as a white solid. Hl-ΝMR (methanol-D4 ) : 1.22 (s, 9H) , 1.24 (d, 6H) , 2.52 ( , 2H) , 3.07 (m, 2H) , 3.68 (m, 2H) , 3.87 (s, 3H) , 4.50 (m, IH) , 7.08 (m, 2H) , 7.19 (m, 5H) , 7.75 (m, 2H) . MS (ESI): 531 (M+Na) .
Example 7
Step 1:
Figure imgf000079_0001
2- (cyclopentyloxy) -lH-isoindole-1 ,3 (2H) -dione. A mixture of N-hydroxypthalimide (lO.OOg, 61.3 mmol), cyclopentylbromide (8.21 mL, 76.63 mmol), and 1, 8-diazabicyclo [5.4.0] ndec-7- ene (13.75 L, 76.6 mmol) were combined under an Argon atmosphere in dimethylformamide (50 mL) . The mixture was heated to 55°C and stirred vigorously for 1.5 hours. After cooling to ambient temperature, the solvent was removed in vacuo and the residue was partitioned between ethyl acetate and IN hydrochloric acid. After separating the phases, the aqueous layer was extracted again with ethyl acetate. The combined organic layers were washed with 5% w/v potassium carbonate, saturated aqueous brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was triturated with hexane, filtered, and dried under high vacuum to provide 2- (cyclopentyloxy) - 1H- isoindole-1,3 ( 2H) -dione (11.37 g, 80%). Hl-NMR (chloroform- D3) : 1.61 (m, 2H) , 1.77 ( , 2H) , 1.97 (m, 4H) , 4.91 (m, IH) , 7.73 ( , 2H) , 7.82 (m, 2H) . MS(ESI): 254 (M+Na).
Step 2:
Figure imgf000080_0001
N1- (cyclopentyloxy) -4-methoxy-l-benzenesulfonamide. A mixture of 2- (cyclopentyloxy) -lH-isoindole-1, 3 {2H) -dione (3.00 g, 12.99 mmol) in anhydrous tetrahydrofuran (15 mL) at ambient temperature under an Argon atmosphere was treated with anhydrous hydrazine (0.448 mL, 14.29 mmol). After stirring vigorously for 1.5 hours, the resulting slurry was filtered and washed with approximately 15 mL of anhydrous tetrahydrofuran. The filtrate was combined with 4- methoxybenzenesulphonyl chloride (2.95 g, 14.29 mmol) and N,N-diisopropylethylamine (2.72 mL, 15.6 mmol). After stirring at ambient temperature for approximately 18 hours, the reaction mixture was evaporated in vacuo to a residue and partitioned between ethyl acetate and IN hydrochloric acid. The layers were separated and the organic phase was extracted again with ethyl acetate. The combined organic layers were washed with 5% w/v potassium carbonate and brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified on flash grade silica gel eluting with 15:85 ethyl acetate : hexane. Fractions containing the product were combined, evaporated in vacuo, and dried under high vacuum to provide N- (cyclopentyloxy) -4-methoxy-l- benzenesulfonamide (2.771 g, 79%) as an oil. Hl-ΝMR
(chloroform-D3) : 1.61 (m, 8H) , 3.87 (s, 3H) , 4.57 ( , IH) , 6.67 (s, IH) , 6.99 (m, 2H) , 7.83 (m, 2H) . MS(ESI): 294 (M+Νa) .
Step 3:
Figure imgf000081_0001
(7) tert-butyl N- ( ( 1S, 2R) -l-benzyl-3- (cyclopentyloxy) [ (4- methoxyphenyl ) sulfonyl] amino-2-hydroxypropyl) carbamate. A solution of N- (cyclopentyloxy) -4-methoxy-l- benzenesulfonamide (1.005 g, 3.71 mmol) and tert-butyl N- (lS)-l-[ (2S)oxiran-2-yl]-2-phenylethylcarbamate (0.780 g,
2.97 mmol) in anhydrous tetrahydrofuran (5 L) under an Argon atmosphere was treated with phosphazene base P<t/4>t- Bu (0.593 L, 0.593 mmol, 1.0 M in hexane) . The mixture was stirred at ambient temperature for 2.5 hours and then quenched with several drops of glacial acetic acid. The solution was evaporated in vacuo to a residue and partitioned between ethyl acetate and IN hydrochloric acid. After separating the phases, the aqueous layer was extracted with ethyl acetate. The combined ethyl acetate layers were washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was purified on flash grade silica gel eluting with 9:1 hexane ethyl acetate (0.5 L) , 85:15 hexane ethyl acetate (0.5 L) , and finally 4:1 hexane ethyl acetate (1.5 L) . Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide tert-butyl N- ( (IS, 2R) -l-benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate (1.418 g, 89%) as a foam. Hl-ΝMR (chloroform-D3) : 1.38 (s, 9H) , 1.70 (m, 8H) ,
2.98 ( , 4H) , 3.85 (bm, 2H) , 3.92 (s, 3H) , 4.61 (bs, IH) , 4.85 (m, IH) , 7.02 (m, 2H) , 7.29 (m, 5H) , 7.76 ( , 2H) . MS (ESI) : 535 (MH+) .
Example 8
Step 1:
Figure imgf000082_0001
Tert-butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2- [ (methoxycarbonyl) amino] -lH-benzimidazol-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate. Tert-butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) amino] -2- hydroxypropylcarbamate (Step 1, Example 54) (1.73 g, 4.75 mmol), methyl N- [5- (chlorosulfonyl) -lH-benzimidazol-2- yl] carbamate (1.37g, 4.75 mmol), anhydrous diisopropylethylamine (0.83 mL, 4.75 mmol), and N,N- dimethylaminopyridine (170 mg, 1.42 mmol) were combined in anhydrous tetrahydrofuran (15 mL) and anhydrous N,N- dimethylformamide (8 mL) in a 50 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the product was isolated as a white foam (2.56 g, 4.14 mmol) and used directly without further purification. **H NMR (d6-DMS0) δ: 7.60-6.64 (m, 9H) , 5.11 (d, J=6.1 Hz, IH) , 4.83 (bs, IH) , 3.81 (s, 3H) , 3.54-1.42 (m, 14H) , 1.15 (s, 9H) . MS(ES): 618 (M+l), 616 (M-l).
Step 2:
Figure imgf000083_0001
Tert-butyl N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) (2-amino- lH-benzimidazol-5-ylsulfonyl) amino] -2- hydroxypropylcarbamate. Tert-butyl N- (IS, 2R) -l-benzyl-3- [(cyclopentyloxy) (2- [ (methoxycarbonyl) amino] -1H- benzimidazol-5-ylsulfonyl) amino] -2-hydroxypropylcarbamate (Step 1, above) (2.52 g, 4.08 mmol) and lithium iodide hydrate (2.60 g, 19.4 mmol) were dissolved in pyridine (15 mL) in a 50 L round bottomed flask and heated at 100°C for 8 hours. The reaction was allowed to cool and then concentrated in vacuo. After the workup described in Step 3, Example 54, the product was purified by silica gel flash chromatography using a gradient elution of chloroform: methanol: water (90:10:0 to 10:3:0.5) to yield a beige powder (1.75 g, 3.13 mmol, 77%). lE NMR (d6-DMS0) δ: 7.50- 6.64 (m, 9H) , 5.07 (d, J=6.0 Hz, IH) , 4.80 (bs, IH) , 3.56- 1.40 (m, 16H), 1.18 (s, 9H) . MS(ES): 560 (M+l), 558 (M-l).
Step 3:
Figure imgf000083_0002
Tert-butyl N- (IS,2R) -l-benzyl-3- [ (cyclopentyloxy) (2- [ (N- morpholinocarbonyl) -amino] -lH-benzimidazol-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate. Tert-butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2-amino-lH- benzimidazol-5-ylsulfonyl) amino] -2-hydroxypropylcarbamate
(Step 2, above) (300 mg, 0.536 mmol), 4-morpholine carbonyl chloride (0.08 mL, 0.643 mmol), and anhydrous diisopropylethylamine (0.11 L, 0.643 mmol), were combined in anhydrous tetrahydrofuran (8 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was refluxed for 18 hours, allowed to cool, and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using
90:10 chloroform: methanol as an eluent to give the product as a beige solid (70 mg, 0.104 mmol, 20%). lE NMR (d6-DMS0) δ: 7.54-6.65 (m, 8H) , 5.11 (d, J=6.0 Hz, IH) , 4.81 (bs, IH) , 3.82-1.40 (m, 23H) , 1.17 (s, 9H) . MS(ES): 673 (M+l), 671 (M-l) .
Example 9
Figure imgf000084_0001
Prepartion of tert-butyl N- [ ( IS, 2R) -l-benzyl-4- (cyclopentyloxy) -2-hydroxy-4- (6- quinoxalinylsulfonyl) butyl] carbamate. A mixture of tert- butyl N- ( (IS, 2R) -l-benzyl-3- (cyclopentyloxy) [ (3, 4- diaminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate (Example 10), (750 mg, 1.41 mmol) and 1 , 5-dioxane-2, 3-diol (219 mg, 1.83 mmol) were combined under Argon in absolute ethanol (3 mL) at ambient temperature. After stirring for approximately 11 days, the reaction was evaporated in vacuo and the residue was purified on flash grade silica gel eluting with ethyl acetate : hexane (1:1). Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide tert-butyl N- [ (IS, 2R) -l-benzyl-4- (cyclopentyloxy) -2-hydroxy-4- (6- quinoxalinylsulfonyl) butyl] carbamate as a yellow foam (696 mg, 89%). An analytical sample was prepared by purification of 75 mg on a preparative TLC plate (20X20 cm, 1000 μM) eluting with 95:5 dichloromethane : methanol. The product band was removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was triturated with water and filtered to provide tert-butyl N- [ (IS, 2R) -l-benzyl-4- (cyclopentyloxy) -2-hydroxy-4- (6- quinoxalinylsulfonyl) butyl] carbamate as a white solid. Hl- ΝMR (dimethylsulfoxide-D6) : 1.05 (s, 9H) , 1.74 ( , 8H) , 2.47 (m, IH) , 2.73 (m, IH) , 3.07 (m, 2H) , 3.55 (m, 2H) , 4.90 (m, IH) , 5.24 ( , b, IH) , 6.68 (d, IH) , 7.19 (m, 5H) , 8.15 (m, IH) , 8.39 (m, IH) , 8.49 (s, IH) , 9.18 (m, 2H) . MS(ESI): 579(M+Νa) .
Example 10
Step 1
Figure imgf000085_0001
o-nitroaniline-p-sulfonyl chloride. A mixure of o- nitroaniline-p-sulfonic acid sodium salt (25.00 g, 104 mmol; and phosphoryl chloride (75 mL, 804 mmol) under Argon was heated to reflux and vigorously stirred for 4 hours. After cooling to ambient temperature, the reaction mixture was carefully added to a large excess of ice. The resulting slurry was stirred for 15 min., filtered and dried under vacuum to provide o-nitroaniline-p-sulfonyl chloride (21.43 g, 87%) as a yellow solid. Hl-NMR (dimethylsulfoxide-D6) : 5.8 (b, 2H) , 6.97 (d, IH, J = 8.8), 7.57 (m, IH) , 8.18 (d, IH, J = 2.0) .
Step 2:
Figure imgf000086_0001
4 -amino-N- (cyclopentyloxy) -3-nitrobenzenesul onamide. A solution of 2- (cyclopentyloxy) -liϊ-isoindole-1, 3 ( 2H) -dione
(10.00 g, 43.30 mmol) in anhydrous tetrahydrofuran (100 mL) at ambient temperature under an Argon atmosphere was treated with anhydrous hydrazine (1.49 mL, 47.63 mmol). After stirring vigorously for 2.5 hours, the resulting slurry was filtered and washed with approximately 20 mL of anhydrous tetrahydrofuran. The filtrate was combined with o- nitroaniline-p-sulfonyl chloride (11.26 g, 47.63 mmol) and N,N-diisopropylethylamine (9.05 mL, 51.96 mmol) and stirred under an Argon atmosphere for 16 hrs. at ambient temperature. The reaction mixture was diluted with IN
NaHS0 and dichloromethane and transferred to a separatory funnel. The organic phase was separated and the aqueous layer was extracted twice with dichloromethane. The combined organic layers were washed with 5% aqueous potassium carbonate, dried over anhydrous magnesium sulfate, filtered through a pad of diatomaceous earth and evaporated in vacuo . The residue was purified on flash grade silica gel eluting with 1:1 ethyl acetate : hexane. Fractions containing the product were combined, evaporated in vacuo to a residue and triturated with hexane. The slurry was filtered and the product was dried under high vacuum to provide 4-amino-N- (cyclopentyloxy) -3-nitrobenzenesulfonamide (8.89 g, 68%) as a yellow solid. Hl-ΝMR (chloroform-D3) :
1.57 (m, 4H) , 1.74 (m, 4H) , 4.61 (m, IH) , 6.52 (b, 2H) , 6.73 (s, IH) , 6.90 (d, IH) , 7.79 ( , IH) , 8.70 (d, IH) . MS(ESI): 324 (M+Νa) .
Step 3:
Figure imgf000087_0001
3,4-dιamino-Ν- (cyclopentyloxy) benzenesulfonamide. A solution of 4-amino-N- (cyclopentyloxy) -3- nitrobenzenesulfonamide (4.50 g, 14.95 mmol) in 1 : 1 ethyl acetate : ethanol (150 mL) was combined with 5% Pd on barium sulfate and reduced under a hydrogen atmosphere over 72 hours. The reaction mixture was filtered through a pad of diatomaceous earth and evaporated in vacuo to a residue which crystallized on standing. The solid was slurried in hexane, filtered and dried under high vacuum to provide 3,4- diamino-N- (cyclopentyloxy) benzenesulfonamide (4.086 g, 100%) as a light brown solid Hl-NMR (dimethylsulfoxide-D6) : 1.61 (m, 8H) , 4.37 (m, IH) , 4.90 (b, 2H) , 5.38 (b, 2H) , 6.57 (d, IH) , 6.88 ( , IH) , 6.96 (d, IH) , 9.64 (s, IH) . . MS(ESI): 272 (M+H) . Step 4:
Figure imgf000088_0001
( 1 0 )
tert-butyl N- ( (IS,22?) -l-benzyl-3- (cyclopentyloxy) [(3,4- diaminophenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate. A solution of 3, 4-diamino-N- (cyclopentyloxy) benzenesulfonamide (2.00 g, 7.38 mmol) and tert-butyl N- (IS) -1- [ (2S) oxiran-2- yl] -2-phenylethylcarbamate (1.553 g, 5.90 mmol) in anhydrous tetrahydrofuran (10 mL) under an Argon atmosphere was treated with phosphazene base P<t/4>t-Bu (1.2 mL, 1.2 mmol, 1.0 M in hexane). After stirring at ambient temperature for approximately 18 hours, the reaction mixture was quenched with several drops of glacial acetic acid and evaporated in vacuo . The residue was partitioned between ethyl acetate and IN aqueous sodium hydrogen sulfate. After separating the layers, the organic phase was washed with 5% w/v aqueous potassium carbonate, brine, dried over anhydrous sodium sulfate and evaporated in vacuo to a residue. The crude product was purified on flash grade silica gel eluting with 3:2 ethyl acetate : hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide tert-butyl N- ( (IS, 2R) -l-benzyl-3- (cyclopentyloxy) [ (3, 4-diaminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (2.553 g, 65%) as a foam. Hl-ΝMR (chloroform-D3) : 1.33 (s, 9H) , 1.53 (m, 4H) , 1.74 ( , 4H) , 2.91 (m, 3H) , 3.04 (m, IH) , 3.61 (b, 4H) , 3.79 (m, 2H) , 4.58 (m, IH) , 4.77 (m, IH) , 6.69 (d, IH) , 7.09 (s, IH) , 7.22 (m, 7H) . MS (ESI) : 535 (M+H) . Example 11
Step 1:
Figure imgf000089_0001
N1- (cyclopentyloxy) -3-nitro-l-benzenesulfonamide . A mixture of 2- (cyclopentyloxy) -lH-isoindole-1, 3 ( 2H) -dione (3.00 g, 12.99 mmol) in anhydrous tetrahydrofuran (25 mL) under an Argon atmosphere was treated with anhydrous hydrazine (0.448 mL, 14.29 mmol). After stirring vigorously for 2.5 hours, the resulting slurry was filtered and washed with approximately 15 mL of anhydrous tetrahydrofuran. The filtrate was combined with 3-nitro-l-benzenesulphonyl chloride (3.17 g, 14.29 mmol) and N,N-diisopropylethylamine (2.72 mL, 15.6 mmol). After stirring at ambient temperature for approximately 18 hours, the reaction mixture was evaporated in vacuo to a residue and partitioned between ethyl acetate and IN hydrochloric acid. The phases were separated and the aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed with 5% w/v potassium carbonate and brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified on flash grade silica gel eluting with 15:85 ethyl acetate : hexane. Fractions containing the product were combined, evaporated in vacuo, and dried under high vacuum to provide N1- (cyclopentyloxy) -3-nitro-l-benzenesulfonamide (3.224 g, 87%) as a solid. Hl-NMR (chloroform-D3) : 1.71 (m, 8H) , 4.71 (m, IH) , 6.93 (bs, IH) , 7.83 (m, IH) , 8.28 (m, IH) , 8.55 ( , IH) , 8.81 (m, IH) .
Step 2:
Figure imgf000090_0001
3-amino-.Nrl- (cyclopentyloxy) -1-benzenesulfonamide. A solution of N1- (cyclopentyloxy) -3-nitro-l-benzenesulfonamide (2.98 g, 10.41 mmol) in 50 mL of absolute ethanol was combined with 5 wt% Palladium on barium sulfate (300 mg) and reduced under a balloon of hydrogen gas with vigorous agitation for 18 hours. The mixture was filtered, washed with ethanol, and evaporated in vacuo to a residue. The crude product was purified on flash grade silica gel eluting with 4:1 hexane : ethyl acetate. Fractions containing the product were combined, evaporated in vacuo and dried under vacuum to provide 3-amino-N1- (cyclopentyloxy) -1- benzenesulfonamide (2.67 g, 100%) as an oil. Hl-ΝMR ■chioroform-D3) : 1.62 (m, 8H) , 3.92 (bs, 2H) , 4.58 (m, IH) , 6.74 (bs, IH) , 6.88 (m, IH) , 7.16 (m, IH) , 7.27 (m, 2H) . MS (ESI) : 257 (MH+) .
Figure imgf000090_0002
11' tert-butyl N-(1S,2R) -3- [ [ (3-aminophenyl) sulfonyl] (cyclopentyl oxy) amino] -1-benzyl-2-hydroxypropylcarbamate .
A solution of 3-amino-N1- (cyclopentyloxy) -1- benzenesulfonamide (2.654 g, 10.36 mmol) and tert-butyl N- (IS) -1- [ (2S)oxiran-2-yl] -2-phenylethylcarbamate (2.181 g, 8.29 mmol) in anhydrous tetrahydrofuran (10 mL) under an Argon atmosphere was treated with phosphazene base P<t/4>t- Bu (1.60 L, 1.60 mmol, 1.0 M in hexane) . After stirring at ambient temperature for approximately 18 hours, the reaction mixture was quenched with several drops of glacial acetic acid and evaporated in vacuo . The residue was partitioned between ethyl acetate and IN ΝaHS04. After separating the phases, the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with saturated aqueous brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude product was purified on flash grade silica gel eluting with 95:5 methylene chloride : ethyl acetate (2L) ; 9:1 methylene chloride : ethyl acetate (2L) ; and finally 1:1 methylene chloride : ethyl acetate. Fractions containing the product were combined, evaporated in vacuo, and dried under high vacuum to provide tert-butyl N- (IS, 2R) -3- [ [ (3- aminophenyl) sulfonyl] (cyclopentyl oxy) amino] -l-benzyl-2- hydroxypropylcarbamate (3.328 g, 77%) as a foam. An analytical sample was obtained by purifying 100 mg on two preparative TLC plate (20x20 cm, 1000 μM, silica gel) eluting with 9:1 methylene chloride : methanol. The product bands were removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue purified again on a preparative TLC plate (20x20 cm, 1000 μM, silica gel) eluting with 1:1 ethyl acetate : hexane. The product band was removed, eluted with ethyl acetate, filtered, and evaporated in vacuo . The residue was dissolved in diethylether, evaporated in vacuo and dried under high vacuum to provide tert-butyl N- (IS, 2R) -3- [ [ (3- aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (54 mg) as a foam. Hl-NMR (methanol- D4) : 1.24 (s, 9H) , 1.71 (m, 8H) , 2.55 (m, IH) , 2.90 (bm,
IH) , 3.04 (m, 2H) , 3.73 (m, 2H) , 4.81 (m, IH) , 6.44 (d, IH) , 6.93 (m, IH) , 7.02 '(m, IH) , 7.17 (m, 7H) . MS (ESI): 520 (MH+) .
Example 12
Figure imgf000092_0001
(12) Tert-butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2- [(3,4,5- trimethoxyphenyl-carbonyl) amino] -lH-benzimidazol-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate. Tert-butyl N- (1S, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2-amino-lH- benzimidazol-5-ylsulfonyl) amino] -2-hydroxypropylcarbamate (Step 2, Example 8) (130 mg, 0.232 mmol), 3,4,5- trimethoxybenzoyl chloride (70 mg, 0.302 mmol), and anhydrous pyridine (5 mL) were combined in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 18 hours and then concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to give the product as a white film (3 mg,
0.004 mmol). XHNMR (d6-DMSO) δ: 7.56-6.63 ( , 7H) , 5.21 (bs, IH) , 4.64 (bs, IH) , 3.86 (s, 6H) , 3.76 (s, 3H) , 3.40-1.30 (m, 18H), 1.23 (s, 9H) . MS(ES): 754 (M+l), 752 (M-l). Example 13
Figure imgf000093_0001
13:
Tert-butyl N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) (2- [ (methyl 3-oxopropionate) amino] -lH-benzimidazol-5-ylsulfonyl) amino] - 2-hydroxypropylcarbamate. Tert-butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2-amino-lH-benzimidazol-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate (Step 2, Example 8) (130 mg, 0.232 mmol), methyl malonyl chloride (0.04 mL, 0.348 mmol), and anhydrous pyridine (5 mL) were combined in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 18 hours and then concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to give the product as a pale yellow solid (6 mg, 0.009 mmol). *H NMR (d6-DMSO) δ: 8.62 (d, J=8.5 Hz, IH) , 7.89-6.67 (m, 9H) , 5.17 (d, J=6.0 Hz, IH) , 4.85 (bs, IH) , 3.65 (s, 3H) , 3.77-1.40 (m, 16H), 1.14 (s, 9H) . MS(ES): 660 (M+l), 658 (M-l).
Example 14
Figure imgf000093_0002
(14; Tert-butyl N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) (2- [ (dimethylamino-carbonyl) amino] -lH-benzimidazol-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate. Tert-butyl N- (1S, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2-amino-lH- benzimidazol-5-ylsulfonyl) amino] -2-hydroxypropylcarbamate (Step 2, Example 8) (100 mg, 0.179 mmol), dimethyl carbamyl chloride (0.03 mL, 0.286 mmol), and anhydrous pyridine (5 mL) were combined in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 18 hours and then concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to give the product as a white film (35 mg, 0.056 mmol, 31%). --H NMR (d6-DMSO) δ: 7.53-6.66 (m, 8H) , 5.10 (bs, IH) , 4.80 (bs, IH) , 3.56 (bs, 2H) , 3.20 (s, 3H) , 3.18 (s, 3H) , 3.10-1.40 (m, 13H) , 1.18 (s, 9H) . MS(ES): 631 (M+l), 629 (M-l) .
Example 15 Step 1
Figure imgf000094_0001
2- (sec-butoxy) -lH-isoindole-1 , 3 (2H) -dione . N- hydroxylphthalimide (18.4 mmol, 3.0 g) was dissolved in anhydrous DMF (20 mL) under nitrogen. To the stirring solution, DBU ( 1, 8-diazabicyclo [5.4.0] undec-7-ene) (27.6 mmol, 4.13 mL) was injected followed by 2-bromobutane (22.1 mmol, 2.41 mL) and the reaction was warmed to 55°C. After stirring for 18 hour, the reaction was cooled to room temperature and concentrated to a red oil. The reaction was partitioned between ethyl acetate and IN HCl. The organic layer was washed with saturated aqueous sodium bicarbonate solution, distilled water, brine and dried over magnesium sulfate. The solvent was removed under vacuum providing 3.57 g (89%) of a yellow solid. Rf: 0.8 (2:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.80 (2H,m), 7.73 (2H,m), 4.31 (lH,m), 1.81 (lH,m), 1.64 (lH,m), 1.32 (3H,d), 1.03 (3H,t).
Step 2:
Figure imgf000095_0001
N1- (sec-butoxy) -4-methoxy-l-benzenesulfonamide. O-sec- butoxy-N-hydroxylphthalimide (16.3 mmol, 3.57 g) was combined with hydrazine (17.9 mmol, 0.56 mL) in anhydrous THF (30 mL) under nitrogen. The reaction immediately formed a white suspension and was allowed to stir at room temperature for 5 hours. The suspension was filtered directly into a flask containing 4-methoxybenzenesulfonyl chloride (14.6 mmol, 3.03 g) and diisopropylethylamine (17.6 mmol, 3.1 mL) was added. After stirring at room temperature for 15 hours, the reaction was concentrated to a yellow solid and partitioned between ethyl acetate and IN HCl. The organic layer was separated and washed with a saturated aqueous solution of sodium bicarbonate and brine, and dried over magnesium sulfate. The product was concentrated to a white solid and purified by silica gel chromatography (5:1 hexanes/ethyl acetate), providing 3.13 g (66%) of a white solid. Hl- MR (CDC13) : δ 7.84 (2H,d), 6.98 (2H,d), 6.64 (lH,s), 4.02 (lH,m), 3.86 (3H,s), 1.62-1.55 (lH,m), 1.45- 1.38 (lH,m), 1.15 (3H,d), 0.87 (3H,t) .
Figure imgf000096_0001
15 )
tert-butyl N- ( (lS, 2i?) -l-benzyl-3-sec-butoxy [ (4 - methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate . N1-
( sec-butoxy) -4-methoxy-l-benzenesulfonamide (12.1 mmol, 3.13 g) was combined with tert-butyl N- (IS) -1- [ (2S) oxiran-2-yl] - 2-phenylethylcarbamate (13.3 mmol, 3.5 g) and THF (25 mL) under nitrogen. Phosphazine base P<t/4>t-Bu (2.4 mmol, 2.4 L, 1M in hexanes) was injected into the stirring solution. The reaction was allowed to stir for 48 hours at room temperature and was quenched by the addition of a few drops of glacial acetic acid. The reaction product was concentrated to an oil and partitioned between ethyl acetate and I HCl. The organic layer was separated and washed with saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate and concentrated under vacuum to a clear oil. The crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) providing 3.03 g
(48%) of a white solid. Hl-ΝMR (CDC13) : δ 7.12 (2H,d), 7.30-7.19 (6H,m), 6.97 (2H,d), 4.55 (lH,bs), 4.31 (lH,m), 3.86 (3H,s), 3.78 (2H,m), 3.5-2.5 (lH,bm), 2.90 (2H,m), 1.80-1.60 (lH,m), 1.5-1.3 (lH,m), 1.32 (9H,s), 1.21-1.18 (3H,m), 0.93-0.85 (3H,m); MS (ESI): M+Νa - 545. Example 16
Step 1:
Figure imgf000097_0001
2- (cyclohexylmethoxy) -lH-isoindole-1 , 3 (2H) -dione . N- hydroxylphthalimide (18.4 mmol, 3.0 g) was dissolved in anhydrous DMF (20 mL) under nitrogen. To the stirring solution, DBU (27.6 mmol, 4.13 mL) was injected followed by cyclohexylmethyl bromide (23.0 mmol, 3.21 mL) and the reaction was warmed to 55°C. After stirring for 15 hours, the reaction was cooled to room temperature and concentrated to a red oil. The reaction was partitioned between ethyl acetate and IN HCl. The organic layer was washed with saturated aqueous sodium bicarbonate solution, brine and dried over magnesium sulfate. The solvent was removed under vacuum, and the crude product was triturated with hexanes providing 3.05 g (64%) of an off-white colored solid. Hl-ΝMR (CDC13) : δ 7.80 (2H,m), 7.73 (2H,m), 3.98 (2H,d), 2.03-1.65 (5H,m), 1.31-1.03 (6H,m).
Figure imgf000097_0002
N1- (cyclohexylmethoxy) -4-methoxy-l-benzenesulfonamide. 2-
(cyclohexylmethoxy) -liϊ-isoindole-1, 3 { 2H) -dione (11.8 mmol, 3.05 g) was combined with hydrazine (12.9 mmol, 0.41 mL) in anhydrous THF (25 mL) under nitrogen. The reaction immediately formed a white suspension and was allowed to stir at room temperature for 48 hours. The suspension was filtered directly into a flask containing 4- methoxybenzenesulfonyl chloride (9.5 mmol, 1.97 g) and diisopropylethylamine (11.6 mmol, 2.03 mL) was added. After 5 stirring at room temperature for 18 hours, the reaction was concentrated to a solid residue and partitioned between ethyl acetate and IN HCl. The organic layer was separated and washed with a saturated aqueous solution of sodium bicarbonate, and brine, and dried over magnesium sulfate. 10 The product was concentrated to a solid and purified by silica gel chromatography (2:1 hexanes/ethyl acetate) providing 2.55g (80%) of a yellow solid. Hl-NMR (CDC13) : δ 7.81 (2H,d), 6.97 (2H,d), 6.78 (lH,s), 3.85 (3H,s), 3.75
(2H,d), 1.65-1.55 (6H,m), 1.25-1.07 (3H,m), 0.93-0.85 i **, (2H,m) .
Step 3:
Figure imgf000098_0001
(16)
20 tert-butyl N- ( (1S,2JR) -l-benzyl-3- (cyclohexylmethoxy) [ (4- methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate.
N1- (cyclohexylmethoxy) -4-methoxy-l-benzenesulfonamide ( 8.52 mmol, 2.55 g) was combined with tert-butyl N- ( 1 S) - 1- 25 [ (2S) oxiran-2-yl] -2-phenylethylcarbamate (9.37 mmol, 2.47 g) and THF (16 mL) under nitrogen. Phosphazine base P<t/4>t-Bu (1.7 mmol, 1.7 mL, 1M in hexanes) was injected into the stirring solution. The reaction was allowed to stir for 15 hours at room temperature and was quenched by the addition of a few drops of glacial acetic acid. The reaction product was concentrated to an oil and partitioned between ethyl acetate and IN HCl. The organic layer was separated and washed with saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate and concentrated under vacuum to a clear oil. The crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) providing a white solid. Hl-NMR (CDC13) : δ 7.70 (2H,d), 7.28-7.19 (6H,m), 6.97 (2H,d), 4.6 (lH,m), 3.96 (lH,m), 3.87 (3H,s), 3.82 (2H,m), 3.21 (lH,m), 2.99 (lH,m), 2.90 (2H,m), 2.80
(lH,m), 1.65 (6H,m), 1.33 (9H,m), 1.2-1.0 (3H,m), 1.00-0.80 (2H,m); MS (ESI): M+Na = 585.
Example 17
Step 1:
Figure imgf000099_0001
4-methoxy-N1-phenoxy-1-benzenesulfonamide. 0- phenylhydroxylamine hydrochloride (6.9 mmol, 1.0 g), 4- methoxybenzenesulfonyl chloride (6.2 mmol, 1.29 g) , diisopropylethylamine (13.1 mmol, 2.28 mL) and andhydrous THF (15 mL) were combined under nitrogen. After stirring for 2 hours at room temperature, a few crystals of 4- dimethylaminopyridine were added and the flask was re- sealed. After another 2 hours, 4 mL of N,N- dimethylformamide was injected and the reaction stirred for an additional 15 hours. The resulting red solution was concentrated to an oil and partitioned between ethyl acetate and IN HCl. The organic layer was separated and washed with saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate and concentrated under vacuum. The resulting dark brown residue was purified by silica gel chromatography (3:1 hexanes/ethyl acetate) providing 360 mg
(21%) of a redish solid. Hl-NMR (CDC13) : δ 7.89 (2H,d), 7.30-7.20 (3H,m), 7.11 (2H,d), 7.02 (lH,s), 7.00 (2H,d), 3.88 (3H,s) .
Step 2 :
Figure imgf000100_0001
: i 7 :
tert-butyl N- ( 1S, 2R) -1-benzyl-2-hydroxy-3- [ [ (4- methoxyphenyl) sulfonyl] (phenoxy) amino]propylcarbamate. 4- methoxy-NL-phenoxy- l-benzenesul fonamide (1.3 mmol, 360 mg) was combined with tert-butyl N- ( IS) -1- [ (2S) oxiran-2-yl] -2- phenylethylcarbamate (1.4 mmol, 373 mg) and THF (3 mL) under nitrogen. Phosphazine base P<t/4>t-Bu (0.26 mmol, 0.26 mL, 1M in hexanes) was injected into the stirring solution. The reaction was allowed to stir for 48 hours at room temperature and was quenched by the addition of a few drops of glacial acetic acid. The reaction product was concentrated to a red oil and partitioned between ethyl acetate and IN HCl. The organic layer was separated and washed with saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate and concentrated under vacuum to a red oil. The crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and crystallization (hexanes/ethyl acetate) providing 300 mg
(43%) of red crystals. Hl-ΝMR (CDC13) : δ 7.74 (2H,d), 7.37-7.10 (10H,m), 7.04 (lH,m), 6.98 (2H,d), 4.56 (IH, bs) , 3.88 (3H,s), 3.76 (2H, bs), 3.35-3.25 (lH,m), 3.20-2.95 (lH,m), 2.95-2.75 (2H,m), 1.30 (9H,s); MS (ESI): M+Na*=565,
Example 18
Step 1:
Figure imgf000101_0001
2- (tetrahydro-2H-pyran-4-yloxy) -lH-isoindole-1 ,3 (2H) -dione. A light suspension containing N-hydroxylphthalimide (18.4 mmol, 3.0 g) , triphenylphosphine (18.4 mmol, 4.82 g) , tetrahydro-4H-pyran-4-ol (18.4 mmol, 1.75 mL) and anhydrous THF (50 mL) , were transferred to a flask containing di-tert- butyl azodicarboxylate (20.2 mmol, 4.66 g) under nitrogen. Over 2 hours the reaction stirred at room temperature and changed from a dark orange to yellow in appearance. The solvent was removed under vacuum and replaced with trifluoroacetic acetic acid (10 mL) . The reaction was stirred for 30 minutes and the TFA was removed under vacuum. The crude residue was then dissolved in ethyl acetate, washed with a saturated aqueous solution of sodium bicarbonate, 5% aqueous solution of potassium carbonate, brine and dried over magnesium sulfate. The solvent was removed under vacuum and the residual triphenylphosphine oxide was crystallized and filtered using hexanes and ether. The solvent was again removed and the crude solid was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and recrystallization using methylene chloride and hexanes providing 1.69 g (37%) of a white crystal. Rf = 0.3 (2:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.84-7.82 (2H,m) , 7.75-7.73 (2H,m) , 4.46-4.40 (lH,m) , 4.08-4.02 (2H,m), 3.50-3.44 (2H,m) , 2.04-1.98 (2H,m), 1.92-1.84 (2H,m) .
Step 2:
Figure imgf000102_0001
27- (tetrahydro-2H-pyran-4-yloxy) -4 -methoxy- 1- benzenesulfonamide. 2- ( tetrahydro-2H-pyran-4-yloxy) -1H- isoindole-1, 3 (2H) -dione (6.8 mmol, 1.69 g) was combined with hydrazine (6.8 mmol, 0.22 mL) in anhydrous THF (20 mL) under nitrogen. The reaction immediately formed a white suspension and was allowed to stir at room temperature for 1 hour. The suspension was filtered directly into a flask containing 4-methoxybenzenesulfonyl chloride (6.5 mmol, 1.34 g) and diisopropylethylamine (20.5 mmol, 3.6 mL) was added. After stirring at room temperature for 15 hours, the reaction was refluxed for 4 hours, then stirred at room temperature for 12 days and concentrated to a yellow solid. The resulting solid was partitioned between ethyl acetate and IN HCl, and the organic layer was separated and washed with a saturated aqueous solution of sodium bicarbonate and brine, and dried over magnesium sulfate. The crude product was concentrated to a white solid and purified by silica gel chromatography (1:1 hexanes/ethyl acetate) and crystallization (hexanes/ethyl acetate) providing 0.554 g (30%) of a white solid. Rf = 0.4 (1:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.83 (2H,d), 7.00 (2H,d), 6.72 (lH,s), 4.23-4.11 (lH,m), 3.91-3.81 (2H,m), 3.87 (3H,s), 3.46-3.38 (2H,m), 2.03-1.94 (2H,m), 1.63-1.51 (2H,m). Step 3 :
Figure imgf000103_0001
tert-butyl N- ( 1S, 2R) -1-benzyl-2-hydroxy-3- [ [ (4- methoxyphenyl) sul onyl ] (tetrahydro-2H-pyran- - yloxy) amino] propylcarbamate. N- (tetrahydro-2H-pyran-4- yloxy) -4-methoxy-l-benzenesulfonamide (1.93 mmol, 554 mg) was combined with tert-butyl N- ( IS) -1- [ (2S) oxiran-2-yl] -2- phenylethylcarbamate (1.54 mmol, 406 mg) and THF (5 mL) under nitrogen. Phosphazine base P<t/4>t-Bu (0.31 mmol, 0.31 mL, 1M in hexanes) was injected into the stirring solution. The reaction was allowed to stir for 15 hours at room temperature, quenched by the addition of a few drops of glacial acetic acid and concentrated. The organic layer was separated and washed with IN ΝaOH, dried over magnesium sulfate and concentrated under vacuum. The crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and crystallization (hexanes/ethyl acetate) providing 367 mg (43%) of a white crystal. Rf = 0.2 (8:1
CH2Cl2/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.70 (2H,d), 7.30- 7.18 (6H,m), 6.97 (2H,d), 4.60-4.51 (lH,m), 4.44-4.33 (2H,m), 3.97-3.88 (2H,m), 3.86 (3H,s), 3.83-3.71 (2H,m), 3.48-3.34 (2H,m), 3.40-2.60 (lH,bs), 2.95-2.85 (2H,m), 2.07- 1.95 (2H,m), 1.56-1.49 (2H,m) , 1.32 (9H,s); MS (ESI): M+Νa=573. Example 19
Step 1
Figure imgf000104_0001
2- (tetrahydro-2H-pyran-2-γlmethoxγ) -lH-isoindole-1 ,3 (2H) - dione. This reaction was conducted according to the procedure reported in Grochowski, E; Jurczak, J. Synthesis 1976, 682. Rf = 0.3 (2:1 hexanes/ethyl acetate); Hl-NMR
(CDCI3) : δ 7.83-7.79 (2H,m), 7.75-7.70 (2H,m), 4.24-4.18 (lH,m), 4.07-4.03 (lH,m), 3.94-3.89 (lH,m), 3.81-3.75 (lH,m), 3.46-3.37 (lH,m), 1.87-1.85 (lH,m), 1.63-1.33 (5H,m) .
Step 2
Figure imgf000104_0002
N- (tetrahydro-2H-pyran-2-ylmethoxy) -4-methoxy-l- benzenesulfonamide. 2- (tetrahydro-2H-pyran-2-ylmethoxy) -1H- isoindole-1, 3 (2H) -dione (6.8 mmol, 1.77 g) was combined with hydrazine (6.8 mmol, 0.21 mL) in anhydrous THF (15 mL) under nitrogen. The reaction immediately formed a white suspension and was allowed to stir at room temperature for 2 hours. The suspension was filtered directly into a flask containing 4-methoxybenzenesulfonyl chloride (6.8 mmol, 1.40 g) and diisopropylethylamine (8.1 mmol, 1.42 mL) was added. After stirring at room temperature for 24 hours, the reaction was concentrated to a yellow solid. The resulting solid was partitioned between ethyl acetate and IN HCl, and the organic layer was separated and washed with a saturated aqueous solution of sodium bicarbonate and brine, and dried over magnesium sulfate. The crude product was concentrated to a yellow solid and purified by silica gel chromatography (2:1 hexanes/ethyl acetate). The purified product was combined with ether and filtered to remove the residual phthalimide-hydraziήe biproduct. The final product was crystallized using hexanes and ethyl acetate to provide 141 mg (7%) of white crystals. Rf = 0.3 (2:1 hexanes/ethyl acetate) ; Hl-NMR (CDC13) : δ 7.83 (2H,d) , 7.05 (lH,s), 6.97 (2H,d), 4.01-3.86 (3H,m), 3.86 (3H,s), 3.63-3.57 (lH,m), 3.42-3.36 (lH,m) , 1.88-1.78 (lH,m), 1.59-1.43 (4H,m), 1.3- 1.15 (lH,m) .
Step 3:
Figure imgf000105_0001
:i9:
tert-butyl N- (1S,2R) -l-benzyl-2-hydroxy-3- [ [ (4- methoxyphenyl) sulfonyl] (tetrahydro-2H-pyran-2- ylmethoxy) amino]propylcarbamate. N- (tetrahydro-2iϊ-pyran-2- ylmethoxy) -4-methoxy-l-benzenesulfonamide (0.47 mmol, 141 mg) was combined with tert-butyl N- (IS) -1- [ (2S) oxiran-2-yl] - 2-phenylethylcarbamate (0.37 mmol, 99 mg) and THF (1 mL) under nitrogen. Phosphazine base P<t/4>t-Bu (0.08 mmol, 0.08 mL, 1M in hexanes) was injected into the stirring solution. The reaction was allowed to stir for 15 hours at room temperature, quenched by the addition of a few drops of glacial acetic acid and concentrated. The crude residue was partitioned between ethyl acetate and IN HCl, and the organic layer was separated and washed with saturated aqueous sodium bicarbonate solution and brine, and dried over magnesium sulfate. The crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate). The purified product was then washed with IN NaOH to remove remaining sulfonamide starting material that coeluted, brine, and was again dried over magnesium sulfate. The silica gel chromatography was repeated and yielded 130 mg (62%) of a white solid. Rf = 0.2 (2:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.68-7.64 (2H,m), 7.28-7.18 (6H,m), 6.96 (2H,d), 4.74-4.60 (lH,m), 4.37-4.18 (lH,m), 4.14-4.06 (lH,m), 4.01-3.93 (2H,m), 3.90-3.75 (2H,m), 3.87 (3H,s), 3.66-3.46 (lH,m), 3.46-3.35 (lH,m), 2.92-2.74 (2H,m), 3.50-2.50 (lH,bs), 1.90-1.81 (lH,m), 1.63-1.42
(4H,m), 1.34 (9H,s), 1.29-1.20 (lH,m); MS (ESI): M=565.
Example 20
Step 1
Figure imgf000106_0001
2- (tetrahydro-3-furanyloxy) -lH-isoindole-1 ,3 (2H) -dione. To a light suspension containing N-hydroxylphthalimide (5.7 mmol, 926 mg) , triphenylphosphine (5.7 mmol, 1.49 g) , tetrahydro-4H-furan-3-ol (5.7 mmol, 0.459 mL) and anhydrous THF (10 mL) , diisopropylazodicarboxylate (6.2 mmol, 1.23 mL) was injected under nitrogen atmosphere. The reaction stirred at room temperature for 5 hours and changed from a dark orange to yellow in appearance. The solvent was removed under vacuum, and the resulting residue was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and crystallization (hexanes/ethyl acetate) providing 373 mg
(28%) of white crystals. Rf = 0.5 (1:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.85-7.82 (2H,m), 7.77-7.74
(2H,m), 5.05 (lH,m), 4.16-4.09 (2H,m), 3.92-3.87 (2H,m) , 2.34-2.28 (lH,m), 2.11-2.03 (lH,m).
Step 2:
C HJO'
Figure imgf000107_0001
N- (tetrahydro-3-furanyloxy) -4-methoxy-l-benzenesulfonamide.
2- (tetrahydro-3-furanyloxy) -lif-isoindole-l, 3 ( 2H) -dione (1.5 mmol, 357 mg) was combined with hydrazine (1.7 mmol, 0.053 mL) in anhydrous THF (3 mL) under nitrogen. The reaction immediately formed a white suspension and was allowed to stir at room temperature for 1 hour. The suspension was filtered directly into a flask containing 4- methoxybenzenesulfonyl chloride (1.5 mmol, 316 mg) and diisopropylethylamine (1.8 mmol, 0.320 mL) was added. After stirring at room temperature for 18 hours, the reaction was concentrated to a solid. The resulting solid was partitioned between ethyl acetate and IN HCl, and the organic layer was separated and washed with a saturated aqueous solution of sodium bicarbonate and brine, and dried over magnesium sulfate. The crude product was concentrated to a white solid and purified by silica gel chromatography (1:1 hexanes/ethyl acetate) . The purified product was then combined with ether and filtered to remove the residual phthalimide-hydrazine biproduct. The filtrate was then crystallized by adding hexanes providing 203 mg (48%) white crystals. Rf = 0.2 (1:1 hexanes/ethyl acetate); Hl-NMR (CDCI3) : δ 7.82 (2H,d), 6.99 (2H,d), 6.85 (lH,s), 4.82-4.79 (lH,m) , 3.97-3.87 (2H,m), 3.87 (3H,s), 3.83-3.70 (2H,m), 2.12-1.99 (2H,m) .
Step 3:
Figure imgf000108_0001
!2o:
tert-butyl N- (1S,2R) -1-benzyl-2-hydroxy-3- [ [ (4- methoxyphenyl) sulfonyl] (tetrahydro-3- furanyloxy) amino] propylcarbamate. N- (tetrahydro-3- furanyloxy) -4-methoxy-l-benzenesulfonamide (1.03 mmol, 283 mg) was combined with tert-butyl N- (IS) -1- [ (2S) oxiran-2-yl] - 2-phenylethylcarbamate (1.35 mmol, 300 mg) and THF (1 mL) under nitrogen. Phosphazine base P<t/4>t-Bu (0.21 mmol, 0.21 mL, 1M in hexanes) was injected into the stirring solution. The reaction was allowed to stir for 15 hours at room temperature, quenched by the addition of a few drops of glacial acetic acid and concentrated. The crude residue was partitioned between ethyl acetate and IN HCl, and the organic layer was separated and washed with saturated aqueous sodium bicarbonate solution and brine, and dried over magnesium sulfate. The crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and reverse phase HPLC (water/acetonitrile) yielding 60 mg (11%) of a white solid. Hl-ΝMR (CDC13) : δ 7.68 (2H,d), 7.32-7.13 (6H,m), 7.01-6.93 (2H,m) , 5.17-5.00 (lH,m), 4.66-4.51 (lH,m), 4.34-4.16 (lH,m), 3.87 (3H,s), 3.83-3.68 (5H, ), 3.67-3.57 (lH,m), 2.95-2.78 (2H,m), 2.70 (lH,bs) , 2.18-1.97 (2H,m) , 1.34 (9H,m); MS (ESI) : M+Na=559.
Example 21 Step 1
Figure imgf000109_0001
N1- (benzyloxy) -4-methoxy-l-benzenesulfonamide. 0-
Benzylhydroxylamine hydrochloride (31.3 mmol, 5.0 g) , 4- methoxybenzenesulfonyl chloride (34.5 mmol, 7.12 g) and anhydrous THF (50 mL) were combined under nitrogen. The reaction was cooled to 0°C and diisopropylethylamine (69.0 mmol, 12.0 mL) was injected. The reaction was allowed to warm to room temperature and continued to stir for 18 hours. An additional 0.25 equivalents of O-Benzylhydroxylamine hydrogen chloride (7.8 mmol, 1.25 g) and 0.75 equivalents of diisopropylethylamine (23.5 mmol, 4.1 mL) were added to encourage complete conversion of the remaining sulfonyl chloride. The reaction stirred for 4 additional hours at room temperature. The reaction solution was concentrated to a solid and partitioned between ethyl acetate and IN HCl. The organic layer was dried over magnesium sulfate and concentrated under vacuum to yield 9.83 g (76%) of an off- white colored solid. Rf: 0.2 (2:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.84 (2H,d), 7.34 (5H,s) 7.08 (2H,d), 4.92 (2H, s) , 3.88 (3H, s) . Step 2:
Figure imgf000110_0001
: 2 i :
tert-butyl N- ( (lS,2i?) -l-benzyl-3- (benzyloxy) [ (4- methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate .
Lithium hexamethyldisilazide (0.6 mmol, 0.6 mL, 1M in THF) was injected into a stirring solution of N1- (benzyloxy) -4- methoxy-1-benzenesulfonamide (3.0 mmol, 1.0 g) , tert-butyl N- (IS) -l-[ (2S)oxiran-2-yl] -2-phenylethylcarbamate (2.4 mmol, 0.64 g) , and anhydrous THF (8 mL) . The reaction was allowed to stir for 15 hours at room temperature under nitrogen. The reaction was quenched with a few drops of glacial acetic acid and concentrated to a thick oil. The crude was partitioned between ethyl acetate and IN HCl, washed with saturated sodium bicarbonate solution and brine, dried over magnesium sulfate and concentrated. The crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and crystallized from ethyl acetate with hexanes, providing 400 mg (22%) of a white crystal. Rf: 0.4 (2:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.72 (2H,d), 7.4- 7.3 ( 5H,m), 7.3-7.2 (5H,m), 7.19 (lH,d), 6.93 (2H,d), 5.08 (2H,s), 4.40 (lH,m), 3.82 (3H,s), 3.69 (lH,m), 3.53 (lH,bs), 2.98 (lH,bs), 2.83 (2H,m), 2.71 (lH,bs), 1.33 (9H,s); MS (ESI) : M+Νa = 579. Example 22
Step 1
Figure imgf000111_0001
N1-isobutoxy-4-methόxy-l-benzenesulfonamide. Isobutoxyamine hydrochloride (7.96 mmol, 1.0 g) , 4-methoxybenzenesulfonyl chloride (7.24 mmol, 1.5 g) , diisopropylethylamine (18.09 mmol, 3.15 mL) and anhydrous THF (15 mL) were combined under nitrogen. The reaction stirred at room temperature for 15 hours. The reaction solution was concentrated to a white solid and partitioned between ethyl acetate and IN HCl. The organic layer was separated and washed with saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate and concentrated under vacuum to yield an off-white colored solid. Rf: 0.5 (2:1 hexanes/ethyl acetate); Hl-NMR
(CDC13) : δ 7.84 (2H,d), 6.99 (2H,d), 6.81 (lH,s) , 3.87 (3H,s), 3.74 (2H,d), 1.90 (IH, septet), 0.86 (6H,d) .
Step 2:
Figure imgf000111_0002
!22'
tert-butyl N- ( (IS,21?) -l-benzyl-2-hydroxy-3-isobutoxy [ (4- methoxyphenyl) sulfonyl] aminopropyl) carbamate. Synthesized under the same conditions as outlined for tert-butyl N-
( (IS, 2i?) -l-benzyl-3- (benzyloxy) [(4-methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate 21. Hl-ΝMR (CDC13) : δ 7.70 (2H,d), 7.30-7.10 (6H,m), 6.96 (2H,d), 4.60 (lH,m), 3.93 (lH,m), 3.86 (3H,s), 3.81 (2H,m), 3.24 (lH,m), 3.01 (lH,m),
2.90 (2H,m), 2.82 (lH,m), 1.82 (IH, septet), 1.32 (9H,s),
0.93-0.81 (6H,m); MS (ESI): M+Na =545.
Example 23
Step 1:
Figure imgf000112_0001
2- (cyclohexyloxy) -lH-isoindole-1 ,3 (2H) -dione. N- hydroxylphthalimide (61.3 mmol, 10.0 g) was dissolved in anhydrous DMF (60 mL) under nitrogen. To the stirring solution, DBU (92.0 mmol, 13.75 mL) was injected followed by cyclohexyl bromide (76.6 mmol, 9.43 mL) and the reaction was warmed to 55°C. After stirring for 15 hours, the reaction was warmed to 80°C for 5 hours, then cooled to room temperature and concentrated to a red oil. The reaction was partitioned between ethyl acetate and IN HCl. The organic layer was washed with IN ΝaOH, brine and dried over magnesium sulfate. The solvent was removed under vacuum and the crude product was triturated with hexanes providing 2.89 g (19%) of a yellow solid. Rf: 0.7 (2:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.80 (2H,m) , 7.73 (2H,m), 4.21 (lH,m), 2.02-1.98 (2H,m), 1.87-1.82 (2H,m), 1.59-1.53 (4H,m), 1.30-1.24 (2H,m).
Figure imgf000112_0002
- I l l -
N1- (cyclohexyloxy) -4-methoxy-l-benzenesulfonamide. 2-
(cyclohexyloxy) -li-f-isoindole-1, 3 { 2H) -dione (11.8 mmol, 2.89 g) was combined with hydrazine (13.0 mmol, 0.41 mL) in anhydrous THF (20 mL) under nitrogen. The reaction immediately formed a white suspension and was allowed to stir at room temperature for 18 hours. The suspension was filtered directly into a flask containing 4- methoxybenzenesulfonyl chloride (10.6 mmol, 2.20 g) and diisopropylethylamine (14.2 mmol, 2.47 mL) was added. After stirring at room temperature for 24 hours, the reaction was concentrated to a yellow solid and partitioned between ethyl acetate and IN HCl. The organic layer was separated and washed with a saturated aqueous solution of sodium bicarbonate, and brine, and dried over magnesium sulfate. The product was concentrated to a yellow solid and purified by silica gel chromatography (1:1 hexanes/ethyl acetate) providing 2.53 g (83%) of a white solid. Rf: 0.2 (2:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.86 (2H,d), 7.00 (2H,d), 6.67 (1H,Ξ), 3.98-3.95 (lH,m), 3.88 (3H,s), 2.00- 1.94 (2H,m), 1.75-1.55 (2H,m), 1.35-1.17 (6H,m).
Step 3 :
Figure imgf000113_0001
123 )
tert-butyl N- ( (IS, 21?) -l-benzyl-3- (cyclohexyloxy) [ (4- methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate.
Synthesized under the same conditions as outlined for tert- butyl N- ( (IS, 2R) -l-benzyl-3- (benzyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate . Hl-NMR (CDC13) : δ 7.77 (2H,d), 7.33-7.25 (6H,m), 7.02 (2H,d), 4.60 (lH,m), 4.24 (lH,m), 3.87 (3H,s), 3.84 (3H,m), 3.5-2.5 (lH,m), 2.96 (2H,m), 2.09 (2H,m), 1.77 (2H,m) , 1.38 (9H,s), 1.2-1.0 (6H,m); MS (APCI): M+Na =571.
Example 24
Figure imgf000114_0001
(24)
Phenylmethyl N- ( (IS, 21?) -l-benzyl-3- (cyclopentyloxy) [ (4- methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate . To a solution of N1- [ ( 2R, 3S) -3-amino-2-hydroxy-4-phenylbutyl] - N- (cyclopentyloxy) -4-methoxy-l-benzenesulfonamide x trifluoracetic acid (Step 1, Example 48), (50 mg, 0.091 mmol) in approximately 1.5 mL of dichloromethane under Argon was added benzylchloroformate (15.6 μL, 0.109 mmol) followed by Ν,Ν-diisopropylethylamine (47.9 μL, 0.273 mmol). After stirring 18 hours, the reaction mixture was evaporated in vacuo to a residue and purified on a preparative silica gel TLC plate (20x20 cm, 1000 μM) eluting with 95:5 methylene chloride : methanol. The product band was removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was partitioned between dichloromethane and water. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, and evaporated in vacuo . The residue was lyophilized from acetonitrile and water to provide phenylmethyl N- ( (IS, 2R) -1- benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (37 mg, 71%). Hl-ΝMR (methanol-D4 ) 1.71 (m, 8H) , 2.59 (m, IH) , 2.93 (m, 2H) , 3.10 (m, IH) , 3.81 (m, 2H) , 3.83 (s, 3H) , 4.86 (m, 3H) , 7.06 (m, 2H) , 7.21 (m, 10H), 7.73 (m, 2H) . ' MS (ESI ) : 591 (M+Νa) .
An isomer of Compound 24, with inverted stereochemistry at C-2 was prepared as follows:
Figure imgf000115_0001
Phenylmethyl N- ( (1S,2S) -l-benzγl-3- (cyclopentyloxy) [ (4- methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate. A mixture of phenylmethyl N- (IS) -1- [ (2S) oxiran-2-yl] -2- phenylethylcarbamate [250 mg, 0.842 mmol, Tetrahedron (1994), 50(21), 6333-46] and N1- (cyclopentyloxy) -4-methoxy- l-benzenesulfonamide (285 mg, 1.05 mmol) in anhydrous tetrahydrofuran (3 mL) under an Argon atmosphere was treated with phosphazene base P<t/4>t-Bu (0.168 mL, 0.168 mmoL, 1.0 M in hexane) . The mixture was stirred at ambient temperature for approximately 18 hours, quenched with several drops of glacial acetic acid and evaporated in vacuo . The residue was purified on flash grade silica gel eluting with 4:1 hexane : ethyl acetate. Fractions containing the product were combined and evaporated in vacuo . The residue was triturated with hexane and then evaporated in vacuo and dried under high vacuum to provide phenylmethyl N- ( (IS, 2S) -l-benzyl-3- (cyclopentyloxy) [ (4- methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate (439 mg, 92%) as a foam. Hl-ΝMR (methanol-D4 ) 1.66 (m, 8H) , 2.94 (m, 4H) , 3.83 (m, 2H) , 3.92 (s, 3H) , 4.59 (m, IH) , 5.10 (m, 2H) , 7.10 (m, 2H) , 7.29 ( , 10H), 7.69 (m, 2H) . MS(ESI): 591 (M+Νa) .
Example 25
Figure imgf000116_0001
(25)
3-pγridylmethyl N- ( (IS,21?) -l-benzyl-3- (cyclopentyloxy) [ (4- methoxyphenyl ) sulfonyl ] amino-2-hydroxypropyl) carbamate .
Carbonyldiimidazole (13.0 mg, 0.080 mmol) and 3- hydroxymethylpyridine (7.8 μL, 0.080 mmol) were combined under an Argon atmosphere in 2.5 mL of anhydrous ethyl acetate. After stirring for 1.5 hours at ambient temperature, N1- [ { 2R, 3S) -3-amino-2-hydroxy-4-phenylbutyl] - N- (cyclopentyloxy) -4-methoxy-l-benzenesulfonamide x trifluoracetic acid (Step 1, Example 48), (40 mg, 0.073 mmol) was added and the mixture was heated at reflux for 5 hours. Heating was discontinued and the solvent was removed under vacuum. The crude product was purified on a preparative TLC plate (20x20 cm, 1000 μM) eluting with 93:7 methylene chloride : methanol. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was dissolved in diethylether, evaporated in vacuo and dried under high vacuum to provide 3-pyridylmethyl N- ( (IS, 2R) -1- benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (18.9 mg, 41%) as a foam. Hl-ΝMR
(chloroform-D3) : 1.66 (m, 8H) , 2.95 (m, 5H) , 3.86 (s, 3H) , 3.87 (m, 2H) , 4.77 ( , IH) , 4.98 (m, 3H) , 6.97 (d, 2H) , 7.20
(m, 6H) , 7.54 (m, IH) , 7.68 (d, 2H) , 8.54 (bm, 2H) . MS (ESI) : 570 (MH+) . '
Example 26
Figure imgf000117_0001
N1- ( (lS,2i?) -l-benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) -2-methy1benzamide . o- Toluoyl chloride (7.8 uL, 0.0602 mmol) was added to a solution of 1- [ (2/x, 3S) -3-amino-2-hydroxy-4-phenylbutyl] -N1- (cyclopentyloxy) -4-methoxy-l-benzenesulfonamide x trifluoracetic acid (Step 1, Example 48), (30 mg, 0.055 mmol) and Ν, Ν-diisopropylethylamine (23.8 μL, 0.137 mmol) in approximately 1.5 mL of dichloromethane under Argon. After stirring for 18 hours at ambient temperature, the reaction solvent was removed in vacuo and the residue. was purified on a preparative TLC plate (20x20 cm, 500 μM) eluting with 96:4 methylene chloride : methanol. The product band was removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was triturated from diethylether and hexane and the solvents were evaporated in vacuo to provide N1- ( (IS, 2R) -l-benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) -2-methylbenzamide (27 mg, 89%) as a solid. Hl-NMR (dimethylsulfoxide-D6) : 1.75 (m, 8H) , 1.87 (s, 3H) , 2.63 ( , IH) , 2.79 (bm, IH) , 3.05 (bm, IH) , 3.21 (bm, IH) , 3.69 (bm, IH) , 3.86 (s, 3H) , 4.13 (bm, IH) , 4.86 (bm, IH) , 5.28 (bs, IH) , 6.79 (m, IH) , 7.21 (m, 10H) , 7.72 (d, 2H) , 8.06 (d, IH) . MS (ESI): 575(M+Na).
Example 27 Step 1
Figure imgf000118_0001
3-amino-N1- [ (2R, 3S) -3-amino-2-hydroxy-4-phenylbutγl] -N1- (cyclopentyloxy) -1-benzenesulfonamide. A mixture of N- (IS, 2R) -3- [[ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate (Step 3, Example 11), (1.500 g, 2.89 mmol) and trifluoroacetic acid (5 mL) was stirred under an Argon atmosphere at ambient temperature for 30 minutes. Trifluoroacetic acid was removed in vacuo and the residue was partitioned between dichloromethane and IN NaOH. After separating the phases, the aqueous layer was extracted twice with dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate, filtered, evaporated in vacuo and dried under high vacuum to provide 3-amino- N1- [ (2iP, 35) -3-amino-2-hydroxy-4-phenylbutyl] -N1-
(cyclopentyloxy) -1-benzenesulfonamide (1.157 g, 96%) as a foam. Hl-ΝMR (methanol-D4 ) : 1.68 (m, 8H) , 2.55 (m, IH) , 2.79 (m, IH) , 2.94 (bm, IH) , 3.12 (m, 2H) , 3.77 (m, IH) , 4 . 76 (m, IH) , 6 . 96 (m, IH ) , 7 . 05 (m, IH ) , 7 . 1 6 (m, 4H ) , 7 . 27 (m, 3H ) . MS (ES I ) : 420 (MH+ ) .
Step 2 :
Figure imgf000119_0001
(3S) tetrahydro-3-furanyl N- (IS,21?) -3- [ [ (3- aminophenyl) sulfonyl] (cyclopentyloxy) amino] -1-benzyl-2- hydroxypropylcarbamate. A mixture of 3-amino-N1- [ (2R, 3S) -3- amino-2-hydroxy-4-phenylbutyl] -N1- (cyclopentyloxy) -1- benzenesulfonamide (100 mg, 0.239 mmol), 2,5-dioxo-l- pyrrolidinyl [ (3S) tetrahydro-3-furanyl] carbonate (55 mg, 0.239 mmol, WO94/05639) and Ν, Ν-diisopropylethylamine (41.6 μL, 0.239 mmol) were combined under Argon at ambient temperature in approximately 1.5 L of acetonitrile. After stirring for approximately 18 hours, the reaction mixture was evaporated in vacuo and purified on two preparative silica gel TLC plates (20x20 cm, 1000 μM) eluting with 95:5 methylene chloride methanol. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, evaporated in vacuo and dried under high vacuum to provide (3S) tetrahydro-3-furanyl N- (IS, 2R) -3- [ [ (3- aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (111 mg, 87%) as a foam. Hl-ΝMR
(methanol-D4) : 1.80 (m, 9H) , 2.61 ( , IH) , 3.02 (m, 2H) , 3.14 (m, IH) , 3.50 ( , IH) , 3.64 (m, IH) , 3.73 (m, IH) , 3.81 (m, 3H) , 4.87 (m, IH) , 5.00 (m, IH) , 6.98 (m, IH) , 7.08 (m, IH) , 7.15 (m, IH) , 7.26 (m, 6H) . MS(ESI) : 534 (MH+).
Example 28
Figure imgf000120_0001
'28'
(3S, 3al?, 7aS) hexahydro-4H-furo [2 , 3-Jb] pyran-3-yl N- ( (IS, 21?) -1- benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl ]amino-2- hydroxypropyl) carbamate and 3i?,3aS, 7ai?) hexahydro-4H- furo[2,3-Jb]pyran-3-yl N- ( (IS, 21?) -1-benzyl-3-
(cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl ]amino-2- hydroxypropyl ) carbamate . A mixture of
(3i?, 3aS, 7ai) + (3S, 3aR, l aS) hexahydro-4H-furo [2, 3-Jb] pyran-3-yl (4-nitrophenyl) carbonate (68 mg, 0.219 mmol), N1- [ ( 2R, 3S) - 3-amino-2-hydroxy-4-phenylbutyl] -N1- (cyclopentyloxy) -4- methoxy-1-benzenesulfonamide x trifluoracetic acid (Step 1, Example 48), (60 mg, 0.109 mmol) and Ν,Ν- diisopropylethylamine (66.8 μL, 0.385 mmol) were combined in approximately 1.5 mL of acetonitrile and stirred at ambient temperature under an Argon atmosphere for 18 hours. An additional quantity of carbonate (20 mg, 0.065 mmol) and
N, N-diisopropylethylamine (40 μL, 0.224 mmol) was added and the reaction mixture was heated at 60°C for 1.5 hours. The reaction was cooled and evaporated in vacuo . The residue was dissolved in ethyl acetate and washed three times with 5% w/v potassium carbonate, saturated aqueous brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude product was purified on a preparative TLC plate (20x20 cm, 500 μM) eluting with 95 : 5/methylene chloride :methanol . The product band was removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was dissolved in diethylether, evaporated in vacuo and dried under high vacuum to provide a 1:1 mixture of (3S, 3aR, 7aS)hexahydro-4Jf-furo[2,3-i-*]pyran-3-yl N- ( (IS, 2R) -1- benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate and 3R, 3aS, 7a.R) hexahydro-4J-J- furo[2,3-J ]pyran-3-yl N- ( (IS, 2i?) -l-benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate as a foam (55 mg, 83%). Hl-ΝMR (chloroform-D3) : 1.80 (m, 12H) , 2.19 (m, IH) , 3.00 (m, 5H) , 3.48 (m, IH) , 3.89 (m, 7H) , 4.21 (m, IH) , 4.92 (m, 2H) , 5.08 (m, IH) , 5.27 (bm, IH) , 7.04 (m, 2H) , 7.28 (m, 5H) , 7.76 (m, 2H) . MS (ESI) : 627 (M+Νa) .
Example 29
Figure imgf000121_0001
[29)
(31?, 3aS, 6ai?) hexahydrofuro [2 , 3-Jb] furan-3-yl N- ( (IS, 21?) -1- benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl ]amino-2- hydroxypropyl) carbamate and (3S,3aR, 6aS) hexahydrofuro [2 ,3- Jb] furan-3-yl N- ( (IS, 21?) -l-benzyl-3- (cyclopentyloxy) [ (4- methoxyphenyl ) sulfonyl ] amino-2-hydroxypropyl ) carbamate . A mixture of (3J?, 3aS, 6ai?) + (3S, 3aR, 6aS) hexahydrofuro [2, 3- b] furan-3-yl (4-nitrophenyl) carbonate (96.5 mg, 0.327 mmol, WO 9721683), N1- [ (2i?, 3S) -3-amino-2-hydroxy-4-phenylbutyl] - N1- (cyclopentyloxy) -4-methoxy-l-benzenesulfonamide x trifluoracetic acid (Step 1, Example 48), (60 mg, 0.109 mmol) and Ν, -diisopropylethylamine (85.6 μL, 0.491 mmol) were combined in approximately 1.5 mL of acetonitrile and stirred at ambient temperature under an Argon atmosphere for 18 hours. The reaction mixture was evaporated in vacuo and the residue was purified on a preparative TLC plate (20x20 cm, 500 μM) eluting with l:l/ethyl acetate :hexane . The product band was removed, eluted with 3 : 1/methylene chloride: ethanol, filtered, and evaporated in vacuo . The residue was dissolved in diethylether, evaporated in vacuo and dried under high vacuum to provide a 1:1 mixture of (3i,3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 2R) -1- benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate and (3S, 3aR, 6aS) hexahydrofuro [2, 3- J ] furan-3-yl N- (( IS, 2R) -l-benzyl-3- (cyclopentyloxy) [(4- methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate (50 mg, 26%) as a foam. Hl-ΝMR (chloroform-D3) : 1.68 (m, 10H) , 2.95 ( , 6H) , 3.64 (m, 2H) , 3.88 (s, 3H) , 3.93 (m, 4H) , 4.82 (m, 2H) , 5.01 (bm, IH) , 5.65 (m, IH) , 6.98 (m, 2H) , 7.23 (m, 5H) , 7.71 (m, 2H) . MS (ESI): 613 (M+Νa) .
Example 30
Figure imgf000122_0001
: 30 ) tert-butyl 2-(3-[ [ (22?, 3S) -3- ( [ ( 3R, 3aS, 6ai?) hexahydrofuro [2 ,3- Jb] furan-3-yloxy] carbonylamino) -2-hydroxy-4- phenylbutyl ] (cyclopentyloxy) amino] sulfonylanilino) acetate and tert-butyl 2- (3- [[ (2i?,3S) -3- ([ (3S,3aR, 6aS) hexahydrofuro [2 ,3-Jb] furan-3-yloxy] carbonylamino) -2-hydroxy-4- phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) acetate A solution of 0.250 g (0.434 mmol) of a 1:1 mixture of ( 3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 2i?) -1- benzyl-3- (cyclopentyloxy) [ (3-aminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate and (3S, 3a.R, 6aS) hexahydrofuro [2, 3- b] furan-3-yl N- ( ( IS, 2i?) -l-benzyl-3- (cyclopentyloxy) [ (3- aminophenyl ) sulfonyl ] amino-2-hydroxypropyl ) carbamate (see example 31), 0.13 mL (0.87 mmol) of tert-butyl bromoacetate, and 0.15 mL (0.87 mmol) of N,A7-diisopropylethylamine in 5 mL of anyhydrous DMF was stirred at 80°C for 18 hours. The solution was cooled to RT and concentrated in vacuo . The residue was dissolved in dichloromethane. The solution was washed with saturated aqueous brine (3x), dried over anhydrous MgS04, and concentrated in vacuo . The crude product was purified by flash chromatography (silica gel, 4:6 hexane/EtOAc) to afford 0.28 g (94%) of the desired product as a light yellow foam. Hl-ΝMR (DMSO-d6) : 7.31-7.07 (7H), 6.93-6.80 (3H) , 6.61 (IH), 5.47 (IH), 5.19 (IH), 4.83- 4.64 (2H), 3.81-3.40 (7H), 3.06-2.60 (5H), 2.53-2.27 (IH), 1.95-1.16 (19H) . LCMS(ESI): 690 (M+H) .
Example 31
Figure imgf000124_0001
(32?,3aS,6a2?) hexahydrofuro [2, 3-jb] furan-3-yl N- (IS,22?) -3- [ [ (3- aminophenyl) sulfonyl ] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (1) and (3S,3a2?,6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ [ (3- aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (2) as a white lyophile. A mixture of (32?, 3aS, 6ai?) + (3S, 3ai, 6aS) hexahydrofuro [2, 3-b] furan-3- yl (4-nitrophenyl) carbonate (211 mg, 0.716 mmol), 3-amino- N1- [ ( 2R, 3S) -3-amino-2-hydroxy-4-phenylbutyl] -N1-
(cyclopentyloxy) -1-benzenesulfonamide (Step 1, Example 27), (100 mg, 0.239 mmol), and Ν, Ν-diisopropylethylamine (166.4 μL, 0.955 mmol) were combined in approximately 3 mL of acetonitrile and stirred at ambient temperature under an Argon atmosphere for approximately 18 hours. The reaction mixture was evaporated in vacuo and purified on two preparative silica TLC plates (20x20 cm, 1000 μM) eluting with 93 : 7/methylene chloride :methanol . The product band was removed, eluted with 4 : 1/methylene chloride :methanol, filtered, and evaporated in vacuo . The residue was partitioned between IN ΝaOH and dichloromethane. The layers were separated and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a foam. The mixture of diastereomers were separated by supercritical fluid chromatography [Chiralpak AD (2 cm, Chiral Technologies), 21 Mpa; 11.3 mL/min methanol+0.1% triethylamine; 45 g/min C02; 40°C.]. The fraction containing the diastereomer possessing a shorter retention time was evaporated in vacuo to a residue and then purified again by preparative TLC as above. The product was lyophilized from acetonitrile and water to provide (3.R, 3aS, βaR) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 2R) -3- [ [ (3- aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (1) as a white lyophile (18 mg, 13%) . The fraction containing the diastereomer possessing a longer retention time was evaporated in vacuo to a residue and then purified again by preparative TLC as above. The product was lyophilized from acetonitrile and water to provide (3S, 3aR, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- ( IS, 2i?) -3- [ [ (3- aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (2) as a white lyophile (18 mg, 13%) . 1 Hl-ΝMR (methanol-D4) 1.62 (m, 10H) , 2.52 (m, IH) , 2.88
(m, 2H) , 3.10 (m, 2H) , 3.62 (m, 2H) , 3.76 (m, 3H) , 3.87 (m, IH) , 4.81 ( , IH) , 4.90 ( , IH) , 5.55 (d, IH) , 6.93 (m, IH) , 7.02 (m, IH) , 7.08 (m, IH) , 7.14 (m, IH) , 7.21 (m, 5H) . MS (ESI) : 598 (M+Νa) . 2 Hl-ΝMR (methanol-D4 ) : 1.73 (m, 10H) , 2.57 (m, IH) , 2.93 (m, 2H),1 3.09 ( , 2H) , 3.46 (m, IH) , 3.79 ( , 5H) , 4.84 (m, 2H) , 5.57 (d, IH) , 6.92 (m, IH) , 7.02 ( , IH) , 7.09 ( , IH) , 7.20 (m, 6H) . MS (ESI): 598 (M+Νa) .
Example 32
Step 1:
Figure imgf000126_0001
methyl 2-(3-[ [ (22?,3S)-3-( [ (32?, 3aS, 6a2?) hexahydrofuro [2 ,3- b] furan-3-yloxy] carbonylamino) -2-hydroxy-4- phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) acetate and methyl 2- (3- [ [ (22?,3S) -3- ( [ (3S,3a2?, 6aS) hexahydrofuro [2 ,3- b] furan-3-yloxy] carbonylamino) -2-hydroxy-4- phenylbutyl ] (cyclopentyloxy) amino] sulfonylanilino) acetate . A solution of 0.500 g (0.869 mmol) of a 1:1 mixture of ( 3R, 3aS, βaR) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 2R) -1- benzyl-3- (cyclopentyloxy) [ (3-aminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate and (3S, aR, 6aS) exahydrofuro [2, 3- b] furan-3-yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate (see example 31), 0.250 mL (2.61 mmol) of methyl bromoacetate, and 0.450 mL (2.61 mmol) of N,N-diisopropylethylamine in 5 mL of anyhydrous DMF was stirred at 80° C for 18 hours. The solution was cooled to RT and concentrated in vacuo . The residue was dissolved in ethyl acetate. The solution was washed with saturated aqueous brine (3x) , dried over anhydrous MgS04, and concentrated in vacuo . The crude product was purified by flash chromatography (silica gel, 97:3 CH2Cl2/MeOH) to afford 0.50 g (89%) of the desired product as a light yellow foam. Hl-ΝMR (DMSO-d6) : 7.38-7.08 (7H), 7.01-6.85 (3H), 6.71 (IH), 5.52 (IH), 5.21 (IH), 4.88- 4.70 (2H) , 3.99 (2H) , 3.88-3.46 (8H) , 3.13-2.64 (5H) , 2.57- 2.35 (IH), 2.01-1.17 (10H) . LCMS(ESI) : 648 (M+H) .
Figure imgf000127_0001
:32:
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl N- ( (IS,22?) -1- benzyl-3- (cyclopentyloxy) [ (3- [2- (methylamino) -2- oxoethyl ] aminophenyl) sulfonyl ] amino-2- hydroxypropyl) carbamate and (3S,3a2?, 6aS) hexahydrofuro [2 ,3- Jb]furan-3-yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [(3- [2- (methylamino) -2-oxoethyl ] aminophenyl) sulfonyl ] amino-2- hydroxypropyl) carbamate. A solution of 50.0 mg (0.0770 mmol) of a 1:1 mixture of methyl 2- (3- [ [ (22?, 3S) -3- ( [ (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3- yloxy] carbonylamino) -2-hydroxy-4- phenylbutyl] (cyclopentyloxy) amino] sulfonylanilmo) acetate and methyl 2- (3- [ [ (22?, 3S) -3- ( [ (3S, 3aR, 6aS) hexahydrofuro [2, 3- j] furan-3-yloxy] carbonyl amino) -2-hydroxy-4- phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) acetate in 5 mL of 2M methylamine in MeOH was stirred at RT in a sealed tube. After 4 hours the solution was concentrated in vacuo and the residue subjected to flash chromatography
(silica gel, 97:3 EtOAc/MeOH) to afford 38 mg (76%) of the desired product as a white foam. Hl-NMR (CDC13) : 7.53-7.00 (11H), 6.80-6.59 (IH), 6.68 (IH), 5.50-5.18 (IH), 5.06 (IH), 4.85 (IH), 4.09-3.60 (7H) , 3.28-2.78 (8H), 2.00-1.47 (10H). MS (ESI): 647 (M+H) , 669 (M+Na).
Example 33
Figure imgf000128_0001
' 33 '
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-Jb] furan-3-yl N- ( (IS,22?) -1- benzyl-3- (cyclopentyloxy) [ (3- [2-
(dimethylamino) ethyl ] aminophenyl) sulfonyl ] amino-2- hydroxypropyl) carbamate and (3S, 3a2?, 6aS) hexahydrof ro [2,3- b]furan-3-yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- [2-
(dimethylamino) ethyl ] aminophenyl) sulfonyl ] amino-2- hydroxypropyl) carbamate . A solution of 65.0 mg (0.110 mmol) of a 1:1 mixture of
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate and
(3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3-
[ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate (see example 83), 0.050 mL (0.55 mmol) of 37% aqueous formaldehyde, and 0.117 g (0.550 mmol) of NaBH (OAc) 3 was treated with 0.150 g of powdered 4A molecular sieves and the mixture was stirred at RT . After stirring at RT for 18 hours, tic (silica gel, 9:1 CH2Cl2/MeOH) indicated complete loss of starting material at Rf=0.05 and two new components at Rf=0.31 and 0.63. The reaction mixture was filtered and the filtrate concentrated to dryness. The residue was dissolved in CH2C12. The solution was washed with saturated aqueous NaHC03 (3x), dried over MgS04, and concentrated in vacuo . The crude product was subjected to flash chromatography (silica gel, 95:5 to 90:10 CH2Cl2/MeOH) to afford 14 mg (20%) of the Rf=0.31 product as a white foam. Hl-NMR (CDC13) : 7.37-7.11 (8H), 7.10-6.90 (2H), 6.85 (IH), 5.62 (IH), 5.18-4.89 (2H) , 4.79 (IH), 4.00-3.49 (5H), 3.32-2.60 (10H), 2.38 (6H), 1.94- 1.40 (10H) . LCMS(ESI): 647 (M+H) .
Example 34
Figure imgf000129_0001
: 34 :
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] uran-3-yl N- [ (IS,22?) -1- benzyl-3- ( (cyclopentyloxy) [3- (3-methyl-l- imidazolidinyl) phenyl] sulfonylamino) -2- hydroxypropyl ] carbamate and (3S,3a2?, 6aS) hexahydrofuro [2 ,3- ]furan-3-yl 27- [ (IS,22?) -l-benzyl-3- ( (cyclopentyloxy) [3-(3- methyl-1-imidazolidinyl) phenyl] sulfonylamino) -2- hydroxypropyl ] carbamate
A solution of 65.0 mg (0.110 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl ) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate and
(3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino]phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate (see example 83), 0.050 mL (0.55 mmol) of 37% aqueous formaldehyde, and 0.117 g (0.550 mmol) of NaBH (OAc) 3 was treated with 0.150 g of powdered 4A molecular sieves and the mixture stirred at RT. After stirring at RT for 18 hours, tic (silica gel, 9:1 CH2Cl2/MeOH) indicated complete loss of starting material at Rf=0.05 and two new components at Rf=0.31 and 0.63. The reaction mixture was filtered and the filtrate concentrated to dryness. The residue was dissolved in CH2C12. The solution was washed with saturated aqueous NaHC03 (3x), dried over MgS04, and concentrated in vacuo . The crude product was subjected to flash chromatography (silica gel, 95:5 to 90:10 CH2Cl2/MeOH) to afford 20 mg (28%) of the Rf=0.63 product as a white foam. Hl-NMR (CDC13) : 7.40-7.01 (8H), 6.88 (IH), 6.70 (IH), 5.62 (IH), 5.06-4.73 (3H), 4.21- 3.39 (7H), 3.23-2.62 (10H), 2.52 (3H), 1.93-1.20 (10H). LCMS (ESI) : 645 (M+H) .
Example 35
Figure imgf000130_0001
.35) 2-2- (3- [ [ (22?, 3S) -3- ( [ (32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan- 3-yloxy] carbonylamino) -hydroxy-4- phenylbutyl ] (cyclopentyloxy) amino] sulfonylanilino) acetic acid and 2-2- (3- [[ (22?, 3S) -3- ([ (3S,3a2?, 6aS) hexahydrofuro [2,3- b] furan-3-yloxy] carbonylamino) -hydroxy-4 - phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) acetic acid.
A solution of 0.218 g (0.316 mmol) of a 1:1 mixture of tert- butyl 2- (3- [ [ (22?, 3S)-3- ( [ (32?, 3aS, 6a2?) hexahydrofuro [2, 3- Jb] furan-3-yloxy] carbonylamino) -2-hydroxy-4- phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) acetate and tert-butyl 2- (3- [ [ (22?, 3S) -3-
( [ (3S, 3a2?, 6aS) hexahydrofuro [2, 3-Jb] furan-3- yloxy] carbonylamino) -2-hydroxy-4- phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) acetate (see example 30) in 5 mL of CH2C12 was treated with 6 mL of trifluoroacetic acid. After stirring at RT for 2 hours tic (silica gel, hexane/EtOAc) indicated complete loss of starting material and the formation of a new more polar product. The solution was concentrated in vacuo . The residue was dissolved in a minimum volume of CH2C12 and the solution added dropwise to rapidly stirred 4:1 hexane/ether . An off-white solid precipitated which was collected by filtration and dried in vacuo . yield=0.183 g (92%). Hl-NMR (DMSO-de) : 7.25-7.05 (7H) , 6.87 (3H) , 6.53 (IH), 5.46 (IH), 5.16 (IH), 4.82-4.65 (2H) , 3.83-3.23 (7H) , 3.08-2.60 (5H) , 2.38 (IH), 1.91-1.04 (10H). MS(ESI): 634 (M+H) , 656 (M+Na).
Example 36
Step 1
Figure imgf000132_0001
methyl 2-(3-[ [ (22?,3S) -3- ( [ (32?, 3aS, 6a2?) hexahydrofuro [2 ,3- b] furan-3-yloxy] carbonylamino) -2-hydroxy-4- phenylbutyl ] (cyclopentyloxy) amino] sulfonylanilino) acetate and methyl 2- (3- [ [ (22?,3S) -3- ( [ (3S,3a2?, 6aS) hexahydrofuro [2 ,3- b] furan-3-yloxy] carbonylamino) -2-hydroxγ-4- phenylbutyl ] (cyclopentyloxy) amino] sulfonylanilino) acetate A solution of 0.500 g (0.869 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (3-aminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3- b]furan-3-yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate (see example 31), 0.250 L (2.61 mmol) of methyl bromoacetate, and 0.450 mL (2.61 mmol) of N, N-diisopropylethylamine in 5 mL of anyhydrous DMF was stirred at 80°C for 18 hours. The solution was cooled to RT and concentrated in vacuo . The residue was dissolved in ethyl acetate. The solution was washed with saturated aqueous brine (3x) , dried over anhydrous MgS04, and concentrated in vacuo . The crude product was purified by flash chromatography (silica gel, 97:3 CH2Cl2/MeOH) to afford 0.50 g (89%) of the desired product as a light yellow foam. Hl-ΝMR (DMSO-d6) : 7.38-7.08 (7H), 7.01-6.85 (3H), 6.71 (IH), 5.52 (IH), 5.21 (IH), 4.88- 4.70 (2H) , 3.99 (2H), 3.88-3.46 (8H), 3.13-2.64 (5H) , 2.57- 2.35 (IH) , 2.01-1.17 (10H) . LCMS(ESI) : 648 (M+H) .
Step 2:
Figure imgf000133_0001
(36)
(32?,3aS, 6a2?) hexahydrofuro [2 ,3-b] furan-3-γl 27- (IS,22?) -1- benzyl-3- [ (cyclopentyloxy) (3- [ (2- hydroxyethyl) amino]phenylsulfonyl) amino] -2- hydroxypropylcarbamate and (3S,3a2?, 6aS) hexahydrofuro [2 ,3- b] furan-3-yl 27- (IS,22?) -l-benzyl-3- [ (cyclopentyloxy) (3- [ (2- hydroxyethyl) amino]phenylsulfonyl) amino] -2- hydroxypropylcarbamate. A solution of 0.100 g (0.154 mmol) of a 1:1 mixture of methyl 2- (3- [ [ (22?, 3S) -3- ( [ (32?, 3aS, 6a2?) hexahydrofuro [2, 3-jb] furan-3- yloxy] carbonylamino) -2-hydroxy-4- phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) acetate and methyl 2- (3- [ [ (22?, 3S) -3- ( [ (3S, 3a2?, 6aS) hexahydrofuro [2, 3- b] furan-3-yloxy] carbonyl amino) -2-hydroxy-4-- phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) acetate in 10 mL of anhydrous THF at -78°C was treated with 0.23 mL (0.34 mmol) of 1.5 M diisobutylaluminum hydride in toluene by dropwise addition. The solution was allowed to warm to RT. The reaction progress was monitored by tic (silica gel, hexane/EtOAc) . Two additional 0.30 mL aliquots of DIBAL solution were added at 1 hour intervals (cooling the reaction vessel to -78°C each time) to induce complete loss of starting material. After 2 additional hours the reaction mixture was mixed with 25 mL of saturated potassium sodium tartrate and stirred vigorously for 30 minutes. The mixture was diluted with water and extracted with CH2C12 (3x) . The combined extracts were washed with water (3x) , dried over anhydrous MgS0 , and concentrated in vacuo . The residue was purified by flash chromatography (silica gel, 99:1 EtOAc/MeOH) to afford 25 mg (26%) of the desired product as a white foam. Hl-NMR (CDC13) : 7.40-7.03 (10H), 6.92 (IH), 5.62 (IH), 5.13-4.88 (2H) , 4.81 (IH), 3.96-3.44 (8H), 3.32 (2H), 3.22-2.59 (6H), 1.90-1.20 (10H). LCMS(ESI): 620 (M+H) . Example 37
Figure imgf000134_0001
(37;
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- (IS, 22?) -1- benzyl-3- [ (cyclopentyloxy) (3- [2- [ (2-hydroxyethyl) amino] -2- oxoethyl (isobutoxycarbonyl) amino]phenylsulfonyl) amino] -2- hydroxypropylcarbamate and (3S,3a2?, 6aS) hexahydrofuro [2 ,3- b]furan-3-yl 27- (IS, 22?) -l-benzyl-3- [ (cyclopentyloxy) (3- [2- [ (2-hydroxyethyl) amino] -2- oxoethyl (isobutoxycarbonyl) amino]phenylsulfonyl) amino] -2- hydroxypropylcarbamate .
A solution of 60.0 mg (0.0947 mmol) of a 1:1 mixture of 2-2- (3- [ [ (22?, 3S) -3- ( [ (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3- yloxy] carbonylamino) -hydroxy-4-phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) acetic acid and 2-2- (3- [ [ (22?, 3S) -3- ( [ (3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yloxy] carbonyl amino) -hydroxy-4-phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) acetic acid (see example 35) in 3 mL of anhydrous DMF at 0°C was treated with 0.033 mL (0.19 mmol) of N,N-diisopropylethylamine followed by 0.025 mL (0.19 mmol) of isobutyl chloroformate . After stirring at 0°C for 15 minutes the reaction was treated with 3 drops (excess) of ethanolamine . After warming to RT and stirring for 18 hours the solution was concentrated to dryness. The residue was purified by flash chromatography (silica gel, 93:7 CH2Cl2/MeOH) to afford 66 mg (90%) of the desired compound as a white foam. Hl-ΝMR (DMSO-d6) : 8.05 (IH), 7.80 (IH), 7.69 (IH), 7.63-7.50 (2H) , 7.24-7.02 (5H), 6.96 (IH), 5.47 (IH), 5.21 (IH), 4.80-4.67 (2H) , 4.63 (IH), 4.56 (IH), 4.20 (2H), 3.82-3.20 (8H), 3.10 (2H) , 3.05-2.35 (8H), 1.88-1.10 (11H), 0.90-0.72 (6H) . LCMS (ESI): 777 (M+H) .
Example 38 Step 1
Figure imgf000135_0001
(IS,22?) -l-benzyl-3- (isopropyloxy) [ (3- nitrophenyl) sulfonyl ] amino-2-hydroxypropylamine •trifluoroacetic salt. tert-Butyl-N- (( IS, 22?) -l-benzyl-3- (isopropyloxy) [ (3-nitrophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (1.37 g, 2.62 mmol) was dissolved in CH2CI2 (50 ml) . Trifluoroacetic acid (10 mL) was added at 0°C with stirring and the reaction was stirred 2h at room temperature. The solvent was removed by evaporation and was keeped under vacuum. The product was used without purification.
Step 2:
Figure imgf000136_0001
(32?, 3aS,6a2?) Hexahydrofuro [2,3b] furan-3-yl-N- (IS,22?) -1- benzyl-3- [ (isopropyloxy) [ (3-nitrophenyl) sulfonyl]amino-2- hydroxypropylcarbamate. (IS, 22?) -l-benzyl-3- (isopropyloxy) [ (3-nitrophenyl) sulfonyl] amino-2- hydroxypropylamine* trifluoroacetic salt (305 mg, 0.57 mmol) was combined with (32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl (4-nitrophenyl) carbonate (184 mg, 0.62 mmol) in anhydrous CH3CN (8 ml) under a N2 atmosphere. Triethylamine (400 μL,
2.8 mmol) was added and the reaction was stirred at 50°C for 16 hours. Reaction mixture was diluted in EtOAc and washed with water and brine. The organic phase was dried with MgSθ4 and solvent was removed in vacuo . Purification by flash chromatography (30% EtOAc /Hex) . Recovered 204 mg (62%) of the product as a white foam. HPLC showed the material to be 98% pure; Ret. time = 10.10 min. 1-H NMR (CDCI3) : 8.60 (s, IH) , 8.46 (m, IH) , 8.02 (m, IH) , 7.72 (m, IH) , 7.10-7.23 (m, 5H) , 5.58 (m, IH) , 4.97 (m, IH) , 4.80 (m, IH) , 4.94 (m, IH) , 4.50-4.55 (m, IH) , 3.77-3.96 (m, 4H) , 3.59-3.64 (m, 2H) , 2.70-2.97 (m, 5H) , 1.60 (m, IH) , 1.45 (m, IH) , 1.21 (m, 6H) . MS (ES+): Obs M+H @ 580.1 amu.
Step 3:
Figure imgf000137_0001
(32?, 3aS, 6a2?) Hexahydrofuro [2 , 3b] furan-3-yl-N- (IS,22?) -1- benzyl-3- [ (isopropyloxy) [ (3-aminophenyl) sulfonyl ] amino-2- hydroxypropylcarbamate . (32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl-N- (IS, 22?) -1- benzyl-3-[ (isopropyloxy) [ (3-nitrophenyl) sulfonyl] amino-2- hydroxypropylcarbamate (100 mg, 0.17 mmol) was added in 10 mL of NH3 (2N) in MeOH. To this solution was added 100 mg of 10 % Pd/C. The hydrogenetion was performed under 30 psi of hydrogen over 30 minutes. The catalyst was removed by filtration throught a pad of celite. The solvant was removed in vacuo . Recovered 91 mg (96%) of the product as a white foam. HPLC showed the material to be 98% pure; Ret. time =
9.12 min. !H NMR (CDCI3): 7.09-7.24 (m, 9H) , 7.00 (s, IH) , 6.84 (m, IH) , 5.58 (d, IH) , 4.97 (m, IH) , 4.78 (m, IH) ,
4.44-4.48 (m, IH) , 3.77-3.91 (m, 5H) , 3.64 (m, 2H) , 2.71- 3.10 (m, 6H) , 1.44-1.62 (2x m, 2H) , 1.17 (d, 6H) . MS (ES+) : Obs M+H @ 550.2 amu. Example 39
Figure imgf000138_0001
: 39 )
(3S,3a2?,6aS) Hexahydrofuro [2, 3-b] furan-3-yl-N- ( (1S,22?)-1- benzyl-3- (cyclopentyloxy) (2-
[ (methylsulfonyl) amino]benzimidazol-5-ylsulfonyl) amino-2- hydroxypropyl) carbamate. (3S, 3a2?, 6aS) Hexahydrofuro [2, 3- b] furan-3-yl-N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) amino-2- hydroxypropyl) carbamate (0.050 g, 0.1 mmol) was combined with 2- [ (methylsulfonyl) amino] benzimidazol-5-ylsulfonyl chloride (0.055 g, 0.2 mmol) in anhydrous DMF (1 ml) under a
N2 atmosphere. The resulting solution was chilled to 0°C and diisopropylethylethyl amine (0.062 ml, 0.4 mmol) was added. The reaction was allowed to warm to room temperature and stirred for 24 hours. Reaction mixture was diluted in EtOAc and washed with sat. NaHCθ3, 0.5N KHSO4 and brine. Organic phase was dried with MgSθ4 and solvent was removed in vacuo . Purification by preparative TLC (5% MeOH/EtOAc) . Recovered 0.051 g (62%) of the product as a white foam. Rf=
0.42 (5% MeOH/EtOAc) . ^ NMR (CDCI3) 8.09 (1H,Ξ), 7.76 (lH,d), 7.39 (lH,d), 7.32-7.12 (5H,m), 6.54-6.40 (2H,m) , 5.67 (lH,d), 5.10-4.92 (2H,m) , 4.85 (lH,m), 4.00-3.83 (3H,m), 3.82-3.70 (2H,m), 3.62-3.51 (lH,m), 3.38 (lH,m), 3.31 (3H,s), 3.10 (lH,m), 3.04-2.80 (4H,m) , 1.92-1.70
(6H,m), 1.69-1.44 (4H,m). LRMS (M+H) + 694.1. Example 40
Figure imgf000139_0001
: 40 !
(32?, 3aS, 6a2?) Hexahydrofuro [2 , 3-b] furan-3-yl-N- ( (IS,22?) -1- benzyl-3- (cyclopentyloxy) (2-
[ (methylsulfonyl) amino]benzimidazol-5-ylsulfonyl) amino-2- hydroxypropyl) carbamate. (32?, 3aS, 6a2?) Hexahydrofuro [2, 3- b] furan-3-yl-N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) amino-2- hydroxypropyl) carbamate (Step 2, Example 54), (0.065 g, 0.2 mmol) was combined with 2-
[ (methylsulfonyl) amino] benzimidazol-5-ylsulfonyl chloride
(0.071 g, 0.2 mmol) in anhydrous DMF (2 ml) under a N2 atmosphere. The resulting solution was chilled to 0°C and diisopropylethylethyl amine (0.080 ml, 0.5 mmol) was added. The reaction was allowed to warm to room temperature and stirred for 24 hours. Reaction mixture was diluted in EtOAc and washed with sat. NaHCθ3, 0.5N KHSO4 and brine. Organic phase was dried with MgSθ4 and solvent was removed in vacuo . Purification by preparative TLC (5% MeOH/EtOAc) . Recovered 0.051 g (62%) of the product as a white foam. Rf= 0.53 (5%
MeOH/EtOAc) . XH NMR (CDCI3) 8.09 (lH,s), 7.69 (lH,d), 7.43 (lH,d), 7.32-7.08 (5H,m), 6.31-6.18 (2H,m), 5.71-5.59 (2H,m), 5.10-4.92 (2H,m) , 4.85 (lH,m), 4.00-3.83 (3H,m), 3.82-3.70 (2H,m), 3.62-3.51 (lH,m), 3.38 (lH,m), 3.31 (3H,s), 3.10 (lH,m), 3.04-2.80 (4H,m), 1.92-1.70 (6H,m),
1.69-1.44 (4H,m) . LRMS (M+H) + 694.0. Example 41
Figure imgf000140_0001
(41) (32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- ( (IS,22?) -1- benzyl-3- (cyclopentyloxy) [ (4-hydroxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate . (32?, 3aS, 6a2?) hexahydrofuro [2, 3- Jb] furan-3-yl - ( IS, 22?) -l-benzyl-3- [ [4- (benzyloxy) phenyl] sulfonyl (cyclopentyloxy) amino] -2- hydroxypropylcarbamate (Example 95), (1.4 mmol, 903 mg) was stirred vigorously with 10% palladium on carbon (200 mg) , glacial acetic acid (2.8 mmol, 0.156 mL) and ethyl acetate (1 mL) under hydrogen for 20 hours at room temperature. The reaction was filtered and the filtrate concentrated to produce 781 mg (>99%) of a white solid. Rf = 0.2 (1:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.66 (2H,d), 7.30-7.12 (6H,m), 6.93 (2H,d), 5.78 (lH,bs), 5.66 (lH,s), 4.98 (lH,m), 4.81-4.70 (2 H,m), 3.98-3.80 (4H,m), 3.80-3.54 (3H,m), 3.15-2.53 (6H,m), 1.85-1.65 (4H,m), 1.65-1.35 (4H,m); M.S. (ESI) M+H=577.
Example 42
Figure imgf000141_0001
■42:
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- [ (1S,22?)-1- benzyl-3- ( (cyclopentyloxy) [4- (2-hydroxyethoxy) phenyl ] sul onylamino) -2-hydroxypropyl ] carbamate .
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (1S,22?)-1- benzyl-3- (cyclopentyloxy) [ (4-hydroxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (Example 41), (0.13 mmol, 75 mg) , (2-bromoethoxy) ( ert-butyl) dimethylsilane (0.16 mmol, 37 mg) , potassium carbonate (0.40 mmol, 54 mg) , and anhydrous DMF (0.5 mL) were stirred at room temperature for 20 hours under nitrogen. The reaction was warmed to 50°C for 2 additional hours. The reaction was concentrated under vacuum, dissolved in ethyl acetate, washed with distilled water and brine, and dried over magnesium sulfate. The crude material was concentrated under vacuum and the resulting clear oil was purified by silica gel flash chromatography (2:1 hexanes/ethyl acetate) to yield 60 mg (63%) of a clear oil. The resulting silyl ether was then stirred in a 3:1 (CH3CΝ/HF (49%) ) solution for 1 hour and quenched with a saturated aqueous solution of sodium bicarbonate. The reaction was concentrated under vacuum, dissolved in ethyl acetate, washed with distilled water and brine, and dried over magnesium sulfate. The desired alcohol was crystallized from an ether/hexanes solution yielding 20 mg (39%) of white powdery crystals. Rf = 0.1 (1:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 1 . 12 (2H,d), 7.30-7.12 (6H,m), 7.01 (2H,d), 5.64 (lH,s), 4.98 (lH,m), 4.85-4.70 (2H,m), 4.18-4.11 (2H,m) , 4.04-3.76 (7H,m), 3.73- 3.55 (2H,m), 3.10 (lH,bs), 3.04-2.55 (5H,m), 2.10 (IH, m) , 1.86-1.68 (4H,m), 1.68-1.44 (4H,m); MS (ESI): M+H=621.
Example 43
Figure imgf000142_0001
: 43 i
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- (IS, 22?) -3- [ [ (3- N,N-dimethylaminophenyl) sulfonyl] (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate. A mixture of 58mg (0.1 mMol) of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (1S, 22?) -3- [ [ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate (Example 77) and 0.25 L of 37% formaldehyde in 25 mL ethanol was treated with ca.lO mg of 5% palladium on carbon and hydrogenated at 50PSI for 20 minutes. The mixture was filtered, evaporated and purified on a 2 inch plug of silica gel (5% methanol- dichloromethane) to give the desired product as a white foam (30mg) . 1H-NMR (CDC13): 1.5-1.9 (13H), 2.8 (4H), 2.97 (6H), 3.18 (IH), 3.64 (2H) , 3.9 (4H), 4.75-4.95 (4H), 4.99 (IH),
5.62 (IH), 6.95 (IH), 7.0-7.4 (8H). MS: (LC-MS): 604 (MH+) . O 99/65870
- 141
Example 44
Figure imgf000143_0001
( 44 ;
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- ( (IS,22?) -1- benzyl-3- (cyclopentyloxy) [ (3-hydroxyphenyl) sulfonyl ]amino-2- hydroxypropyl) carbamate. This compound was formed (from Example 96) under the same conditions used for (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (4-hydroxyphenyl) sulfonyl] amino- 2-hydroxypropyl) carbamate (Example 41). Rf = 0.2 (1:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.43-7.35 (2H,m) , 7.30-7.10 (8H,m), 6.63 (lH,bs), 5.70 (lH,s), 5.11-4.95 (2H,m), 4.79 (lH,m), 4.03-3.64 (7H,m) , 3.16-2.79 (6H,m), 1.88-1.69 (4H,m), 1.69-1.43 (4H,m) ; MS (ESI): M+Νa=599.
Example 45
Figure imgf000143_0002
(45)
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- (IS,22?) -3- [ [ (3- N-methylaminophenyl) sulfonyl ] (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate. A mixture of 40mg (0.069 mMol) of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (1S, 22?) -3- [ [ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate (Example Example 77) , 0.0048 L (0.077 mMol) of iodomethane and 0.014 mL (0.1 mMol) of triethylamine in 1 mL of dimethyl formamide was heated to 80°C for 12h. The volatiles were removed in vacuo and the residue was purified by semi-prep C-18 HPLC to give the desired mono-amine as a white soild (8 mg) . 1H-ΝMR (CDC13) :1.5-1.9 (13H), 2.75 (IH), 2.8-3.0 (3H), 2.99 (3H), 3.15 (IH), 3.7 (IH), 3.9 (5H), 4.8 (IH), 5.0 (IH), 5.5 (IH), 7.0-7.4 (7H), 7.5 (2H) . MS (LC-MS): 590 (MH+).
Alternatively this material can also be obtained according to the following method: In a dried flask was introduced 1 eq. of (32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl-Ν- (IS, 22?) -l-benzyl-3- [ (cyclopentyloxy) [ (3- (N- (methyl- ert-Butoxycarbonyl) )phenyl) sulfonyl] amino-2-hydroxy propylcarbamate (21.5 mg, 0.031 mmol) in 2 mL dichloromethane. To this solution was added 1 L of trifluoroacetic acid. The reaction was continued at room temperature for 45 min. The solvant was evaporated in vacuo to an oil. The crude material was purified on flash grade silica gel eluting with 50% ethyl acetate in hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide
(32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl-Ν- (IS, 2.2?) -1- benzyl-3-[ (cyclopentyloxy) [ ( 3-N-methylphenyl ) sulfonyl] amino-2-hydroxypropyl carbamate (17.1 mg, 93%). HPLC showed the material to be 98% pure; Ret. time = 11.0 min. Hi-ΝMR (CDCI3): 7.12-7.35 (m, 9H) , 5.60 ( , IH) , 4.75- 5.10 (m, 3H) , 3.70-3.91 (m, 6H) , 3.54 ( , 2H) , 3.29 (m, IH) , 2.84-3.09 (m, 7H) , 1.18-1.98 (m, 9H) and LCMS (ES+) , M+H = 590.2. Example 46
Step 1
Figure imgf000145_0001
27- [ (22?, 3S) -3-amino-2-hydroxy-4-phenylbutyl] -27-
(cyclopentyloxy) -lH-benzimidazole-6-sulfonamide. A mixture of tert-butyl N- ( IS, 22?) -3- [ ( 122-benzimidazol-6- ylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (Example 82), (0.500 g, 0.919 mmol) and trifluoroacetic acid (5mL) was stirred under an Argon atmosphere at ambient temperature for approximately one hour. The reaction was evaporated in vacuo and the residue was partitioned between IN aqueous sodium hydroxide and dichloromethane. After separating the layers, the aqueous phase was diluted with saturated aqueous brine and extracted three times with dichloromethane followed by two extractions with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, evaporated in vacuo and dried under high vacuum to provide N- [ (22?, 3S) -3-amino-2- hydroxy-4-phenylbutyl] -N- (cyclopentyloxy) -122-benzimidazole- 6-sulfonamide (0.423 g, 104%). Hl-ΝMR (chloroform-D3) : 1.60 (m, 4H) , 1.84 (m, 4H) , 2.52 (m, 4H) , 2.90 (m, IH) , 3.03 (m, IH) , 3.27 (m, 2H) , 3.86 (m, IH) , 4.90 ( , IH), 7.25(m, 6H) , 7.81(m, 2H) , 8027 (m, 2H) . MS(ESI): 445(M+H).
Step 2:
Figure imgf000146_0001
:
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- (IS,22?) -3- [ (1H- benzimidazol-6-ylsulfonyl) (cyclopentyloxy) amino] -1-benzyl-2- hydroxypropylcarbamate. A mixture of
(22?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-2-yl 4-nitrophenyl carbonate (38.3 mg, 0.124 mmol) and imidazole (15 mg, 0.222 mmol) were heated under Argon in approximately 2 mL of acetonitrile for 1.5 hrs. To this mixture was then added (N- [ (22?, 3S) -3-amino-2-hydroxy-4-phenylbutyl] -N- (cyclopentyloxy) -12f-benzimidazole-6-sulfonamide (50 mg, 0.113 mmol) and Ν,Ν-diisopropylethylamine (58.9 μL, 0.338 mmol) . After heating at reflux for an additional 6 hrs., the reaction was cooled and evaporated in vacuo . The residue was dissolved in ethyl acetate, washed three times with 5% aqueous potassium carbonate, washed with brine, dried over anhydrous sodium sulfated, filtered and evaporated in vacuo . The residue was purified on a preparative TLC plate (20X20 cm, 1000 μM) eluting with 95:5 methylene chloride : methanol. The plate was allowed to dry through evaporation and then eluted again with 93:7 chloroform : methanol. The product band was removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was lyophilized from acetonitrile : water to provide
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (122- benzimidazol-6-ylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (25 mg, 37%). Hl-NMR (dimethylsulfoxide-D6) : 1.05 (m, IH) , 1.27 (m, IH) , 1.58 ( , 8H) , 2.33 (m, IH) , 2.64 (m, 2H) , 2.96 (m, 2H) , 3.45 (m, 4H) , 3.62 (m, 2H) , 4.72 (m, 2H) , 5.16 (m, IH) , 5.42 (d, IH) , 7.10 (m, 6H) , 7.51 (m, IH) , 7.72 (m, IH) , 7.93 ( , IH) ; 8.44 (s, IH) , 13.0 (b, IH) . MS (ESI): 601 (M+H) .
Example 47
Figure imgf000147_0001
3S) tetrahydro-3-furanyl 27- ( (IS,22?) -l-benzyl-3-
(cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl]amino-2- hydroxypropyl) carbamate. A mixture of 2,5-dioxo-l- pyrrolidinyl [ (3S) tetrahydro-3-furanyl] carbonate (13.8 mg, 0.0602 mmol, WO94/05639) , N1- [ (22?, 3S) -3-amino-2-hydroxy-4- phenylbutyl] -N1- (cyclopentyloxy) -4-methoxy-l- benzenesulfonamide x trifluoracetic acid (Step 1, Example 48), (30 mg, 0.0547 mmol), and Ν, Ν-diisopropylethylamine
(23.8 μL, 0.137 mmol) were combined at ambient temperature under an Argon atmosphere. After stirring for 18 hours, the reaction mixture was evaporated in vacuo to a residue and purified on a preparative silica gel TLC plate (20x20 cm, 500 μM) eluting with 96:4 chloroform : methanol. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, evaporated in vacuo and dried under high vacuum to provide (3S) tetrahydro-3-furanyl N- ( ( 1S, 22?)- l-benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] a ino- 2-hydroxypropyl) carbamate (26 mg, 87%) as a foam. Hl-NMR (chloroform-D3) : 1.73 (m, 9H) , 2.14 (m, IH) , 2.92 (m, 5H) , 3.77 (m, 6H) , 3.87 (s, 3H) , 4.79 (bm, 2H) , 5.10 (bs, IH) , 6.97 (d, 2H), 7.23 (m, 5H) , 7.70 (d, 2H) . MS(ESI): 571 (M+Na) .
Example 48
Step 1
Figure imgf000148_0001
271- [ (22?, 3S) -3-amino-2-hydroxy-4-phenylbutyl ] -271- (cyclopentyloxy) -4-methoxy-l-benzenesulfonamide. trifluoracetic acid. Tert-butyl N- ( (IS, 22?) -l-benzyl-3- -* (cyclopentyloxy) [(4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (0.693 g, 1.29 mmol) was combined with trifluoroacetic acid (5 mL) under an Argon atmosphere at ambient temperature. After stirring for 20 minutes, the reaction mixture was evaporated in vacuo . The residue was0 dissolved several times in dichloromethane and evaporated to remove excess trifluoroacetic acid. The crude product was triturated with hexane and then evaporated and dried under high vacuum to provide the trifluoracetic acid salt of N1- [ (22?, 3S) -3-amino-2-hydroxy-4-phenylbutyl] -N1-5 (cyclopentyloxy) -4-methoxy-l-benzenesulfonamide (0.769g, 108%). Hl-ΝMR (chloroform-D3 + ΝaOD) : 1.58 (m, 4H) , 1.78 (m, 4H) , 2.45 (m, IH) , 2.85 ( , IH) , 2.96 (m, IH) , 3.15 (m, IH) , 3.22 (m, IH) , 3.77 (m, IH) , 3.88 (s, 3H) , 4.78 ( , IH) , - 147 -
7.00 (m, 2H) , 7.23 ( , 5H) , 7.78 (m, 2H) . MS (ESI] 435 (MH+) .
Figure imgf000149_0001
:48)
l,3-dioxan-5-yl 27- ( (IS,22?) -l-benzyl-3- (cyclopentyloxy) [(4- methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate. A mixture of 1, 3-dioxan-5-yl (4-nitrophenyl) carbonate [16.2 mg, 0.0602 mmol, Application: WO 96-US5473) , N1- [ (22?, 3S) -3- amino-2-hydroxy-4-phenylbutyl] -N1- (cyclopentyloxy) -4- methoxy-1-benzenesulfonamide. trifluoracetic acid (30 mg, 0.0547 mmol], and Ν,Ν-diisopropylethylamine (23.8 μL, 0.137 mmol) were combined in approximately 1.5 mL acetonitrile at ambient temperature under an Argon atmosphere. After stirring for 18 hours, the reaction mixture was evaporated in vacuo to a residue and purified on a preparative silica gel TLC plate (20x20 cm, 500 μM) eluting with 96:4 chloroform : methanol. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was dissolved in diethylether, evaporated in vacuo and dried under high vacuum to provide 1, 3-dioxan-5-yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (20. 6 mg, 67%) as a foam. Hl-ΝMR (chloroform-D3) : 1.66 (m, 8H) , 2.94 (m, 5H) , 3.87 (m, 8H) , 4.48 (bs, IH) , 4.76 (m, 2H) , 4.94 (m, 2H) , 6.97 (m, 2H) , 7.24 (m, 5H) , 7.69 (m, 2H) . MS (ESI): 587 (M+Na).
Example 49
Figure imgf000150_0001
:49:
(2S) -271- (IS, 22?) -3- [ [ (3-aminophenyl) sulfonyl ] (cyclopentyl oxy) amino] -l-benzyl-2-hydroxypropyl-2- [ (2-quinolinyl carbonyl) amino]butanediamide. A mixture of 3-amino-N1- [ (22?, 3S) -3-amino-2-hydroxy-4-phenylbutyl] -N1- ( cyclopentyloxy) -1-benzenesulfonamide (Step 1, Example 27), (60 mg, 0.143), 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (29 mg, 0.15 mmol), Ν- hydroxybenzotriazole (20 mg, 0.15 mmol), and (2S) -4-amino-4- oxo-2- [ (2-quinolinylcarbonyl) amino ]butanoic acid • hydrochloride (49 mg, 0.15 mmol, Eur. Pat. Appl . EP 432694) was combined under an Argon atmosphere at ambient temperature in anhydrous dimethyl formamide (2 mL) . After addition of Ν,Ν- diisopropylethylamine (76 μL, 0.437 mmol), the mixture was stirred for 16 hours. The reaction solvent was removed in vacuo and the residue was dissolved in ethyl acetate. The solution was transferred to a separatory funnel and washed twice with IN sodium hydrogen sulfate. The combined aqueous layers were extracted with ethyl acetate. The combined organic layers were washed with 5% aqueous potassium carbonate and brine, dried over anhydrous sodium sulfate, filtered and evaporated in vacuo . The residue was purified on a preparative TLC plate (20X20 cm, 1000 μM) eluting with 95:5 methylene chloride : methanol. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was purified again on a preparative TLC plate (20X20 cm, 500 μM) eluting with 95:5 methylene chloride : methanol. The product band was removed, eluted with 3:1 methylene chloride: methanol, filtered, and evaporated in vacuo . The residue was lyophilized from acetonitrile : water to provide (25) -N1- (IS, 22?) -3- [ [ ( 3-aminophenyl ) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2-hydroxypropyl-2- [ (2-quinolinylcarbonyl) amino] butanediamide (32 mg, 33%) as a white lyophile. Hl-ΝMR (chloroform-D3) : 1.57 ( , 8H) , 2.57 (m, IH) , 2.82 (m, 4H) , 3.09 ( , IH) , 3.35 (b, IH) , 3.73 (b, IH) , 4.18 (m, 3H) , 4.74 (m, IH) , 4.87 (m, IH) , 5.47 (b, IH) , 5.86 (b, IH) , 7.00 (m, 10H), 7.56 (m, IH) , 7.73 (m, IH) , 7.81 (d, IH) , 8.11 (m, 2H) , 8.24 (d, IH) , 9.15 (d, IH) . MS(ESI): 689(M+H).
Example 50
Figure imgf000151_0001
(50;
(2S)-271-( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (4- methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) -2- [ (2- quinolinylcarbonyl) amino] butanediamide. A mixture of N1- [ (22?, 3S) -3-amino-2-hydroxy-4-phenylbutyl] -N1- (cyclopentyloxy) -4-methoxy-l-benzenesulfonamide (Step 1,
Example 48), (73 mg, 0.168), 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (34 mg, 0.18 mmol), N- hydroxybenzotriazole (24 mg, 0.18 mmol), and (25) -4-amino-4- oxo-2- [ (2-quinolinylcarbonyl) amino ]butanoic acid hydrochloride (57 mg, 0.18 mmol, Eur. Pat. Appl . EP 432694) was combined under an Argon atmosphere at ambient temperature in anhydrous dimethylformamide (2 mL) . After addition of N,N- diisopropylethylamine (896 μL, 0.513 mmol), the mixture was stirred for 16 hours. The reaction solvent was removed in vacuo and the residue was dissolved in ethyl acetate. The solution was transferred to a separatory funnel and washed twice with IN sodium hydrogen sulfate. The combined aqueous layers were extracted with ethyl acetate. The combined organic layers were washed with 5% aqueous potassium carbonate and brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was purified on a preparative TLC plate (20X20 cm, 1000 μM) eluting with 97:3 chloroform : methanol. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was triturated with hexane and diethyl ether. The slurry was evaporated in vacuo to a residue and dried under high vacuum to provide (2S) -N1- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) -2- [ (2-quinolinylcarbonyl) amino] butanediamide (49 mg, 41%) as a white solid. Hl-ΝMR (chloroform-D3) : 1.52 (m, 4H) , 1.75 (m, 4H) , 2.82 (m, 5H) , 3.10 (m, IH) , 3.82 (b, IH) , 3.84 (s, 3H) , 3.91 m, IH) , 4.29 ( , IH) , 4.78 ( , IH) , 4.95 (m, IH) , 5.76 (b, IH) , 6.22 (b, IH) , 7.00 (m, 5H) , 7.12 (d, 2H) , 7.22 (d, IH) , 7.60 (m, IH) . 7.75 (m, 3H) , 7.83 (d, IH) , 8.14 (m, 2H) , 8.25 (d, IH) , 9.15 (d, IH) . MS(ESI): 704 (M+H) . Example 51
Step 1:
Figure imgf000153_0001
(2S) -4-Amino-4-oxo-2- [ (2-quinolinylcarbonyl) amino]butanamido N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) amino] -2- hydroxypropylcarbamate. Tert-butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate (412 mg, 1.13 mmol) was dissolved in dichloromethane (8 mL) in a 25 mL round bottomed flask under nitrogen and trifluoroacetic acid (4 L) was added slowly. After the solution was stirred for 4 hours, TLC indicated loss of starting material. After the workup described in Step 2, Example 54, the residue was dissolved in anhydrous DMF (5 mL) followed by (2S) -4-amino-4-oxo-2- [ (2-quinolinylcarbonyl) amino] butanoic acid hydrochloride (320 mg, 1.13 mmol), anhydrous diisopropylethylamine (0.4 mL, 2.26 mmol), l-(3- dimethyl-aminopropyl) -3-ethylcarbodiimide hydrochloride (220 mg, 1.13 mmol), and 1-hydroxy-benzotriazole (150 mg, 1.13 mmol) . The reaction was stirred for 18 h and concentrated in vacuo. Ethyl acetate (15 mL) and IN HCl (15 mL) were added and the layers were separated. The aqueous layer was adjusted with solid sodium carbonate to pH 9 and then extracted with ethyl acetate (25 mL) . The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. Preparative silica gel TLC of the residue using 90:10 chloroform: methanol as eluent yielded the product as a white solid (91 mg, 0.171 mmol, 15%). MS(ES): 534 (M+l), 532 (M-l) . Step 2 :
Figure imgf000154_0001
' 5i :
(2S) -4-Amino-4-oxo-2- [ (2-quinolinylcarbonyl) amino]butanamido N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) (2- { (methoxycarbonyl) amino] -lH-benzimidazol-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate. (2S) -4-Amino-4- oxo-2- [ (2-quinolinylcarbonyl) amino] butanamido- N- (IS, 2R) -1- benzyl-3- [ (cyclopentyloxy) -amino] -2-hydroxypropylcarbamate (Step 1, above), (44 mg, 0.0825 mmol), methyl N-[5- (chlorosulfonyl) -lH-benzimidazol-2-yl] carbamate (24 mg, 0.0825 mmol), and anhydrous diisopropylethylamine (0.05 mL, 0.280 mmol) were combined in anhydrous tetrahydrofuran (3 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. Ethyl acetate (30 mL) and water (10 mL) were added and the layers were separated. The organic layer was washed with brine (10 mL) , dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to provide the desired product as a white solid (11 mg, 0.014 mmol,- 17%). **HNMR (d6-DMS0) δ: 8.86 (d, J=8.4 Hz, IH) , 8.62 (d, J=8.4 Hz,
IH) , 8.22-6.94 (m, 12H) , 5.19 (d, J=6.2 Hz, IH) , 4.77-4.72 (m, 2H) , 4.02-1.35 (m, 17H) , 3.80 (s, 3H) . MS(ES): 787 (M+l) , 785 (M-l) . Example 52
Figure imgf000155_0001
52 '
(2S) -4-Amino-4-oxo-2- [ (2-quinolinylcarbonyl) amino]butanamido N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) (lH-indazol-6- ylsulfonyl) amino] -2-hydroxypropylcarbamate. (2S) -4-Amino-4- oxo-2- [ (2-quinolinylcarbonyl) -amino] butanamido N- (IS, 2R) -1- benzyl-3- [ (cyclopentyloxy) -amino] -2-hydroxypropylcarbamate (Step 1, Example 51), (44 mg, 0.0825 mmol), 1-trityl-lH- indazole-6-sulfonyl chloride (38 mg, 0.0825 mmol), and anhydrous diisopropylethylamine (0.05 mL, 0.280 mmol) were combined in anhydrous tetrahydrofuran (3 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. Ethyl acetate (30 mL) and water (10 mL) were added and the layers were separated. The organic layer was washed with brine (10 mL) , dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The compound was deprotected as described in Example 57 and purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to provide the desired product as a white film (9 mg, 0.013 mmol, 15%). XHNMR (d6-DMS0) δ: 8.84 (d, J=8.5 Hz, IH) , 8.61 (d, J=8.5 Hz, IH) , 8.31-6.95 (m, 13H) , 5.24 (d, J=6.6 Hz,
IH) , 4.81-4.72 (m, 2H) , 3.97 (bs, IH) , 3.68 (bs, IH) , 3.40- 1.20 (m, 15H) . MS(ES): 714 (M+l), 712 (M-l). Example 53
Step 1:
Figure imgf000156_0001
(3S)Tetrahydro-3-furanyl N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate. Tert- butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) amino] -2- hydroxypropylcarbamate [Example 54] (1.05 g, 2.88 mmol) was dissolved in dichloromethane (12 mL) in a 50 mL round bottomed flask under nitrogen and trifluoroacetic acid (8 L) was added slowly. After the solution was stirred for 4 hours, TLC indicated loss of starting material. After the workup described in Step 2, Example 54, the residue was dissolved in anhydrous acetonitrile (15 mL) , followed by 1- ( [ (3S) tetrahydro-3-furanyloxy] -carbonyloxy) dihydro-122- pyrrole-2, 5-dione (660 mg, 2.88 mmol), anhydrous diisopropylethylamine (0.50 mL, 2.88 mmol), and N,N- dimethylaminopyridine (105 mg, 0.86 mmol). The reaction was heated at 50°C for 2 hours, allowed to cool, and concentrated in vacuo. After the workup described in Step 2, Example 54, the residue was purified by flush chromatography over a bed of silica gel using a gradient elution of hexane: ethyl acetate (1:2 to 1:5) to give the desired product as a white foam (440 mg, 1.16 mmol, 40%). MS (ES) : 379 (M+l) . Step 2 :
Figure imgf000157_0001
53 '
(3S)Tetrahydro-3-furanyl N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) (2- [ (methoxycarbonyl) amino] -1H- benzimidazol-5-ylsulfonγl) amino] -2-hydroxypropylcarbamate.
(3S)Tetrahydro-3-furanyl N- (IS, 2R) -l-benzyl-3-
[ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate (120 mg, 0.317 mmol), methyl N- [5- (chlorosulfonyl) -lH-benzimidazol-2- yl] carbamate (100 mg, 0.345 mmol), anhydrous diisopropylethylamine (0.06 mL, 0.345 mmol), and N,N- dimethylaminopyridine (12 mg, 0.09 mmol) were combined in anhydrous tetrahydrofuran (6 mL) and anhydrous N,N- dimethylformamide (3 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to provide the desired product as a colorless glass (43 mg,
0.068 mmol, 21%). XHNMR (d6-DMS0) δ: 7.96-7.08 (m, 10H) ,
5.19 (d, J=6.7 Hz, IH) , 4.96-4.82 (m, 3H) , 3.81 (s, 3H) ,
3.75-3.40 (m, 6H) , 3.09-2.40 ( , 4H) , 2.09-1.35 (m, 8H) . MS(ES): 632 (M+l), 630 (M-l). Example 54
Step 1
Tert-butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) aminoJ -2- hydroxypropylcarbamate. To a solution of 2- (cyclopentyloxy) -lH-isoindole-1, 3 (2H) -dione (11.3 g, 48.9 mmol) in anhydrous tetrahydrofuran (60 mL) in a 200 mL round bottomed flask under nitrogen was added anhydrous hydrazine (1.6 g, 48.9 mmol) dropwise via syringe. The resulting thick white slurry was vigorously stirred for 2.5 hours and then filtered through a fritted funnel. The cake was washed with tetrahydrofuran (2 x 20 mL) and the combined filtrates were placed in a 300 mL round bottomed flask under nitrogen and equipped with a condenser. Tert-butyl N-(1S)-1- [ (2S) oxiranyl] -2-phenylethylcarbamate (7.50 g, 28.5 mmol) was added along with anhydrous lithium triflate (6.20 g, 39.7 mmol) and the reaction was heated at reflux for 24 hours. The reaction was allowed to cool and was concentrated in vacuo to a viscous oil. Diethyl ether (150 mL) and water (50 mL) were added and the layers were separated. The ethereal layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flush chromatography over a bed of silica gel using a gradient elution of hexane: ethyl acetate (4:1 to 2:1) gave the desired product as a white solid (8.90 g, 24.4 mmol, 86% based upon starting epoxide) . XHNMR (CDC13) δ: 7.32-7.19 ( , 5H) , 5.90 (bs, IH) , 4.59 (d, J=8.1 Hz, IH) , 4.24-4.20 (m, IH) , 3 . 90- 3 . 58 ( , 3H ) , 3 . 1 6-2 . 83 (m, 4H ) , 1 . 69- 1 . 35 (m, 16H) MS (ES ) : 365 (M+ l ) , 2 65 (M-BOC ) .
Figure imgf000159_0001
(3aS,6aR) Hexahydrofuro [2, 3-b] furan-3-yl N- (1S,2R) -1-benzyl- 3- [ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate . Tert- butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) amino] -2- hydroxy-propylcarbamate (step 1 above), (1.50 g, 4.12 mmol) was dissolved in dichloromethane (15 mL) in a 50 mL round bottomed flask under nitrogen and trifluoroacetic acid (10 mL) was added slowly. After the solution was stirred for 3 hours, TLC indicated loss of starting material. The reaction was concentrated in vacuo and ethyl acetate (30 L) was added. A 10% solution of aqueous sodium carbonate was added portionwise until the pH was adjusted to 9. The layers were separated and the organic layer was extracted withl N HCl (20 mL) . The aqueous layer was then neutralized with solid sodium carbonate until the pH was 9. The resulting white precipitate was dissolved by the addition of ethyl acetate (100 mL) and the layers were separated. The aqueous layer was extracted with ethyl acetate (25 mL) and the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to a sticky white solid. Anhydrous acetonitrile (20 mL) was added, followed by racemic (3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl 4-nitrophenyl carbonate (1.21 g, 4.12 mmol), anhydrous diisopropylethylamine (0.72 mL, 4.12 mmol), and N,N- dimethylaminopyridine (150 mg, 1.23 mmol). The reaction was heated at 50°C for 2 hours, allowed to cool, and concentrated in vacuo. Diethyl ether (50 mL) and 5% sodium carbonate (20 mL) were added and the layers were separated. The organic layer was washed with water (20 mL) , brine (15 mL) , dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flush chromatography over a bed of silica gel using a gradient elution of hexane: ethyl acetate (1:1 to 1:4) gave the desired product as a pale yellow foam (1.41 g, 33.5 mol, 81%). XHNMR (d6-DMS0) : δ 7.29-7.13 (m, 5H) , 6.18 (bs, IH) , 5.58-5.52 (m, IH) , 4.96-4.82 (m, 2H) , 4.14 (bs, IH) , 3.88-3.34 (m, 6H) , 3.04-2.53 (m, 6H) , 1.92- 1.30 (m, 9H) . MS(ES): 421 (M+l), 419 (M-l).
Step 3
Figure imgf000160_0001
: 54 :
(3aS,6aR) Hexahydrofuro [2, 3-b] furan-3-yl N- (1S,2R) -1-benzyl- 3- [ (cyclopentyloxy) (2- [ (methoxycarbonyl) amino] -1H- benzimidazol-5-ylsulfonyl) amino] -2-hydroxypropylcarbamate .
(3aS, 6aR) Hexahydrofuro [2, 3-b] furan-3-yl N- ( IS, 2R) -1-benzyl- 3- [ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate (100 mg, 0.238 mmol), methyl N- [5- (chlorosulfonyl) -lH-benzimidazol-2- yl]carbamate (70 mg, 0.238 mmol), anhydrous diisopropylethylamine (0.04 mL, 0.238 mmol), and N,N- dimethylamino-pyridine (9 mg, 0.07 mmol) were combined in anhydrous tetrahydrofuran (5 mL) and anhydrous N,N- dimethylformamide (3 mL) in a 25 L round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. Ethyl acetate (30 mL) and 0.5 N HCl (10 mL) were added and the layers were separated. The organic layer was washed with brine (10 mL) , dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Preparative silica gel TLC using 90:10 chloroform: methanol as an eluent provided the product as a white foam (83 mg, 0.123 mmol, 52%). :HNMR (d6-DMS0) δ: 7.60-7.15 (m, 10H), 5.51-5.46 (m, IH) , 5.21 (bd, J=5.9 Hz, IH) , 4.82-4.69 (m, 2H) , 3.81 (s, 3H) , 3.78-3.57 (m, 8H) , 3.19-2.42 (m, 4H) , 2.02-1.30 (m, 8H) . MS(ES): 674 (M+l), 672 (M-l).
Example 55
Figure imgf000161_0001
1 ,3-Dioxan-5-yl N- (1S,2R) -l-benzyl-3-
[ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate. Tert-butyl
N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) amino] -2- hydroxypropylcarbamate (1.38 g, 3.79 mmol) was dissolved in dichloromethane (15 L) in a 50 mL round bottomed flask under nitrogen and trifluoroacetic acid (8 mL) was added slowly. After the solution was stirred for 4 hours, TLC indicated loss of starting material. After the workup described in Step 2, Example 54, the residue was dissolved in anhydrous acetonitrile (20 mL) , followed by 1, 3-dioxan-5- yl 4-nitrophenyl carbonate (1.02 g, 3.79 mmol), anhydrous diisopropylethylamine (0.65 mL, 3.8 mmol), and N,N- dimethylaminopyridine (140 mg, 1.14 mmol). The reaction was heated at 50°C for 2 hours, allowed to cool, and concentrated in vacuo. After the workup described in Step 2, Example 54, the residue was purified by flush chromatography over a bed of silica gel using a gradient elution of hexane: ethyl acetate (1:2 to 1:4) to give the desired product as a white foam (600 mg, 1.52 mmol, 40%).
2HNMR (ds-DMSO) δ: 7.30-7.17 (m, 5H) , 6.15 (bs, IH) , 4.91- 4.67 (m, 3H) , 4.35-3.50 (m, 4H) , 3.11-2.52 (m, 8H) , 1.68- 1.36 (m, 8H) . MS (ES) : 395 (M+l).
Step 2:
Figure imgf000162_0001
: 55)
l,3-Dioxan-5-yl N- (IS,2R) -l-benzyl-3- [ (cyclopentyloxy) (2- { (methoxycarbonyl) amino] -lH-benzimidazol-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate. 1, 3-Dioxan-5-yl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) -amino] -2- hydroxypropylcarbamate (Step 1, above), (100 mg, 0.254 mmol), methyl N- [5- (chlorosulfonyl) -lH-benzimidazol-2- yl] carbamate (73 mg, 0.254 mmol), anhydrous diisopropylethyl-amine (0.05 mL, 0.254 mmol), and N,N- dimethylaminopyridine (9 mg, 0.08 mmol) were combined in anhydrous tetrahydrofuran (5 mL) and anhydrous N,N- dimethylformamide (2 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 93:7 chloroform: methanol as an eluent to provide the desired product as a colorless glass (40 mg, 0.0618 mmol, 24%) . -"H MR (d6-DMSO) δ: 7.96-7.16 (m, 10H) , 5.17 (d, J=6.4 Hz, IH) , 4.82-4.65 (m, 3H) , 4.26 (bs, IH) , 3.81 (s, 3H) , 3.78-3.49 ( , 5H) , 3.05-2.40 (m, 4H) , 2.05- 1.40 (m, 8H) . MS(ES) : 648 (M+l) , 646 (M-l) .
Example 56
Figure imgf000163_0001
:56!
(3S) Tetrahydro-3-f ranyl N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) (lH-indazol-5-ylsulfonyl) amino] -2- hydroxypropylcarbamate. (3S) Tetrahydro-3-furanyl N-(1S,2R)- 1-benzyl-3- [ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate (Step 1, Example 53), (90 mg, 0.238 mmol), 1-trityl-lH- indazole-5-sulfonyl chloride (110 mg, 0.238 mmol), anhydrous diisopropylethylamine (0.04 mL, 0.238 mmol), and N,N- dimethylaminopyridine (9 mg, 0.07 mmol) were combined in anhydrous tetrahydrofuran (4 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 1:1 hexane: ethyl acetate as an eluent to give the tritylated product as a colorless film. The compound was deprotected as described in Example 57 and purified by preparative silica gel TLC using 3:1 ethyl acetate: hexane as an eluent to provide the desired product as a colorless film (6 mg, 0.01 mmol, 5%) . (no HNMR data available). MS(ES): 559 (M+l), 557 (M-l). Example 57
Figure imgf000164_0001
57'
(3aS,6aR) Hexahydrofuro [2, 3-b] furan-3-yl N- (1S,2R) -1-benzyl- 3- [ (cyclopentyloxy) (lH-indazol-5-ylsulfonyl) amino] -2- hydroxypropylcarbamate. (3aS, 6aR) Hexahydrofuro [2, 3-b] furan- 3-yl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) -amino] -2-hydroxy propylcarbamate (100 mg, 0.238 mmol) (Step 2, Example 54), l-trityl-lH-indazole-5-sulfonyl chloride (110 mg, 0.238 mmol), anhydrous diisopropylethylamine (0.04 mL, 0.238 mmol), and N, -dimethylaminopyridine (9 mg, 0.07 mmol) were combined in anhydrous tetrahydrofuran (5 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 1:1 hexane: ethyl acetate as an eluent to give the tritylated product as a colorless film (80 mg, 0.095 mmol, 40%). The trityl protecting group was removed by dissolving the compound in dichloromethane (3 mL) and adding trifluoroacetic acid (1 mL) . After 2.5 hours of stirring, the reaction was concentrated in vacuo. Ethyl acetate (15 mL) and 10% aqueous sodium carbonate (5 L) were added and the layers separated. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative silica gel TLC using 3:1 ethyl acetate: hexane as an eluent to provide the desired product as a white solid (30 mg, 0.05 mmol, 53%). ""HNMR (d6-DMS0) δ: 8.39-8.30 (m, 2H) , 7.81-7.67 ( , 2H) , 7.25-
7.17 (m, 5H) , 5.51-5.46 (m, IH) , 5.25 (d, J=6.3 Hz, IH) ,
4.83-4.62 (m, 2H) , 4.14-4.12 (m, 4H) , 3.72-1.26 (m, 18H) . MS(ES): 601 (M+l), 599 (M-l).
Example 58
Figure imgf000165_0001
(3S) Tetrahydro-3-furanyl N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) (lH-indazol-6-ylsulfonyl) amino] -2- hydroxypropylcarbamate. (3S) Tetrahydro-3-furanyl N-(1S,2R)- 1-benzyl-3- [ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate (Step 1, Example 53), (120 mg, 0.317 mmol), 1-trityl-lH- indazole-6-sulfonyl chloride (146 mg, 0.317 mmol), anhydrous diisopropylethylamine (0.06 L, 0.317 mmol), and N,N- dimethylaminopyridine (12 mg, 0.1 mmol) were combined in anhydrous tetrahydrofuran (5 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 1:1 hexane: ethyl acetate as an eluent to give the tritylated product as a colorless film (100 mg, 0.125 mmol) . The compound was deprotected as described in Example 57 and purified by preparative silica gel TLC using 3:1 ethyl acetate: hexane as an eluent to provide the desired product as a colorless glass (30 mg, 0.0537 mmol, 43%). :HNMR (de-DMSO) δ: 8.33 (bs, IH) , 8.07-8.00 (m, 2H) , 7.49-7.41 (m, IH) , 7.26-7.08 (m, 5H) , 5.32-4.78 (m, 4H) , 3.81-1.25 ( , 20H) . MS(ES): 559 (M+l), 557 (M-l) .
Example 59
Figure imgf000166_0001
:59)
(3aS,6aR)Hexahydro[2,3-b]furan-3-yl N- (1S,2R) -1-benzyl-3- [(cyclopentyloxy) (lH-indazol-6-ylsulfonyl) amino] -2- hydroxypropylcarbamate. (3aS, 6aR) Hexahydrofuro [2, 3-b] furan- 3-yl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) -amino] -2- hydroxypropyl arbamate (Step 2, Example 54), (100 mg, 0.238 mmol), l-trityl-lH-indazole-6-sulfonyl chloride (110 mg, 0.238 mmol), anhydrous diisopropylethylamine (0.04 mL, 0.238 mmol), and N,N-dimethylamino-pyridine (9 mg, 0.07 mmol) were combined in anhydrous tetrahydrofuran (5 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 1:1 hexane: ethyl acetate as an eluent to give the tritylated product as a colorless film (117 mg, 0.139 mmol, 58%) . The compound was deprotected as described in Example 57 and purified by preparative silica gel TLC using 3:1 ethyl acetate: hexane as an eluent to provide the desired product as a colorless film (60 mg, 0.100 mmol, 72%). :HNMR (d6-DMS0) δ: 8.33 (bs, IH) , 8.08-7.99 (m, 2H) , 7.50-7.45 (m, IH) , 7.23-7.15 (m, 5H) , 5.51-5.45 (m, IH) , 5.26 (bd, J=5.9 Hz, IH) , 4.85-4.66 ( , 2H) , 3.77-1.14 (m, 22H) . MS(ES): 601 (M+l), 599 (M-l). Example 60
6o;
l,3-Dioxan-5-yl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (1H- indazol-6-ylsulfonyl) amino] -2-hydroxypropylcarbamate. 1, 3-
Dioxan-5-yl N- ( IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) amino] -2- hydroxypropylcarbamate (Step 1, Example 55), (100 mg, 0.254 mmol) , l-trityl-lH-indazole-6-sulfonyl chloride (117 mg, 0.254 mmol), anhydrous diisopropylethylamine (0.05 mL, 0.254 mmol), and N, N-dimethylaminopyridine (9 mg, 0.08 mmol) were combined in anhydrous tetrahydrofuran (5 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 1:1 hexane: ethyl acetate as an eluent to give the tritylated product as a beige foam. The compound was deprotected as described in Example 57 and purified by preparative silica gel TLC using 3:1 ethyl acetate: hexane as an eluent to provide the desired product as a colorless glass (53 mg, 0.0922 mmol, 36%). --HNMR (dg-DMSO) δ: 8.32 (bs, IH) , 8.06-8.00 (m, 2H) , 7.49-7.46 (m, IH) , 7.33-7.16 (m, 5H) , 5.22 (d, J=6.5 Hz, IH) , 4.85-4.66 (m, 3H) , 4.23-3.00 (m, 12H) , 2.01-1.43 (m, 8H) . MS(ES): 575 (M+l), 573 (M-l). Example 61
Figure imgf000168_0001
β i ;
(3S) tetrahydro-3-furanyl N- (1S,2R) -3- [ [ (3- aminophenyl) sulfonyl] (isopropoxy) amino] -l-benzyl-2- hydroxypropylcarbamate. tert-Butyl N- (IS, 2R) -3- [ [ (3- aminophenyl) sulfonyl] (isopropoxy) amino] -l-benzyl-2- hydroxypropylcarbamate (0.50 g, 1.01 mmol) was dissolved in TFA/CH2C12 (50/50, 5.0 mL) at rt . After 0.5h., the TFA/CH2C12 was removed in vacuo and the reside was partitioned between CH2C12(100 mL) and 1. ON NaOH (50 mL) . The organic layer was washed with water (1 x 25 mL) , brine (1 x 25 mL) , dried (MgS04), filtered, and evaporated to give the free base. To a solution of the free base in CH3CN ( 10 mL) was added DIEA (0.175 mL, 1.01 mmol) and 2, 5-dioxo-l-pyrrolidinyl [ (3S) tetrahydro-3-furanyl] carbonate (0.213 g, 0.93 mmol) respectively with stirring at rt. After l.Oh., the reaction mixture was evaporated and the crude residue purified by column chromatography: 40/60 hexane/ethyl acetate to give the product as a white solid (0.320g, 63%) . MS: M+NA = 530. !H NMR (CD30D) 1.25(m, 6H) ; 1.80 (m, IH) ; 2.05(m, IH) ; 2.40- 3.10 (m, 4H) ; 3.45 (d, IH) ; 3.75 (m, IH) ; 3.70-3.90 (m, 5H) ; 4.50(m, IH) ; 4.95 (m, IH) ; 6.90(d, IH) ; 7.05(d, IH) ; 7.10- 7.35 (m, 7H) . Example 62
Figure imgf000169_0001
: 62 )
(3S) tetrahydro-3-furanyl N- ( (1S,2R) -1-benzyl-2-hydroxy-3- isopropoxy [ (2-oxo-2 ,3-dihydro-lH-l ,3-benzimidazol-5- yl) sulfonyl ] aminopropyl) carbamate. Prepared using the procedure outlined in Example 61. The product was purified by column chromatography: 97/3 CH2Cl2/Me0H and isolated as a white solid (40%). MS: M+H = 549 XH NMR (CD3OD) 1.25(m, 6H) ; 1.60 (m, IH) ; 1.95 (m, IH) ; 2.40-3.10 ( , 4H) ; 3.40 (d, IH) ; 3.70-3.90 (m, 5H) ; 4.55 (m, IH) ; 4.90 (m, IH) ; 7.20 (m, 5H) ; 7.80 ( , 2H) 8.20(s, IH) ; 8.40(s,lH) 7.20 ( , 6H) ; 7.50(m, 2H) .
Example 63
Figure imgf000169_0002
63 !
(3S) tetrahydro-3-furanyl N- (1S,2R) -3- [ (1H-1 ,3-benzimidazol- 5-γlsulfonyl) (isopropoxy) amino] -l-benzyl-2- hydroxypropylcarbamate. Prepared using the procedure outlined in Example 6. The product was purified by column chromatography: 97/3 CH2Cl2/MeOH and isolated as white solid
(31%). MS: M+H = 533 **H NMR (CD3OD) 1.25 (m, 6H) ; 1.60(m, IH) ; 1.95(m, IH) ; 2.40-3.10 ( , 4H) ; 3.40 (d, IH) ; 3.70- 3.90 (m, 5H) ; 4.55 (m, IH) ; 4.90 ( , IH) ; 7.20 (m, 5H) ; 7.80(m, 2H) 8.20 (s, IH) ; 8.40 (s, IH) .
Example 64
Figure imgf000170_0001
(64!
(3S) tetrahydro-3-furanyl 27- ( (IS,22?) -l-benzyl-3-
(cyclohexyloxy) [(4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate . tert-butyl N- ( (IS, 22?) -l-benzyl-3- (cyclohexyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (0.09 mmol, 50 mg) was dissolved in a 1:1 solution of CH2C12/TFA (1 mL) and allowed to stir at room temperature for 1 hour. The solution was then extracted into ethyl acetate, washed with saturated sodium bicarbonate solution and brine, dried over magnesium sulfate, and concentrated to a clear oil. The resulting oil was then dissolved in THF (1 mL) and combined with 2,5- dioxo-1-pyrrolidinyl [ (3S) tetrahydro-3-furanyl] carbonate (0.05 mmol, 13 mg) DIEA (0.08 mmol, 14 μL) and allowed to stir for 15 hours. The reaction was neutralized by the addition of acetic acid and partitioned between water and ethyl acetate. The organic layer was washed with saturated sodium bicarbonate and brine, and dried over magnesium sulfate. The crude product was concentrated to a white solid and purified by silica gel chromatography (1:1 hexanes/ethyl acetate), providing 19 mg (37%) of a white solid. Hl-NMR (CDC13) : δ 7.70 (2H,d), 7.29-7.17 (6H,m), 6.97 (2H,d), 5.1 (lH,s), 4.76 (lH,d), 4.17 (lH,m), 3.86 (3H,s), 3.87-3.70 (6H,m), 3.68-3.60 (lH,m), 3.06 (lH,bs), 2.89 (2H,m), 2.02 (3H,m), 1.89 (lH,m), 1.71 (2H,m) , 1.28-1.08 (6H,m); MS (ESI): M+Na =585.
Example 65
Figure imgf000171_0001
65]
l,3-dioxan-5-yl 27- ( (IS, 22?) -l-benzyl-3- (cyclohexyloxy) [ (4- methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate. tert-butyl N- { (IS, 22?) -l-benzyl-3- (cyclohexyloxy) [ (4- methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate (0.09 mmol, 50 mg) was stirred in 1 mL trifluoroacetic acid (TFA) at room temperature for 5 hours. The TFA was removed under vacuum, and the resulting residue was dissolved in ethyl acetate, washed with 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated to a residue. The resulting free amine, 1, 3-dioxan-5-yl 4- nitrophenyl carbonate (0.09 mmol, 25 mg) , diisopropylethylamine (0.14 mmol, 0.024 mL) , a crystal of , N-dimethylaminopyridine , 4 A molecular sieves and acetonitrile (0.5 mL) were combined and stirred at room temperature for 20 hours. The reaction solution was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated under vacuum. The crude residue was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and crystallization from ether and hexanes to yield 10 mg (19%) of white solid. Rf = 0.2 (2:1 hexanes/ethyl acetate); Hl- NMR (CDC13) : δ 7.69 (2H,d), 7.29-7.18 (6H,m), 6.96 (2H,d), 5.01-4.93 (IH, m) , 4.93-4.85 (lH,m), 4.74-4.70 (lH,m), 4.51- 4.45 (lH,m), 4.22-4.11 (lH,m), 3.95-3.72 (7H,m), 3.86 (3H,s), 3.00-2.80 (3H,m), 2.10-1.97 (2H,m), 1.79-1.67 (2H,m), 1.61-1.53 (2H,m), 1.38-1.02 (6H,m); MS (ESI): M+H=580.
Example 66
Figure imgf000172_0001
( 66 )
(2S) -N1- ( (IS,22?) -l-benzyl-3- (cyclohexyloxy) [ (4- methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) -2- [ (2- quinolinylcarbonyl)amino]butanediamide. tert-butyl N- ( (IS, 22?) -l-benzyl-3- (cyclohexyloxy) [ (4- methoxyphenyl) sulfonylj amino-2-hydroxypropyl) carbamate (0.18 mmol, 100 mg) was stirred in 1 mL trifluoroacetic acid (TFA) at room temperature for 1 hour. The TFA was removed under vacuum, and the resulting residue was dissolved in ethyl acetate, washed with 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated to a residue. The resulting free amine, (2S) -4-amino-4-oxo-2- [ (2-quinolinylcarbonyl) amino] butanoic acid hydrochloride (0.18 mmol, 56 mg) , 1-hydroxybenzotriazole hydrate (0.18 mmol, 25 mg) , N- (3-Dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (0.20 mmol, 38 mg) , diisopropylethylamine (0.91 mmol, 0.157 mL) and anhydrous N,N-dimethylformamide (0.5 mL) were combined at room temperature and stirred for 15 hours. The crude reaction mixture was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine and dried over magnesium sulfate. The solution was concentrated to a residue, purified by silica gel chromatography (ethyl acetate) , and lyophylized providing a fluffy white solid. H- 1-ΝMR (CDC13) : δ 9.19-9.17 (lH,m), 8.32-8.30 (lH,m), 8.23- 8.16 (2H,m), 7.89-7.87 (lH,m), 7.79-7.76 (3H,m), 7.65-7.61 (lH,m), 7.13-7.11 (2H,m), 7.05-6.94 (6H,m), 5.73-5.64 (lH,m), 5.41-5.33 (lH,m), 4.96-4.85 (lH,m), 4.28-4.08 (2H,m), 3.89-3.74 (lH,m), 3.86 (3H,s), 3.25 (lH,bs), 2.95- 2.79 (5H,m), 2.65-2.60 (lH,m), 2.04 (2H,bs), 1.70 (2H,bs), 1.57-1.41 (lH,m), 1.30-1.10 (5H,m); MS (ESI): M+H=719.
Example 67
Step 1
Figure imgf000173_0001
27- [ (22?, 3S) -3-amino-2-hydroxy-4-phenylbutyl ] -27- (sec-butoxy) - 4-methoxybenzene-sulfonamide. tert-butyl N- ( (IS, 22?) -1- benzyl-3-sec-butoxy [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxy-propyl) carbamate (1.9 mmol, 1 g) was stirred in neat trifluoroacetic acid (TFA) at room temperature for 1 hour. The TFA was removed under vacuum, and the resulting residue was dissolved in ethyl acetate, washed with 5% aq. potassium carbonate solution, brine and dried over magnesium sulfate. The dried solution was concentrated under vacuum and stored as a sticky white solid. Hl-NMR (CDC13) : δ 7.81 (2H,d), 7.28-7.16 (5H,m), 7.01 (2H,d), 4.31 (2H,bs), 4.01-3.90 (lH,bs), 3.88 (3H,s), 3.5-2.5 (lH,bs), 3.33 (2H,bs), 2.89 (2H,bs), 2.63 (2H,bs), 1.71 (lH,bs), 1.43-1.40 (lH,m), 1.27- 1.19 (3H,m), 0.98-0.85 (3H,m); MS (ESI): M+H=423.
Step 2
Figure imgf000174_0001
( 67 )
(3S) tetrahydro-3-furanyl 27- ( (IS, 22?) -l-benzyl-3-sec- butoxy [ (4-methoxyphenyl) sulf-onyl]amino-2- hydroxypropyl) carbamate. N- [ (22?, 3S) -3-amino-2-hydroxy-4- phenylbutyl] -N- (sec-butoxy) -4-methoxybenzenesulfon-amide (0.12 mmol, 50 mg) , 1- ( [ (3S) tetrahydro-3- furanyloxy] carbonyloxy) dihydro-12f-pyrrole-2 , 5-dione (0.12 mmol, 29 mg) , diisopropylethylamine (0.18 mmol, 0.031 mL) and anhydrous THF (1 mL) were combined and stirred at room temperature for 20 hours. The reaction product was concentrated to a residue, purified directly by silica gel chromatography (2:1 hexanes/ethyl acetate) and crystallized from diethyl ether providing 40 mg (63%) of a white crystal.
Hl-ΝMR (CDCI3) : δ 7.74-7.70 (2H,m) , 7.30-7.17 (6H,m), 7.00- 6.96 (2H,m), 5.11 (lH,bs), 4.75 (lH,bs), 4.31-4.30 (lH,m), 3.87 (3H,s), 3.87-3.75 (6H,m), 3.65-3.60 (lH,m), 3.21-2.64 (lH,bs), 2.89 (2H,bs), 2.15-2.01 (lH,m), 1.95-1.78 (lH,m), 1.78-1.58 (lH,m), 1.47-1.32 (lH,m), 1.24-1.13 (3H,m), 0.94- 0.84 (3H,m); MS (ESI): M+Νa=560. Example 68
Figure imgf000175_0001
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- ( (IS, 22?) -1- benzyl-3-sec-butoxy[ (4-methoxyphenyl) sulfonyl ] amino-2- hydroxypropyl) carbamate. N- [ (22?, 3S) -3-amino-2-hydroxy-4- phenylbutyl ] -N- ( sec-butoxy) -4-methoxybenzenesulfon-amide (step 1, Example 67) (0.12 mmol, 50 mg) was combined with (22?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-2-yl 4-nitrophenyl carbonate (0.12 mmol, 35 mg) , diisopropylethylamine (0.18 mmol, 0.031 L) and acetonitrile (1 mL) . The reaction was allowed to stir at room temperature for 15 hours, then heated to reflux for a minute and cooled to room temperature. The reaction was concentrated to a yellow oil, dissolved in ethyl acetate, washed with IN HCl, saturated aq. sodium bicarbonate solution, brine and dried over magnesium sulfate. The crude product was purified by silica gel chromatgraphy (1:1 hexanes/ethyl acetate) and crystallization from an ether/hexanes solution to yield 30 mg (43%) of white crystals. Rf = 0.2 (1:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.74-7.71 (2H,m) , 7.28-7.14 (6H,m), 7.00-6.97 (2H,m), 5.63-5.62 (lH,m), 5.05-4.93 (lH,m), 4.87-4.75 (lH,m), 4.36-4.23 (lH,m), 3.98-3.76
(4H,m), 3.87 (3H,s), 3.68 (2H,m), 3.10 (lH,bs), 3.08-2.70 (6H,m) ,1.77-1.57 (lH,m), 1.50-1.32 (lH,m), 1.23-1.18 (3H,m), 0.93-0.86 (3H,m); MS (ESI): M+Νa=601. Example 69
Figure imgf000176_0001
69!
l,3-dioxan-5-yl 27- ( (IS,22?) -l-benzyl-3-sec-butoxy [ (4- methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl ) carbamate . N-
[ (22?, 3S) -3-amino-2-hydroxy-4-phenylbutyl] -N- (sec-butoxy) -4- methoxybenzenesulfon-amide (Step 1, Example 67) (0.09 mmol, 38 mg) , 1, 3-dioxan-5-yl 4-nitrophenyl carbonate (0.09 mmol, 24 mg) , diisopropylethylamine (0.13 mmol, 0.024 mL) , 4 A molecular sieves, a crystal of N,N-dimethylaminopyridine and acetonitrile (1 mL) were combined and allowed to stir for 20 hours at room temperature. The reaction was then concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, and dried over magnesium sulfate. The reaction was purified directly by crystallization from a solution of diethyl ether and hexanes to yield 30 mg (60%) of white crystals. Rf = 0.7 (1:1 hexanes/ethyl acetate); Hl-ΝMR
(CDC13) : δ 7.72-7.69 (2H,m) , 7.29-7.18 (6H,m), 6.98-6.95 (2H,m), 5.03-4.93 (lH,m), 4.93-4.87 (lH,m), 4.76-4.69 (lH,m), 4.53-4.44 (lH,m), 4.38-4.25 (lH,m), 3.95-3.72 (7H,m), 3.86 (3H,s), 3.24-2.62 (3H,m), 1.76-1.60 (lH,m), 1.47-1.29 (lH,m), 1.22-1.16 (3H,m), 0.94-0.83 (3H,m); MS (ESI) : M+H=553. Example 70
Figure imgf000177_0001
(70)
27- (sec-butoxy) -27- [ (22?, 3S) -2-hydroxy-3- (3-hγdroxy-2- methylanilino) - -phenylbutyl] -4-methoxybenzenesulfonamide.
N- [ (22?, 3S) -3-amino-2-hydroxy-4-phenylbutyl] -N- (sec-butoxy) - 4-methoxybenzenesulfon-amide (Step 1, Example 67) (0.12 mmol, 50 mg) , 3-hydroxy-2-methylbenzoic acid (0.12 mmol, 18 mg) , 1-hydroxybenzotriazole hydrate (0.12 mmol, 16 mg) , N- ( 3- Dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (0.13 mmol, 25 mg) , diisopropylethylamine (0.14 mmol, 0.025 mL) and anhydrous N,N-dimethylformamide (0.5 mL) were combined at room temperature and stirred for 18 hours. The crude reaction mixture was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine and dried over magnesium sulfate. The solution was concentrated to a residue, purified by RPHPLC (water/acetonitrile) and lyophylized providing 20 mg (30%) of a white solid. Hl-ΝMR (CDC13) : δ 7.76-7.73 (2H,m), 7.32-7.23 (5H,m) , 7.00-6.97 (3H,m) , 6.78- 6.76 (IH,m), 6.56-6.53 (lH,m), 5.90 (lH,bs), 4.42-4.27 (2H,m), 4.09-3.95 (lH,m), 3.87 (3H,s), 3.25-2.27 (5H,m) , 2.05-1.95 (3H,m), 1.77-1.58 (lH,m), 1.55-1.22 (lH,m), 1.24- 1.20 (3H,m), 0.93-0.86 (3H,m); MS (ESI): M+H=557. Example 71
Figure imgf000178_0001
(2S) -271- ( (IS, 22?) -1-benzyl-3-sec-butoxy [ (4- methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) -2- [ (2- quinolinylcarbonyl) amino] butanediamide. N- [ (22?, 35) -3-amino- 2-hydroxy-4-phenylbutyl] -N- (sec-butoxy) -4- methoxybenzenesulfon-amide (Step 1, Example 67) (0.114 mmol, 48 mg) , (2S) -4-amino-4-oxo-2- [ (2- quinolinylcarbonyl) amino ]butanoic acid hydrochloride (0.136 mmol, 42 mg) , 1-hydroxybenzotriazole hydrate (0.136 mmol, 19 mg) , N- (3-Dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (0.148 mmol, 28 mg) , diisopropylethylamine (5.68 mmol, 0.990 mL) and anhydrous N^N-dimethylformamide (0.5 mL) were combined at room temperature and stirred for 15 hours. The crude reaction mixture was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine and dried over magnesium sulfate. The solution was concentrated to a residue, purified by silica gel chromatography (1:1 hexanes/ethyl acetate) and crystallization from ether and hexanes, providing 20 mg (25%) of a pink solid. Hl-ΝMR (CDCI3) : δ 9.20-9.18 (lH,m), 8.32-8.30 (lH,m), 8.22-8.16 (2H,m), 7.89-7.87 (lH,m), 7.80-7.76 (3H,m) , 7.65-7.61 (lH,m), 7.14-7.11 (2H,m) , 7.05-6.97 (6H,m), 5.76-5.64 (lH,bs), 5.49-5.26 (lH,m), 4.94-4.86 (lH,m), 4.36-4.14 (2H,m), 3.99-3.80 (lH,m), 3.86 (3H,s), 3.14 (lH,bs), 2.98- 2.71 (5H,m), 2.71-2.59 (lH,m), 1.80-1.52 (lH,m), 1.48-1.30 ( lH, m) , 1 . 22- 1 . 14 ( 3H, m) , 0 . 94 - 0 . 80 ( 3H, m) ; MS (ES I ) : M+H=692 .
Example 72
Figure imgf000179_0001
:
(3S) tetrahydro-3-furanyl 27- (IS,22?) -l-benzyl-2-hydroxy-3- [ [ (4-methoxyphenyl) sulfonyl] (tetrahydro-2H-pyran-4- yloxy)amino] propylcarbamate. tert-butyl N- ( IS, 22?) -1- benzyl-2-hydroxy-3- [ [ (4-methoxyphenyl) sulfonyl] (tetrahydro- 22f-pyran-4-yloxy) amino] propylcarbamate, (Example 18), (0.09 mmol, 50 mg) was stirred in 1 mL trifluoroacetic acid (TFA) at room temperature for 1 hour. The TFA was removed under vacuum, and the resulting residue was dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, and dried over magnesium sulfate. The resulting free amine, 1- ( [ (35) tetrahydro-3- furanyloxy] carbonyloxy) dihydro-12f-pyrrole-2, 5-dione (0.09 mmol, 22 mg) , diisopropylethylamine (0.14 mmol, 0.024 mL) and acetonitrile (0.5 mL) were combined and stirred at room temperature for 30 minutes. The reaction product was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, and dried over magnesium sulfate. The crude solution was concentrated, and the purified reaction product crystallized out of diethyl ether providing 28 mg (55%) of a white crystal. Rf = 0.1 (1:1 hexanes/ethyl acetate); Hl-ΝMR (CDCI3) : δ 7.70 (2H,d), 7.32-7.15 (6H,m) , 6.98 (2H,d), 5.11 (lH,bs) , 4.81-4.71 (lH,m) , 4.44-4.35 (lH,m), 3.97-3.70 (8H,m), 3.87 (3H,s), 3.65 (lH,m), 3.52-3.33 (2H,m) , 3.25-2.5 (lH,bs), 2.93-2.88 (2H,m) , 2.12-1.95 (3H,m) , 1.93-1.80 (lH,m), 1.57-1.41 (2H,m) ; MS (ESI) : M+H=565.
Example 73
Figure imgf000180_0001
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- (IS,22?) -1- benzyl-2-hydroxy-3- [ [ (4-methoxyphenyl) sulfonyl] (tetrahydro- 2H-pyran-4-yloxy) amino]propylcarbamate tert-butyl N- (IS, 2R) -l-benzyl-2-hydroxy-3- [ [ (4- methoxyphenyl) sulfonyl] (tetrahydro-222-pyran-4- yloxy) amino] propylcarbamate (Example 18), (0.09 mmol, 50 mg) was stirred in 1 mL trifluoroacetic acid (TFA) at room temperature for 1 hour. The TFA was removed under vacuum, and the resulting residue was dissolved in ethyl acetate, washed with 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated to a residue, The resulting free amine, (22?, 3aS, 6a2?) hexahydrofuro [2, 3- b] furan-2-yl 4-nitrophenyl carbonate (0.09 mmol, 27 mg) , diisopropylethylamine (0.14 mmol, 0.024 L) , a crystal of N,N-dimethylaminopyridine, 4 A molecular sieves and acetonitrile (0.5 mL) were combined and stirred at room temperature for 15 hours. The reaction solution was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated under vacuum. The crude residue was purified by silica gel chromatography (1:1 hexanes/ethyl acetate) and crystallization from ether and hexanes to yield 20 mg (36%) of white crystals. Rf = 0.2 (1:1 hexanes/ethyl acetate); Hl- NMR (CDC13) : δ 7.71 '(2H,d), 7.31-7.12 (6H,m), 6.99 (2H,d), 5.65-5.61 (lH,m), 5.05-4.95 (lH,m), 4.90-4.72 (lH,m), 4.49- 4.34 (lH,m), 4.00-3.76 (7H,m), 3.88 (3H,s), 3.71-3.60 (2H,m), 3.48-3.35 (2H,m) , 3.40-2.40 (lH,bs), 3.28-2.61 (5H,m), 3.04-2.71 (2H,m), 2.09-1.97 (2H,m); MS (ESI): M+H=607.
Example 74
Figure imgf000181_0001
: 4 :
l,3-dioxan-5-yl 27- (IS, 22?) -1-benzyl-2-hydroxy-3- [ [ (4- methoxyphenyl) sulfonyl] (tetrahγdro-2H-pyran-4- yloxy) amino] propylcarbamate. tert-butyl N- (IS, 22?) -1-benzyl- 2-hydroxy-3- [ [ (4-methoxyphenyl) sulfonyl] ( tetrahydro-222- pyran-4-yloxy) amino] propylcarbamate (Example 18), (0.09 mmol, 50 mg) was stirred in 1 mL trifluoroacetic acid (TFA) at room temperature for 5 hours. The TFA was removed under vacuum, and the resulting residue was dissolved in ethyl acetate, washed with 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated to a residue. The resulting free amine, 1, 3-dioxan-5-yl 4- nitrophenyl carbonate (0.08 mmol, 22 mg) , diisopropylethylamine (0.14 mmol, 0.024 mL) , a crystal of N,N-dimethylaminopyridine , 4 A molecular sieves and acetonitrile (0.5 mL) were combined and stirred at room temperature for 20 hours. The reaction solution was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated under vacuum. The crude residue was purified by silica gel chromatography (1:1 hexanes/ethyl acetate) and crystallization from ether and hexanes to yield 3 mg (6%) of white crystals. Rf = 0.2 (1:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.69 (2H,d), 7.32-7.17 (6H,m), 6.98 (2H,d), 5.02-4.94 (lH,m), 4.94-4.87 (lH,m), 4.76-4.69 (lH,m), 4.53- 4.45 (lH,m), 4.45-4.34 (lH,m), 4.00-3.70 (9H,m), 3.87 (3H,s), 3.49-3.30 (2H,m) , 3.10 (lH,bs), 3.47-3.35 (2H,m) , 2.99-2.78 (2H,m), 2.07-1.95 (2H,m); MS (ESI): M+H=581.
Example 75
Figure imgf000182_0001
(751
27- (IS,22?) -l-benzyl-2-hydroxy-3- [ [ (4-methoxyphenyl) sulfonyl] (tetrahydro-2H-pyran-4-yloxy) amino]propyl-3-hydroxy-2- methylbenzamide . tert-butyl N- ( IS, 22?) -l-benzyl-2-hydroxy-3- [ [ (4-methoxyphenyl) sulfonyl] ( tetrahydro-222-pyran-4- yloxy) amino] propylcarbamate (Example 18), (0.10 mmol, 54 mg) was stirred m 1 mL trifluoroacetic acid (TFA) at room temperature for 5 hours. The TFA was removed under vacuum, and the resulting residue was dissolved in ethyl acetate, washed with 5% aq. potassium carbonate solution, brme, dried over magnesium sulfate, and concentrated to a residue. The resulting free amine, 3-hydroxy-2-methylbenzoιc acid (0.10 mmol, 15 mg) , 1-hydroxybenzotriazole hydrate (0.10 mmol, 14 mg) , N- (3-Dιmethylammopropyl) -N'-ethylcarbodιιmιde hydrochloride (0.11 mmol, 21 mg) , diisopropylethylamine (0.15 mmol, 0.026 mL) and anhydrous N,N-dιmethylformamide (0.5 mL) were combined at room temperature and stirred for 20 hours. The crude reaction mixture was concentrated to a residue, dissolved m ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brme and dried over magnesium sulfate. The solution was concentrated to a residue, and purified by crystallization from ether and hexanes providing 21 mg (37%) of a white solid. Rf = 0.2
(1:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.73 (2H,d), 7.33-7.17 (5H,m), 7.02-6.94 (3H,m), 6.77 (lH,d), 6.53 (lH,d), 5.84-5.76 (lH,m), 4.49-4.28 (2H,m), 3.99-3.89
(3H,m), 3.87 (3H,s), 3.47-3.35 (2H,m), 3.50-2.50 (lH,bs), 3.14-3.04 (2H,m), 3.00-2.88 (2H,m), 2.08-1.88 (2H,m), 2.01 (3H,s), 1.7-1.3 (2H,m) ; MS (ESI) : M+H=585.
Example 76
Figure imgf000183_0001
(76; (2S) -271- (IS, 22?) -1-benzyl-2-hydroxy-3- [ [ (4- methoxyphenyl) sulfonyl ] (tetrahydro-22-pyran-4- yloxy) amino]propyl-2- [ (2-quinolinyl carbonyl) amino]butanediamide. tert-butyl N- (IS, 22?) -1- benzyl-2-hydroxy-3- [ [ (4-methoxyphenyl) sulfonyl] (tetrahydro- 222-pyran-4-yloxy) amino] propylcarbamate (Example 18), (0.09 mmol, 50 mg) was stirred in 1 mL trifluoroacetic acid (TFA) at room temperature for 5 hours. The TFA was removed under vacuum, and the resulting residue was dissolved in ethyl acetate, washed with 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated to a residue. The resulting free amine, (2S) -4-amino-4-oxo-2- [ (2- quinolinylcarbonyl) amino] butanoic acid hydrochloride (0.09 mmol, 28 mg) , 1-hydroxybenzotriazole hydrate (0.09 mmol, 13 mg) , N- ( 3-Dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (0.10 mmol, 19 mg) , diisopropylethylamine (0.27 mmol, 0.047 mL) and anhydrous N,N-dimethylformamide (0.5 L) were combined at room temperature and stirred for 20 hours. The crude reaction mixture was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine and dried over magnesium sulfate. The solution was concentrated to a residue, purified by silica gel chromatography (20:1 ethyl acetate/methanol) and crystallization from ether and hexanes, providing 6 mg (8%) of a pink solid. Hl-ΝMR
(CDCI3) : δ 9.18 (lH,d), 8.31 (lH,d), 8.24-8.13 (2H,m) , 7.88 (lH,d), 7.80-7.74 (3H,m), 7.66-7.60 (lH,m), 7.15-7.08 (2H,m), 7.08-6.93 (6H,m), 5.74 (lH,bs), 5.46 (lH,bs), 4.94- 4.85 (lH,m), 4.44-4.35 (lH,m), 4.27-4.18 (lH,m), 3.96-3.80 (3H,m), 3.88 (3H,s), 3.47-3.34 (2H,m), 3.14 (lH,bs), 2.98- 2.76 (5H,m), 2.72-2.60 (lH,m), 2.09-1.95 (2H,bs), 1.65-1.39 (2H,m); MS (ESI): M+H=720. Example 77
Figure imgf000185_0001
: 77 :
(32?, 3aS,6a2?) hexahydrofuro [2,3-b] furan-3-yl 27- (IS,22?) -3- [ [ (3- aminophenyl) sulfonyl ] (cyclopentyloxy) ammo] -l-benzyl-2- hydroxypropylcarbamate. This material was obtained from the corresponding m-nitro precursor (Example 100, Step 1) via hydrogenation. The material was identical to isomer 1 of Example 31.
Example 78
Figure imgf000185_0002
( 78 )
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- ( (IS,22?) -1- benzyl-3- (cyclohexyloxy) [ (4-methoxyphenyl) sulfonyl ] amino-2- hydroxypropyl) carbamate. tert-butyl N- ( (IS, 22?) -l-benzyl-3- (cyclohexyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (0.09 mmol, 50 mg) was stirred in 1 mL trifluoroacetic acid (TFA) at room temperature for 5 hours. The TFA was removed under vacuum, and the resulting residue was dissolved in ethyl acetate, washed with 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated to a residue. The resulting free amine, (22?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-2-yl 4- nitrophenyl carbonate (0.09 mmol, 27 mg) , diisopropylethylamine (0.13 mmol, 0.018 L) , a crystal of N,N-dimethylaminopyridine, 4 A molecular sieves and acetonitrile (0.5 mL) were combined and stirred at room temperature for 3 days. The reaction solution was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated under vacuum. The crude residue was purified by crystallization from ether to yield 15 mg (27%) of white crystals. Hl-ΝMR (CDC13) : δ 7.71 (2H,d), 7.28-7.16 (6H,m), 6.97 (2H,d), 5.63-5.61 (lH,m), 5.00-4.98 (lH,m), 4.87-4.77 (lH,m), 4.24- 4.11 (lH,m), 3.98-3.79 (4H,m), 3.87 (3H,s), 3.72-3.61 (2H,m), 3.05 (lH,bs), 3.05-2.72 (6H,m), 2.10-1.98 (2H,m), 1.78-1.68 (2H,m), 1.37-1.04 (6H,m); MS (ESI): M+H=605.
Example 79
Figure imgf000186_0001
(79)
(3S,3a2?,7aS)hexahydro-4H-furo[2,3-b]pyran-3-yl 27- (IS, 22?) -3- [ [ (3--aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate + (32?,3aS, 7a2?) hexahydro-4H-furo [2 ,3- b]pyran-3-yl 27- (IS, 22?) -3- [[ (3- aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate. A mixture of
(32?, 3aS, 7a2?) + (3S, 3a2?, 7aS) hexahydro-42f-furo [2, 3-b] pyran-3-yl (4-nitrophenyl) carbonate (332 mg, 1.074 mmol, WO 9633187), 3-amino-N1- [ (22?, 3S) -3-amino-2-hydroxy-4-phenylbutyl] -N- (cyclopentyloxy) -1-benzenesulfonamide (Step 1, Example 27), (150 mg, 0.358 mmol) ,and Ν, Ν-diisopropylethylamine (249 μL, 1.432 mmol) were combined in approximately 3 L of acetonitrile and stirred at ambient temperature under an Argon atmosphere for 18 hours. The reaction solvent was removed in vacuo and the residue was partitioned between dichloromethane and IN ΝaOH. After separating the layers, the aqueous phase was extracted with dichloromethane. The combined organic layers were combined, dried over anhydrous magnesium sulfated, filtered and evaporated in vacuo . The residue was purified on three preparative silica gel TLC plates (20x20 cm, 1000 μM) eluting with 65:35 ethyl acetate : hexane. The product band was removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was dissolved in dichloromethane, dried over anhydrous magnesium sulfate, filtered, evaporated in vacuo, and dried under high vacuum to provide a 1:1 mixture of (3S,3a2?, 7aS)hexahydro-422-furo[2,3-b]pyran-3-yl N- ( 1S, 22?)- 3- [ [ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -1-benzyl- 2-hydroxypropylcarbamate and (32?, 3aS, 7a2?) hexahydro-422- furo[2,3-b]pyran-3-yl N- ( IS, 22?) -3- [ [ (3- aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (146 mg, 69%) as a foam. Hl-ΝMR (methanol-D4) 1.14 (m, IH) , 1.78 (m, 11H) , 2.56 (m, IH) , 3.05 ( , 3H) , 3.41 (m, IH) , 3.76 (m, 5H) , 4.06 ( , IH) , 4.84 (m, IH) , 4.96 (m, IH) , 5.06 (m, IH) , 6.93 (m, IH) , 7.02 (m, IH) , 7.09 (m, IH) , 7.14 ( , IH) , 7.22 ( , 5H) . MS(ESI): 612 (M+Νa) . Example 80
Step 1:
Figure imgf000188_0001
tert-butyl 27- [ (IS, 22?) -l-benzyl-3-hydrazino-2- hydroxypropyl ] carbamate . A mixture of tert-butyl N- ( 1S) -1- [ (2S) oxiran-2-yl] -2-phenylethylcarbamate (2.50 g, 9.51 mmol) and anhydrous hydrazine (3.00 mL, 95.0 mmol) in 15 mL of isopropanol was heated at reflux under an Argon atmosphere for 18 hours. The reaction solvent was removed in vacuo and the residue was triturated with diethylether, filtered and dried under high vacuum to provide tert-butyl N- [ ( IS, 22?) -1- benzyl-3-hydrazino-2-hydroxypropyl] carbamate (1.766 g, 63%) as a white solid. Hl-ΝMR (chloroform-D3) 1.35 (d, 9H) ,
1.67 (b, 4H) , 2.89 (m, 4H) , 3.91 (m, 3H) , 4.63 (m, IH) , 7.25 (m, 5H) . MS (ESI): 318 (M+Νa) .
Figure imgf000188_0002
tert-butyl 27- [ (IS, 22?) -l-benzyl-3- (2- cyclopentylidenhydrazino) -2-hydroxypropyl] carbamate.
A solution of tert-butyl N- [ (IS, 22?) -l-benzyl-3-hydrazino-2- hydroxypropyl] carbamate (500 mg, 1.695 mmol) in 5 mL of isopropanol under Argon was treated with cyclopentanone (180 μL, 2.034 mmol). After stirring for approximately 18 hours, the reaction solvent was removed in vacuo and the residue was triturated with diethylether. The slurry was filtered and the solid was dried under high vacuum to provide tert- butyl N- [ (IS, 22?) -l-benzyl-3- (2-cyclopentylidenhydrazino) -2- hydroxypropyl] carbamate (85 mg, 14%) as a white solid. Hl- ΝMR (chloroform-D3) 1.34 (s, 9H) , 1.54 (b, 2H) , 1.73 (m, 2H) , 1.83 (m, 2H) , 2.22 (m, 2H) , 2.35 (m, 2H) , 2.90 (m, IH) , 3.02 (m, IH) , 3.14 (m, IH) , 3.38 (m, IH) , 3.64 (bm, IH) , 3.84 (bm, IH) , 4.52 (m, IH) , 7.25 (m, 5H) . MS(APCI): 361 (M+Νa) .
Step 3:
Figure imgf000189_0001
(80)
tert-butyl 27- ( (IS,22?) -l-benzyl-3-2-cyclopentyliden-l- [ (4- methoxyphenyl) sulfonyl ] hydrazino-2-hydroxypropyl) carbamate .
A solution of tert-butyl N- [ (IS, 22?) -l-benzyl-3- (2- cyclopentylidenhydrazino) -2-hydroxypropyl] carbamate (76 mg, 0.210 mmol) in 2 mL of dichloromethane at ambient temperature under Argon was treated with 4- methoxyphenylsulphonylchloride (46 mg, 0.221 mmol) and Ν,Ν- diisopropylethylamine (38.5 μL, 0.221 mmol) and allowed to stir at ambient temperature over approximately 18 hours. The reaction solvent was removed in vacuo and the residue was purified on flash grade silica gel eluting with 2:3 ethyl acetate : hexane. Fractions containing the product were combined, evaporated in vacuo to a residue and triturated with hexane and diethyl ether. The solvents were removed in vacuo and the residual solid was dried under high vacuum to provide tert-butyl N- ( (IS, 22?) -l-benzyl-3-2- cyclopentyliden-1- [ (4-methoxyphenyl ) sulfonyl ] hydrazino-2- hydroxypropyl) carbamate (26 mg, 23%) as a solid. Hl-ΝMR (chloroform-D3) : 1.34 (m, 9H) , 1.62 (m, 4H) , 1.83 (m, 2H) , 2.42 (m, IH) , 2.87 (m, 3H) , 3.12 ( , IH) , 3.58 (m, IH) , 3.83 ( , 5H) , 4.32 (m, IH) , 4.57 (b, IH) , 6.97 (m, 2H) , 7.20 (m, 5H) , 7.69 (m, 2H) . MS(APCI): 554 (M+Νa) .
Example 81
Figure imgf000190_0001
tert-butyl 27- ( (IS, 22?) -1-benzyl-2-hydroxy-3-1- [ (4- methoxyphenyl) sulfonyl] -2- [ (Z) -2-methylpropγlidene] hydrazinopropyl) carbamate. A solution of tert-butyl N- [ (IS, 22?) -l-benzyl-3-hydrazino-2-hydroxypropyl] carbamate
(Step 1, Example 80), (100 mg, 0.339 mmol) in approximately 2 mL of dichloromethane under Argon was treated with isobutyraldehyde (46.2 μL, 0.508 mmol). After stirring at ambient temperature for 20 minutes, 4- methoxyphenylsulphonylchloride (77 mg, 0.372 mmol) and Ν,Ν- diisopropylethyla ine (88.6 μL, 0.508 mmol) were added and the reaction was maintained for an additional 18 hours. The reaction mixture was evaporated in vacuo and purified on flash grade silica gel eluting with 3:7 ethyl acetate : hexane. Fractions containing the product were combined, evaporated in vacuo, and crystallized from ethyl acetate and hexane. The slurry was filtered, washed with hexane, and dried under high vacuum to provide tert-butyl N- ( (IS, 22?) -1- benzyl-2-hydroxy-3-l- [ (4-methoxyphenyl) sulfonyl] -2- [ ( Z) -2- methylpropylidene] hydrazinopropyl) carbamate (34 mg, 19 %) as a solid. Hl-ΝMR (chloroform-D3) : 1.00 (m, 6H) , 1.44 (s, 9H) , 1.77 (m, IH) , 2.57 (m, IH) , 2.94 ( , 3H) , 3.54 (m, IH) , 3.93 (s, 3H) , 3.94 (m, 2H) , 4.35 (m, IH) , 7.02 ( , 2H) , 7.17 (m, 2H) , 7.31 (m, 4H) , 7.81 (m, 2H) . MS (ESI): 542 (M+Νa) .
Example 82
Figure imgf000191_0001
tert-butyl 27- (IS,22?) -3- [ (lH-benzimidazol-6-ylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate . A solution of tert-butyl N- ( (IS, 22?) -l-benzyl-3-
(cyclopentyloxy) [ (3, 4-diaminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (Step 4, Example 10), (0.600 g, 1.12 mmol) in absolute ethanol (15 mL) was treated with triethylorthofor ate (280 μL, 1.69 mmol) followed by trifluoroacetic acid (15 μL, 0.19 mmol). After stirring at ambient temperature under an Argon atmosphere for 1.5 hrs., the reaction mixture was quenched with several drops of 5% w/v aqueous potassium carbonate and evaporated in vacuo . The residue was purified on flash grade silica gel sequentially eluting with 4:1 ethyl acetate : hexane (0.5 L) ; ethyl acetate (0.5 L) ; and 95:5 ethyl acetate : methanol (0.5 L) . Fractions containing the product were combined, evaporated in vacuo to a residue and dried under high vacuum to provide tert-butyl N- (IS, 22?) -3- [ (12J-benzimidazol-6- ylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (0.570 g, 93%). Hl-ΝMR (dimethylsulfoxide-D6) : 1.14 (s, 9H) , 1.72 ( , 8H) , 2.47 ( , IH) , 2.70 (m, IH) , 2.99 (m, 2H) , 3.55 (m, 2H) , 4.85 (m, IH) , 5.14 (m, IH) , 6.67 (d, IH) , 7.20 (m, 6H) , 7.61 (d, IH) , 7.81 (d, IH) , 8.04 (s, IH) , 8.52 (s, IH) . MS(ESI): 545 (M+H) .
Example 83
Figure imgf000192_0001
( 83 ;
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- (IS,22?) -3- [ (3- [ (2-aminoethyl) amino]phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate and
(3S, 3a2?, 6aS) hexahydrofuro [2 , 3-b] furan-3-yl 27- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino]phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate. A solution of 25 mg (0.041 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -1- benzyl-3- [ (3- [ (cyanomethyl ) amino] phenylsulfonyl) (cyclopentyloxy) amino] -2-hydroxypropylcarbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -1- benzyl-3- [ (3- [ (cyanomethyl) amino] phenylsulfonyl)
(cyclopentyloxy) amino] -2-hydroxypropylcarbamate (see example 86) in 8 mL of 2M ΝH3/MeOH in a Parr bottle was treated with approximately 20 mg of Raney nickel. The resulting mixture was subjected to hydrogenation at 30 psi for 1 hour. The vessel was purged, catalyst removed by filtration through celite and the filtrate concentrated in vacuo . The residue was dissolved in a minimum volume of CH2C12 and the solution added dropwise to rapidly stirred 1:1 ether/hexane . A white solid precipitated which was collected by filtration and dried in vacuo . yield=16 mg (64%). 1H-NMR (DMSO-d6) : 7.32- 7.03 (7H), 6.95-6.78 (3H) , 6.20 (IH), 5.45 (IH), 5.19 (IH), 4.82-4.65 (2H), 3.81-3.40 (7H) , 3.18-2.60 (9H), 2.39 (IH), 1.93-1.04 (10H) . MS(ESI): 619 (M+H).
Example 84
Figure imgf000193_0001
( 84 :
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- (IS,22?) -3- [[ (3- [2- (acetylamino) ethyl] aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate and (3S,3a2?,6aS) hexahydrofuro [2, 3-b] furan-3-yl 27- (IS, 22?) -3- [ [ (3- [2- (acetylamino) ethyl ] aminophenyl) sulfonyl ] (cyclopentyloxy) amino] -1-benzyl-2-hydroxypropylcarbamate. A solution of 33 mg (0.053 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate and
(3S, 3aR, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate in 3 mL of anhydrous THF at 0°C was treated with 0.010 mL (0.058 mmol) of N,N- diisopropylethylamine followed by 0.004 L (0.06 mmol) of acetyl chloride. The resulting solution was allowed to warm to RT with stirring. After 18 hours the solution was concentrated in vacuo and the residue subjected to flash chromatography (silica gel, 95:5 CH2C12/2M ΝH3 in MeOH) to afford 30 mg (86%) of the desired product as a white foam. 1H-NMR (CDC13) : 7.71-7.00 (10H), 6.90 (IH), 6.40-6.02 (IH), 5.62 (IH), 5.32 (IH), 4.99 (IH), 4.80 (IH), 4.02-3.40 (7H) , 3 . 38-2 . 60 ( 8H ) , 2 . 20- 1 . 40 ( 13H) . LCMS (ES I ) : 661 (M+H) .
Example 85
Figure imgf000194_0001
85 ; (32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- (IS,22?) -3- [ (3-
[ (2-amino-2-oxoethyl) amino] phenylsulfonyl)
(cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate and
(3S, 3a2?, 6aS) hexahydrof ro [2 , 3-b] f ran-3-yl 27- (IS, 22?) -3- [ (3- [ (2-amino-2-oxoethyl) amino]phenylsulfonyl)
(cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate. A solution of 0.100 g (0.163 mmol) of a 1:1 mixture of
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -1- benzyl-3- [ (3- [ (cyanomethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] -2-hydroxypropylcarbamate and
(3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -1- benzyl-3- [ (3- [ (cyanomethyl) amino] phenylsulfonyl )
(cyclopentyloxy) amino] -2-hydroxypropylcarbamate (see example 86) and 5.0 mg (0.033 mmol) of K2C03 in 2 mL of 3:1 acetone/water was treated with 0.150 g (1.63 mmol) of urea- hydrogen peroxide addition compound and stirred at RT. After 18 hours tic (silica gel, 95:5 CH2Cl2/MeOH) indicated no remaining starting material at Rf=0.43, a major new component at R£=0.21, and a lesser component at Rf=0.61. The solution was diluted with CH2C12, washed with water
(3x), dried over anhydrous MgSO-j, and concentrated. The residue was subjected to flash chromatography (silica gel,
95:5 CH2Cl2/MeOH) to afford 49 mg (46%) of the Rf=0.21 product as a white foam. 1H-ΝMR (CDC13) : 7.46-6.92 (11H), 6.60-5.80 (2H) , 5.60 (2H) , 5.06-4.77 (2H) , 4.03-3.40 (7H) , 3.24-2.43 (6H), 1.91-1.32 (10H). LCMS(ESI): 633 (M+H) . Example 86
Figure imgf000196_0001
( 86 :
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- (IS,22?) -1- benzyl-3- [ (3- [ (cyanomethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] -2-hydroxypropylcarbamate and (3S, 3a2?, 6aS) hexahydrofuro [2 , 3-b] furan-3-yl 27- (IS, 22?) -1- benzyl-3- [ (3- [ (cyanomethyl) amino]phenylsulfonyl) (cyclo pentyloxy) amino] -2-hydroxypropylcarbamate A solution of 0.200 g (0.347 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (3-aminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3- b] furan-3-yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate (see example 31), 0.050 mL (0.70 mmol) of bromoacetonitrile, and 0.12 mL (0.70 mmol) of N^N-diisopropylethylamine in 5 mL of anhydrous DMF was heated to 80°C with stirring in a sealed tube. After 21 hours the solution was cooled to RT and concentrated in vacuo . The residue was dissolve in CH2C12. The resulting solution was washed with aqueous brine (3x), dried over anhydrous MgS04, and concentrated to dryness. The crude product was purified by flash chromatography
(silica gel, 95:5 CH2Cl2/MeOH) to afford 145 mg (67%) of the desired product as a tan solid. 1H-ΝMR (DMSO-d6) : 7.41 (IH), 7.28-6.99 (9H), 6.83 (IH), 5.46 (IH), 5.20 (IH), 4.82- 4.63 (2H), 4.30 (2H) , 3.80-3.40 (5H), 3.04-2.60 (5H), 2.40 (IH), 1.98-1.10 (10H) . MS (ESI): 615 (M+H).
Example 87
Figure imgf000197_0001
17)
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- (IS, 22?) -1- benzyl-3- [ (cyclopentyloxy) (3- [ (2-morpholino-2- oxoethyl) amino]phenylsulfonyl) amino] -2- hydroxypropylcarbamate and (3S,3a2?, 6aS) hexahydrofuro [2 ,3- b]furan-3-yl 27- (IS, 22?) -l-benzyl-3- [ (cyclopentyloxy) (3-[(2- morpholino-2-oxoethyl) amino]phenylsulfonyl) amino] -2- hydroxypropylcarbamate. A solution of 0.100 g (0.174 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3- yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (3-aminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (see example 31), 54.0 mg (0.261 mmol) of N- (bromoacetyl)morpholine, and 0.050 mL (0.26 mmol) of N^N-diisopropylethylamine in 4 mL of anhydrous DMF was heated to 80°C with stirring in a sealed tube. After 4.5 hours the solution was cooled to RT and was treated with an additional 54.0 mg of N- (bromoacetyl) morpholine, and 0.050 mL (0.26 mmol) of N, N-diisopropylethylamine . The solution was heated at 80°C for an additional 18 hours, cooled to RT, and concentrated in vacuo . The crude product was purified by flash chromatography (silica gel, EtOAc) to give a viscous yellow oil. This material was dissolved in a minimum volume of CH2C12 and the solution was added to rapidly stirred 1:1 ether/hexane . A white solid precipitated which was collected by filtration and dried in vacuo . yield=54 mg (44%). 1H-ΝMR (DMSO-d6) : 7.31-7.06
(7H), 7.03-6.83 (3H) , 6.26 (IH), 5.45 (IH), 5.18 (IH), 4.71 (2H), 3.92 (2H) , 3.79-3.22 (13H), 3.08-2.60 (5H) , 2.39 (IH), 1.95-1.04 (10H) . LCMS(ESI): 703 (M+H) .
Example 88 step 1 :
Br
Figure imgf000198_0001
27-methoxy-27-methylbromoacetamide
A solution of 4.5 mL (51.3 mmol) of bromoacetylbromide and 5.00 g (51.3 mmol) of N,O-dimethylhydroxylamine hydrochloride in 80 mL of anhydrous CH2C12 at 0°C was treated with a solution of 18.7 mL (108 mmol) of N,N- diisopropylethylamine in 40 mL of CH2C12 via addition funnel over 10 minutes. A dark brown solution resulted which was allowed to warm to RT . After 18 hours the solution was washed with 5% aqueous citric acid (3x) , saturated aqueous ΝaHC03 (3x) , dried over MgS04, and concentrated to give a dark brown oil. This material was subjected to flash chromatography (8:2 to 6:4 hexane/EtOAc) to afford 2.97 g (32%) of the desired product as a yellow-brown liquid. 1H- NMR (CDC13) : 4.22 (2H) , 3.72 (3H), 3.20 (3H) .
Figure imgf000199_0001
(88)
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- [ (1S,22?)-1- benzyl-3- ( (cyclopentyloxy) [3- (2- [methoxy (methyl) amino] -2- oxoethylamino) phenyl] sulfonylamino) -2- hydroxypropyl ] carbamate and (3S,3a2?, 6aS) hexahydrofuro [2 ,3- b]furan-3-yl 27- [ (IS, 22?) -l-benzyl-3- ( (cyclopentyloxy) [3- (2- [methoxy (methyl) amino] -2- oxoethylamino) phenyl ] sulfonylamino) -2- hydroxypropyl ] carbamate . A solution of 0.100 g (0.174 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3- yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- ( (1S,22?)-1- benzyl-3- (cyclopentyloxy) [ (3-aminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (see example 31), 40.0 mg (0.210 mmol) of N-methoxy-N-methylbromoacetamide , and 0.040 mL (0.21 mmol) of N,N-diisopropylethylamine in 3 mL of anhydrous DMF was heated to 80°C with stirring in a sealed tube. After 24 hours the solution was cooled to RT and was treated with an additional 20.0 mg of N-methoxy-N- methylbromoacetamide and 0.020 mL of N,N- diisopropylethylamine. The solution was again warmed to 80°C. After an additional 18 hours the solution was cooled to RT and was concentrated in vacuo . The residue was dissolved in CH2C12. The solution was washed with saturated aqueous brine (3x) , dried over MgS04, and concentrated to dryness. The crude product was purified by flash chromatography (silica gel, 85:15 hexane/EtOAc) to afford 40 mg (34%) of the desired product as a white foam. lH-NMR
(CDC13) : 7.40-6.84 (11H), 5.62(1H), 5.18-4.87 (2H) , 4.81 (IH), 4.05 (2H), 3.99-3.53 (8H), 3.26-2.70 (9H), 1.92-1.41
(10H) . LCMS(ESI): 677 (M+H) .
Example 89
Figure imgf000200_0001
: 89 :
(32?, 3aS, 6a2?) hexahydrofuro [2 ,3-b] furan-3-yl 27- ( (IS,22?) -1- benzyl-3- (cyclopentyloxy) [ (3-nitrophenyl) sulfonyl ]amino-2- hydroxypropyl) carbamate and (3S,3a2?, 6aS) hexahydrofuro [2 ,3- b]furan-3-yl 27- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- nitrophenyl ) sulfonyl ] amino-2-hydroxypropyl) carbamate A solution of 0.100 g (0.163 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -1- benzyl-3- [ (3- [ (cyanomethyl) amino] phenylsulfonyl) (cyclo pentyloxy) amino] -2-hydroxypropylcarbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -1- benzyl-3- [ (3- [ (cyanomethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] -2-hydroxypropylcarbamate (see example 86) and 5.0 mg (0.033 mmol) of K2C03 in 2 mL of 3:1 acetone/water was treated with 0.150 g (1.63 mmol) of urea- hydrogen peroxide addition compound and was stirred at RT . After 18 hours tic (silica gel, 95:5 CH2Cl2/MeOH) indicated no remaining starting material at Rf=0.43, a major new component at Rf=0.21, and a lesser component at Rf=0.61. The solution was diluted with CH2C12, washed with water (3x), dried over anhydrous MgS04, and concentrated. The residue was subjected to flash chromatography (silica gel, 95:5 CH2Cl2/MeOH) to afford 15 mg (15%) of the Rf=0.61 product as a white foam. 1H-ΝMR (CDC13) : 8.62 (IH), 8.51 (IH), 8.06 (IH), 7.75 (IH), 7.31-7.14 (6H), 5.65 (IH), 5.08- 4.78 (3H), 3.98-3.57 (5H), 3.22-2.60 (6H), 1.95-1.40 (10H) . LCMS (ESI) : 606 (M+H) .
Example 90 Step 1
Figure imgf000201_0001
(32?,4S) -4-amino-l- (cyclopentyloxy) -5-phenyl-l- (6- quinoxalinyl sulfonyl) -3-pentanol . A mixture of tert-butyl N- [ (IS, 22?) -l-benzyl-4- (cyclopentyloxy) -2-hydroxy-4- (6- quinoxalinylsulfonyl) butyl] carbamate (563 mg, 1.01 mmol) and trifluoroacetic acid (5 mL) was stirred under an Argon atmosphere for 0.5 hrs. The acid was removed in vacuo and the residue was partitioned between dichloromethane and IN sodium hydroxide. The organic layer was separated and the aqueous layer was extracted again with dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. The crude product was purified on flash grade silica gel eluting with dichloromethane : methanol (98:2). Fractions containing the product were combined and evaporated in vacuo and dried under high vacuum to provide (32?, 4S) -4-amino-l- (cyclopentyloxy) -5-phenyl-l- ( 6-quinoxalinylsulfonyl) -3- pentanol as a foam (379 mg, 82 %) . Hl-NMR (chloroform-D3) : 1.66 (m, 11H), 2.51 (m, IH) , 2.86 (m, IH) , 3.07 (m, IH) , 3.23 (m, IH) , 3.32 (m, IH) , 3.84 (m, IH) , 4.90 (m, IH) , 7.20 (m, 5H) , 8.16 (m, IH) , 8.28 (d, IH) , 8.70 (m, IH) , 8.99 (m, 2H) . MS (ESI) : 457 (M+H) .
Step 2:
Figure imgf000202_0001
:9o:
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- [ (1S,22?)-1- benzyl-4- (cyclopentyloxy) -2-hydroxy-4- (6- quinoxalinylsulfonyl)butyl] carbamate. A mixture of (32?, 45) -4-amino-1- (cyclopentyloxy) -5-phenyl-l- (6- quinoxalinylsulfonyl) -3-pentanol (50 mg, 0.110 mmoL) ,
(22?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-2-yl 4-nitrophenyl carbonate (37.3 mg, 0.121 mmol), and N,N- diisopropylethylamine (47.8 μL, 0.274 mmol) were combined under an Argon atmosphere in approximately 1.5 mL of acetonitrile. After stirring at ambient temperature for 16 hours, the solvent was removed in vacuo and the residue was dissolved in ethyl acetate and washed three times with 5% w/v aqueous potassium carbonate. The combined aqueous layers were back-extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo. The crude product was purified on a preparative TLC plate (20X20 cm, 1000 μM) eluting with 95:5 dichloromethane : methanol. The product band was removed, eluted with 3:1 methylene chloride:methanol, filtered, and evaporated in vacuo . The residual solid was dried under high vacuum to provide (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- [ (IS, 22?) -1- benzyl-4- (cyclopentyloxy) -2-hydroxy-4- (6- quinoxalinylsulfonyl) butyl] carbamate (53 mg, 79 %). Hl-NMR (chloroform-D3) : 1.58 (m, 6H) , 1.81 (m, 4H) , 2.80 (m, IH) , 2.95 (m, 4H) , 3.17 ( , IH) , 3.65 (m, 2H) , 3.88 (m, 4H) , 4.85 (m, 2H) , 4.98 (m, IH) , 5.62 (d, IH) , 7.21 (m, 5H) , 8.08 ( , IH) , 8.26 (d, IH) , 8.63 (m, IH) , 9.00 (m, IH) . MS(ESI): 613 (M+H) .
Example 91
Figure imgf000203_0001
(91)
(3aS, 6aR) Hexahydrofuro [2 ,3-b] furan-3-yl N- (1S,2R) -1-benzyl- 3- [ (cyclopentyloxy) (benzotriazole-5-ylsulfonyl) amino] -2- hydroxypropylcarbamate. (3aS, 6aR) Hexahydrofuro [2, 3-b] furan- 3-yl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) -amino] -2- hydroxypropylcarbamate (280 mg, 0.666 mmol) (Step 2, Example 54), benzotrizole-5-sulfonyl chloride (140 mg, 0.666 mmol), and anhydrous diisopropylethylamine (0.04 mL, 0.238 mmol) were combined in anhydrous tetrahydrofuran (5 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to give the product as a white foam (70 mg, 0.116 mmol, 17%). 'HNMR (d6-DMSO) δ: 8.42 (bs, IH) , 8.16 (bs, IH) , 7.84 (bs, IH) , 7.26-7.15 (m, 5H) , 5.51-5.47 (m, IH) , 5.31-5.28 (m, IH) , 4.85-4.70 (m, 2H) , 4.12 (m, IH) , 3.79-1.15 ( , 21H) . MS(ES): 602 (M+l), 600 (M-l) .
Example 92
Figure imgf000204_0001
92)
l,3-Dioxan-5-yl N- (1S,2R) -l-benzyl-3-
[ (cyclopentyloxy) (benzotriazole-5-ylsulfonyl) amino] -2- hydroxypropylcarbamate. 1, 3-Dioxan-5-yl N- (IS, 2R) -1-benzyl- 3- [ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate (Step 1, Example 55), (130 mg, 0.330 mmol), benzotriazole-5-sulfonyl chloride (72 mg, 0.330 mmol), and anhydrous diisopropylethylamine (0.06 mL, 0.330 mmol), were combined in anhydrous tetrahydrofuran (5 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to give the product as a white film (56 mg, 0.0973 mmol, 30%). 'HNMR (d6-DMSO) δ: 8.43 (bs, IH) , 8.14 (m, IH) , 7.83 ( , IH) , 7.27-7.15 (m, 5H) , 4.86-4.66 (m, 3H) , 4.23-3.02 (m, 13H) , 1.93-1.40 (m, 8H) . MS(ES): 576 (M+l), 574 (M-l) .
Example 93
Figure imgf000205_0001
93 :
tert-butyl 27- (IS,22?) -l-benzyl-3- [ [4- (benzyloxy)phenyl] sulfonyl (cyclopentyloxy) amino] -2-hydroxypropylcarbamate. tert-butyl N- (IS, 22?) -l-benzyl-3- [ (cyclopentyloxy) amino] -2- hydroxypropylcarbamate (3.5 mmol, 807 mg) , 3- phenoxybenzenesulfonyl chloride (3.5 mmol, 1.0 g) , and diisopropylethylamine (5.3 mmol, 0.924 mL) were dissolved in anhydrous THF (10 mL) , and the solution was stirred at room temperature under nitrogen for 72 hours. The reaction was concentrated to a white solid under vacuum, dissolved in ethyl acetate, washed with IN HCl, IN ΝaOH, brine, dried over magnesium sulfate and concentrated. The crude product was purified by silica gel chromatography (2:1 hexanes/ethyl acetate) and yielded 1.08 g (50%) of a white solid. Note: The 3-phenoxybenzenesulfonyl chloride was prepared from 4- bromophenylbenzylether (Corrie, J.; Papageorgiou, G. J. Chem . Soc , Perkin Trans . 1 1996, 1583). Rf = 0.3 (5:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.69 (2H,d), 7.41-7.28 (5H,m) , 7.27-7.19 (6H,m) , 7.03 (2H,d), 5.11 (2H,s), 4.79 (lH,m), 4.56 (lH,m), 3.79 (2H,bs), 3.31 (lH,bs), 3.02 (lH,m), 2.91 (2H,m) , 2.79 (lH,m) , 1.85-1.67 (4H,m), 1.67-1.43 (4H,m), 1.32 (9H,s) .
Example 94
Figure imgf000206_0001
(94:
tert-butyl 27- (IS, 22?) -l-benzyl-3- [ [3-
(benzyloxy) phenyl ] sulfonyl (cyclopentyloxy) amino] -2- hydroxypropylcarbamate. This compound was prepared under the same conditions described for the tert-butyl A'- (IS, 22?) - l-benzyl-3- [ [4- (benzyloxy) phenyl] sulfonyl (cyclopentyloxy) amino] -2-hydroxypropylcarbamate. Rf = 0.3 (5:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.44-7.30 (8H,m), 7.29-7.16 (7H,m) , 5.08 (2H,s), 4.79 (lH,m), 4.53 (lH,m), 3.78 (2H,bs), 3.34 (lH,bs), 3.06 (lH,m), 2.91 (2H,m), 1.85-1.66 (4H,m), 1.66-1.43 (4H,m), 1.32 (9H,s).
Example 95
Figure imgf000206_0002
(95) (32?, 3aS, 6a2?) hexahydrof ro [2 , 3-b] furan-3-yl 27- (IS, 22?) -1- benzyl-3- [ [4- (benzyloxy) phenyl ] sulfonyl (cyclopentyloxy) amino] -2-hydroxypropylcarbamate. This compound was prepared
(from Example 93) under the conditions described for (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( ( IS, 22?) -1- benzyl-3- (cyclohexyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate . Rf = 0.2 (2:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.70 (2H,d), 7.44-7.31 (5H,m) , 7.29-7.11 (6H,m), 7.05 (2H,d), 5.63 (lH,s), 5.11 (2H,s), 5.00 (lH,m), 4.88-4.74 (2H,m), 3.96-3.78 (4H,m), 3.67
(2H,m) , 3.08 (lH,bs), 3.05-2.94 (2H,m), 2.90 (2H,m), 2.81
(2H,m), 1.87-1.68 (4H,m), 1.68-1.44 (4H,m) .
Example 96
Figure imgf000207_0001
(96)
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- (IS,22?) -1- benzyl-3- [ [3- (benzyloxy) phenyl ] sulfonyl (cyclopentyloxy) amino] -2-hydroxypropylcarbamate. This compound was prepared under the conditions (from Example 94) described for
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclohexyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate. Rf = 0.2 (2:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.48-7.30 (8H,m), 7.30-7.11
(7H,m), 5.59 (lH,s), 5.09 (2H,s), 4.97 (lH,m), 4.78 (2H,m) ,
3.95-3.77 (4H,m), 3.71-3.57 (2H,m), 3.12 (lH,bs), 3.05-2.90 (3H,m), 2.90-2.72 (3H,m), 1.88-1.67 (4H,m), 1.67-1.42 (4H,m) .
Example 97
Figure imgf000208_0001
: 9 )
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- [ (IS, 22?) -1- benzyl-3- ( (cyclopentyloxy) [3- (2-hydroxyethoxy) phenyl ] sulfonylamino) -2-hydroxypropyl ] carbamate . This compound was synthesized (from Example 44) under the same conditions as Example 42 (32?, 3aS, 6a2?) hexahydrofuro [2,3- b]furan-3-yl N- [( IS, 22?) -l-benzyl-3- ( (cyclopentyloxy) [4-(2- hydroxyethoxy) phenyl] sulfonylamino) -2-hydroxypropyl] carbamate. Rf = 0.1 (1:1 hexanes/ethyl acetate); Hl-ΝMR
(CDC13) : δ 7.47-7.14 (10H,m), 5.63 (lH,s), 5.00 (lH,m), 4.88-4.70 (2H,m), 4.12 (2H,m), 3.98 (2H,m), 3.94-3.72 (5H,m), 3.72-3.51 (2H,m), 3.14 (lH,bs), 3.07-2.69 (5H,m) , 2.20 (lH,bs), 1.89-1.69 (4H,m), 1.69-1.42 (4H,m); MS (ESII M+H=621. Example 98
Figure imgf000209_0001
( 98 :
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- [ (1S,22?)-1- benzyl-3- ( (cyclopentyloxy) [4- (2-morpholinoethoxy) phenyl] sulfonylamino) -2-hydroxypropyl] carbamate. To a solution of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (4-hydroxyphenyl) sulfonyl] amino-2- hydroxypropyl ) carbamate (Example 41), (0.13 mmol, 75 mg) , triphenylphosphine (0.16 mmol, 43 mg) , 4- (2- hydroxyethyl) morpholine (0.16 mmol, 0.020 L) , and anhydrous THF (0.5 mL) stirring under nitrogen, diethylazodicarboxylate (0.17 mmol, 0.027 mL) was injected. The reaction stirred for 3 hours at room temperature and was then concentrated to a viscous oil under vacuum. The crude was purified directly by silica gel flash chromatography (1:1 hexanes/ethyl acetate) resulting in 50 mg (56%) of a white solid. Rf = 0.15 (ethyl acetate); Hl-ΝMR (CDC13) : δ 7.70 (2H,d), 7.30-7.10 (6H,m), 6.99 (2H,d), 5.63 (lH,s), 5.00 (lH,m), 4.86-4.73 (2H,m) , 4.16 (2H,m), 3.97-3.79 (4H,m), 3.78-3.58 (6H,m), 3.15-2.69 (9H,m), 2.57 (4H,m), 1.88-1.66 (4H,m), 1.66-1.43 (4H,m); MS (ESI): M+H=690. Example 99
Figure imgf000210_0001
99;
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- [ (IS,22?) -1- benzγl-3- ( (cyclopentyloxy) [3- (2-morpholinoethoxy) phenyl ] sulfonylamino) -2-hydroxypropyl ] carbamate . This compound was prepared from Example 44 under the same conditions used for the preparation of Example 98
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- [ (IS, 22?) -1- benzyl-3- ( (cyclopentyloxy) [4- (2-morpholinoethoxy) phenyl] sulfonylamino) -2-hydroxypropyl] carbamate . Rf = 0.15
(ethyl acetate); Hl-ΝMR (CDC13) : δ 7.44-7.14 (10H,m), 5.62 (lH,s), 5.00 (lH,m), 4.79 (2H,m), 4.16 (2H,m), 3.98-3.60
(10H,m), 3.12 (lH,bs), 3.02-2.71 (8H,m), 2.58 (4H,m), 1.90- 1.72 (4H,m), 1.72-1.42 (4H,m); MS (ESI): M+H=690.
Example 100
Phosphate ester of (32?,3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3- yl 27- (IS, 22?) -3- [ [ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate . Step 1:
Figure imgf000211_0001
A solution of 0.792g (2.18 mMol) of tert-butyl N-(1S,2R)-1- benzyl-3- [ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate (Example 54), 0.445g (2.4 mMol) of m-nitrobenzenesulfonyl chloride and 0.35 mL (2.5 mMol) of triethylamine in lOmL of tetrahydrofuran was stirred at rt for 12h, diluted with ethyl acetate and exracted with IN HCl and saturated sodium bicarbonate. Purification on silica gel afforded the desired sulfonamide which was treated with 50 mL of 1:1 trifluoroacetic acid/ dichloromethane for lh at rt . Evaporation of the volatiles and partitioning between ethyl acetate and IN sodium hydroxide, afforded the free base which was treated with 0.885g (3 mmol) of (32?, 3aS, 6a2?) - hexahydrofuro [2, 3-b] furan-3-yl (4-nitrophenyl) carbonate, 10 mg of dimethylamino pyridine, and 0.7 mL of triethylamine in 20 mL of tetrahydrofuran for 12h at rt . The resulting mixture was loaded onto a bed of silica gel and eluted with 50% to 100% ethylacetate-hexanes) to give the desired compound (750 mg) as a white foam. Step 2
Figure imgf000212_0001
( 100 )
A solution of 60.5 mg (0.1 mmol) of the material obtained in Step 1 above, 0.042 mL (0.125 mmol) of diisopropylamino- dibenzylphosphite and 9 mg (0.13 mmol) of tetrazole in 2 mL of dichloromethane was stirred for 3 h at rt and then loaded onto a bed of silica gel and eluted with 30% ethylacetate- hexane to give the intermediate phosphite which was redissolved in 3 mL of acetonitrile and treated with 48.3 mg (0.15 mmol) of iodosobenzene diacetate. The mixture was stirred at rt for lh and then loaded on a plug of silica gel and eluted with 80% ethylacetate-hexane . The resulting phosphate ester was obtained as a white foam (48 mg) , which was re-dissolved in 50 ml methanol and treated with ca. 50 mg of 5% palladium on carbon. The mixture was hydrogenated at 55PSI for 8h, filtered and evaporated. Purification on C-18 semi-preparative HPLC gave the desired phosphate (6 mg) as a white fluffy solid. 1H-NMR (methanol-d4) : 1.4-2.0 (14H), 2.65 (IH), 2.9 (IH), 3.2 (2H) , 3.55 (IH), 3.6-4.0 (4H), 4.4 (IH), 4.65 (IH), 4.8 (2H) , 5.6 (IH), 7.2-7.6 (9H). 31P-NMR: 1.1 ppm. MS (LC-MS) : 656 (MH+). Example 101
Figure imgf000213_0001
(101)
Phosphate ester of (32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3- yl 27- ( (IS,22?) -l-benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate. A solution of 0.6 g (1 mmol) of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (4- methoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate (Example 102), 0.42 mL (1.25 mmol) of diisopropylamino- dibenzylphosphite and 0.09g (1.25 mmol) of tetrazole in 10 mL of dichloromethane was stirred at rt for 12h. The mixture was loaded onto a plug of silica gel and eluted with 40% ethylacetate-hexane to give the desired phosphite. 250 mg of the material so obtained were dissolved in 15 mL of acetonitrile and treated with 0.19 g (0.6 mmol) of iodosobenzene diacetate. After 2h at rt, the mixture was diluted with ethyl acetate and extracted with IN HCl and IN ΝaOH. The volatiles were removed and the residue was chromatographed on silica gel to give 220 mg of the protected phosphate as a white foam. 100 mg of the so obtained material was dissolved in 20 mL of methanol and trated with ca . 20 mg of 5% palladium on carbon.
Hydrogenation at 50 PSI for lh and filtration gave the desired acid which was dissolved in 2M methanolic ammonia and re-evaporated, The ammoinum salt was isolated as a white solid (65mg) . 1H-NMR (methanol-D4 1.5-2.2 (14H), 2.7 (IH), 2.9 (3H), 3.15
(IH), 3.4-4 (5H), 3.97 (3H), 4.2-4.7 (2H) , 4.9 (2H) , 5.6 (IH), 7.2 (3H), 7.3 (4H), 7.85 (2H). 31P-NMR: 0.08ppm MS (LC-MS) : 671 (MH+) .
Example 102
Figure imgf000214_0001
:ιo2)
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- ( (IS,22?) -1- benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate . This compound was obtained in analogous manner to Example 29, using the appropriate optically pure activated carbonate. lH-NMR (CDC13) : 1.4-1.9 (12H), 2.75 (2H), 2.9 (IH), 3.1 (2H) , 3.65 (2H) , 3.9 (6H), 4.75 (2H) , 5.00 (IH), 5.62 (IH), 7.0 (2H) , 7.15 (5H), 7.75 (2H) .
Example 103
Prepared as outlined for Example 86, using chiral starting materials. Example 104
Figure imgf000215_0001
: ι o4 '
l,3-Dioxan-5-yl-N- (IS,2R) -l-benzyl-3- [ (cyclopentyloxy) (3- (carbomethoxyamino) -indazole-5-ylsulfonyl) amino] -2- hydroxypropylcarbamate. 1, 3-Dioxan-5-yl N- (IS, 2R) -1-benzyl- 3- [ (cyclopentyloxy) (l-carbomethoxy-3- (carbomethoxyamino) indazole-5-ylsulfonyl) amino] -2-hydroxypropylcarbamate
(Example 120), (40 mg, 0.057 mmol) and lithium iodide (23 mg, 0.17 mmol) were dissolved in pyridine (3 mL) in a 10 mL round bottomed flask and heated at 95°C for 2 hours. The reaction was allowed to cool and then concentrated in vacuo. The product was purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to yield a beige solid (35 mg, 0.054 mmol, 95 %). 'HNMR (d6-DMSO) δ: 13.12 (s, IH) , 10.26 (s, IH) , 8.42 (s, IH) , 7.62 (m, 2H) , 7.25- 7.09 (m, 6H) , 5.12 (d, J=6.2 Hz, IH) , 4.76-4.18 (m, 5H) , 3.76-2.91 (m, 9H) , 3.66 (s, 3H) , 1.90-1.40 (m, 8H) . MS(ES): 648 (M+l) , 646 (M-l) .
Example 105
Figure imgf000215_0002
(105) Tert-butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2-[(3- chloropropionyl) amino] -lH-benzimidazol-5-ylsulfonyl) amino] - 2-hydroxypropylcarbamate. Tert-butyl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2-amino-lH-benzimidazol-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate (Step 2, Example 8) (65 mg, 0.116 mmol), 3-chloropropionyl chloride (0.01 mL, 0.116 mmol), and 4, 4-dimethylaminopyridine were combined in anhydrous THF (5 mL) in a 25 L round bottomed flask under nitrogen. The reaction was stirred for 18 hours and then concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 10:3:0.5 chloroform: methanol: water as an eluent to give the product as a white solid (17 mg, 0.026 mmol, 22%) . XHNMR (d6-DMSO) δ: 7.55-6.62 (m, 8H) , 5.08 (bs, IH) , 4.62 (bs, IH) , 4.15 (bs, IH) , 3.57 (m, 2H) , 3.10-1.40 (m, 16H), 1.18 (s, 9H) . MS(ES) : 650, 652 (M+l) .
Example 106
Prepared as outlined in Example 8, Step 2.
Example 107
Figure imgf000216_0001
(107:
Tert-butyl N- (1S,2R) -l-benzyl-3- [ (cyclopentyloxy) (2-arnino-l- methyl-lH-benzimidazol-5-ylsulfonyl) amino] -2- hydroxypropylcarbamate and Tert-butyl N- (IS ,2R) -l-benzyl-3- [ (cyclopentyloxy) (2-amino-3-methyl-lH-benzimidazol-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate. Tert-butyl N-
(1S, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2-amino-lH- benzimidazol-5-ylsulfonyl) amino] -2-hydroxypropyl-carbamate (Step 2, Example 8) (120 mg, 0.214 mmol), methyl iodide
(0.03 L, 0.429 mmol), and anhydrous diisopropylethylamine
(0.07 mL, 0.429 mmol) were combined in anhydrous THF (5 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was heated at reflux for 18 hours and then concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to give the product as mixture of two compounds methylated at the 1- and 3- positions of the imidazole ring (76 mg, 0.133 mmol, 62%). LC-MS: 574 (M+l), 572 (M-l).
Example 108
Figure imgf000217_0001
(108)
(3R, 3aS, 6aR) Hexahydrofuro [2 ,3-b] furan-3-yl N- (IS ,2R) -1- benzyl-3-[ (cyclopentyloxy) (3-aminoindazole-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate . (3R,3aS, 6aR) Hexahydrofuro [2, 3-b] furan-3-yl N-(1S,2R)-1- benzyl-3- [ (cyclopentyloxy) (l-carbomethoxy-3-aminoindazole-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate (100 mg, 0.148 mmol) and lithium iodide hydrate (50 mg, 0.37 mmol) were dissolved in pyridine (3 mL) in a 10 mL round bottomed flask and heated at 75 C for 5 hours. The reaction was allowed to cool and then concentrated in vacuo. The product was purified by preparative silica gel TLC using 90:10 chloroform: methanol as an eluent to yield a glass (76 mg, 0.124 mmol, 84 %). -"HNMR (d6-DMSO) : 12.05 (s, IH) , 8.35 (m, IH) , 7.56-7.14 (m, 7H) , 5.86 (bs, 2H) , 5.50 (d, J=5.2 Hz, IH) 5.22 (d, J=6.5 Hz, IH) , 4.85-4.79 (m, 2H) , 3.78- 1.14 (m, 22H) . MS(ES): 616 (M+l), 614 (M-l).
Example 109
Step 1:
Figure imgf000218_0001
271- (cyclopentyloxy) -4- (methoxymethoxy) -1-benzenesulfonamide
The 4-methoxymethoxybenzenesulfonyl chloride (2.4 mmol, 568 mg) was prepared from methylmethoxy-protected 4-bromophenol (Come, J.; Papageorgiou, G. J. Chem. Soc , Perkin Trans . 1 1996, 1583) and was combined with cyclopentyl hydroxylamine (2.4 mmol, 243 mg) in the presence of diisopropylethylamine (3.6 mmol, 0.628 mL) , and anhydrous THF. The reaction stirred under nitrogen for 36 hours at room temperature and was concentrated under vacuum. The resulting oil was diluted in ethyl acetate, washed with IN HCl, 5% potassium carbonate, brine and was dried over magnesium sulfate. The crude product was concentrated under vacuum and purified by silica gel chromatography (5:1 hex/ethyl acetate) followed by crystallization from ether/hexanes. The reaction produced 173 mg (24%) of white crystals. Rf = 0.15 (1:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.82 (2H,d), 7.12 (2H,d), 6.67 (lH,s), 5.23 (2H,s), 4.58 (lH,m), 3.47 (3H,s), 1.84-1.64 (4H,m), 1.64-1.43 (4H,m). Step 2 : Phosphazine
Figure imgf000219_0001
Figure imgf000219_0002
(109)
tert-butyl 27- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (4- methoxymethoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate. N1- (cyclopentyloxy) -4-methoxymethoxy-l- benzenesulfonamide (0.57 mmol, 173 mg) was combined with tert-butyl N- (IS) -1- [ (25) oxiran-2-yl] -2-phenylethylcarbamate (0.46 mmol, 121 mg) and anhydrous THF (1 mL) under nitrogen. Phosphazine base P<t/4>t-Bu (0.09 mmol, 0.092 mL, 1M in hexanes) was injected into the stirring solution. The reaction was allowed to stir for 4 hours at room temperature and was quenched by the addition of a few drops of glacial acetic acid. The reaction product was concentrated to an oil and partitioned between ethyl acetate and IN HCl. The organic layer was separated and washed with 1 Ν ΝaOH and brine, dried over magnesium sulfate and concentrated under vacuum to a clear oil. The crude product was purified by silica gel chromatography (5:1 hexanes/ethyl acetate) and crystallization from ether/hexanes providing 110 mg (43%) of a white crystal. Rf = 0.5 (2:1 hexanes/ethyl acetate); Hl- ΝMR (CDC13) : 7.69 (2H,d), 7.31-7.16 (6H,m), 7.11 (2H,d),
5.21 (2H,s), 4.83-4.75 (lH,m), 4.61-4.51 (lH,m), 3.85-3.70 (2H,m), 3.47 (3H,s), 3.12-2.95 (lH,m), 2.95-2.87 (2H,m) , 2.87-2.68 (lH,m), 1.86-1.66 (4H,m), 1.66-1.43 (4H,m), 1.33 (9H,s); MS (ESI): M+H=565. Example 110
Figure imgf000220_0001
no:
(3S) tetrahydro-3-furanyl 27- [ (IS,22?) -l-benzyl-4- (cyclopentyloxy) -2-hydroxy-4- (6-quinoxalinylsul onyl) b tyl ] carbamate . A mixture of (32?, 4S) - -amino-1- (cyclopentyloxy) -5-phenyl-l- ( 6-quinoxalinylsulfonyl) -3- pentanol (50 mg, 0.110 mmoL) , 2, 5-dioxo-l-pyrrolidinyl
[ (3S) tetrahydro-3-furanyl] carbonate (28 mg, 0.121 mmol, WO 94/05639) and N,N-diisopropylethylamine (47.8 uh, 0.274 mmol) were combined under Argon at ambient temperature in approximately 1.5 mL of acetonitrile. After stirring for approximately 16 hours at ambient temperature, the reaction mixture was evaporated in vacuo and partitioned between ethyl acetate and aqueous potassium carbonate (5% w/v) . The layers were separated and the aqueous layer was back extracted with ethyl acetate. The combined organic layers were washed twice with IN sodium hydrogen sulfate. The acid layers were combined and back extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo. The residue was purified on a preparative TLC plate (20X20 cm, 1000 μM) eluting with 93:7 dichloromethane :methanol . The product band was removed, eluted with 3:1 methylene chloride: methanol, filtered, and evaporated in vacuo . The residue was crystallized with several drops of methanol. The residual solid was dried under high vacuum to provide (3S) tetrahydro-3-furanyl N- [ (IS, 22?) -l-benzyl-4- (cyclopentyloxy) -2-hydroxy-4- (6- quinoxalinyl sulfonyl) butyl] carbamate (54 mg, 86%) as a white solid. Hl-ΝMR (chloroform-D3) : 1.61 ( , 5H) , 1.86 (m, 4H) , 2.09 (m, IH) , 2.97 (m, 3H) , 3.20 (m, 2H) , 3.80 (m, 6H) , 4.83 (m, IH) , 4.93 (m, IH) , 5.14 (m, IH) , 7.28 (m, 5H) , 8.13 (m, IH) , 8.31 (d, IH) , 8.69 (d, IH) , 9.05 (s, 2H) . MS (ESI) : 571 (M+H) .
Example 111
Step 1:
Figure imgf000221_0001
(IS, 22?) -l-benzyl-3- (tert-butyloxy) [ (phenyl) sulfonyl] amino-2- hydroxypropylamine hydrochloride. tert-Butyl-N- (( IS, 22?) -1- benzyl-3- ( ert-butyloxy) [ (phenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (Example 112, Step 2), (0.060 g, 0.12 mmol) was dissolved in EtOAc (50 ml) . Dry hydrochloric acid gas was bubbled through the stirred solution 15 minutes at -10 °C. The reaction was warmed to ambient temperature, solvent removed in vacuo and the resulting crude residue used directly in the next reaction. Step 2 :
Figure imgf000222_0001
:in :
(3S) Tetrahydro-3-furanyl-N- (IS,22?) -l-benzyl-3- (tert butyloxy) [ (phenyl) sulfonyl ] amino-2-hydroxypropylcarbamate.
(IS, 22?) -l-benzyl-3- ( ert-butyloxy) [(phenyl) sulfonyl] amino- 2-hydroxypropylamine hydrochloride ( 0.12 mmol) was combined with diisopropylethylamine (0.064 ml, 0.37 mmol) in CH2CI2 (10 ml). To the reaction was added 2, 5-dioxo-l-pyrrolidinyl [ (3S) tetrahydro-3-furanyl] carbonate (0.042g, 0.18 mmol) with stirring. After 3 h at ambient temperature, the reaction mixture was concentrated in vacuo, taken up in EtOAc, washed with sat. aq. NaHCθ3, and brine. The organic phase was dried over MgSθ4, filtered and solvent removed in vacuo . Purification by preparative TLC (1:1 EtOAc/Hex) . Recovered 0.044 g (67%) of the product as a white foam. Rf=
0.38 (1:1 EtOAc/Hex) , LRMS (M+H) + 507.3.
Example 112
Step 1
Figure imgf000223_0001
tert-Butyl-N- ( (IS,22?) -l-benzyl-3- (tert-butyloxy) amino-2- hydroxypropyl) carbamate. tert-Butyl-N- ( (IS) -1- [ (2S) oxiranyl] -2-phenylethylcarbamate (0.155 g, 0.59 mmol) and 0- ( tert-butyl) hydroxylamine hydrochloride (0.089 g, 0.71 mmol) were heated with diisopropylethylamine (0.154 ml, 0.88 mmol) in isopropanol (2 ml) in a sealed tube at 60°C for 5 days. The reaction mixture was concentrated in vacuo, taken up in EtOAc, washed with sat. aq. NaHCθ3, and brine. The organic phase was dried over MgS04, filtered and solvent removed in vacuo . Purication by column chromatography (1% MeOH in CH2CI2) gave 100 mg of a white solid which was used directly in the next reaction.
Step 2:
Figure imgf000223_0002
: ιi2 )
tert-Butyl-N- ( (IS,22?) -l-benzyl-3- (tert- butyloxy) [ (phenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate , tert-Butyl-N- ( (IS, 22?) -l-benzyl-3- ( ert-butyloxy) amino-2- hydroxypropyl) carbamate (0.100 g, 0.28 mmol) was combined with diisopropylethylamine (0.075 ml, 0.43 mmol) in CH2CI2 (10 ml). Benzenesulfonyl chloride (0.060 g, 0.34 mmol) was added and the reaction was stirred at room temperature overnight. Reaction mixture was concentrated in vacuo, taken up in EtOAc, washed with sat. aq. NaHCθ3, and brine. The organic phase was dried over MgSθ4, filtered and solvent removed in vacuo . Purication by preparative TLC (1: 1/EtOAc/Hex) . Recovered 0.064 g (46%) of the product as a white foam. Rf= 0.78 ( 1 : 1/EtOAc/Hex) , LRMS (M+H)+ 493.4.
Example 113
Figure imgf000224_0001
113 :
Ethyl 2-[ ([2-(3-[ [ (22?,3S) -3- ( [ (32?, 3aS, 6a2?) hexahydrofuro [2 ,3- b] furan-3-yloxy] carbonylamino) -2-hydroxγ-4- phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) ethyl ]amin ocarbonyl) amino] acetate and ethyl 2- [ ( [2- (3- [ [ (22?,3S) -3- ( [ (3S, 3a2?, 6aS) hexahydrofuro [2 , 3-b] f ran-3-yloxy] carbonylamino) -2-hydroxy-4 phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) ethyl] aminocarbonyl) amino] acetate. A solution of 50 mg (0.081 mmol) of a 1:1 mixture of
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2- aminoethyl) amino]phenylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate (Example 83) in 1.5 mL of anhydrous THF was treated with 0.010 mL (0.085 mmol) of ethyl isocyanatoacetate . The resulting solution was stirred at RT . After 18 hours the solution was concentrated in vacuo and the residue subjected to flash chromatography (silica gel, 95: 5/CH2Cl2/2M ΝH3 in MeOH) to afford 56 mg (92%) of the desired product as a white foam. 1H-NMR
(CDCI3) : 7.60-7.06 (13H), 6.00-4.80 (4H), 4.34-2.62 (19H), 2.10-1.43 (10H), 1.32 (3H) . LCMS(ESI): 748 (M+H).
Example 114
Figure imgf000225_0001
( i :
l,3-Dioxane-5-yl N- (IS,2R) -l-benzyl-3- [ (cyclopentyloxy) (2- acetamido) ] -benzothiazol-6-ylsulfonyl) amino] -2- hydroxypropylcarbamate. To 21 mg (0.034 mmol) of 1,3- Dioxane-5-yl N- ( IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2- amino) ] -benzothiazol-6-ylsulfonyl ) amino] -2- hydroxypropylcarbamate, (Example 125, Step 3) , dissolved in 1 mL of dichloromethane and cooled to approximately 0°C, was added 5.3 μL (1.2 eq.) of chlorotrimethylsilane . The reaction was warmed to 25°C and stirred for 45 minutes. Triethylamine (12 μL, 2.5 eq. ) was added followed by 100 μl (1.2eq.) of a dilute solution of (24 μl acetyl chloride in 1 mL CH2C12) . The reaction was stirred at 25°C for 3 hours. 105 μL (3.0 eq.) of 1.0 M tetrabutylammonium fluoride was added and the reaction stirred for 1 hour. The solvent was removed in vacuo and the residue was purified by preparative chromatography to give 8 mg of carbamate, 114. HPLC showed the material to be over 80% pure. Ret. time = 10.48 min. LC/MS, M+H = 649.1.
Example 115
Figure imgf000226_0001
115 )
IN- (3-Methylsulfonylisobutyryl) - (IS,22?) -l-benzγl-3- (cyclopentyloxy) [4-methoxyphenylsulfonyl] amino-2- hydroxypropylamine. (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (4- methoxyphenyl) sulfonyl] amino-2-hydroxypropylamine trifluoroacetic acid salt (0.012 g, 0.03 mmol) was combined with 3-methylsulfonylisobutyric acid (0.005 g, 0.03 mmol) and 1-hydroxybenzotriazole hydrate (0.004 g, 0.03 mmol) in anhydrous DMF (1 ml). Triethylamine (0.010 ml, 0.05 mmol) was added followed by 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (0.009 g, 0.03 mmol). Reaction was stirred at room temperature for 2 hours. Reactiom mixture was diluted in EtOAc and washed with sat. NaHC03, 0.5N KHSO4 and brine. Organic phase was dried with
MgSθ4 and the solvent was removed in vacuo . Purification by preparative TLC (3 : 1/EtOAc/Hex) . Recovered 0.010 g (70%) of the product as a colorless residue. Rf=0.44 (3:1 EtOAc/Hex). ^ NMR (CDCI3) 8.78 (lH,d), 7.38-7.17 (5H,m), 7.05-6.98 (2H,m), 6.09 (0.5H,d), 5.98 (0.5H,d), 5.80 (lH,m), 4.32 (0.5H,m), 4.20 (0.5H,m), 4.02 (0.5H,m), 3.90 (3H,s), 3.60 (0.5H,m), 3.49 (lH,m), 3.12-2.96 (2H,m), 2.95-2.70 (4H,m), 1.90-1.70 (4H,m) , 1.69-1.50 (4H,m) , 1.20 (1.5H,d),
1.00 (1.5H,d). LRMS (M+H) + 583.0.
Example 116
Step 1:
(3S, 3aS, 6a2?) hexahydrofuro [2 , 3b] furan-3-p-nitrobenzoyl ester (A) and (32?, 3a2?, 6aS) hexahydrofuro [2 ,3b] furan-3-p- nitrobenzoyl ester (B)
Figure imgf000227_0001
(A) (B)
In a dried flask was introduced 1 eq. of (3S, 3aS, 6a2?) -3-Hydroxyhexahydrofuro [2, 3b] furan (200 mg, 1.54 mmol) in 10 mL of dried THF. To this solution was introduced 1.1 eq. of PPh3 (443 mg, 1.69 mmol) and 1.1 eq. of p-nitrobenzoic acid (282 mg, 1.69 mmol). The solution was cooled to 0°C and then 1.2 eq of diethyl azodicarboxylate (290 μL, 1.84 mmol) was added dropwise. The reaction was continued at room temperature for 24 h. The solvent was evaporated in vacuo to an oil which was solubilized in dichloromethane washed with IN hydrochloric acid, saturated sodium bicarbonate and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified on flash grade silica gel eluting with 20-50% ethyl acetate in hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide (35, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-p-nitrobenzoyl ester (914 mg, 98%) . HPLC showed the material to be 98% pure; Ret. time = 9.88 min. lE NMR (CDCI3) : 8.14-8.24 (dd, 4H) , 5.88 (d, IH), 5.29 (s, IH) , 4.07-4.17 (m, 2H) , 3.83-3.93 (m, 2H) , 2.97 (m, IH) , 2.19-2.28 (m, IH) , 1.86-1.98 (m, IH) .
Step 2:
(3S,3aS,6a2?) -3-Hydroxyhexahydrofuro [2 ,3b] furan (C) and (32?,3a2?,6aS) -3-Hydroxyhexahydrofuro [2 ,3b] furan (D)
Figure imgf000228_0001
(C) (D)
In a flask was introduced 1 eq. of (32?3a2?, 6aS) Hexahydrofuro [2, 3b] furan-3-p-nitrobenzoyl ester (1.34 g, 4.82 mmol) in 20 L of methanol. To this solution was introduced at room temperature 1 eq. of lithium hydroxide (202 mg, 4.82 mmol). After 45 min the solvant was evaporated in vacuo to an oil who was purified on flash grade silica gel eluting with 50- 100% ethyl acetate in hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide (32?, 3a2?, 6aS) -3-Hydroxyhexahydrofuro [2, 3b] furan (401 mg, 80%). ^H NMR (CDCI3): 5.82 (s IH) , 4.15 (s, IH) , 3.74-3.94 (m, 4H) , 2.72-2.76 (m, IH) , 2.06- 2.14 (m, IH) , 1.99 (s, IH) , 1.60-1.66 (m, IH) . Step 3 :
(3S,3aS,6a2?) Hexahydrofuro [2, 3b] furan-3-yl (4-nitrophenyl) carbonate (E) and (32?, 3a2?, 6aS) hexahydrofuro [2 ,3b] furan-3-yl (4-nitrophenyl) carbonate (F)
Figure imgf000229_0001
(E) (F)
In a dried flask was introduced 1 eq. of (3S,3aS, 6a2?) -3-
Hydroxy hexahydrofuro [2, 3b] furan (210 mg, 1.61 mmol) in 5 mL of dried dichloromethane. To this solution was introduced 1 eq. of p-nitrobenzylchloroformate (325 mg, 1.61 mmol) and 1 eq. of N-methylmorpholine (177 μL, 1.61 mmol). The reaction was continued at room temperature for 24 h. The precipitate was filtered off and the solvant was evaporated in vacuo to an oil. The crude material was purified on flash grade silica gel eluting with 50% ethyl acetate in hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide
(3S, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl (4-nitrophenyl) carbonate (350 mg, 99%) . HPLC showed the material to be 99% pure; Ret. time = 8.8 min. 1H ΝMR (CDCI3) : 7.28-8.25 (dd, 4H) , 5.88 (d, IH) , 5.05 (s, IH) , 4.04-4.15 (m, 2H) , 3.80- 3.91 (m, 2H) , 2.97-3.01 (m, IH) , 2.18-2.26 (m, IH) , 1.77- 1.83 (m, IH) . Step 4 :
Figure imgf000230_0001
116 )
(32?, 3a2?, 6aS) hexahydrofuro [2 , 3b] furan-3-yl-N- (IS, 22?) -1- benzyl-3- [ (cyclopentyloxy) [ (4 -methoxyphenyl ) sulfonyl ] amino- 2 -hydroxypropylcarbamate . In a dried flask was introduced 1 eq. of N1- [ ( 22?, 35) -3-amino-2-hydroxy-4-phenylbutyl ] -N1- (cyclopentyloxy) -4-methoxy-l-benzenesulfonamide trifluoroacetic acid (40.9 mg, 0.083 mmol) in 1 mL of N, N- dimethy1formamide. To this solution was added 1.1 eq. of (32?, 3a2?, 6aS) hexahydrofuro [2, 3b] furan-3-yl- (4-nitrophenyl) carbonate (27 mg, 0.091 mmol) and 5 eq. of triethylamine (58 μL, 0.4 mmol) . The reaction was continued at room temperature for 4 days. The reaction mixture was solubilized in ethyl acetate washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified on a preparative TLC plate (20x20 cm, 1 mm) eluting with 50% ethyl acetate in hexane. The product band was removed, eluted (4 : l/dichloromethane:methanol) , filtered and evaporated in vacuo and dried under high vacuum to provide (3S,3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (19.5 mg, 40%). HPLC showed the material to be 96% pure; Ret. time = 11.88 min. λE ΝMR (CDCI3) : 7.65 (d, 2H) , 7.13-7.24 ( , 5H) , 6.92 (d, 2H) , 5.71 (m, IH) , 4.73-4.82 (m, 3H) , 3.71-3.91 (m, 7H) , 2.68-3.03 (m, 7 H) , 2.12 ( , IH) , 1.48-1.74 (m, 10H) and MS (ES+), M+H = 591.0.
Example 117
(3S, 3aS,6a2?) hexahydrofuro [2,3b] furan-3-yl-N- (IS, 22?) -1- benzyl-3- [ (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl ]amino- 2 -hydroxypropyl carbamate
Figure imgf000231_0001
In a dried flask was introduced 1 eq. of N1- [ (22?, 35) -3- amino-2-hydroxy-4-phenylbutyl] -Nl- (cyclopentyloxy) -4- methoxy-l-benzenesulfonamide* trifluoroacetic acid (40.2 mg, 0.081 mmol) in 1 mL of N, N-dimehylformamide . To this solution was added 1.1 eq. of (3S, 3aS, 6a2?) hexahydrofuro [2,3b] furan-3-yl (4-nitrophenyl) carbonate (26 mg, 0.089 mmol) and 5 eq. of triethylamine (56 μL, 0.4 mmol). The reaction was continued at room temperature for 4 days. The reaction mixture was solubilized in ethyl acetate washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified on a preparative TLC plate (20x20 cm, 1 mm) eluting with 50% ethyl acetate in hexane. The product band was removed, eluted (4 : l/dichloromethane:methanol) , filtered and evaporated in vacuo and dried under high vacuum to provide (35, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (18.4 mg, 38%). HPLC showed the material to be 96% pure; Ret. time = 11.8 min. 1H NMR (CDCI3) : 7.65 (d, 2H) , 7.13-7.24 (m, 5H) , 6.92 (d, 2H) , 5.71 (m, IH) , 4.73-4.82 (m, 3H) , 3.71-3.91 (m, 7H) , 2.68-3.03 (m, 7 H) , 2.12 (m, IH) , 1 .48-1.74 (m, 10H) and MS (ES+) , M+H = 591.0.
Example 119
Figure imgf000232_0001
Phosphate ester of (32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3- yl 27- (IS, 22?) -3- [ [ (3-N-methylaminophenyl) sulfonyl]
(cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate .
A solution of 0.145g (0.25 mMol) of
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ [ (3- Ν-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (Example 77), 0.042 mL (0.3 mMol) of triethylamine and 0.081g (0.3 mMol) of 2,4- dinitrobenzenesulfonyl chloride in 2 mL of tetrahydrofuran was treated with 0.2 mL of pyridine and 0.03 g of 4-Ν,Ν- dimethylamino pyridine and stirred at rt overnight. The mixture was diluted with ethylacetate and extracted with IN HCl and saturated sodium bicarbonate. Chromatography on silica gel (1:1 ethyl acetate-hexanes) gave 75mg of a yellow foam which was dissolved in 1 mL of dimethylformamide and treated with 0.03 L of iodomethane and 0.06 mL of triethylamine. The resulting mixture was heated to 70°C for lOh and then evaporated. Chromatography on silicagel (40% ethylacetate-hexanes) gave a white foam which was dissolved in lmL of acetonitrile and 1 mL of dichloromethane. This solution was treated with 0.06 mL of dibenzyldiisopropyl phosphoramidite and 0.02g of tetrazole. The resulting solution was stirred at rt for 0.5 h and evaporated. Chromatography on silicagel (40% ethylacetate - hexanes) gave a colorless oil which was dissolved in 1 L of acetonitrile and 1 mL of dichloromethane and treated with
0.2g of iodosobenzene diacetate. After two hours at rt, the volatiles were removed and the the residue was re-dissolved in dichloromethane. The solution was treated with 1.5 mL of n-propylamine for 15 minutes and then evaporated. Chromatography on silicagel (60% ethylacetate - hexanes) gave a yellow oil which was dissolved in 20 mL of 2M ammonia in methanol and treated with 5 mg of 5% palladium on carbon. The mixture was hydrogenated for 1 h at 50 PSI, filtered and evaportated to give 15 mg of a white powdery solid. ""H NMR (CD3CN) : 1.5-1.9 (13H), 2.75 (IH), 2.8-3.0 (3H) , 2.90(3H),
3.15 (IH), 3.7 (IH), 3.9 (5H) , 4.8 (IH), 5.0 (IH), 5.5 (IH), 7.0-7.4 (7H), 7.5 (2H). 31P NMR (CD3CN) : 2.1 ppm). LC-MS :
671 (MH+:
Example 120
Figure imgf000233_0001
i2o;
l,3-Dioxan-5-yl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (1- carbomethoxy-3- (carbomethoxyamino) indazole-5- ylsulfonyl) amino] -2-hydroxypropylcarbamate. 1, 3-Dioxan-5-yl N- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) amino] -2- hydroxypropylcarbamate (Step 1, Example 55), (130 mg, 0.330 mmol) , l-carbomethoxy-3- (carbomethoxyamino) indazole-5- sulfonyl chloride (110 mg, 0.330 mmol), and anhydrous diisopropylethylamine (0.06 mL, 0.330 mmol), were combined in anhydrous tetrahydrofuran (5 mL) in a 25 mL round bottomed flask under nitrogen. The reaction was stirred for 24 hours and concentrated in vacuo. After the workup described in Step 3, Example 54, the residue was purified by preparative silica gel TLC using 3:l/ethyl acetate :hexane as an eluent to give the product as a oil (91 mg, 0.129 mmol, 39%). -"HNMR (dg-DMSO) : 10.99 (s, IH) , 8.73 (s, IH) , 8.35 (d, J=8.9 Hz, IH) , 7.95 (d, J=8.9 Hz, IH) , 7.27-7.16 (m, 5H) , 5.24 (d, J=6.5 Hz, IH) , 4.85-4.63 (m, 3H) , 4.06 (s, 3H) , 3.80-3.00 ( , 11H) , 3.76 (s, 3H) , 1.97-1.40 (m, 8H) . MS(ES): 706 (M+l), 704 (M-l).
Figure imgf000234_0001
:i2i'
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- (IS,22?) -1- benzyl-3- [ (cyclopentyloxy) (3- [ (2- [ (methylamino) carbonyl] aminoethyl) amino]phenylsulfonyl) amino] -2- hydroxypropylcarbamate and (3S, 3a2?, 6aS) hexahydrofuro [2 , 3- b]furan-3-yl 27- (IS,22?) -l-benzyl-3- [ (cyclopentyloxy) (3-[(2- [ (methylamino) carbonyl ] amino ethyl) amino]phenylsulfonyl) amino] -2-hydroxypropylcarbamate .
A solution of 33 mg (0.053 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate and
(3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate (Example 83) in 1 mL of anhydrous 1,4-dioxane was treated with 0.003 mL (0.05 mmol) of methyl isocyanate. The resulting solution was stirred at RT. After 2 hours the solution was concentrated in vacuo to afford 35 mg (97%) of the desired product as a white foam. 1H-ΝMR (CDC13) : 7.43-7.01 (13H), 5.76-4.80 (4H) , 4.08-2.70 (18H), 1.90-1.30 (10H) . LCMS(ESI): 676 (M+H).
Example 122
Figure imgf000235_0001
( 122 )
(32?,3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- [ (IS,22?) -1- benzyl-3- ( (cyclopentyloxy) [3- (2- [ (methylsulfonyl) amino]ethylamino) phenyl] sulfonylamino) -2- hydroxypropyl ] carbamate and (3S,3a2?, 6aS) hexahydrofuro [2 ,3- b]furan-3-yl 27- [ (IS, 22?) -l-benzyl-3- ( (cyclopentyloxy) [3- (2- [ (methylsulfonyl) amino] ethylamino) phenyl] sulfonylamino) -2- hydroxypropyl ] carbamate . A solution of 33 mg (0.053 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3- yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl ) amino] phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate (Example 83) in 2 L of anhydrous THF at 0°C was treated with 0.010 mL (0.059 mmol) of , N-diisopropylethylamine followed by 0.005 mL (0.06 mmol) of methanesulfonyl chloride. The resulting solution was allowed to warm to RT with stirring. After 3 hours the solution was concentrated in vacuo and the residue subjected to flash chromatography (silica gel, 95:5 CH2C12/2M ΝH3 in MeOH) to afford 31 mg (86%) of the desired product as a white foam. 1H-NMR (CDC13) : 7.40-6.81 (12H), 5.62 (IH), 5.43-5.04 (IH), 4.99 (IH), 4.81 (IH), 3.97-2.60 (18H), 1.90- 1.30 (10H) . LCMS(ESI): 697 (M+H).
Example 123
Figure imgf000236_0001
: i23 :
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- [ (IS, 22?) -1- benzyl-3- ( (cyclopentyloxy) [ (3-methoxyphenyl) sulfonyl ] amino) -2-hydroxypropyl ] carbamate (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (3-hydroxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate was combined with potassium carbonate (0.86 mmol, 120 mg) , iodomethane (0.86 mmol, 0.054 mL) , and anhydrous DMF (0.5 mL) under nitrogen. The reaction stirred for 3 hours at 50°C and was concentrated to an oil under vacuum, diluted in ethyl acetate, washed with distilled water and brine, and dried over magnesium sulfate. The crude reaction product was concentrated and purified by silica gel chromatography (1 : 1/hexanes/ethyl acetate) and yielded 51 mg (>99%) of a fine white powder.; Rf = 0.15 (1:1 hexanes/ethyl acetate); XH ΝMR (CDC13) : δ 7.46-7.39 (lH,m) , 7.38-7.32 (lH,m), 7.32-7.13 (8H,m), 5.65-5.60 (lH,m), 5.03- 4.94 (lH,m), 4.84-4.71 (2H,m), 3.95-3.84 (5H,m), 3.84 (3H,s), 3.70-3.61 (2H,m), 3.13 (IH, bs), 3.06-2.72 (5H,m) , 1.87-1.69 (4H,m), 1.70-1.54 (4H,m); MS (ESI): M+H=591.
Example 124
Figure imgf000237_0001
: i24 :
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- [ (IS,22?) -1- benzyl-3- ( (cyclopentyloxy) [3- (2- [ (methoxycarbonyl) amino] ethylamino) phenyl] sulfonylamino) -2- hydroxypropyl ] carbamate and (3S,3a2?, 6aS) hexahydrofuro [2,3- b]furan-3-yl 27- [ (IS,22?) -l-benzyl-3- ( (cyclopentyloxy) [3-(2- [ (methoxycarbonyl) amino]ethylamino) phenyl] sulfonylamino) -2- hydroxypropyl ] carbamate . A solution of 33 mg (0.053 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3- yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate (Example 83) in 2 mL of anhydrous THF at 0°C was treated with 0.010 mL (0.059 mmol) of N,N-diisopropylethylamine followed by 0.005 mL (0.06 mmol) of methyl chloroformate . The resulting solution was allowed to warm to RT with stirring. After 3 hours the solution was concentrated in vacuo and the residue subjected to flash chromatography (silica gel, 95:5 CH2C12/2M ΝH3 in MeOH) to afford 32 mg (89%) of the desired product as a white foam. 1H-NMR (CDC13) : 7.40-6.81 (12H), 5.61 (IH), 5.40-4.87 (2H), 4.80 (IH), 3.97-2.63 (18H), 1.90-1.30 (10H) . LCMS (ESI) : 677 (M+H) .
Example 125
Figure imgf000238_0001
Preparation of 1 , 3-Dioxane-5-yl N- ( 1S , 2R) -l-benzyl-3- [ (cyclopentyloxy) (2-amino) ] -benzothiazol-6- ylsulfonyl ) amino] -2-hydroxypropylcarbamate Step 1 :
To a suspension of 2-aminobenzothiazole (4 g, 26.6 mmol) in 20 ml of dichloromethane under nitrogen was added 4 mL of anhydrous DMF. The solution was cooled to -5°C and triethylamine (7.4 mL, 53.2 mmol, 2.0 eq.) was added.
Methanesulfonyl chloride (2.3 mL, 29.3 mmol, 1.1 eq.) was added over 5 minutes followed by an additional 4 L of dichloromethane. The reaction was warmed to 25°C. After approximately 24 hours at 25°C, the reaction was quenched with saturated bicarbonate solution and partitioned between water and ethyl acetate. The aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with water (4X), saturated brine solution, dried over sodium sulfate, filtered and the solvent removed in vacuo to give 930 mg of a residue that was shown by LCMS to contain almost no product. The combined aqueous layers were extracted with excess ethyl acetate. These organic layers were washed with saturated brine solution, dried over sodium sulfate, filtered and the solvent removed in vacuo to give 1.2 g of product that was shown by HPLC and LCMS to be over 97% pure desired product which was used without further purification. LCMS: 229.0(M+H).
Step 2: To 2.4 mL (35 mmol, 20 eq. ) of chlorosulfonic acid, stirred under nitrogen at -40°C, was added 2-methane- sulfonamidobenzothiazole (Step 1) (400 mg, 1.75 mmol) in small portions over 10 minutes. The suspension was stirred at -40°C for 5 minutes, then was warmed to 0°C for 2.5 hours, then warmed to 25°C. After approximately 4 days at 25°C, the reaction was quenched by adding dropwise to well stirred ice water. A small amount of solid was filtered off and shown by HPLC to contain only a small amount of the desired product. The aqueous layer was extracted with ethyl acetate (2x) and the combined organic layers were washed with saturated brine solution, dried over sodium sulfate, filtered and the solvent removed in vacuo to give 146 mg of the desired material. HPLC showed the material to be ~80% pure, Ret. time = 9.42 min. The material was used without further purification.
Step 3: To 64 mg (.26 mmol) of 2-aminobenzothiazole-6-sulfonyl chloride, (2), was added 102 mg (.26 mmol, 1.0 eq.) of 1,3- Dioxane-5-yl N- (IS, 2R) -l-benzyl-3- (cyclopentyloxyamino) 2- hydroxypropylcarbamate (Example 55, Step 1) and 7 mg of 4- dimethylaminopyridine . The mixture was dissolved in 3 mL of anhydrous pyridine to give a yellow solution. Solid formed within 5 minutes and the suspension stirred at 25°C, under nitrogen, for approximately 21 hours. The reaction was quenched with saturated sodium bicarbonate solution and ethyl acetate. The solvent removed in vacuo to remove excess pyridine, and the residue was extracted with ethyl acetate (2x) . The combined organic layers were washed with saturated brine solution, dried over sodium sulfate, filtered and the solvent was removed in vacuo to give 100 mg of 2-aminobenzothiazole-6-sulfonyl chloride, (2) . HPLC showed the material to be 94% pure, Ret. time = 8.343 min. The material was used without further purification. !H NMR (chloroform-D3) 5.71(s, 2H) , 8.62 (d, IH) , 7.95 (d, IH) , 8.29 (s, IH) and LC/MS, M+H = 248.9 confirms no methanesulfonyl group present.
Example 126
Step 1:
Figure imgf000241_0001
3-Bromo-N-tert-butoxycarbonylaniline. 3-Bromoaniline (0.50 ml, 4.6 mmol) di- ert-butyldicarbonate (1.20 g, 5.5 mmol) and 4-dimethylaminopyridine (0.003 g) were combined in anhydrous CH2CI2 (10 ml) . Solution chilled to 0°C and triethylamine (1.28 ml, 9.2 mmol) was added. Reaction was allowed to warm to room temperature then was heated to reflux for 1 hour. Reactiom mixture was diluted in EtOAc and washed with sat. NaHCθ3, 0.5N KHSO4 and brine. Organic phase was dried with MgSθ4 and the solvent was removed in vacuo . Purification by flash chromatography (1 : /EtOAc/Hex to 1:3 to 1:2). Recovered 1.01 g (81%) of the product as a light yellow solid. Rf=0.62 (1:4 EtOAc/Hex). 1H NMR (CDCI3) 7.68 (lH,s), 7.22-7.10 (3H,m), 6.48 (lH,b), 1.51 (9H,s) .
Step 2:
Figure imgf000241_0002
3-Bromo-N-tert-butoxycarbonyl-N-methylaniline . 3-Bromo-N- tert-butoxycarbonylaniline (0.50 g, 1.8 mmol) was dissolved in anhydrous DMF (5 ml). Sodium hydride (0.088 g, 2.2 mmol) was added to the solution and the deprotonation was stirred 10 minutes at room temperature. Methyl iodide (0.137 ml, 2.2 mmol) was added slowly and the reaction was stirred overnight at room temperature. Reaction mixture was diluted in EtOAc and washed with H2O and brine. The organic phase was dried with MgS04 and and the solvent was removed in vacuo to give 0.51 g (96%) of the product cleanly as a light yellow oil. Rf=0.63 (1:4 EtOAc/Hex). 1H NMR (CDCI3) 7.41 (lH,s), 7.30 (lH,m), 7.20 (2H,m), 3.23 (3H,s), 1.49 (9H,s).
Step 3:
Figure imgf000242_0001
N-tert-Butoxycarbonyl-3-chlorosulfonyl-N-methylaniline. 3-
Bromo-N-tert-butoxycarbonyl-N-methylaniline (0.358g, 1.2 mmol) was dissolved in freshly distilled THF (5 ml) under a N2 atmosphere. The solution was chilled to -78 °C and n- butyl lithium (0.750 ml, 2.0 M solution in cyclohexane, 1.5 mmol) was added. After 15 minutes, sulfuryl chloride (0.121 ml, 1.5 mmol) was added and the reaction was allowed to warm to room temperature and stirring was continued overnight. THF was removed by evaporation and the resulting residue was diluted in EtOAc. Organic phase was washed with H20 and brine before being dried with MgSθ . The solvent was removed in vacuo . Purification by flash chromatography (1: 19/EtOAc/Hex gradient to 1:9 and then to 1:4). Recovered 0.089 g (23%) of the product as a colorless oil. Rf=0.14 (1:9 EtOAc/Hex) . λE NMR (CDCI3) 7.96 (lH,s), 7.80 (lH,d), 7.68 (lH,d), 7.57 (lH,t), 3.33 (3H,s), 1.50 (9H,s).
Step 4:
(32?, 3aS, 6a2?) Hexahydrofuro [2 , 3b] furan-3-γl-N- (IS,22?) -1- benzyl-3- [ (isopropyloxy) [ (3- (27- (methyl-tert- Butoxycarbonyl) ) phenyl) sulfonyl ] amino-2- hydroxypropylcarbamate
Figure imgf000243_0001
126 )
In a dried flask was introduced 1 eq. of (32?, 3aS, 6a2?)
Hexahydrofuro [2, 3b] furan-3-yl-N- (IS, 22?) -l-benzyl-3-
[ (isopropyloxy) amino] -2-hydroxypropylcarbamate (53.6 mg, 0.14 mmol) in 2 mL of dried pyridine. To this solution was added 1.2 eq. of N- ert-Butoxycarbonyl-3-chlorosul fonyl-N- methylaniline (50 mg, 0.16 mmol) and catalytic amount of N, N-dimethyl aminopyridine. The reaction was continued at room temperature for 24 h. The solvent was evaporated in vacuo to an oil who was solubilized in ethyl acetate washed with IN hydrochloric acid, and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified on flash grade silica gel eluting with 50% ethyl acetate in hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide (32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl-Ν- (IS, 22?)- l-benzyl-3- [ (isopropyloxy) [ (3- ( N- (methyl-tert- Butoxycarbonyl) ) phenyl) sulfonyl] amino-2-hydroxy propylcarbamate (29.2 mg, 31%). HPLC showed the material to be 98% pure; Ret. time = 12.1 min. lE ΝMR (CDCI3) : 7.09-7.78 (m, 9H) , 5.56 (d, IH) , 5.15 (bs, IH) , 4.91 (q, IH) , 4.49 (q, IH) , 3.57-3.88 (m, 5H) , 3.24 (s, 3H) , 2.96 (m, 2H) , 2.72 (m, IH) , 2.56 (m, IH) , 1.42-1.50 (m+s, 13H) , 1.19 (d, 6H) and LCMS (ES+), M+H = 664.3.
Example 127
(32?, 3aS, 6a2?) Hexahydrofuro [2 , 3b] furan-3-yl-N- (IS,22?) -1- benzyl-3- [ (isopropyloxy) [ (3-27-methylphenyl) sulfonyl ]amino-2- hydroxypropylcarbamate
Figure imgf000244_0001
127:
In a dried flask was introduced 1 eq. of (32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl-N- (IS, 22?) -l-benzyl-3- [ (isopropyloxy) [ (3- (N- (methyl- ert-Butoxycarbonyl) )phenyl) sulfonyl] amino-2-hydroxy propylcarbamate (10.8 mg, 0.016 mmol) in 1 L dichloromethane. To this solution was added 600 μL of trifluoroacetic acid. The reaction was continued at room temperature for 45 min. The solvent was evaporated in vacuo to an oil. The crude material was purified on flash grade silica gel eluting with 50% ethyl acetate in hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide (32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl-Ν- (IS, 22?) -1- benzyl-3- [ (isopropyloxy) [ ( 3-N-methylphenyl ) sulfonyl] amino- 2-hydroxypropyl carbamate (7.2 mg, 78%). HPLC showed the material to be 98% pure; Ret. time = 10.1 min. HΪ-ΝMR (CDCI3) : 7.09-7.35 (m, 9H) , 6.86 (m, IH) , 5.58 (d, IH) , 4.92-4.96 (m, 2H) , 4.46-4.50 (m, 2H) , 3.56-3.85 (m, 5H) , 2.71-2.97 (m+s, 7H) , 1.45-1.80 (m, 3H) , 1.17 (d, 6H) and LCMS (ES+), M+H = 564.3.
Example 128
(32?,3aS,6a2?) hexahydrofuro [2,3b] furan-3-yl-N- (IS,22?) -1- benzyl-3- [ (cyclopentyloxy) [ (3- (27- (methyl-tert- Butoxycarbonyl) ) phenyl) sulfonyl ] amino-2- hydroxypropylcarbamate
Figure imgf000245_0001
(128) In a dried flask was introduced 1 eq. of (32?, 3aS, 6a2?) Hexa hydrofuro [2, 3b] furan-3-yl-N- (IS, 22?) -l-benzyl-3- [(cyclopentyloxy) amino] -2-hydroxypropylcarbamate (60 mg, 0.14 mmol) in 2 mL of dried pyridine. To this solution was added 1.3 eq. of N- tert-Butoxycarbonyl-3-chlorosulfonyl-N- methylaniline (57 mg, 0.19 mmol) and catalytic amount of N, N-dimethylaminopyridine . The reaction was continued at room temperature for 24 h. The solvent was evaporated in vacuo to an oil who was solubilized in ethyl acetate washed with IN hydrochloric acid, and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified on flash grade silica gel eluting with 50% ethyl acetate in hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide (32?, 3aS, 6a2?) hexahydrofuro [2, 3b] furan-3-yl-Ν- (IS, 22?)- 1-benzyl-3- [ (cyclopentyloxy) [ (3- (N- (methyl- tert- Butoxycarbonyl) ) phenyl) sulfonyl] amino-2- hydroxypropylcarbamate (26.8 mg, 28%). HPLC showed the material to be 99% pure; Ret. time = 12.88 min. Hi-NMR (CDCI3) : 7.74 (m, IH) , 7.09-7.51 (m, 9H) , 5.60 (m, IH) , 5.25 (bs, IH) , 4.94 (q, IH) , 4.77 (q, IH) , 3.71-3.86 (m, 6H) ,
3.52 (m, IH) , 3.24 (m, 3H) , 3.08 (m, IH) , 2.85-2.93 ( , 4H) , 2.68 (m, IH) , 1.73-1.83 (m, 5H) , 1.42-1.59 (m+s, 12H) and LCMS (ES+) , M+H = 690.2.
Example 129
Step 1 :
Figure imgf000246_0001
tert-Butyl-N- ( (IS,22?) -l-benzyl-3- (cyclopentyloxy) [ (3- nitrophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate. tert-Butyl-N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) amino-2- hydroxypropyl) carbamate (0.52 g, 1.4 mmol) was combined with 3-nitrobenzenesulfonyl chloride (0.47 g, 2.1 mmol) in freshly distilled THF (5 ml). Diisopropylethylamine (0.74 ml, 4.3 mmol) was added and the reaction was stirred at room temperature overnight. Reaction mixture was diluted in
EtOAc and washed with 0.5 N KHSO4, and brine. Organic phase was dried with MgS04 and solvent was removed in vacuo . Purication by flash chromatography (1 : 4/EtOAc/Hex gradient to 1:3, to 1:2, to 1:1 and then to 2:1). Recovered 0.44 g (56%) of the product as a white foam. Rf= 0.45 (2:1
EtOAc/Hex), 1H NMR (CDCI3) 8.67 (IH, s) , 8.49 (IH, d) , 8.08 (IH, d) , 7.77 (IH, t) , 7.36-7.17 (5H, m) , 4.88 (lH,m), 4.62 (lH,b), 3.88-3.71 (2H,m) , 3.41 (lH,b), 3.07 (lH,b), 2.98- 2.79 (3H,m), 1.92-1.75 (4H,m), 1.73-1.52 (4H,m), 1.45 (9H,s) .
Step 2
Figure imgf000247_0001
(IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- nitrophenyl) sulfonyl ]amino-2-hydroxypropylamine. tert- Butyl-N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- nitrophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate (0.34 g, 0.6 mmol) was dissolved in CH2C12 (3 ml) . Trifluoroacetic acid was added with stirring and the reaction was stirred 15 minutes at room temperature. The solvent was removed by evaporation and the resulting residue was partitioned between EtOAc and sat. NaHC03. Organic phase was washed with sat. NaHC03 and brine then dried with MgSO-j. Solvent was removed in vacuo to give 0.27 g (100%) of the product as a white foam. Rf= 0.11 (2:1 EtOAc/Hex). 1H NMR (CDCI3) 8.75 (IH, s) , 8.52 (IH, d) , 8.19 (IH, d) , 7.80 (IH, t), 7.40-7.08 (5H, m) , 4.90 (lH,m), 3.80 (lH,m), 3.36- 3.14 (2H,m), 3.05 (lH,b), 2.88 (lH,d), 2.48 (lH,m), 1.96- 1.75 (4H,m), 1.74-1.50 (4H,m).
Step 3:
Figure imgf000248_0001
l,3-Dioxan-5-yl-N- (IS, 22?) -benzyl-3- (cyclopentyloxy) [ (3- nitrophenyl) sulfonyl] amino-2-hydroxypropylcarbamate.
(IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- nitrophenyl) sulfonyl] amino-2-hydroxypropylamine (0.070 g, 0.2 mmol) was combined with 1, 3-dioxan-5-yl- (4- nitrophenyl) carbonate (0.066g, 0.2 mmol) in anhydrous DMF (4 ml) under a N2 atmosphere. Triethyl amine (0.045 ml, 0.3 mmol) was added and the reaction was stirred at room temperature for 2 hours. Reaction mixture was diluted in EtOAc and washed with sat. NaHC03, 0.5N KHSO4 and brine. The organic phase was dried with MgSθ4 and solvent was removed in vacuo . Purification by flash chromatography (1:2 EtOAc/Hex to 1:1 to 2:1). Recovered 0.073 g (78%) of the product as a white foam. Rf= 0.26 (1:1 EtOAc/Hex). 1H NMR (CDCI3) 8.66 (IH, s), 8.50 (IH, d) , 8.08 (IH, d) , 7.77 (IH, t), 7.36-7.13 (5H, m) , 5.01 (lH,d), 4.92 (lH,d), 4.88 (lH,m), 4.73 (lH,d), 4.50 (lH,s), 4.00-3.79 (6H,m), 3.13 (lH,m), 3.08-2.88 (2H,m), 2.77 (lH,m), 1.96-1.73 (4H,m) , 1 . 72- 1 . 52 ( 4H, m) .
Step 4 :
Figure imgf000248_0002
: i29 : l,3-Dioxan-5-yl-N- (IS,22?) -benzyl-3- (cyclopentyloxy) [ (3- aminophenyl) sulfonyl ] amino-2-hydroxypropylcarbamate .
1, 3-Dioxan-5-yl-N- (IS, 22?) -benzyl-3- (cyclopentyloxy) [ (3- nitrophenyl) sulfonyl] amino-2-hydroxypropylcarbamate (0.070 g, 0.1 mmol) was combined with tin chloride dihydrate (0.109 g, 0.5 mmol) is absolute ethanol (10 ml). Reation was heated to reflux and stired for 2.5 hours. Ethanol was removed in vacuo and the material was purified by preparative TLC (2 : 1/EtOAc/Hex) . Recovered 0.045 g (68%) of the product as a colorless residue. Rf= 0.36 (2:1
EtOAc/Hex). 1H NMR (CDCI3) 7.38-7.18 (6H, m) , 7.15 (lH,d), 7.07 (lH,s), 6.85 (lH,d), 5.00 (lH,d), 4.92 (lH,d), 4.83 (lH,m), 4.76 (lH,d), 4.53 (lH,s), 4.05-3.80 (5H,m) , 3.73 (lH,m), 3.19 (lH,m), 3.10 (lH,m), 3.00-2.82 (2H,m), 1.91- 1.70 (4H,m), 1.69-1.50 (4H,m). LRMS (M+H) + 550.3.
Example 130
Figure imgf000249_0001
(130)
tert-Butyl-N- ( (IS,22?) -l-benzyl-3- (cyclopentyloxy) (2-
[ (methoxycarbonyl) amino]benzimidazol-5-ylsulfonyl) amino-2- hydroxypropyl) carbamate . tert-Butyl-N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) amino-2-hydroxypropyl) carbamate (step 1,
Example 54), (0.75 g, 2.1 mmol) was combined with 2- (methoxycarbonyl) amino benzimidazol-5-ylsulfonyl chloride (0.89g, 3.1 mmol) in anhydrous DMF (15 ml) under a N2 atmosphere. Diisopropylethylethyl amine (1.08 ml, 6.2 mmol) was added and the reaction was stirred at room temperature for 24 hours. The reaction mixture was diluted in EtOAc and washed with sat. NaHCθ3, 0.5N KHSO4 and brine. Organic phase was dried with MgSθ4 and solvent was removed in vacuo . Purification by flash chromatography (CH2CI2 to 1% MeOH in CH2CI2 to 2% to 3% to 4%). Recovered 0.79 g (62%) of product as a white foam. Rf= 0.08 (3% MeOH/CH2Cl2) • HPLC tR=10.47 min (C18 column). LRMS (M+H) + 618.2.
Example 131
Figure imgf000250_0001
tert-Butyl-N- ( (IS,22?) -l-benzyl-3- (cyclopentyloxy) (2- oxybenzimidazol-5-ylsulfonyl)amino-2- hydroxypropyl) carbamate. tert-Butyl-N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) amino-2-hydroxypropyl) carbamate (Step 1, Example 54), (0.100 g, 0.3 mmol) was combined with 2- oxobenzimidazol-5-ylsulfonyl chloride (0.070g, 0.3 mmol) in anhydrous DMF (2 ml) under a N2 atmosphere. Diisopropylethylethyl amine (1.08 ml, 6.2 mmol) was added and the reaction was stirred at room temperature overnight. The reaction mixture was diluted in EtOAc and washed with sat. NaHCθ3, 0.5N KHSO4 and brine. Organic phase was dried with MgSθ4 and solvent was removed in vacuo . Purification by flash chromatography ( 1 : 1/EtOAc/Hex to 2:1 to 3:1 to EtOAc) . Recovered 0.052 g (54%) of product as a white foam. Rf= 0.10 (2:1 EtOAc/Hex). HPLC tR=10.08 min (C18 column).
LRMS (M+H) + 561 . 2 .
Example 132
Figure imgf000251_0001
l,3-Dioxan-5-yl-N-( (IS,22?) -l-benzyl-3- (cyclopentyloxy) (2- [ (methylsulfonyl) amino]benzimidazol-5-γlsulfonyl) amino-2- hydroxypropyl) carbamate . 1, 3-Dioxan-5-yl-N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) amino-2-hydroxypropyl) carbamate (Step 1, Example 55), (0.148 g, 0.4 mmol) was combined with 2- [ (methylsulfonyl) amino] benzimidazol-5-ylsulfonyl chloride (0.162 g, 0.5 mmol) in anhydrous DMF (4 ml) under a N2 atmosphere. The resulting solution was chilled to 0°C and diisopropylethylethyl amine (0.196 ml, 1.1 mmol) was added. The reaction was allowed to warm to room temperature and stirred for 24 hours. Reaction mixture was diluted in EtOAc and washed with sat. NaHC03, 0.5N KHSO4 and brine. Organic phase was dried with MgSθ4 and solvent was removed in vacuo . Purification by flash chromatography (EtOAc to 2% MeOH/EtOAc to 4%). Recovered 0.159 g (64%) of the product as a white foam. Rf= 0.48 (5% MeOH/EtOAc) . λE NMR (CDCI3) 8.10
(lH,s), 7.67 (lH,d), 7.41 (lH,d), 7.30-7.15 (5H,m), 6.35 (2H,s), 5.14 (lH,d), 4.90 (lH,d), 4.85 (lH,m) , 4.72 (lH,d), 4.48 (lH,m), 3.93-3.73 (5H,m), 3.29 (3H,s), 1.89-1.70 (4H,m), 1.69-1.47 (4H,m) . LRMS (M+H)+ 668.0.
Example 133
Figure imgf000252_0001
:i33)
27-[2-(3-[ [ (22?,3S)-3-([ (32?, 3aS, 6a2?) hexahydrofuro [2 ,3-b] furan- 3-yloxy] carbonylamino) -2-hydroxy-4-phenylbutyl ]
(cyclopentyloxy) amino] sulfonylanilino) ethyl] -O-methy1-27' - (nitro) isourea and 27- [2- (3- [ [ (22?,3S) -3- ( [ (3S,3a2?, 6aS) hexahydrofuro [2 ,3-b] furan-3-yloxγ] carbonylamino) -2-hydroxy- 4-phenylbutyl] (cyclopentyloxy) amino] sulfonylanilino) ethyl ] - O-methyl-27' - (nitro) isourea. A solution of 25 mg (0.040 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3- b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate and (35, 3a2?, 6aS) hexahydrofuro [2, 3- b]furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) "amino] phenyl sulfonyl) (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (Example 83) and 0.008 mL (0.048 mmol) of N,N-diisopropyl ethylamine in 1.5 mL of anhydrous DMF was treated with 6 mg (0.05 mmol) of O-methyl-N- nitroisourea (Heyboer et al . Rec. Chim Trav. Pay-Bas (1962), 81, 69-72) . The resulting solution was stirred at RT . After 20 hours the solution was concentrated in vacuo and the residue subjected to flash chromatography (silica gel, 85:15 CH2C12/2M NH3 in MeOH) to afford 21 mg (72%) of the desired product as a white foam. 1H-NMR (CDC13) : 7.60-7.06 (12H), 5.63-4.65 (4H), 4.10-2.50 (18H), 1.90-1.31 (10H). LCMS(ESI): 721 (M+H) .
Example 134
Figure imgf000253_0001
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-γl 27- ( (IS,22?) -1- benzyl-3- (cyclohexyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate. tert-butyl N- ( (IS, 22?) -l-benzyl-3- (cyclohexyloxy) [ (4-methoxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (0.09 mmol, 50 mg) was stirred in 1 mL trifluoroacetic acid (TFA) at room temperature for 5 hours. The TFA was removed under vacuum, and the resulting residue was dissolved in ethyl acetate, washed with 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated to a residue. The resulting free amine, (22?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-2-yl 4- nitrophenyl carbonate (0.09 mmol, 27 mg) , diisopropylethylamine (0.13 mmol, 0.018 mL) , a crystal of N,N-dimethylaminopyridine , 4 A molecular sieves and acetonitrile (0.5 mL) were combined and stirred at room temperature for 3 days. The reaction solution was concentrated to a residue, dissolved in ethyl acetate, washed with IN HCl, 5% aq. potassium carbonate solution, brine, dried over magnesium sulfate, and concentrated under vacuum. The crude residue was purified by crystallization from ether to yield 15 mg (27%) of white crystals. Hl-NMR
(CDC13) : δ 7.71 (2H,d), 7.28-7.16 (6H,m), 6.97 (2H,d), 5.63-5.61 (lH,m), 5.00-4.98 (lH,m), 4.87-4.77 (lH,m), 4.24- 4.11 (lH,m), 3.98-3.79 (4H,m) , 3.87 (3H,s), 3.72-3.61
(2H,m), 3.05 (lH,bs), 3.05-2.72 (6H,m), 2.10-1.98 (2H,m), 1.78-1.68 (2H,m), 1.37-1.04 (6H,m); MS (ESI): M+H=605.
Example 135
Figure imgf000254_0001
(32?,3aS,6a2?)hexahydrofuro[2,3-b]furan-3-yl 27- [ (IS,22?) -1- benzyl-3- ( (cyclopentyloxy) [3- (2-morpholino-2- oxoethoxy) phenyl ] sulfonylamino) -2-hydroxypropyl ] carbamate .
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (3-hydroxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (0.09 mmol, 50 mg) was combined with 2-bromo-l-morpholino-l-ethanone (0.09 mmol, 18 mg) and potassium carbonate (0.26 mmol, 36 mg) , and stirred in anhydrous DMF (1 mL) under nitrogen for 15 hours at room temperature. The reaction was concentrated to a residue, dissolved in ethyl acetate, washed in distilled water and brine, and dried over magnesium sulfate. The dried solution was then concentrated and purified by silica gel flash chromatography (1:1 hexanes/ethyl acetate) to provide 41 mg (67%) of a white solid. Rf = 0.1 (1:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.47 (2H,m), 7.38 (lH,m), 7.32- 7.14 (7H,m), 5.64 (lH,s), 5.03 (2H,m), 4.91-4.76 (lH,m), 4.78 (2H,s), 3.98-3.89 (2H,m) , 3.89-3.77 (2H,m), 3.74-3.63 (8H,m), 3.63-3.52 (2H,m), 3.15 (lH,br.s), 3.08-2.98 (2H,m), 2.98-2.84 (3H,m), 2.84-2.74 (lH,m), 1.89-1.71 (4H,m), 1.71- 1.49 (4H,m) . MS (ESI): M+H=704.
Example 136
Figure imgf000255_0001
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- (IS,22?) -3- [ [3- (2-amino-2-oxoethoxy)phenyl] sulfonyl (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate. This reaction was setup, run and purified under the same conditions as for (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- [ (IS, 22?) -1- benzyl-3- ( (cyclopentyloxy) [3- (2-morpholino-2- oxoethoxy) phenyl] sulfonylammo) -2-hydroxypropyl] carbamate and generated 44 mg (80%) of a white solid. Rf = 0.1 (1:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.58-7.42 (2H,m) , 7.33-7.06 (8H,m), 6.39 (lH,s), 5.79 (lH,s), 5.63 (lH,s), 5.20-5.12 (lH,m), 5.09-4.99 (lH,m), 4.85 (lH,m), 4.60
(2H,s), 4.0-3.78 (4H,m), 3.71 (2H,m) , 3.14 (lH,br.s), 3.09- 2.70 (6H,m), 1.93-1.70 (4H,m) , 1.70-1.51 (4H,m). MS (ESI): M+H=634. Example 137
Figure imgf000256_0001
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- ( (IS,22?) -1- benzyl-3- (cyclopentyloxy) [ (3-2- [methoxy (methyl) amino] -2- oxoethoxyphenyl) sulfonyl ] amino-2-hydroxypropyl) carbamate .
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (15, 22?) -1- benzyl-3- (cyclopentyloxy) [ (3-hydroxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (0.17 mmol, 100 mg) , 2-bromo-N- methoxy-N-methylacetamide (0.26 mmol, 43 mg) and excess potassium carbonate were stirred in anhydrous DMF (1 L) under nitrogen for 20 hours at room temperature. The DMF was removed under vacuum and the residue was dissolved in ethyl acetate. The crude solution was washed with IN HCl, saturated aqueous sodium bicarbonate and brine, and dried over magnesium sulfate. The dried solution was concentrated to an oil and purified by silica gel flash chromatography (1:1 hexanes/ethyl acetate) to yield 65 mg (55%) of a white solid. Rf = 0.1 (1:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.45 (2H,m), 7.26 (5H,m) , 7.20 (3H,m), 5.64 (lH,s), 5.09- 4.97 (2H,m), 4.91 (2H,s), 4.83 (lH,m), 3.92 (2H,m), 3.78 (3H,s), 3.85-3.74 (2H,m), 3.73-3.59 (2H,m), 3.23 (3H,s), 3.28-3.11 (lH,br.s), 3.06-2.84 (5H,m), 2.75 (lH,m), 1.89- 1.72 (4H,m), 1.71-1.48 (4H,m). MS (ESI): M+H=678. Example 138
Step 1:
Figure imgf000257_0001
tert-butyl 27- (IS,22?) -3- [ (1 ,3-benzodioxol-5- ylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate. tert-butyl N- (IS, 22?) -l-benzyl-3- [ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate (0.19 mmol, 69 mg) was combined with 1, 3-benzodioxole-5-sulfonyl chloride (0.23 mmol, 50 mg) and diisopropylethylamine (0.57 mmol, 73 mg) in anhydrous THF (2 mL) . The reaction stirred under nitrogen for 72 hours at room temperature. The reaction was diluted with diethyl ether, washed with 1 Ν HCl, saturated aqueous sodium bicarbonate, brine, and was dried over magnesium sulfate. The crude product was concentrated to an oil and purified by silica gel flash chromatography (5:1 hexanes/ethyl acetate) to provide 82 mg (79%) of a white solid. The 1, 3-benzodioxole-5-sulfonyl chloride was synthesized as described in Eur. Pat. Appl . 583960, 23 Feb 1994. Rf = 0.40 (2:1 hexanes/ethyl acetate);
Hl-ΝMR (CDCI3) : δ 7.37-7.15 (8H,m), 6.89 (lH,d), 6.10 (2H,s), 4.82 (lH,m), 4.60 (lH,m), 3.82 (2H,m), 3.06 (lH,br.s), 2.94 (2H,m), 2.86 (lH,m), 1.90-1.70 (4H,m) , 1.65- 1.48 (4H,m), 1.35 (9H,s). MS (ESI): M+H=549.
Step 2:
Figure imgf000258_0001
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- (IS, 22?) -3- [ (1 ,3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate. tert-butyl N- ( IS, 22?) -3- [ (1, 3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate (0.15 mmol, 80 mg) was dissolved in neat trifluoroacetic acid (TFA) and stirred for 2 hours at room temperature. The TFA was removed under vacuum, and the reaction residue was dissolved in ethyl acetate. The reaction solution was washed with 5% aqueous potassium carbonate, brine and dried over magnesium sulfate. The crude solution was concentrated and re-dissolved in 1:1 hexanes/methylene chloride to exchange out the ethyl acetate. The resulting oil was combined with (22?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-2-yl 4-nitrophenyl carbonate (0.22 mmol, 65 mg) , diisopropylethylamine (0.44 mmol, 0.076 mL) , 4 Amolecular sieves and stirred in anhydrous THF (2 mL) under nitrogen for 15 hours at room temperature. The reaction was diluted with ethyl acetate, washed with IN HCl, saturated aqueous sodium bicarbonate, brine and was dried over magnesium sulfate. The crude product was purified by silica gel flash chromatography (2:1 hexanes/ethyl acetate) to provide 41 mg (47%) of a white solid. Rf = 0.20 (1:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.41-7.14 (8H,m), 6.91 (lH,d), 6.12 (2H,s), 5.66 (lH,s), 5.03 (2H,m), 4.84 (2H,m) , 3.91 (4H,m), 3.70 (2H,m), 3.12 (lH,s), 3.01 (2H,m), 2.93 (lH,m), 2.84 (2H,m), 1.91- 1.71 (4H,m), 1.71-1.49 (4H,m). MS (ESI): M+H=606. Example 139
Step 1
Figure imgf000259_0001
tert-butyl 27- (IS,22?) -l-benzyl-3- [ (cyclopentyloxy) (2,3- dihydro-1 , 4-benzodioxin-6-ylsulfonyl) amino] -2- hydroxypropylcarbamate. This reaction was set-up, run and purified using the same protocol described for tert-butyl N- (1S, 22?) -3- [ (l,3-benzodioxol-5- ylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate. The 1, -benzodioxan-6-sulfonyl chloride was synthesized according to the procedure described in Eur. Pat. Appl . 583960, 23 Feb 1994. Rf = 0.40
(2:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.36-7.18 (8H,m), 6.95 (lH,d), 4.82 (lH,m), 4.60 (lH,m), 4.32 (4H,m), 3.82 (2H,m), 3.05 (IH, br.s), 2.93 (2H,m), 2.87 (lH,m),
1.88-1.69 (4H,m), 1.69-1.47 (4H,m) , 1.35 (9H,s). MS (ESI): M+H=563.
Step 2:
Figure imgf000259_0002
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- (IS, 22?) -1- benzyl-3-[ (cyclopentyloxy) (2,3-dihydro-l ,4-benzodioxin-e- ylsulfonyl) amino] -2-hydroxypropylcarbamate. This reaction was set-up, run and purified using the same protocol described for (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N-
(1S, 22?) -3- [ (1, 3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate . Rf = 0.20 (1:1 hexanes/ethyl acetate) ; Hl-NMR (CDC13) : δ 7.37- 7.12 (8H,m), 6.97 (lH,d), 5.65 (lH,s), 5.03 (2H,m), 5.06- 4.77 (2H,m), 4.81 (lH,m), 4.33 (4H,d), 3.91 (4H,m), 3.70 (2H,m), 3.12 (lH,s), 3.07-2.97 (2H,m) , 2.93 (2H,m), 2.85 (2H,m), 1.90-1.70 (4H,m), 1.7-1.46 (4H,m) . MS (ESI) : M+H=619.
Example 140
Step 1:
Figure imgf000260_0001
3,4-dimethoxybenzenesulfonyl chloride. 3,4- dimethoxybenzenesulfonyl chloride was synthesized as described in Eur. Pat. Appl . 583960, 23 Feb 1994. R£ = 0.4
(2:1 hexanes/ethyl acetate). Hl-NMR: δ 7.69 (lH,d), 7.45 (lH,m), 7.00 (lH,d), 4.00 (3H,s), 3.98 (3H,s).
Step 2:
Figure imgf000260_0002
tert-butyl 27- ( (IS,22?) -l-benzyl-3- (cyclopentyloxy) [ (3,4- dimethoxyphenyl) sulfonyl]amino-2-hydroxypropyl) carbamate. tert-butyl N- (IS, 22?) -l-benzyl-3- [ (cyclopentyloxy) amino] -2- hydroxypropylcarbamate (0.41 mmol, 150 mg) was combined with 3,4-dimethoxybenzenesulfonyl chloride (0.82 mmol, 142 mg) and diisopropyl-ethylamine (2.05 mmol, 0.358 mL) in anhydrous THF (1 mL) . The reaction was allowed to reflux for 72 hours. The reaction was worked-up by diluting with an equal volume of ethyl acetate, washing with IN HCl, saturated aq. sodium bicarbonate and brine, and dried over magnesium sulfate. The crude solution was concentrated to an oil and purified by silica gel chromatography (2:1 hexanes/ethyl acetate) yielding 100 mg (43%) of a white solid. Rf = 0.1 (1:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.41 (lH,d), 7.33-7.17 (7H,m), 6.95 (lH,d), 4.82 (lH,m), 4.52 (lH,m), 3.96 (3H,s), 3.93 (3H,s), 3.80 (2H,m), 3.08 (lH,br.s), 3.00-2.79 (3H,m), 1.90-1.45 (8H,m), 1.32 (9H,s) .
Step 3 :
Figure imgf000261_0001
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl 27- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (3,4-dimethoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate. This reaction was set-up, run and purified using the same protocol described for (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3-
[ (1, 3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate. Rf = 0.20 (2:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.42 (lH,d), 7.35-7.14 (8H,m), 6.97 (lH,d), 5.64 (lH,s), 5.00 (lH,m), 4.80 (2H,m), 3.96 (3H,s), 3.93 (3H,s), 3.99-3.80 (4H,m), 3.67 (2H,m), 3.15 (lH,br.s), 3.08-2.98 (2H,m), 2.95-2.75 (3H,m), 1.90-1.71 (4H,m), 1.70-1.43 (4H,m). MS (ESI): M+H=621. Example 141
Figure imgf000262_0001
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-γl 27- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (4- isopropoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate.
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (4-hydroxyphenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (0.13 mmol, 75 mg) was combined with 2-bromopropane (0.26 mmol, 0.025 mL) , potassium carbonate (0.65 mmol, 90 mg) , tetrabutylammonium iodide (5 mg) and anhydrous DMF (1 mL) . The reaction stirred under a nitrogen atmosphere at room temperature for 15 hours, then was heated to 50°C for 3 hours. The reaction mixture was concentrated under vacuum to a residue and diluted with ethyl acetate (2 mL) . The reaction was washed in distilled water and brine, and was dried over magnesium sulfate. The dried solution was then concentrated to an oil and purified by silica gel chromatography (2:1 hexanes/ethyl acetate) to yield 61 mg (76 %) of a white solid. Rf = 0.50 (2:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.69 (2H,d), 7.33-7.13 (6H,m), 6.96 (2H,d), 5.65 (lH,s), 5.02 (lH,m), 4.86 (lH,m), 4.80 (lH,m), 4.65 (lH,m), 3.99-3.80 (5H,m), 3.69 (2H,m), 3.11 (lH,br.s), 3.09-2.98 (3H,m), 2.91 (lH,m), 2.83 (lH,m), 1.89- 1.72 (4H,m), 1.7-1.46 (4H,m), 1.38 (6H,d). MS (ESI): M+H=619. Example 142
Figure imgf000263_0001
(32?,3aS,6a2?)hexahydrofuro[2,3-b]furan-3-yl 27- ( (1S,22?)-1- benzyl-3- (cyclopentyloxy) [ (3-isopropoxyphenyl) sulfonyl] amino-2-hydroxypropyl) carbamate. (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- hydroxyphenyl ) sulfonyl ] amino-2-hydroxypropyl ) carbamate (0.13 mmol, 75 mg) was combined with 2-bromopropane (0.26 mmol, 0.025 mL) , potassium carbonate (0.65 mmol, 90 mg) , tetrabutylammonium iodide (5 mg) and anhydrous DMF (1 mL) . The reaction was stirred under a nitrogen atmosphere at room temperature for 72 hours. The reaction mixture was concentrated under vacuum to a residue and diluted with ethyl acetate (2 mL) . The reaction was washed in distilled water and brine, and was dried over magnesium sulfate. The dried solution was then concentrated to an oil and purified by silica gel chromatography (2:1 hexanes/ethyl acetate) to yield 38 mg (48 %) of a white solid. Rf = 0.40 (2:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.40 (lH,m),
7.33-7.10 (9H,m), 5.63 (lH,s), 5.00 (lH,m), 4.80 (2H,m) , 4.58 (lH,m), 3.88 (4H,m), 3.67 (2H,m) , 3.13 (lH,br.s), 3.00 (2H,m), 2.94-2.74 (2H,m), 1.88-1.71 (5H,m), 1.69-1.43 (5H,m) , 1.35 (6H,d) . Example 143
Figure imgf000264_0001
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- [ (IS,22?) -3- [ (1 ,3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2- (phosphonooxy) propyl ] carbamate .
Step 1:
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (lS,22?)-3- [ (1, 3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate (0.38 mmol, 231 mg) was combined with dibenzyl diisopropylphosphoramidite (0.57 mmol, 0.192 mL) , imidazole (0.38 mmol, 27 mg) and methylene chloride (5 mL) , and stirred for 15 hours at room temperature. The reaction was concentrated to a residue and purified by silica gel chromatography (2:1 hexanes/ethyl acetate) which produced 325 mg of a clear oil.
Step 2:
The oil from the previous step was oxidized by combining with iodobenzene diacetate (0.57 mmol, 185 mg) and acetonitrile (10 mL) . The reaction was instantaneous and was concentrated to a crude white solid. The product was purified by silica gel chromatography (1:1 hexanes/ethyl acetate) and produced 170 mg of a sticky white residue. Step 3:
The phosphate ester from the previous step was stirred vigorously with 10% Pd/Carbon (34 mg) and methanolic ammonia (2 M in methanol, 2 mL) under a hydrogen atmosphere for 3 hours at room temperature. The reaction was filtered, and the filtrate was concentrated to a residue and crystallized from methylene chloride/diethyl ether. The reaction produced 80 mg (31% - 3 steps) of white crystals. Rf = 0.20 (1:1 hexanes/ethyl acetate); Hl-NMR (D20) : δ 7.38 (lH,m) , 7.26-7.05 (6H,m), 6.95 (lH,m), 6.00 (2H,d), 5.51-5.42 (lH,m), 4.78 (lH,m), 4.30 (lH,m), 4.16-3.99 (lH,m), 3.86- 3.62 (3H,m), 3.57-3.42 (lH,m), 3.41-3.27 (lH,m), 3.07-2.90 (2H,m), 2.89-2.72 (lH,m), 2.55-2.43 (lH,m), 1.82-1.57 (5H,m), 1.57-1.30 (5H,m), 1.00-0.90 (lH,m). MS (ESI): M+H=685.
Example 144
Figure imgf000265_0001
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl 27- [ (1S,22?)-1- benzγl-3-[ (cyclopentyloxy) (2,3-dihydro-l ,4-benzodioxin-6- ylsulfonyl) amino] -2- (phosphonooxy) propyl ] carbamate
Step 1:
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -1- benzyl-3-[ (cyclopentyloxy) (2, 3-dihydro-l, 4-benzodioxin-6- ylsulfonyl) amino] -2-hydrσxypropylcarbamate (0.14 mmol, 86 mg) was combined with dibenzyl diisopropylphosphoramidite (0.21 mmol, 0.070 mL) , imidazole (0.18 mmol, 13 mg) and methylene chloride (3 L) , and stirred for 20 hours at room temperature. The reaction was concentrated to a residue and purified by silica gel chromatography (2:1 hexanes/ethyl acetate) which produced 100 mg of a clear oil.
Step 2:
The oil from the previous step was oxidized by combining with iodobenzene diacetate (0.18 mmol, 56 mg) and acetonitrile (3 mL) . The reaction was instantaneous and was concentrated to a crude white solid. The product was purified by silica gel chromatography (1:1 hexanes/ethyl acetate) and produced 65 mg of a white foam.
Step 3:
The phosphate ester from the previous step was stirred vigorously with 10% Pd/Carbon (12 mg) and methanolic ammonia
(2 M in methanol, 2 mL) under a hydrogen atmosphere for 2 hours at room temperature. The reaction was filtered, and the filtrate was concentrated to a residue and crystallized from methylene chloride/diethyl ether. The crystals were purified by RP HPLC (acetonitrile/water) and produced 20 mg
(20% - 3 steps) of a white solid after lyophylization. Rf = 0.20 (1:1 hexanes/ethyl acetate); Hl-NMR (D20) : δ 7.31 (lH,m), 7.26-7.07 (6H,m), 7.03-6.97 (lH,m), 5.52-5.43 (lH,m), 4.78 (lH,m), 4.34-4.15 (5H,m), 4.15-4.00 (lH,m), 3.79-3.65 (3H,m), 3.53-3.41 (lH,m), 3.38-3.23 (lH,m), 3.08- 2.92 (2H,m), 2.89-2.71 (lH,m), 2.52-2.43 (lH,m), 1.80-1.57 (5H,m), 1.56-1.33 (5H,m) , 0.98 - 0.88 (lH,m) . MS (ESI) : M+H=699.
Example 145
Figure imgf000266_0001
(32?, 3aS, 6a2?) hexahydrof ro [2 , 3-b] furan-3-yl 27- ( (IS, 22?) -1- benzyl-2-hydroxy-3-isobutoxy [ (4- methoxyphenyl) sulfonyl ]aminopropyl) carbamate. This reaction was set-up, run and purified using the same protocol described for (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (1, 3-benzodioxol-5-ylsulfonyl)
(cyclopentyloxy) amino] -l-benzyl-2-hydroxypropylcarbamate . R£
= 0.20 (1:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.74 (2H,d), 7.35-7.12 (6H,m), 7.01 (2H,d), 5.65 (lH,s), 5.03 (lH,m), 4.89 (lH,m), 3.90 (3H,s), 4.03-3.79 (7H,m) , 3.70 (2H,m), 3.11 (lH,br.s), 3.04-2.69 (5H,m), 1.86 (lH,m), 0.92 (6H,m) . MS (ESI): M+Na=601.
Example 146 Step 1:
Figure imgf000267_0001
4-nitro-27- (tetrahydro-2H-pyran-4-yloxy) benzenesulfonamide
4-tetrahydropyranoxyhydroxylamine (33.2 mmol, 3.77g) and 4- nitrobenzenesulfonylchloride (38.6 mmol, 8.56 g) were combined in anhydrous THF (100 mL) with diisopropylethylamine (69.3 mmol, 11.2 mL) . The reaction was stirred at room temperature for 48 hours. Hydrazine (2 mL) was injected to the stirring solution to break-up the bisarylsulfonamide dimer biproduct. The reaction was stirred for an additional 24 hours. The reaction was diluted in ethyl acetate, washed in brine, filtered to remove insoluble solids and concentrated. The crude was purified by crystallization from hot ethyl acetate to provide 3.5 g (36%) of white crystals. Rf = 0.3 (2:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 8.-42 (2H,d), 8.13 (2H,d), 6.93 (lH,s), 4.27 (lH,m), 3.91 (2H,m) , 3.45 (2H,m) , 2.02 (2H,m) , 1.61 (2H,m) .
Step 2. x
Figure imgf000268_0001
tert-butyl (IS,22?) -1-benzyl-2-hydroxy-3- [ [ (4- nitrophenyl) sulfonyl] (tetrahydro-2H-pyran-4- yloxy) amino]propylcarbamate. 4-nitro-N- (tetrahydro-222- pyran-4-yloxy) benzenesulfonamide (8.6 mmol, 2.61 g) was combined with tert-butyl N- (IS) -1- [ (2S) oxiran-2-yl] -2- phenylethylcarbamate (7.2 mmol, 1.89 g) , lithium bis (trimethylsilyl) amide (1.0 M in THF) (1.4 mmol, 1.4 mL) and anhydrous THF (80 mL) . The reaction was stirred under nitrogen at room temperature for 96 hours. The reaction was diluted in ethyl acetate (200 mL) and washed with a 5% aqueous solution of potassium carbonate, brine, and was dried over magnesium sulfate. The crude solution was concentrated to a foam and purified by crystallization from diethylether to provide 3.5 g (86%) of light yellow crystals. Rf = 0.3 (2:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 8.36 (2H,d), 7.96 (2H,d), 7.33-7.15 (6H,m), 4.55 (lH,m), 4.42 (lH,m), 3.95 (2H,m) , 3.77 (2H,m), 3.43 (2H,m), 3.07 (lH,br.s), 2.90 (2H,m), 2.03 (2H,m), 1.65-1.42 (3H,m), 1 . 32 ( 9H, s ) .
Step 3 :
Figure imgf000268_0002
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl (IS,22?) -1-benzγl- 2-hydroxγ-3- [ [ (4-nitrophenyl) sulfonyl] (tetrahydro-2H-pyran- 4-yloxy) amino]propylcarbamate. This reaction was set-up, run and purified using the same protocol described for (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (1, 3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate . Rf = 0.1 (1:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 8.38 (2H,d), 7.95 (2H,d), 7.33- 7.20 (4H,m), 7.17 (2H,m), 5.64 (lH,s), 5.02 (lH,m), 4.87 (lH,m), 4.45 (lH,m), 4.00-3.77 (6H,m), 3.68 (2H,m), 3.43 (2H,m), 3.31-2.30 (4H,m), 2.05 (2H,m), 1.86 (lH,m), 1.76- 1.42 (4H,m) .
Step 4 :
Figure imgf000269_0001
(3R,3aS,6aR) hexahydrofuro [2, 3-b] furan-3-yl 3- [ [ (4- aminophenyl) sulfonyl] (tetrahydro-2H-pyran-4-yloxy) amino] -1- benzyl-2-hydroxypropylcarbamate. (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl ( IS, 22?) -l-benzyl-2-hydroxy-3- [ [ (4- nitrophenyl) sulfonyl] (tetrahydro-222-pyran-4- yloxy) amino] propylcarbamate (0.16 mmol, 100 mg) was combined with 10% palladium on carbon (20 mg) and ethyl acetate (2 mL) , and the reaction was stirred vigorously under a hydrogen atmosphere for 15 hours. The reaction was filtered and the filtrate was concentrated to an oil. The crude product was purified by crystallization from hexanes/ethyl acetate to provide 30 mg (32%) of fine white crystals. Rf = 0.5 (ethyl acetate); Hl-NMR (CDC13) : δ 7.56 (2H,d), 7.33- 7.11 (6H,m), 6.72 (2H,d), 5.64 (lH,s), 5.0 (lH,m), 4.83 (lH,m), 4.39 (IH, septet), 4.01-3.78 (6H,m), 3.73-3.59 (2H,m), 3.48-3.33 (2H,m), 3.31-2.28 (2H,br.s), 3.16-2.72 (6H,m), 1.74-1.45 (5H,m). MS (ESI): M+H=592.
Example 147
Step 1
Figure imgf000270_0001
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS,22?) -1-benzyl- 2-hydroxy-3- [ (tetrahydro-22-pyran-4-yloxy) amino] propylcarbamate. (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -l-benzyl-2-hydroxy-3- [ [ (4-nitrophenyl) sulfonyl] (tetrahydro-222-pyran-4-yloxy) amino] propylcarbamate (3.62 mmol, 2.25g) was combined with mercaptoacetic acid (7.24 mmol, 0.501 L) , lithium hydroxide (14.5 mmol, 607 mg) and anhydrous DMF (10 mL) and stirred for 2 hours at room temperature under nitrogen. The reaction was concentrated to a red suspension under vacuum and disolved in 700 mL ethyl acetate. The crude solution was washed with distilled water, saturated aqueous sodium bicarbonate, brine and dried over magnesium sulfate. The crude product was concentrated to a yellow solid and purified by silca gel chromatography (10:1 ethyl acetate/methanol) followed by crystallization from methylene chloride/hexanes to provide 650 mg (41%) of white crystals. Rf = 0.15 (ethyl acetate); Hl-NMR (CDC13) : δ 7.39-7.18 (6H,m), 5.69 (lH,s), 5.08 (2H,m) , 4.25 (lH,m), 4.10-3.58 (8H,m), 3.52-3.27 (3H,m), 3.19 (lH,m), 3.03 (lH,br.s), 2.90 (lHm), 2.71 (lH,m), 2.13-1.80 (3H,m), 1.74- 1.29 (4H,m) . Step 2 :
Figure imgf000271_0001
(3R, 3aS , 6aR) hexahydrofuro [2 , 3-b] furan-3-yl 3- [ [ (3- aminophenyl ) sulfonyl ] (tetrahydro-2H-pyran-4 -yloxy) amino] -1- benzyl -2 -hydroxypropyl carbamate .
Step 1 :
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl ( IS, 22?) -1-benzyl- 2-hydroxy-3- [ (tetrahydro-222-pyran-4- yloxy) amino] propylcarbamate (0.17 mmol, 75 mg) was combined with 3-nitrobenzenesulfonyl chloride (0.26 mmol, 57 mg) , diisopropylethylamine (0.69 mmol, 0.120 mL) , N,N- dimethylaminopyridine (5 mg) , and anhydrous THF (5 mL) . The reaction was stirred at 50°C for 15 hours under nitrogen. The reaction product was diluted in ethyl acetate (10 L) , washed with IN HCl, saturated aqueous sodium bicarbonate, brine, and was dried over magnesium sulfate. The crude solution was concentrated under vacuum and purified by silica gel chromatography (1:1 methylene chloride/ethyl acetate) to provide 100 mg (93%) of a white solid.
Step 2:
The product of the previous step was combined with 10% palladium on carbon (20 mg) and stirred vigorously in ethyl acetate (2 mL) under hydrogen for 20 hours. The reaction was filtered and concentrated under vacuum. The crude product was purified by crystallization (diethylether/ethyl acetate/hexanes) to yield 40 mg (42%) of white crystals. Rf = 0.45 (ethyl acetate); Hl-ΝMR (CDC13) : 6 7.41-7.02 (10H,m) , 6.96 (lH,br.s), 5.62 (lH,s), 5.02 (lH,m), 4.85 (lH,br.s), 4.42 (lH,m), 4.02-3.77 (6H,m), 3.69 (2H,m) , 3.48-
3.33 (3H,m), 3.22-2.52 (6H,m), 1.87-1.30 (5H,m) . MS (ESI) :
M+H=592.
Example 148
Step 1
Figure imgf000272_0001
3-benzyloxybenzenesulfonyl chloride
The aryl bromide (12 g, 45.6 mmol) was dissolved in THF (100 mL) and cooled to -78°C. n-Butyl lithium 1.6 M in hexanes (28.5 mL, 45.6 mmol) was injected and the reaction stirred for 1 hr. before being warmed to 0°C. The resulting solution was then transferred to a -78°C solution of S02 (41 mL, 913 mmol), Et20 (100 mL) and THF (100 mL) . The solution became a yellow suspension immediately upon addition of the aryl lithium. The suspension was warmed to room temperature and stirred for 3 days. The yellow mixture was sparged with nitrogen for 2 hr. The suspension was concentrated and the resulting solid triturated with Et20 to provide 7.23 g of the sulfinate intermediate. The lithium sulfinate was stirred in a bi-phasic mixture of pH 6 aqueous dibasic sodium phosphate buffer (27 g in 200 mL distilled water - adjusted to pH 6 with cone, phosphoric acid) and ethyl acetate (200 mL) and cooled to 0°C. While stirring vigorously, N-chlorosuccinimide (3.80 g, 28.4 mmol) was added. The reaction was immediately warmed to room temperature and the aqueous layer was drained. The organic layer was washed with distilled water, brine and dried over magnesium sulfate. The crude was concentrated to a yellow solid under reduced pressure and washed with Et20. The product was purified by .eluting through a silica gel column with Et20 and resulted in 4.81 g (37%) of the desired product. Rf = 0.2 (5:1 hexanes/ethyl acetate). Hl-NMR: 7.67-7.27 (9H,m), 5.13 (2H,s).
Step 2
Figure imgf000273_0001
(3R,3aS,6aR) hexahydrofuro [2, 3-b] furan-3-yl l-benzyl-2- hydroxγ-3- [ [ (3-hydroxyphenyl) sulfonyl] (tetrahydro-2H-pyran- -yloxy) amino] propylcarbamate.
Step 1: (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl- 2-hydroxy-3- [ (tetrahydro-22f-pyran-4- yloxy) amino] propylcarbamate (0.17 mmol, 75 mg) was combined with 3-benzyloxybenzenesulfonyl chloride (0.26 mmol, 73 mg) , diisopropylethylamine (0.69 mmol, 0.12 L) in methylene chloride (2 mL) and allowed to stir for 15 hours at room temperature under nitrogen. The reaction was diluted with ethyl acetate and washed with IN HCl, 5% aqueous potassium bicarbonate solution, brine and was dried over magnesium sulfate. The solution was concentrated under vacuum and the crude product was purified by silica gel chromatography (1:1 hexanes/ethyl acetate) to provide 60 mg (51%) of a clear oil.
Step 2: The product of the previous step was stirred vigorously with 10% palladium on carbon (20 mg) , acetic acid (0.5 mL) , and ethyl acetate (2mL) under hydrogen for 6 hours. The reaction was filtered and concentrated to an oil. The crude product was purified by silica gel chromatography (1:1 hexanes/ethyl acetate) , and crystallized from diethylether/hexanes to provide 31 mg (36%) of white crystals. Rf = 0.2 (1:1 methylene chloride/ethyl acetate);
Hl-NMR (CDC13) : δ 7.40 (2H,m), 7.32-7.21 (5H,m), 7.17 (3H,m), 6.81 (lH,br.s), 5.69 (lH,s), 5.00 (2H,m) , 4.40 (lH,m), 4.02-3.70 (8H,m), 3.48-3.35 (2H,m), 3.23-2.71 (6H,m), 2.04 (2H,m), 1.79-1.67 (lH,m), 1.65-1.42 (3H,m). MS (ESI) : M+H=593.
Example 149
Figure imgf000274_0001
4-benzyloxybenzenesulfonyl chloride. The aryl bromide (12 g, 45.6 mmol) was dissolved in THF (100 mL) and cooled to -78 °C. n-Butyl lithium 1.6 M in hexanes (28.5 mL, 45.6 mmol) was injected and the reaction stirred for lhr. before being warmed to 0°C. The resulting solution was then transferred to a -78°C solution of S02 (41 mL, 913 mmol), Et20 (100 mL) and THF (100 mL) . The solution became a yellow suspension immediately upon addition of the aryl lithium. The suspension was warmed to room temperature and sparged with nitrogen for 1 hr. The suspension was concentrated to a yellow solid and triturated with Et20 to provide 6.27 g of the sulfinate intermediate. The lithium sulfinate was stirred in a bi-phasic mixture of pH 6 aqueous dibasic sodium phosphate buffer (27 g in 200 mL distilled water - adjusted to pH 6 with cone, phosphoric acid) and ethyl acetate (200 mL) and cooled to 0°C. While stirring vigorously, N-chlorosuccinimide (3.27 g, 24.7 mmol) was added. The reaction was immediately warmed to room temperature and the aqueous layer was drained. The organic layer was concentrated to a yellow solid under reduced pressure. The crude sulfonyl chloride was purified by silica gel chromatography (5:1 hexanes/ethyl acetate) to provide 3.35g (26%) of an off-white solid. Rf = 0.2 (5:1 hexanes/ethyl acetate). Hl-ΝMR: δ 7.97 (2H,d), 7.45-7.30 (5H,m), 7.10 (2H,d), 5.16 (2H,s).
Step 2:
Figure imgf000275_0001
(3R, 3aS , 6aR) hexahydrofuro [2 , 3-b] furan-3-yl 1-benzyl-2- hydroxy-3- [ [ (4-hydroxyphenyl) sulfonyl] (tetrahydro-2H-pyran- 4-yloxy) amino]propylcarbamate .
Step 1:
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl- 2-hydroxy-3- [ (tetrahydro-222-pyran-4- yloxy) amino] propylcarbamate (0.17 mmol, 75 mg) was combined with 4-benzyloxybenzenesulfonyl chloride (0.26 mmol, 73 mg) , diisopropylethylamine (0.69 mmol, 0.12 mL) , and a few crystals of N,N-dimethylaminopyridine in a 1:1 solution of anhydrous THF/methylene chloride (2 mL) and allowed to stir for 15 hours at room temperature under nitrogen. The reaction was diluted with ethyl acetate and washed with IN HCl, 5% aqueous potassium carbonate solution, brine and was dried over magnesium sulfate. The solution was concentrated under vacuum and the crude product was purified by silica gel chromatography (1:1 hexanes/ethyl acetate) to provide 50 mg (43%) of a clear oil.
Step 2:
The product of the previous step was stirred vigorously with 10% palladium on carbon (10 mg) , acetic acid (0.5 mL) , and ethyl acetate (2 L) under hydrogen for 15 hours. The reaction was filtered and concentrated to an oil. The crude product was crystallized from diethylether/hexanes to provide 8 mg (19%) of white crystals. Rf = 0.2 (1:1 methylene chloride/ethyl acetate); Hl-NMR (CDC13) : δ 7.66 (2H,d), 7.32-7.12 (6H,m), 6.94 (2H,d), 6.25 (lH,br.s), 5.66 (lH,s), 4.98 (lH,m), 4.76 (lH,m), 4.41 (lH,m), 4.00-3.78 (6H,m), 3.68 (2H,m), 3.51-3.36 (2H,m), 3.29-2.51 (6H,m),
2.12-1.95 (2H,m), 1.69 (lH,m), 1.63-1.45 (2H,m) . MS (ESI):
M+H=593.
Example 150
Figure imgf000276_0001
(3R,3aS,6aR) hexahydrofuro [2, 3-b] furan-3-yl l-benzyl-3- [ (2,3- dihydro-1 , 4-benzodioxin-6-ylsulfonyl) (tetrahydro-2H-pyran-4- yloxy) amino] -2-hydroxypropylcarbamate .
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl ( IS, 22?) -1-benzyl- 2-hydroxy-3- [ (tetrahydro-22f-pyran-4- yloxy) amino] propylcarbamate (0.17 mmol, 75 mg) was combined with 1, -benzodioxan-6-sulfonyl chloride (0.21 mmol, 48 mg) , diisopropylethylamine (0.69 mmol, 0.12 mL) in anhydrous THF (2 mL) and allowed to stir for 20 hours at room temperature under nitrogen. The reaction was diluted with diethylether and washed with IN HCl, 5% aqueous potassium carbonate solution, brine and was dried over magnesium sulfate. The solution was concentrated under vacuum and the crude product was purified by silica gel chromatography (1:1 hexanes/ethyl acetate) . The purified oil was lyophylized to provide 13 mg (12%) of a white powder. Rf = 0.6 (ethyl acetate); Hl-NMR (CDC13) : δ 7.37-7.14 (8H,m), 6.98 (lH,d), 5.66 (lH,s), 5.03 (lH,m), 4.83 (lH,m), 4.43 (lH,m), 4.33 (4H,d), 4.03-3.79 (6H,m), 3.70 (2H,m), 3.45 (2H,m), 3.29-2.68 (6H,m), 2.06 (2H,m), 1.74-1.46 (3H,m). MS (ESI): M+H=635.
Example 151
Figure imgf000277_0001
(3R, 3aS , 6aR) hexahydrofuro [2 , 3-b] furan-3-yl 3- [ (1 , 3- benzodioxol-5-ylsulfonyl) (tetrahydro-2H-pyran-4- yloxy) amino] -1-benzyl-2-hydroxypropylcarbamate.
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl-
2-hydroxy-3- [ (tetrahydro-22f-pyran-4- yloxy) amino] propylcarbamate (0.23 mmol, 100 mg) was combined 1, 3-benzodioxole-5-sulfonyl chloride (0.28 mmol, 61 mg) , diisopropylethylamine (0.69 mmol, 0.12 mL) in anhydrous THF (2 mL) and allowed to stir 72 hours at room temperature under nitrogen. The reaction was diluted with ethyl acetate and washed with IN HCl, saturated sodium bicarbonate solution, brine and was dried over magnesium sulfate. The solution was concentrated under vacuum and the crude product was purified by silica gel chromatography (1:5 hexanes/ethyl acetate) . The purified oil was crystallized to provide 55 mg (39%) of white crystals. Rf = 0.2 (1:5 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.38-7.13 (9H,m), 6.90 (lH,d), 6.10 (2H,s), 5.64 (lH,s), 5.02 (lH,m), 4.82 (lH,m), 4.41 (lH,m), 3.99-3.79 (6H,m), 3.72-3.59 (2H,m), 3.49-3.33 (2H,m), 3.25-2.51 (6H,m), 2.09-1.98 (2H,m), 1.69-1.43 (2H,m) . MS (ESI): M+H=621.
Example 152
Step 1
^ ^ 1. O3, CH2CI2/MeOH ϊι
4-oxobutanenitrile. 4-butenenitrile (43.9 mmol, 3.56 grams) was dissolved in 150 mL of a 3:1 methylene chloride/methanol solution, cooled to -78°C, and ozonated until the solution turned blue (15 minutes) . The excess ozone was sparged by bubbling nitrogen through the solution while warming to room temperature. Excess dimethylsulfoxide was added and the reaction stirred for 15 hours at room temperature. The reaction was concentrated to a clear liquid, dissolved in ethyl acetate, washed in distilled water, brine and dried over magnesium sulfate. The concentrated crude product was purified by silica gel flash chromatography (2:1 hexanes/ethyl acetate) to provide a brown liquid which was distilled at reduced pressure (150°C/15 mbar) to provide 2.11 grams (58%) of the purified clear liquid. Rf = 0.2 (2:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 9.78 (IH, s) , 2.90 (2H,m) , 2.61 (2H,m) . Step 2:
H
Figure imgf000279_0001
4-hydroxypentanenitrile. The 4-oxobutanenitrile (17.9 mmol, 1.49 grams) was dissolved in anhydrous THF (50 mL) and cooled to -78°C. Methylmagnesiu bromide (17.9 mmol, 5.98 L, 3M in diethyl ether) solution was injected slowly by syringe. The reaction stirred at -78°C for 15 min. and was warmed to room temperature. The reaction was diluted in methylene chloride (50 mL) and dried over magnesium sulfate. The concentrated crude product was purified by silica gel flash chromatography (4:1 methylene chloride/ethyl acetate) and provided 1.2 grams (67%) of the desire alcohol as a yellow liquid. Rf = 0.2 (4:1 methylene chloride/ethyl acetate); Hl-NMR (CDC13) : δ 3.91 (lH,m), 2.47 (2H,m), 1.86- 1.60 (3H,m) , 1.23 (3H,m) .
Step 3:
Figure imgf000279_0002
PPh3, DTBAD, THF 4- (aminooxy)pentanenitrile. A solution of ditertbutylazodicarboxylate (DTBAD) (13.9 mmol, 3.21 grams) in anhydrous THF (20 mL) was canulated dropwiseinto a stirring slurry of 4-hydroxypentanenitrile (11.6 mmol, 1.15 grams), N-hydroxyphthalimide (11.6 mmol, 1.89 grams), triphenylphosphine (13.9 mmol, 3.65 grams) and anhydrous THF (30 mL) . The slurry dissolved on addition and changed color first to orange, then to yellow. The yellow solution stirred at room temperature for 3 hours. The solvent was removed under vacuum and the residue was dissolved in TFA. The reaction stirred in TFA for 2 hours to decompose the DTBAD biproduct. The TFA was removed under vacuum and the crude product was dissolved in ethy acetate, washed in distilled water, 5% aqueous potassium carbonate solution, brine and dried over magnesium sulfate. The crude yellow solid was purified by silica gel flash chromatography (2:1 hexanes/ethyl acetate) and provided 850 mg (32%) of a white crystalline solid. R£ = 0.3 (2:1 hexanes/ethyl acetate); H- 1-NMR (CDC13) : δ 7.83 (2H,m), 7.76 (2H,m), 4.39 (lH,m), 2.78 (2H,m), 2.03 (2H,m), 1.41 (3H,d).
Step 4:
Figure imgf000280_0001
4-{ [ (4-methoxybenzyl) amino] oxy}pentanenitrile
4- (aminooxy)pentanenitrile (1.3 mmol, 150 mg) and 4- methoxybenzenesulfonylchloride (1.3 mmol, 272 mg) were combined in anhydrous THF with diisopropylethylamine (1.4 mmol, 0.69 mL) and a few crystals of DMAP. The reaction was stirred at 50°C for 15 hours. The reaction was diluted in diethyl ether, washed with IN HCl, IN NaOH and brine and dried over mangesium sulfate. NMR analysis revealed that the isolated crude was the double sulfonyl chloride addition product. The aqueous NaOH fraction was acidified to neutral pH, extracted into ethyl acetate and dried over magnesium sulfate. The solvent was removed under vacuum leaving a very clean 195 mg (52%) crude product. Rf = 0.4 (1:1 hexanes/ethyl acetate); Hl-NMR (CDC13) : δ 7.82 (2H,d), 7.01 (2H,d) , 6.84 (lH,s), 4.17 (lH,m), 3.88 (3H,s), 2.42 (2H,m), 1.88 (2H,m) , 1.23 (3H,d) .
Step 5:
Figure imgf000281_0001
tert-butyl l-benzyl-3-{ (3-cyano-l-methylpropoxy) [ (4- methoxyphenyl) sulfonyl] amino} -2-hydroxypropylcarbamate. 4- {[ (4-methoxybenzyl) amino] oxy}pentanenitrile (0.69 mmol, 195 mg) was combined with tert-butyl N- (IS) -1- [ (2S) oxiran-2-yl] - 2-phenylethylcarbamate (0.57 mmol, 151 mg) , lithium bis (trimethylsilyl) amide (0.11 mmol, 0.114 mL, 1.0 M in THF) and anhydrous THF (2 mL) . The reaction was stirred under nitrogen at room temperature for 20 hours. The reaction was diluted in ethyl acetate (2 mL) and washed with IN HCl, saturated aqueous sodium bicarbonate, brine, and was dried over magnesium sulfate. The crude solution was concentrated and purified by silica gel flash chromatography (1:1 hexanes/ethyl acetate) and RP HPLC followed by lyophylization to yield 78 mg (25%) of a white solid. Rf =
0.2 (1:1 hexanes/ethyl acetate); Hl-ΝMR (CDC13) : δ 7.76- 7.61 (2H,m), 7.34-7.11 (6H,m), 7.04-6.92 (2H,m), 4.72-4.53 (lH,m), 4.42 (IH, m) , 3.89 (3H,s), 3.78 (2H,m) , 3.25-2.51 (6H,m), 2.42 (2H,m), 2.02-1.79 (2H, m) , 1.43-1.15 (10H,m). MS (ESI) : M+H=548.
Example 153
Step 1:
Figure imgf000282_0001
2- (cyclohexyloxy) -lH-isoindole-1 ,3 (2H) -dione. A solution of triphenylphosine (15.53 g, 59.2 mmol), cyclohexanol (6.25 mL, 59.2mmol), and N-hydroxypthalimide (9.66 g, 59.2 mmol) in anhydrous tetrahydrofuran (500 mL) under Argon was treated dropwise over approximately20 minutes with a solution of di-tert-butyl azodicarboxylate (15.00 g, 65.14 mmol) in tetrahydrofuran (100 mL) with a water bath to control the exotherm. After the reddish color had dissipated, a mixture of di-tert-butyl azodicarboxylate (3.00 g, 13.0 mmol) and triphenylphosine (3.11 g, 11.8 mmol) in anhydrous tetrahydrofuran (50 mL) was added to the reaction mixture and allowed to stir overnight at ambient temperature. After evaporation in vacuo, the residue was treated with trifluoroacetic acid (100 mL) and stirred for 20 minutes. The reaction was evaporated in vacuo and the residue was partitioned between water and dichloromethane. The layers were separated and the aqueous phase was extracted with dichloromethane. The combined organic layers were dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified twice by flash silica gel chromatography eluting with hexane : ethyl acetate (4:1 and 9:1). Pure fractions were concentrated in vacuo to a solid and dried under high vacuum to provide 2- (cyclohexyloxy) -lH-isoindole-1, 3 (2H) - dione as a solid (10.90 g, 75%).
Step 2:
Figure imgf000283_0001
tert-butyl (IS,2R) -l-benzyl-3- [ (cyclohexyloxy) amino] -2- hydroxypropylcarbamate. A solution 2- (cyclohexyloxy) -1H- isoindole-1, 3 (2H) -dione (10.00 g, 40.82 mmol) in anhydrous tetrahydrofuran (100 mL) under Argon was treated with anhydrous hydrazine (1.28 mL, 40.82 mmol). After stirring for approximately two hours, the slurry was treated with additional anhydrous hydrazine (0.13 mL, 4.1 mmol). After stirring an additional hour, the reaction mixture was filtered and washed with a minimum quantity of anhydrous tetrahydrofuran. The filtrate was combined with lithium triflate (5.09 g, 32.7 mmol) and tert-butyl N-(1S)-1- [ (2S) oxiran-2-yl] -2-phenylethylcarbamate (8.58 g, 32.6 mmol) and brought to reflux. After heating for 16 hours, additional lithium triflate (5.00 g, 32.1 mmol) was added. The reaction was stirred at reflux for an additional 24 hours and then evaporated in vacuo . The residue was partitioned between ethyl acetate and water. After separating the layers, the organic phase was washed again with water. The aqueous phases were combined and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and evaporated in vacuo. The residue was triturated with diethyl ether and then filtered. The mother liquor was evaporated in vacuo and the residue was triturated again with diethyl ether. The second crop was collected by filtration and the mother liquor was evaporated in vacuo . The residue was dissolved in diethyl ether and placed in the freezer overnight. A third crop was collected by filtration. All three crops were dried under high vacuum to provide tert-butyl (IS, 2R) -l-benzyl-3-
[ (cyclohexyloxy) amino] -2-hydroxypropylcarbamate (4.48 g, 36%) as a solid. Hl-NMR (chloroform-D3) : 1.34 (m, 14H) , 1.52 (m, IH), 1.72 (m, 2H) , 1.95 (m, 2H) , 2.97 (m, 4H) , 3.25
(m, IH) , 3.67 (m, IH) , 3.83 (m, IH) , 3.92 (m, IH) , 4.32 (b, IH) , 4.61 (d, IH) , 7.26 (m, 5H) . MS (ESI): 379 (M+H) . Step 3:
Figure imgf000284_0001
(2R,3S) -3-amino-l- [ (cyclohexyloxy) amino] -4-phenyl-2-butanol .
A combination of trifluoroacetic acid (20 mL) and tert-butyl (IS, 2R) -l-benzyl-3- [ (cyclohexyloxy) amino] -2- hydroxypropylcarbamate (2.00 g, 5.29 mmol) was stirred under Argon at ambient temperature for approximately 30 minutes. The reaction was evaporated in vacuo and the residue was partitioned between dichloromethane and aqueous sodium hydroxide (IN) . After separating the layers, the aqueous phase was extracted with dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a solid which was dried under high vacuum to provide (2R, 3S) -3-amino-l- [ (cyclohexyloxy) amino] -4-phenyl-2-butanol (1.426 g, 97%). Hl-NMR (chloroform-D3) : 1.24 (m, 5H) , 1.58 (m, 4H) , 1.73 (m, 2H) , 1.95 (m, 2H) , 2.51 (m, IH) , 2.97 ( , 2H) , 3.16 (m, 2H) , 3.33 (m, IH) , 3.57 (m, IH) , 3.77 (m, IH) , 7.26 (m, 5H) .MS (ESI) : 279 (M+H) . Step 4 :
Figure imgf000285_0001
(3R, 3aS , 6aR) hexahydrofuro [2 , 3-b] furan-3-yl (IS ,2R) -1-benzyl- 3- [ (cyclohexyloxy) amino] -2-hydroxypropylcarbamate. A mixture of (2R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-2-yl 4- nitrophenyl carbonate (1.49 g, 4.82 mmol), (2R, 3S) -3-amino- 1- [ (cyclohexyloxy) amino] -4-phenyl-2-butanol (1.341 g, 4.82 mmol) and diisoproylethylamine (0.841 mL, 4.82 mmol) in acetonitrile (15 mL) under Argon was stirred at ambient temperature for 16 hours. The resulting slurry was filtered and washed with cold acetonitrile to provide the first crop of product. The mother liquor was evaporated in vacuo dissolved in ethyl acetate and washed twice with aqueous sodium hydroxide (IN) . The combined aqueous phases were extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered and evaporated in vacuo . The residue was triturated with diethyl ether and filtered to provide a second crop of product. The mother liquor was evaporated in vacuo and a third crop was crystallized from the residue dissolved in a minimum quantity of diethyl ether. The three crops were dried under high vacuum to provide (3R,3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -1-benzyl- 3- [ (cyclohexyloxy) amino] -2-hydroxypropylcarbamate (1.555 g, 74%). Hl-NMR (chloroform-D3) : 1.31 (m, 7H) , 1.56 (m, 2H) ,
1.73 (m, 2H) , 1.99 (m, 2H) , 2.74 (m, IH) , 2.89 (m, IH) , 3.10 (m, 2H) , 3.30 (m, IH) , 3.83 (m, 8H) , 5.01 (m, 2H) , 5.63 (d, IH) , 7.21 (m, 5H) . ). MS (ESI): 456 (M+Na). Step 5 :
Figure imgf000286_0001
(3R,3aS , 6aR) hexahydrofuro [2 ,3-b] furan-3-yl (IS ,2R) -1-benzyl- 3-{ (cyclohexyloxy) [ (4-nitrophenyl) sulfonyl]amino} -2- hydroxypropylcarbamate. A mixture (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -l-benzyl-3- [ (cyclohexyloxy) amino] - 2-hydroxypropylcarbamate (100 mg, 0.23 mmol), 4- nitrobenzenesuphonyl chloride (61 mg, 0.276 mmol), diisoproylethylamine (0.048 mL, 0.276 mmol) and 4- dimethylaminopyridine (~1 mg, cat.) was combined in anhydrous tetrahydrofuran (3 mL) and stirred at ambient temperature under an Argon atmosphere for approximately 16 hours. The reaction mixture was evaporated in vacuo and the residue was partitioned between ethyl acetate and aqueous hydrochloric acid (IN) . The organic phase was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo. The residue was purified on flash silica gel eluting with 3:2 hexane : ethyl acetate followed by 1 : 1 hexane : ethyl acetate. Fractions containing the product werecombined, evaporated in vacuo, and triturated with diethyl ether. The solvent was removed and the residual solid was dried under high vacuum to provide (3R,3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -1-benzyl- 3-{ (cyclohexyloxy) [ (4-nitrophenyl) sulfonyl] amino} -2- hydroxypropylcarbamate (129 mg, 91%) . %) . Hl-NMR (chloroform-D3) : 1.22 ( , 7H) , 1.64 (m, 2H) , 1.78 (m, 2H) , 2.08 (m, 2H) , 2.90 (m, 5H) , 3.69 (m, 2H) , 3.88 (m, 4H) , 4.23 (m, IH) , 4.87 (m, IH) , 5.04 (m, IH) , 5.64 (d, IH) , 7.18 ( , 2H) , 7 . 25 ( , 3H) , 7 . 96 ( d, 2H ) , 8 . 36 ( d, 2H) . MS (ES I ) : 642 (M+Na ) .
Step 6 :
Figure imgf000287_0001
(3R,3aS,6aR) hexahydrofuro [2,3-b] furan-3-yl (lS,2R)-3-[ [ (4- aminophenyl) sulfonyl] (cyclohexyloxy) amino] -1-benzyl-2- hydroxypropylcarbamate. To a solution of (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl ( IS, 2R) -1-benzyl- 3-{ (cyclohexyloxy) [ (4-nitrophenyl) sulfonyl] amino} -2- hydroxypropylcarbamate (115 mg, 0.186 mmol) in a 1:1 mixture of ethanol : ethyl acetate (6 mL) was added Palladium on charcoal (10 wt%, 30 mg) . The starting material was reduced under an atmosphere of Hydrogen gas over 16 hrs. The reaction mixture was filtered and evaporated in vacuo . The residue was purified on a preparative TLC plate (20x20 cm, 500 uM) eluting with 3:1 ethyl acetate : hexane. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was triturated with water, filtered and dried under high vacuum to provide (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -3- [ [ (4-aminophenyl) sulfonyl] (cyclohexyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate (89 mg, 81%). Hl-NMR (chloroform-D3) : 1.26 (m, 6H) , 1.58 (m, 5H) , 2.05 (m, 2H) , 2.90 (m, 4H) , 3.09 (b, 2H) , 3.68 ( , 2H) , 3.88 (m, 4H) , 4.16 (m, IH) , 4.24 (b, IH) , 4.81 (d, IH) , 5.00 (m, IH) , 5.63 (d, IH) , 6.66 (d, 2H) , 7.23 (m, 5H) , 7.56 (d, 2H) . MS(ESI): 612 (M+Na) . Example 154
Step 1
Figure imgf000288_0001
(32?, 3aS,6a2?) hexahydrofuro [2,3-b] furan-3-yl (IS,22?) -1-benzyl- 3-{ (cyclohexyloxy) [ (3-nitrophenyl) sulfonyl] amino} -2- hydroxypropylcarbamate. A mixture
(3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -1-benzyl- 3- [ (cyclohexyloxy) amino] -2-hydroxypropylcarbamate (342 mg, 0.788 mmol), 3-nitrobenzenesuphonyl chloride (175 mg, 0.788 mmol) and diisoproylethylamine (0.137 mL, 0.867 mmol) was combined in anhydrous tetrahydrofuran (10 L) and stirred at ambient temperature under an Argon atmosphere for approximately 40 hours. The reaction mixture was partitioned between ethyl acetate and aqueous hydrochloric acid (IN) . After separating the phases, the aqueous layer was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, and evaporate in vacuo . The residue was purified on flash grade silica gel eluting with 1:1 ethyl acetate : hexane. The fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?)- l-benzyl-3-{ (cyclohexyloxy) [ (3-nitrophenyl) sulfonyl] amino }- 2-hydroxypropylcarbamate (428 mg, 88%) as a foam. Hl-NMR
(chloroform-D3) : 1.29 (m, 6H) , 1.57 (m, 3H) , 1.76 (m, 2H) , 2.08 (m, 2H) , 2.91 (m, 4H) , 3.10 (b, IH) , 3.68 (m, 2H) , 3.88 (m, 4H) , 4.25 ( , IH) , 4.83 (d, IH) , 5.00 (m, IH) , 5.64 (d, IH) , 7 . 22 (m, 5H) , 7 . 76 (m, IH) , 8 . 07 ( d, IH) , 8 . 50 ( d, IH) , 8 . 66 ( s , IH ) . MS (ES I ) : 642 (M+Na ) .
Step 2 :
Figure imgf000289_0001
(3R, 3aS, 6aR) hexahydrofuro [2 , 3-b] furan-3-yl (IS ,2R) -3- [ [ (3- aminophenyl) sulfonyl] (cyclohexyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate. A solution of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl- 3- { (cyclohexyloxy) [ (3-nitrophenyl) sulfonyl] amino} -2- hydroxypropylcarbamate (403 mg, 0.651 mmol) in absolute ethanol (12 mL) was combined with Palladium on carbon (10 wt%, 80 mg) and reduced under a Hydrogen atmosphere for 16 hours. The reaction mixture was filtered and evaporated in vacuo to provide (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -3- [ [ (3-aminophenyl) sulfonyl] (cyclohexyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate (356 mg, 93%) as a foam. A sample of the product (30 mg) was purified on a preparative TLC plate (20x20 cm, 500 uM) eluting with 95:5 dichloromethane : methanol. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was triturated with water, filtered and dried under high vacuum to provide (3R,3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -3- [ [ (3- aminophenyl ) sulfonyl] (cyclohexyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (18 mg) as a solid. Hl-NMR (chloroform-D3) : 1.26 (m, 6H) , 1.64 ( , 5H) , 2.07 (m, 2H) , 2.93 (m, 4H) , 3.14 (b, IH) , 3.69 (m, 2H) , 3.87 (m, 4H) , 3.94 (b, 2H) , 4.19 (m, IH) , 4.83 (b, IH) , 5.03 (m, IH) , 5.64 (d, IH) , 6.89 (d, IH) , 7.06 (s, IH) , 7.21 (m, 7H) . MS(ESI): 612 (M+Na) .
Example 155
Figure imgf000290_0001
(3R, 3aS , 6aR) hexahydrofuro [2 , 3-b] f ran-3-yl (IS , 2R) -3- [(1,3- benzodioxol-5-ylsulfonyl) (cyclohexyloxy) amino] -1-benzyl-2- hydroxypropylcarbamate. A mixture of (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl ( IS, 2R) -1-benzyl- 3- [ (cyclohexyloxy) amino] -2-hydroxypropylcarbamate (100 mg, 0.230), 1, 3-benzodioxole-5-sulfonyl chloride (Eur. Pat. Appl. 583960, 23 Feb 1994, 56 mg, 0.253 mmol) and diisoproylethylamine (0.042 mL, 0.242 mmol) in anhydrous tetrahydrofuran (3 mL) was stirred at ambient temperature under an Argon atmosphere for 16 hours. A catalytic quantity of dimethylaminopyridine (~1 mg) was added and the reaction was heated at reflux for approximately 2 hours. An additional quantity of 1, 3-benzodioxole-5-sulfonyl chloride (11 mg, 0.050 mmol) was added and the reaction was heated for an additional hour. After cooling to ambient temperature, the reaction mixture was partitioned between ethyl acetate and aqueous hydrochloric acid. After separating the phases, the organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was purified on a preparative TLC plate (20x20 cm, 500 μM) eluting with 1:1 ethyl acetate : hexane. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was triturated with water, filtered and dried under high vacuum to provide
(3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (lS,2R)-3-[ (1,3- benzodioxol-5-ylsulfonyl) (cyclohexyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate (123 mg, 87%) as a white solid. Hl- NMR (chloroform-D3) : 1.32 (m, 6H) , 1.70 (m, 5H) , 2.14 ( , 2H) , 3.00 (m, 4H) , 3.18 (b, IH) , 3.74 (m, 2H) , 3.97 (m, 4H) , 4.27 (m, IH) , 4.90 (m, IH) , 5.07 (m, IH) , 5.70 (d, IH) , 6.15
(s, 2H) , 6.95 (d, IH) , 7.30 (m, 7H) . MS (ESI): 641 (M+Na) .
Example 156
Figure imgf000291_0001
(3R,3aS,6aR) hexahydrofuro [2, 3-b] furan-3-yl (1S,2R) -1-benzyl- 3- [ (cyclohexyloxy) (2 ,3-dihydro-l ,4-benzodioxin-6- ylsulfonyl) amino] -2-hydroxypropylcarbamate. A mixture of
1, 4-benzodioxan-6-sulfonyl chloride (Eur. Pat. Appl. 583960, 23 Feb 1994; 60 mg; 0.253 mmol),
(3R,3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -1-benzyl- 3- [ (cyclohexyloxy) amino] -2-hydroxypropylcarbamate (100 mg, 0.230 mmol), and diisoproylethylamine (0.042 mL, 0.242 mmol) in anhydrous tetrahydrofuran (3 L) was stirred at ambient temperature under an Argon atmosphere for 16 hours. A catalytic quantity of dimethylaminopyridine (~1 mg) was added and the reaction was heated at reflux for approximately 2 hours. An additional quantity of 1,4- benzodioxan-6-sulfonyl chloride (12 mg, 0.051 mmol) was added and the reaction was heated for an additional 30 minutes. After cooling to ambient temperature, the reaction mixture was partitioned between ethyl acetate and aqueous hydrochloric acid. After separating the phases, the organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was purified on a preparative TLC plate (20x20 cm, 500 μM) eluting with 1:1 ethyl acetate : hexane. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was triturated with water, filtered and dried under high vacuum to provide (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -l-benzyl-3- [ (cyclohexyloxy) (2, 3-dihydro-l, 4- benzodioxin-6-ylsulfonyl ) amino] -2-hydroxypropylcarbamate (125 mg, 86%) as a white solid. Hl-NMR (chloroform-D3) : 1.20 (m, 6H) , 1.60 ( , 5H) , 2.07 (m, 2H) , 2.90 (m, 4H) , 3.09 (b, IH) , 3.67 (m, 2H) , 3.90 ( , 4H) , 4.23 (m, IH) , 4.31 (m, 4H) , 4.82 (d, IH) , 5.01 (m, IH) , 5.64 (d, IH) , 6.95 (d, IH) 7.25 ( , 7H) . MS (ESI): 655 (M+Na).
Example 157
Figure imgf000292_0001
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl (IS, 22?) -1- benzyl-3- [{ [4- (benzyloxy) phenyl] sulfonyl }
(cyclohexyloxy) amino] -2-hydroxypropylcarbamate.
A mixture of 4-benzyloxybenzenesulfonyl chloride (65 mg; 0.230 mmol), (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -l-benzyl-3- [ (cyclohexyloxy) amino] -2- hydroxypropylcarbamate (100 mg, 0.230 mmol), diisoproylethylamine (0.042 mL, 0.242 mmol) and 4- dimethylammopyridme (~1 mg) m anhydrous tetrahydrofuran (3 mL) was stirred at ambient temperature under an Argon atmosphere for 16 hours. An additional quantity of 4- benzyloxybenzenesulfonyl chloride (13 mg, 0.046 mmol) and 4- dimethylammopyridme (~1 mg) was added and the reaction was heated at reflux for approximately 2 hours. After cooling to ambient temperature, the reaction mixture was partitioned between ethyl acetate and aqueous hydrochloric acid. The phases were separated and the organic layer was then washed with brme, dried over anhydrous magnesium sulfate, filtered and evaporated m vacuo . The crude product was purified on flash grade silica gel eluting with 1:1 ethyl acetate : hexane. Fractions containing the product were combined and evaporated m vacuo and dried under high vacuum to provide (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl- 3- [ { [4- (benzyloxy) phenyl] sulfonyl } (cyclohexyloxy) ammo] -2- hydroxypropylcarbamate (143 mg, 91%) . Hl-NMR (chloroform- D3) : 1.27 (m, 6H) , 1.61 (m, 5H) , 2.07 (m, 2H) , 2.91 (m, 4H) , 3.10 (b, IH) , 3.68 (m, 2H) , 3.89 (m, 4H) , 4.19 (m, IH) , 4.84 (m, IH) , 5.01 (m, IH) , 5.12 (s, 2H) , 5.64 (d, IH) , 7.05 (d, 2H) , 7.28 (m, 10H) , 7.71 (d, 2H) . MS (ESI): 703 (M+Na) .
Example 158
Figure imgf000293_0001
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl (IS, 22?) -1- benzγl-3- [{ [3- (benzyloxy) phenyl] sulfonyl } (cyclohexyloxy) amino] -2-hydroxypropylcarbamate . A mixture of 3-benzyloxybenzenesulfonyl chloride (65 mg; 0.230 mmol), (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -l-benzyl-3- [ (cyclohexyloxy) amino] -2- hydroxypropylcarbamate (100 mg, 0.230 mmol) and diisoproylethylamine (0.042 mL, 0.242 mmol) in anhydrous tetrahydrofuran (3 mL) was stirred at ambient temperature under an Argon atmosphere for 16 hours. A catalytic quantity of dimethylaminopyridine (~1 mg) was added and the reaction was heated at reflux for approximately one hour. An additional quantity of 3-benzyloxybenzenesulfonyl chloride (13 mg, 0.046 mmol) was added and the reaction was heated at reflux for approximately 1 hour. After cooling to ambient temperature, the reaction mixture was partitioned between ethyl acetate and aqueous hydrochloric acid. The phases were separated and the organic layer was then washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was dried under high vacuum to provide (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -l-benzyl-3- [ { [3- (benzyloxy) phenyl] sulfonyl } (cyclohexyloxy) amino] -2-hydroxypropylcarbamate (140 mg,
89%). Hl-NMR (chloroform-D3) : 1.22 (m, 6H) , 1.62 (m, 5H) , 2.05 (m, 2H) , 2.90 (m, 4H) , 3.11 (b, IH) , 3.66 ( , 2H) , 3.87 (m, 4H) , 4.18 (m, IH) , 4.77 (m, IH) , 4.95 (m, IH) , 5.10 (m, 2H) , 5.60 (d, IH) , 7.29 (m, 14H) . MS (ESI): 703 (M+Na) .
Example 159
Figure imgf000294_0001
(3R, 3aS , 6aR) hexahydrofuro [2 , 3-b] furan-3-yl (IS , 2R) -1-benzyl- 3-{ (cyclohexyloxy) [ (3-hydroxyphenyl) sulfonyl] amino} -2- hydroxypropylcarbamate. A solution of
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl ( IS, 22?) -1-benzyl- 3- [ { [3- (benzyloxy) phenyl] sulfonyl } (cyclohexyloxy) amino] -2- hydroxypropylcarbamate (131 mg, 0.193 mmol) in ethyl acetate (~5 mL) was combined with Palladium on carbon (10 wt%, 25 mg) and reduced under an atmosphere of Hydrogen gas. After stirring for 16 hours, the reaction mixture was filtered and evaporated in vacuo to a residue. The residue was purified on a preparative TLC plate (20x20 cm, 500 μM) eluting with 3:2 ethyl acetate : hexane. The product band was removed, eluted with 3:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was triturated with water, filtered and dried under high vacuum to provide (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (1S,2R) -1-benzyl- 3- { (cyclohexyloxy) [ (3-hydroxyphenyl) sulfonyl] amino} -2- hydroxypropylcarbamate (93 mg, 82%) as a white solid. Hl- NMR (chloroform-D3) : 1.28 (m, 6H) , 1.67 (m, 5H)., 2.06 (m, 2H) , 2.96 (m, 4H) , 3.09 (b, IH) , 3.87 (m, 6H) , 4.19 (m, IH) , 5.01 (m, 2H) , 5.69 (d, IH) , 6.60 (b, IH) , 7.23 (m, 9H) . MS (ESI) : 613 (M+Na) .
Example 160
Figure imgf000295_0001
(3R, 3aS , 6aR) hexahydrofuro [2 ,3-b] furan-3-yl (IS ,2R) -1-benzyl- 3-{ (cyclohexyloxy) [ (4-hydroxyphenyl) sulfonyl] amino} -2- hydroxypropylcarbamate. A solution of
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl- 3- [ { [4- (benzyloxy) phenyl] sulfonyl} (cyclohexyloxy) amino] -2- hydroxypropylcarbamate (140 mg, 0.206 mmol) in ethyl acetate (5 L) was combined with Palladium on carbon (10 wt%, 28 mg) and reduced under an atmosphere of Hydrogen gas. After stirring for 16 hours, the reaction mixture was filtered and evaporated in vacuo to a residue. The residue was purified on a preparative TLC plate (20x20 cm, 500 μM) eluting with 3:2 ethyl acetate : hexane. The product band was removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was triturated with water, filtered and dried under high vacuum to provide (3R,3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl ( IS, 2R) -1-benzyl- 3-{ (cyclohexyloxy) [ (4-hydroxyphenyl) sulfonyl] amino}-2- hydroxypropylcarbamate (106 mg, 87%) as a white solid. Hl- NMR (chloroform-D3) : 1.27 (m, 6H) , 1.67 (m, 5H) , 2.05 (m, 2H) , 2.93 (m, 4H) , 3.11 (b, IH) , 3.68 (m, 2H) , 3.90 (m, 4H) , 4.19 (m, IH) , 4.81 (d, IH) , 4.99 (m, IH) , 5.65 (d, IH) , 6.24 (b, IH) , 6.92 (d, 2H) , 7.22 (m, 5H) , 7.67 (d, 2H) . MS(ESI): 613 (M+Na) .
Example 161 Step 1
Figure imgf000296_0001
tert-butyl (IS,22?) -l-benzyl-3- [ (1-ethylpropoxy) amino] -2- hydroxypropylcarbamate. A solution of 2- (1-ethylpropoxy) - lH-isoindole-1,3 (2H) -dione [ Synth . Comm . , 22 (1 0) , 1427-1 432 (1992) , 10.00 g, 42.9 mmol] in anhydrous tetrahydrofuran (100 mL) under Argon was treated with anhydrous hydrazine (1.48 mL, 47.2 mmol) over approximately 5 minutes. The reaction was stirred for 45 minutes and diluted with anhydrous tetrahydrofuran (50 mL) . An additional quantity of anhydrous hydrazine (0.888 mL, 28.3 mmol) was added in six increments over 90 minutes. The mixture was filtered washing with tetrahydrofuran (~50 mL) . The mother liquor was combined with tert-butyl N- (IS) -1- [ (2S) oxiran-2-yl] -2- phenylethylcarbamate (9.03 g, 34.3 mmol) and lithium triflate (5.36 g, 34.3 mmol) and heated to reflux. After stirring for 3.5 days, the reaction was evaporated in vacuo and the residue was partitioned between aqueous potassium carbonate (5% w/v) and ethyl acetate. The aqueous phase was separated and extracted with ethyl acetate. The combined organic layers were washed with saturated brine, dried over magnesium sulfate, filtered and evaporated in vacuo . The residue was purified on flash grade silica gel eluting with 3:1 hexane : ethyl acetate. Fractions containing the product were evaporated in vacuo and dried under high vacuum to tert-butyl (IS, 22?) -l-benzyl-3- [ (1-ethylpropoxy) amino] -2- hydroxypropylcarbamate (6.425 g, 51%) as a solid. Hl-NMR (chloroform-D3) : 0.88 (m, 6H) , 1.34 (s, 9H) , 1.51 (m, 4H) , 2.91 (m, 4H) , 3.15 (d, IH) , 3.47 (m, IH) , 3.69 (m, 2H) , 3.89 (m, IH) , 4.57 (m, IH) , 7.24 (m, 5H) . MS (ESI): 389(M+Na). Step 2:
Figure imgf000297_0001
(22?, 3S) -3-amino-l- [ (1-ethylpropoxy) amino] -4-phenyl-2- butanol. A mixture of tert-butyl (IS, 22?) -l-benzyl-3- [ (1- ethylpropoxy) amino] -2-hydroxypropylcarbamate (3.285 g, 8.9! mmol) and trifluoroacetic acid (25 mL) was stirred at ambient temperature under Argon for approximately 30 minutes. The reaction was evaporated in vacuo and the residue was partitioned between dichloromethane and aqueous sodium hydroxide (IN) . The phases were separated and the aqueous phase was extracted with dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filter, evaporated in vacuo and dried under high vacuum to provide (22?, 3S) -3-amino-l- [ (1-ethylpropoxy) amino] - 4-phenyl-2-butanol (2.455 g, 100%) as a solid. Hl-NMR (chloroform-D3) : 0.94 (m, 6H) , 1.56 (m, 4H) , 2.55 (m, IH) , 3.01 (m, 2H) , 3.22 (m, 2H) , 3.51 ( , IH) , 3.81 (m, IH) , 7.30 (m, 5H) . MS (ESI): 267 (M+H) .
Step 3:
Figure imgf000298_0001
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl (1S,22?) -1-benzyl- 3- [ (1-ethylpropoxy) amino] -2-hydroxypropylcarbamate. A mixture of (2R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-2-yl 4- nitrophenyl carbonate (2.764 g, 8.94 mmol), (22?, 3S) -3-amino- 1- [ (1-ethylpropoxy) amino] -4-phenyl-2-butanol (2.379 g, 8.94 mmol), and diisoproylethylamine (1.56 mL, 8.94 mmol) in acetonitrile (25 mL) under Argon was stirred at ambient temperature for 16 hours. The reaction mixture was evaporated in vacuo and the residue was partitioned between ethyl acetate and aqueous potassium carbonate (5% w/v) . The phases were separated and the organic layer was washed again with aqueous potassium carbonate (5% w/v) . The aqueous phases were combined and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate and evaporated in vacuo . The residue was triturated with diethyl ether and filtered. The mother liquor was evaporated in vacuo and the residue was purified on flash grade silica gel eluting with 1:1 ethyl acetate : hexane. Fractions containing the product were combined and evaporated in vacuo to a solid. Both crops of product were dried under high vacuum to provide
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl- 3- [ (1-ethylpropoxy) amino] -2-hydroxypropylcarbamate (2.554 g, 68%). Hl-NMR (chloroform-D3) : 0.88 (m, 6H) , 1.52 (m, 7H) , 2.77 (m, IH) , 2.91 (m, 2H) , 3.07 (m, IH) , 3.16 (m, IH) , 3.37 (b, IH) , 3.46 (m, IH) , 3.75 (m, 4H) , 3.94 (m, 2H) , 4.87 (d, IH) , 5.03 (m, IH) , 5.63 (d, IH) , 7.23 (m, 5H) . MS (ESI): 445 (M+Na) .
Step 4:
Figure imgf000299_0001
tert-butyl (1S,2R) -l-benzγl-3-{ (1-ethylpropoxγ) [ (4- methoxyphenyl) sulfonyl ] amino} -2-hydroxypropylcarbamate . A mixture of tert-butyl (IS, 22?) -l-benzyl-3- [ (1- ethylpropoxy) amino] -2-hydroxypropylcarbamate (100 mg, 0.273 mmol), 4-methoxyphenylsulphonyl chloride (57 mg, 0.273 mmol), and diisoproylethylamine (0.0476 mL, 0.273 mmol) in anhydrous tetrahydrofuran (2 mL) was stirred under Argon for 16 hours at ambient temperature. A catalytic quantity of 4- dimethylaminopyridine (~1 mg) was added and the reaction was heated at reflux for approximately two hours. After cooling, the reaction was evaporated in vacuo and the residue was dissolved in ethyl acetate. The solution was washed with aqueous potassium carbonate (5% w/v), aqueous hydrochloric acid (IN) and brine. The organic layer was then dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was purified on a preparative TLC plate (20x20 cm, 500 μM) eluting with 95:5 methylene chloride : methanol. The product band was removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was purified again on a preparative TLC plate (20x20 cm, 500 μM) eluting with 95:5 methylene chloride : ethyl acetate. The product band was removed, eluted with 4 : 1 methylene chloride : methanol, filtered, and evaporated in vacuo to provide tert- butyl (lS,2R)-l-benzyl-3-{ (1-ethylpropoxy) [ (4- methoxyphenyl) sulfonyl] amino} -2-hydroxypropylcarbamate (103 mg, 70%) as a foam. Hl-NMR (chloroform-D3) : 0.95 (m, 6H) , 1.38 (s, 9H) , 1.64 (m, 4H) , 3.01 (m, 5H) , 3.83 (m, 2H) , 3.93 (s, 3H) , 4.20 (m, IH) , 4.61 (m, IH) , 7.03 (d, 2H) , 7.29 (m, 5H) , 7.80 (d, 2H) . MS (ESI): 559(M+Na).
Example 162
Figure imgf000300_0001
(3R,3aS,6aR) hexahydrofuro [2,3-b] furan-3-yl (1S,2R) -3- [ (1 ,3- benzodioxol-5-ylsulfonyl) (1-ethylpropoxy) amino] -l-benzyl-2- hydroxypropylcarbamate. A mixture of
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl- 3- [ (1-ethylpropoxy) amino] -2-hydroxypropylcarbamate (0.100 g, 0.237 mmol), 1, 3-benzodioxole-5-sulfonyl chloride (52 mg,
0.237 mmol), diisoproylethylamine (0.042 mL, 0.237 mmol) and dimethylaminopyridine (~1 mg) in anhydrous tetrahydrofuran (3 mL) was stirred at ambient temperature over 16 hours under an Argon atmosphere. The reaction was evaporated in vacuo and the residue was partitioned between dichloromethane and aqueous hydrochloric acid (IN). The organic phase was separated and dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was purified on a preparative TLC plate (20x20 cm, 500 uM) eluting with 97:3 dichloromethane : methanol. The product band was removed, eluted with 4:1 methylene chloride : methanol, filtered, and evaporated in vacuo . The residue was triturated with water, filtered and dried under high vacuum to provide (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -3- [ (1, 3-benzodioxol-5-ylsulfonyl) (1- ethylpropoxy) amino] -l-benzyl-2-hydroxypropylcarbamate (114 mg, 80%) as a white solid. Hl-NMR (chloroform-D3) : 0.89 (m, 6H) , 1.57 (m, 7H) , 2.95 (m, 5H) , 3.69 (m, 2H) , 3.89 (m, 4H) , 4.15 (m, IH) , 4.82 (d, IH) , 5.01 (m, IH) , 5.64 (d, IH) , 6.10 (s, 2H) , 6.90 (d, IH) , 7.23 (m, 6H) , 7.39 (m, IH) . MS(ESI): 629 (M+Na) .
Example 163
Step 1:
Figure imgf000301_0001
(3R, 3aS , 6aR) hexahydrofuro [2 , 3-b] furan-3-yl (IS ,2R) -1-benzyl- 3-{ (1-ethylpropoxy) [ (4-nitrophenyl) sulfonyl ] amino} -2- hydroxypropylcarbamate. A mixture of
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl- 3- [ (1-ethylpropoxy) amino] -2-hydroxypropylcarbamate (200 mg, 0.474 mmol), 4-nitrophenylsulphonyl chloride (105 mg, 0.474 mmol), diisoproylethylamine (0.084 L, 0.474 mmol) and dimethylaminopyridine (~1 mg) in anhydrous tetrahydrofuran (3 mL) was stirred at ambient temperature over 16 hours under an Argon atmosphere. The reaction was evaporated in vacuo and the residue was partitioned between dichloromethane and aqueous sodium hydrogen sulfate (IN) . The phases were separated and the aqueous layer was extracted with dichloromethane. The combined organic phases were dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was purified on flash grade silica gel eluting with 1:1 ethyl acetate : hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -1-benzyl- 3- { (1-ethylpropoxy) [ (4-nitrophenyl) sulfonyl] amino}-2- hydroxypropylcarbamate (254 mg, 88%) as a foam. Hl-NMR
(chloroform-D3) : 0.90 (m, 6H) , 1.60 (m, 7H) , 2.90 (m, 5H) , 3.68 ( , 2H) , 3.87 (m, 4H) , 4.17 (m, IH) , 4.83 (d, IH) , 5.02 (m, IH) , 5.64 (d, IH) , 7.23 (m, 5H) , 7.99 (d, 2H) , 8.38 (d, 2H) . MS (ESI) : 630 (M+Na) .
Step 2:
Figure imgf000302_0001
(3R, 3aS , 6aR) hexahydrofuro [2 , 3-b] furan-3-yl (IS ,2R) -3- [ [ (4- aminophenyl) sulfonyl] (1-ethγlpropoxy) amino] -1-benzyl-2- hydroxypropylcarbamate. A solution of
(3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -1-benzyl- 3-{ (1-ethylpropoxy) [ (4-nitrophenyl) sulfonyl] amino} -2- hydroxypropylcarbamate (237 mg, 0.390 mmol) in absolute methanol (5 mL) was combined with Palladium on carbon (10 wt%, 50 mg) and reduced under a Hydrogen atmosphere over 16 hours. The reaction was filtered and evaporated in vacuo . The residue was purified on silica gel eluting with 50-60% ethyl acetate in hexane. Fractions containing the product were combined and evaporated in vacuo . The residue was triturated with water, filtered and dried under high vacuum to provide (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -3- [ [ (4-aminophenyl) sulfonyl] (1-ethylpropoxy) amino] - l-benzyl-2-hydroxypropylcarbamate (160 mg, 71%) as a white solid. Hl-NMR (chloroform-D3) : 0.90 (m, 6H) , 1.58 (m, 7H) , 2.95 (m, 5H) , 3.69 (m, 2H) , 3.91 (m, 4H) , 4.13 (m, IH) , 4.26 (b, 2H) , 4.80 (d, IH) , 5.00 (m, IH) , 5.63 (d, IH) , 6.67 (d, 2H) , 7.22 ( , 5H) , 7.58 (d, 2H) . ). MS (ESI): 600 (M+Na) .
Example 164
Step 1:
Figure imgf000303_0001
Preparation of (32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl (lS,22?)-l-benzyl-3-{ (1-ethylpropoxy) [ (3- nitrophenyl) sulfonyl] amino} -2-hydroxypropylcarbamate . A mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -l-benzyl-3- [ (1-ethylpropoxy) amino] -2- hydroxypropylcarbamate (200 mg, 0.474 mmol), 3- nitrophenylsulphonyl chloride (105 mg, 0.474 mmol), diisoproylethylamine (0.084 mL, 0.474 mmol) and dimethylammopyridme (~1 mg) in anhydrous tetrahydrofuran (3 mL) was stirred at ambient temperature over 16 hours under an Argon atmosphere. The reaction was evaporated in vacuo and the residue was partitioned between dichloromethane and aqueous hydrochloric acid (IN). After separating the phases, the aqueous layer was extracted with dichloromethane. The combined organic phases were dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was purified on flash grade silica gel eluting with 1:1 ethyl acetate : hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl ( IS, 22?) -1-benzyl- 3- { (1-ethylpropoxy) [ (3-nitrophenyl) sulfonyl] amino } -2- hydroxypropylcarbamate (246 mg, 86%) . Hl-NMR (chloroform- D3) : 0.98 ( , 6H) , 1.68 (m, 7H) , 2.99 (m, 5H) , 3.73 (m, 2H) , 3.96 (m, 4H) , 4.27 (m, IH) , 4.86 (d, IH) , 5.07 (m, IH) , 5.69 (d, IH) , 7.27 ( , 5H) , 7.84 (m, IH) , 8.16 (d, IH) , 8.57 (d, IH) , 8.76 (s, IH) . MS (ESI): 630 (M+Na) .
Step 2:
Figure imgf000304_0001
(3R,3aS,6aR) hexahydrofuro [2,3-b] furan-3-yl (1S,2R) -3- [ [ (3- aminophenyl) sulfonyl] (1-ethylpropoxy) amino] -1-benzyl-2- hydroxypropylcarbamate. A solution of
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl- 3-{ (1-ethylpropoxy) [ (3-nitrophenyl) sulfonyl] amino} -2- hydroxypropylcarbamate (239 mg, 0.394 mmol) in absolute ethanol (3 mL) was combined with Palladium on carbon (10 wt%, 25 mg) and reduced under a Hydrogen atmosphere over 16 hours. The reaction was filtered and evaporated in vacuo. The residue was purified on flash grade silica gel eluting with 3:2 ethyl acetate : hexane. Fractions containing the product were combined and evaporated in vacuo . The residue was triturated with water, filtered and dried under high vacuum to provide (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3- yl (lS,2R)-3-[ [ (3-aminophenyl) sulfonyl] (1- ethylpropoxy) amino] -l-benzyl-2-hydroxypropylcarbamate (153 mg, 67%) as a white solid. Hl-NMR (chloroform-D3) : 0.96 (m, 6H) , 1.62 (m, 7H) , 3.05 (m, 5H) , 3.76 (m, 2H) , 3.96 ( , 6H) , 4.19 (m, IH) , 4.88 (m, IH) , 5.07 (m, IH) , 5.69 (d, IH) , 6.95 (d, IH) , 7.14 (s, IH) , 7.28 (m, 7H) . MS(ESI): 600 (M+Na) .
Example 165
Figure imgf000305_0001
(3R,3aS,6aR) hexahydrofuro [2, 3-b] furan-3-γl (IS, 2R) -1-benzyl- 3-[{ [4- (benzyloxy) phenyl] sulfonyl} (1-ethylpropoxy) amino] -2- hydroxypropylcarbamate. A mixture of
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (IS, 22?) -1-benzyl- 3- [ (1-ethylpropoxy) amino] -2-hydroxypropylcarbamate (200 mg, 0.474 mmol), 4-benzyloxybenzenesulphonyl chloride (134 mg,
0.474 mmol), diisoproylethylamine (0.083 mL, 0.474 mmol) and dimethylaminopyridine (~1 mg) in anhydrous tetrahydrofuran (3 mL) was stirred at ambient temperature over 16 hours under an Argon atmosphere. The reaction mixture was warmed to 55°C and an additional quantity of dimethylaminopyridine (~2 mg) was added. After stirring for 2 hours, the reaction was evaporated in vacuo and the residue was partitioned between dichloromethane and aqueous sodium hydrogen sulfate (IN) . After separating the phases, the aqueous layer was extracted with dichloromethane. The combined organic phases were dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo . The residue was purified on flash grade silica gel eluting with 3:2 ethyl acetate : hexane. Fractions containing the product were combined, evaporated in vacuo, and dried under high vacuum to provide (3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -1-benzyl- 3- [ { [4- (benzyloxy) phenyl] sulfonyl } (1-ethylpropoxy) amino] -2- hydroxypropylcarbamate (235 mg, 74%) as a foam. Hl-NMR
(chloroform-D3) : 0.94 ( , 6H) , 1.62 (m, 7H) , 3.05 (m, 5H) , 3.74 ( , 2H) , 3.98 (m, 4H) , 4.18 (m, IH) , 4.88 (d, IH) , 5.08 ( , IH), 5.19 (s, 2H) , 5.70 (d, IH) , 7.13 (d, 2H) , 7.34 ( , 10H), 7.80 (d, 2H) . MS (ESI): 691 (M+Na) .
Example 166
Figure imgf000306_0001
(3R, 3aS , 6aR) hexahydrofuro [2 , 3-b] furan-3-yl (IS , 2R) -1-benzyl- 3-{ (1-ethylpropoxy) [ (4-hydroxyphenyl) sulfonyl ] amino} -2- hydroxypropylcarbamate. A solution of
(3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -1-benzyl- 3- [ { [4- (benzyloxy) phenyl] sulfonyl } (1-ethylpropoxy) amino] -2- hydroxypropylcarbamate (222 mg, 0.384 mmol) in 3 : 1 absolute ethanol : ethyl acetate was combined with Palladium on carbon (10 wt%, 44 mg) and reduced under an atmosphere of Hydrogen gas over 16 hours. The reaction was filtered and evaporated in vacuo . The residue was purified on flash grade silica gel eluting with 3:2 ethyl acetate : hexane. Fractions containing the product were combined and evaporated in vacuo . The residue was triturated with water, filtered and dried under high vacuum to provide
(3R, 3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (IS, 2R) -1-benzyl- 3-{ (1-ethylpropoxy) [ (4-hydroxyphenyl) sulfonyl] amino} -2- hydroxypropylcarbamate (103 mg, 46%) as a white solid. Hl- NMR (chloroform-D3) : 0.91 (m, 6H) , 1.61 (m, 7H) , 2.93 (m, 5H) , 3.70 (m, 2H) , 3.92 (m, 4H) , 4.17 (m, IH) , 4.79 (d, IH) , 5.01 ( , IH) , 5.66 (d, IH) , 6.12 (s, IH) , 6.94 (d, 2H) , 7.26
(m, 5H) , 7.72 (d, 2H) . MS (ESI): 601 (M+Na) .
Example 167
Figure imgf000307_0001
(32?, 3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- [ (1S,22?)-1- benzyl-3- ( (cyclopentyloxy) [3- ( [ (2- [methylamino] -2- oxoethylamino) carbonylamino] ethylamino) phenyl ] sulfonylamino)
-2-hydroxypropyl ] carbamate and
(3S,3a2?,6aS) hexahydrofuro [2, 3-b] furan-3-yl N- [ (1S,22?)-1- benzyl-3- ( (cyclopentyloxy) [3- ( [ (2- [methylamino] -2- oxoethylamino) carbonylamino] ethylamino) phenyl] sul onylamino)
-2-hydroxypropyl] carbamate. A solution of 30 mg (0.048 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3- b]furan-3-yl N- ( IS, 22?) -3- [ (3-[ (2- aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate and
(3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ (3- [ (2-aminoethyl) amino] phenylsulfonyl) (cyclopentyloxy) amino] - l-benzyl-2-hydroxypropylcarbamate in 2 mL of anhydrous THF was treated with 6.0 μL (0.05 mmol) of ethyl isocyanatoacetate . After stirring at RT for 2.5 hours the solution was concentrated in vacuo . The residue was dissolved in 3 L of 2M NH3/MeOH and the solution stirred at RT. After 18 hours the solution was concentrated to dryness and the residue subjected to flash chromatography (silica gel, 9:1 CH2C12/2M NH3 in MeOH) to afford 23 mg (66%) of the desired product as a white foam. 1H-NMR (CDC13) : 7.38-7.07 (10H), 6.88 (2H), 6.39 (IH), 6.16-5.88 (2H), 5.68 (IH), 5.09 (IH), 4.84 (IH), 4.17-2.59 (20H), 2.10-1.25 (10H). MS(ESI): 733 (M+H) .
Example 168
Figure imgf000308_0001
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl N- [ (IS,22?) -1- benzyl-3- ( (cyclopentyloxy) [3- (2- [methoxyamino] -2- oxoethylamino) phenyl] sulfonylamino) -2- hydroxypropyl ] carbamate and (3S,3a2?, 6aS) hexahydrofuro [2 ,3- b]furan-3-yl N- [ (IS, 22?) -l-benzyl-3- ( (cyclopentyloxy) [3- (2- [methoxyamino] -2-oxoethylamino) phenyl ] sulfonylamino) -2- hydroxypropyl ] carbamate . A solution of 0.100 g (0.174 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3- yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [(3- aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- ( (1S,22?)-1- benzyl-3- (cyclopentyloxy) [ (3-aminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (see example 31), 44 mg (0.26 mmol) of N-methoxybromoacetamide (prepared in a manner analogous to N-methoxy-N-methylbromoacetamide, example 88) , and 0.045 L (0.26 mmol) of N,N-diisopropylethylamine in 5 mL of anhydrous DMF was heated to 80°C with stirring in a sealed tube. The reaction progress was monitored by HPLC (C18, H2O/MeCΝ/0.1%TFA) . In order to push the reaction further toward completion, additional 1.5 equivalent portions of N- methoxybromoacetamide and N,N-diisopropylethylamine were added after 4 hours and 3 days. After a total reaction time of 4 days the solution was cooled to RT and concentrated in vacuo . The residue was subjected to flash chromatography (Si02, 93:7 CH2C12/2M ΝH3 in MeOH) to afford 16 mg (14%) of the desired product as a white foam. 1H-NMR (CDC13) : 7.36- 7.00 (9H), 6.85 (2H) , 5.60 (IH), 5.20-4.82 (2H) , 4.75(2H), 4.10-3.43 (10H), 3.21-2.45 (6H), 1.90-1.39 (10H). MS(ESI): 663 (M+H) .
Example 169
Figure imgf000309_0001
(32?, 3aS, 6a2?) hexahydrofuro [2 , 3-b] furan-3-yl N- [ (IS, 22?) -1- benzyl-3- ( (cyclopentyloxy) [3- (2- [dimethylamino] -2- oxoethy1amino) phenyl] sulfonylamino) -2- hydroxypropyl ] carbamate and (3S,3a2?, 6aS) hexahydrofuro [2 , 3- b]furan-3-yl N- [ (IS, 22?) -l-benzyl-3- ( (cyclopentyloxy) [3- (2- [dimethylamino] -2-oxoethylamino) phenyl ] sulfonylamino) -2- hydroxypropyl ] carbamate . A solution of 0.100 g (0.174 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3- yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate and (3S, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (3-aminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (see example 31), 32 mg (0.19 mmol) of N,N-dimethylbromoacetamide (prepared in a manner analogous to N-methoxy-N-methylbromoacetamide, example 88) , and 0.033 mL (0.19 mmol) of N,N-diisopropylethylamine in 3 mL of anhydrous DMF was heated to 80°C with stirring in a sealed tube. The reaction progress was monitored by HPLC (C18, H2O/MeCΝ/0.1%TFA) . In order to push the reaction further toward completion, additional 1.1 equivalent portions of N^N-dimethylbromoacetamide and N,N- diisopropylethylamine were added after 18 hours and 42 hours. After a total reaction time of 3 days the solution was cooled to RT and concentrated in vacuo . The residue was dissolved in EtOAc and the solution washed with aqueous brine (3x), dried over MgS04, and concentrated. The crude product was purified by flash chromatography (Si02, EtOAc) to afford 53 mg (46%) of the desired product as a light yellow foam. 1H-ΝMR (CDC13) : 7.32-7.14 (8H), 7.10 (IH), 6.93 (IH), 6.86 (IH), 5.61 (IH), 4.96 (IH), 4.91-4.77 (2H) , 3.92- 3.55 (7H), 3.23-2.77 (12H), 1.86-1.38 (10H). MS (ESI): 661 (M+H) . Example 170
Figure imgf000311_0001
(32?,3aS,6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- [ (IS,22?) -1- benzyl-3- ( (cyclopentyloxy) [3- (2- [ethyl (methyl) amino] -2- oxoethylamino)phenyl] sulfonylamino) -2- hydroxypropyl ] carbamate and (3S,3a2?, 6aS) hexahydrofuro [2 ,3- b] furan-3-yl tf- [ (IS,22?) -l-benzyl-3- ( (cyclopentyloxy) [3- (2- [ethyl (methyl) amino] -2-oxoethylamino)phenyl] sul onylamino) - 2-hydroxypropyl] carbamate. A solution of 0.100 g (0.174 mmol) of a 1:1 mixture of (32?, 3aS, 6a2?) hexahydrofuro [2, 3- b] furan-3-yl N- ( (IS, 22?) -l-benzyl-3- (cyclopentyloxy) [ (3- aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate and (3S,3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) -1- benzyl-3- (cyclopentyloxy) [ (3-aminophenyl) sulfonyl] amino-2- hydroxypropyl) carbamate (see example 31), 34 mg (0.19 mmol) of N-ethyl -N-methylacetamide (prepared in a manner analogous to N-methoxy-N-methylbromoacetamide, example 88), and 0.033 mL (0.19 mmol) of N,N-diisopropylethylamine in 3 mL of anhydrous DMF was heated to 80°C with stirring in a sealed tube. The reaction progress was monitored by HPLC (C18, H2O/MeCΝ/0.1%TFA) . In order to push the reaction further toward completion, additional 1.1 equivalent portions of N- ethyl -N-methylacetamide and N,N-diisopropylethylamine were added after 18 hours and 42 hours. After a total reaction time of 3 days the solution was cooled to RT and concentrated in vacuo . The residue was dissolved in EtOAc and the solution washed with aqueous brine (3x) , dried over MgS04, and concentrated. The crude product was purified by flash chromatography (Si02, EtOAc) to afford 61 mg (52%) of the desired product as a light yellow foam. IH-NMR (CDC13) : 7.32-7.14 (8H), 7.09 (IH), 6.91 (IH), 6.85 (IH), 5.62 (IH), 5.01-4.77 (3H), 3.95-3.53 (7H) , 3.48 (IH), 3.34 (IH), 3.23- 2.75 (9H), 1.88-1.41 (10H), 1.27-1.08 (3H). MS(ESI): 675 (M+H) .
Example 171
Figure imgf000312_0001
(3R,3aS,6aR) hexahydrofuro [2 ,3-b] furan-3-yl N-(lS,2R)-3-
[ [ (4-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -1-benzyl-2- hydroxypropyl carbamate. This material was obtained in an analogous manner to Example 77, but p-nitrobenzenesulfonyl chloride was used instead of meta nitrobenzenesulfonyl chloride.
MS: 598 (M+Na), NMR (chloroform-d) : 1.2-2.0 ( ) , 2.75-3.2 (m) , 3.6 (dd), 3.7-4.0 (m) , 4.2 (s), 4.75 (m) , 4.85 (m) , 5.0 ( ) , 5.62 (d), 6.65 (d) , 7.2-7.3 (m) , 7.55 (d) . Example 172
Figure imgf000313_0001
(3S,3aR,6aS) hexahydrofuro [2 ,3-b] furan-3-yl N-(lS,2R)-3-
[ [ (4-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropyl carbamate. This material was obtained in an analogous manner to Example 77, but p-nitrobenzenesulfonyl chloride was used instead of meta nitrobenzenesulfonyl chloride and the starting scaffold was that used in Example 39 (oposite stereochemistry at the furanylfuran ring system) .
MS: 598 (M+Na). ), NMR (chloroform-d) : 1.2-2.0 (m) , 2.75-3.2 (m) , 3.6 (dd), 3.7-4.0 (m) , 4.2 (s), 4.75 (m) , 4.95 ( ) , 5.1 (m) , 5.8 (d) , 6.65 (d) , 7.2-7.3 (m) , 7.55 (d) .
Example 173
Figure imgf000313_0002
Step 1:
(3R,3aS,6aR) hexahydrofuro [2 ,3-b] furan-3-yl N-(lS,2R)-3-
[ [ (3-cyanophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropyl carbamate. In a dried flask was introduced 1 eq. of (32?, 3aS, 6a2?) Hexahydrofuro [2,3b] furan-3-yl-N- (IS, 22?)- 1-benzyl-3- [ (cyclopentyloxy) amino] -2-hydroxypropylcarbamate (53.6 mg, 0.127 mmol) in 2 mL of dried pyridine. To this solution was added 1.2 eq. of the m-cyanophenyl sulfonyl chloride (31 mg, 0.153 mmol). This was followed by the addition of catalytic DMAP (1 mg) . The reaction was continued at room temperature for 24 h. The solvent was evaporated in vacuo to an oil who was solubilized in ethyl acetate and then washed with IN hydrochloric acid, and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified on flash grade silica gel eluting with 50% ethyl acetate in hexane. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide
(32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl-N- (IS, 22?) -1- benzyl-3- [ (cyclopentyloxy) [ (m-cyanophenyl) sulfonyl] amino-2- hydroxypropyl carbamate (31 mg, 42%) . HPLC showed the material to be 98% pure; Ret. time = 12.1 min, tic in 50% ethyl acetate/ Hexanes indicated an Rf of 0,3 and LCMS (ES+) , M+H = 586.3 (M+H) .
Figure imgf000314_0001
Step 2: (3R,3aS,6aR) hexahydrofuro [2 ,3-b] furan-3-yl N-(lS,2R)-3- [ [ (3-carbamoylphenyl) sulfonyl] (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropyl carbamate. In a flask was introduced 1 eq. (32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl-N- (IS, 22?) -1- benzyl-3- [ (cyclopentyloxy) [ (m-cyanophenyl) sulfonyl] amino-2- hydroxypropyl carbamate (28 mg, 0.048 mmol) in 1 mL acetone. To this solution was added: lurea hydroperoxide (4EQ., 18 mg, 0.19 mmol), K2C03 (0.1 EQ., 0.7 mg) , and the 1 mL H20. The reaction was continued at room temperature for 5 h. The solvent was evaporated in vacuo to an oil who was solubilized in ethyl acetate and then washed with and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to a residue. The crude material was purified on flash grade silica gel eluting with ethyl acetate. Fractions containing the product were combined, evaporated in vacuo and dried under high vacuum to provide (32?, 3aS, 6a2?) Hexahydrofuro [2, 3b] furan-3-yl- N- (IS, 22?) -l-benzyl-3- [ (cyclopentyloxy) [ (m- phenyl - carboxamide) sulfonyl] amino-2-hydroxypropyl carbamate (20.2 mg) . HPLC showed the material to be 98% pure; Ret. time = 10.68 min, tic in ethyl acetate indicated an Rf of 0.5 and LCMS (ES+), M+H = 604.3 (M+H).
Example 173
Tablet Formulation
The following formulations A, B and C are prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.
Formulation A mg/tablet
Active Ingredient 250 Lactose B.P. 210 Povidone B.P. 15 Sodium Starch Glycollate 20 Magnesium Stearate 5
500 Formulation B mg/tabl'et
Active Ingredient 250
Lactose B.P. 150
Avicel PH 101 60
Povidone B.P. 15
Sodium Starch Glycoϊlate 20
Magnesium Stearate 5
500
Formulation C mg/tablet
Active Ingredient 250 Lactose B.P. 200 Starch 50 Povidone 5 Magnesium Stearate 4
359
The following formulations, D and E, are prepared by direct compression of the admixed ingredients. The lactose in formulation E is of the direct compression type (Dairy Crest-"Zeparox") .
Formulation D mg/tablet
Active Ingredient 250 Pregelatinized Starch NF15 150
400 Formulation E mg/tablet Active Ingredient 250
Lactose B.P. 150 Avicel 100
500
Formulation F (Controlled Release Formulation)
The formulation is prepared by wet granulation of the ingredients with a solution of povidone followed by the addition of magnesium stearate and compression. mg/tablet
Active Ingredient 500 Hydroxypropylmethylcellulose 112
(Methocel K4M Premium)
Lactose B.P. 53
Povidone B.P. 28
Magnesium Stearate 7 700
Drug release takes place over a period of about 6-8 hours and is complete after 12 hours.
Example 174
Capsule Formulations Formulation A
A capsule formulation is prepared by admixing the ingredients of formulation D in Example 134 above and filling into a two-part hard gelatin capsule. Formulation B (infra) is prepared in a similar manner. Formulation B mg/capsule
Active Ingredient 250
Lactose B.P. 143 Sodium Starch Glycollate 25
Magnesium Stearate 2
420
Formulation C mg/capsule
Active Ingredient 250
Macrogel 4000 B.P. 350
600 Capsules of formulation C are prepared by melting the Macrogel 4000 B.P., dispersing the active ingredient in the melt and filling the melt into a two-part hard gelatin capsule .
Formulation D mg/capsule
Active Ingredient 250
Lecithin 100
Arachis Oil 100
450
Capsules of formulation D are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules. Formulation E mg/capsule
Active Ingredient 150.0
Vitamin E TPGS 400.0 Polyethylene Glycol 400 NF 200.5
Propylene Glycol USP 39.5
Four (4) kilograms (kg) of Vitamin E TPGS (obtained from Eastman Chemical Co.) was heated at 50°C until liquefied. To the liquified Vitamin E TPGS, 2.005 kg of polyethylene glycol 400 (PEG400) (low aldehyde, <10 ppm, obtained from Union Carbide or Dow Chemical Co.) heated to 50°C was added and mixed until a homogeneous solution was formed. The resultant solution was heated to 65°C. 1.5 kg of active ingredient was dissolved in the liquefied solution of
Vitamin E TPGS and PEG 400. 0.395 kg of propylene glycol at room temperature was added and mixed until a homogenous solution was formed. The solution was cooled to 28-35°C. The solution was then de-gassed. The mixture was preferably encapsulated at 28-35°C at a fill weight equivalent to 150 mg of volatiles-free compound, into Size 12 oblong, white opaque soft gelatin capsules using a capsule filling machine. The capsule shells were dried to a constant fill moisture of 3-6% water and a shell hardness of 7-10 newtons, and placed in a suitable container.
Formulation F (Controlled Release Capsule)
The following controlled release capsule formulation is prepared by extruding ingredients a,b, and c using an extruder, followed by spheronization of the extrudate and drying. The dried pellets are then coated with release- controlling membrane (d) and filled into a two-piece, hard gelatin capsule. mg/capsule
(a) Active Ingredient 250
(b) Microcrystalline Cellulose 125 (c) Lactose B.P. 125
(d) Ethyl Cellulose 13 513
Example 175
Injectable Formulation Formulation A
Active Ingredient 200 mg Hydro chloric Acid Solution 0.1M or
Sodium Hydroxide Solution 0.1M q.s. to pH 4.0 to 7.0 Sterile water q.s. to 10 ml
The active ingredient is dissolved in most of the water (35° - 40° C) and the pH adjusted to between 4.0 and 7.0 with the hydrochloric acid or the sodium hydroxide as appropriate. The batch is then made up to volume with water and filtered through a sterile micropore filter into a sterile 10 ml amber glass vial (type 1) and sealed with sterile closures and overseals.
Formulation B
Active Ingredient 125 mg Sterile, Pyrogen-free, pH 7 Phosphate Buffer, q.s. to 25 ml Example 176
Intramuscular Injection
Active Ingredient 200 mg Benzyl Alcohol 0.10 g
Glycofurol 75 1.45 g
Water for injection q.s. to 3.00 ml
The active ingredient is dissolved in the glycofurol. The benzyl alcohol is then added and dissolved, and water added to 3 ml . The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml amber glass vials (type 1) .
Example 177
Syrup Formulation
Active Ingredient 250 mg
Sorbitol Solution 1.50 g Glycerol 2.00 g
Sodium Benzoate 0.005 g
Flavor, Peach 17.42.3169 0.0125 ml
Purified Water q.s. to 5.00 ml
The active ingredient is dissolved in a mixture of the glycerol and most of the purified water. An aqueous solution of the sodium benzoate is then added to the solution, followed by addition of the sorbital solution and finally the flavor. The volume is made up with purified water and mixed well. Example 178
Suppository Formulation mg/capsule suppository
Active Ingredient 250 Hard Fat, B.P. (Witepsol H15-Dynamit Nobel) 1770
2020 One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200μm sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45° C, the remaining Witepsol H15 is added to the suspension and stirred to ensure a homogenous mix. The entire suspension is passed through a 250μm stainless steel screen and, with continuous stirring, is allowed to cool to 45°C. At a temperature of 38°C to 40° C, 2.02 g of the mixture is filled into suitable, 2 ml plastic molds. The suppositories are allowed to cool to room temperature.
Example 179
Pessary Formulation mg/pessary Active Ingredient 250
Anhydrate Dextrose 380 Potato Starch 363
Magnesium Stearate 7
1000
The above ingredients are mixed directly to form a pessary.
Example 180
Anti-Viral Activity
We measured the enzyme inhibition constants of the compounds listed m Table I agamst HIV-1 protease using the methods of:
Maschera, B., Darby, G., Palu, G., Wright, L. L., Tisdale, M., Myers, R., Blair, E. D. and Furfme, E. S, Human Immunodefflciency Virus: Mutations in the Viral
Protease that Confer Resistance to Saquinavir Increase the Dissociation Rate Constant for the Protease-Saqumavir Complex, J. Biol . Chem. , 271 33231-33235 (1996); and
Toth, M. V. and Marshall, G. R. (1990) Int . J. Peptide Protem Res . 36, 544-550.
Antiviral activity assay m MT4 cells
Antiviral HIV activity and compound-induced cytotoxicity were measured m parallel by means of a propidium iodide based procedure in the human T-cell lymphotropic virus transformed cell lme MT4. Aliquots of the test compounds were serially diluted m medium (RPMI 1640, 10% fetal calf serum (FCS) , and gentamycm) m 96-well plates (Costar 3598) using a Cetus Pro/Pette. Exponentially growing MT4 cells were harvested and centrifuged at 1000 rpm for 10 mm in a Jouan centrifuge (model CR 4 12) . Cell pellets were resuspended in fresh medium (RPMI 1640, 20%
FCS, 20% IL-2, and gentamycm) to a density of 5 x 105 cells/ml. Cell aliquots were infected by the addition of HIV-1 (strain IIIB) diluted to give a viral multiplicity of infection of 100 x TCID50. A similar cell aliquot was diluted with medium to provide a mock-infected control.
Cell infection was allowed to proceed for 1 hr at 37°C m a tissue culture incubator with humidified 5% CO2 atmosphere. After the 1 hr incubation the virus/cell suspensions were diluted 6-fold with fresh medium, and 125 μl of the cell suspension was added to each well of the plate containing prediluted compound. Plates were then placed m a tissue culture incubator with humidified 5% C02 for 5 days. At the end of the incubation period, 27 μl of 5% Nonidet-40 was added to each well of the incubation plate. After thorough mixing with a Costar multitip pipetter, 60 μl of the mixture was transferred to filter-bottomed 96-well plates. The plates were analyzed in an automated assay instrument (Screen Machine, Idexx Laboratories) . The assay makes use of a propidium iodide dye to estimate the DNA content of each well.
REFERENCES
1. Averett, D.R. 1989. Anti-HIV compound assessment by two novel high capacity assays. J. Viroi. Methods 23: 263-276. 2. Schwartz, 0., et al. 1988. A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res . and Human Retroviruses, 4 (6) : 441-447.
3. Daluge, S.M., et al . 1994. 5-chloro-2' 3' -deoxy- 3' fluorouridine (935U83), a selective anti-human immuno- deficiency virus agent with an improved metabolic and toxicological profile. Antimicro . Agents and Chemother. , 38 (7) :1590-1603.
The anti-viral potency of the compounds of Table 1 in MT-4 cells was determined using the above technique. The results are shown in Table 2 as IC50 values expressed in μM. In Table 2, the following classifications have been employed:
"A" Ki of less than 1 nM; "B" Ki between 1 and 10 nM; "C" Ki between 10 and 100 nM;
"D" Ki greater than 100 nM; IC50 of 0.1 μM or less; n pii IC50 between 0.1 and 0.5 μM;
" G" IC50 between 0.5 and 1.0 μM;
II ΉTT I*! IC50 greater than 1.0 μM.
The designation "NA" is used where a given compound was not tested.
The designation ">" is used where a given Ki or IC50 for a compound is greater than the range given for the designated letters.
Table 2
Ki ( enzyme) Ki ( enzyme)
[nM] IC50 [nM] IC50
Compound (MT- 4 cells) [μM] Compound" (MT- 4 cells) [μM]
1 C 19 C H H
2 C 20 B
H H
3 C 21 C H H
4 C 22 B
H H
5 B 23 B G H
6 C 24 A
H H
7 B 25 A
H G
8 A 26 B G H
9 B 27 A >E G
11 B 28 A
H F
12 >B 29 A NA E
13 C 30 A NA F
14 A 31 A F E
15 B 32 A H E
16 C 33 A H E
17 C 34 A
H F
18 B 35 A >G >G 36 A 55 A
E E 37 A 56 A E F 38 A 57 A E E 39 A , 58 A F F 40 A 59 A E E 41 A 60 A E F 42 A 61 B NA G 43 A 62 B NA H 44 A 63 B E NA 45 A 64 A
E H 46 A 65 A E F 47 A 66 A G E 48 A 67 A
F F 49 A 68 A
E E 50 A 69 A
E F 51 A 70 A
F >F 52 A 71 A
E E 53 A 72 B
E G 54 A 73 A
E E 74 A 100 C E F 75 A 103 A
>F E 76 A 104 A
F E 77 A , 105 A E E 78 A 106 A
E F 79 A 107 A
F NA 83 A 108 C
F >F 84 A 109 C NA >E 85 A 110 A NA F 86 A 111 B E H
A 112 B E H
A 113 A E E
89 A NA 114 A E 90 A E 115 D G 91 A NA 116 D G 92 A NA 117 D 97 A G
E
118 D 98 A G NA
119 D
99 A H NA 120 NA 137 A NA E
121 A 138 A
F E
122 A 139 A E E
123 A 140 A E E
124 A 141 A
E H
125 A 142 A
E F
126 D 143 A H E
127 A 144 A E E
128 D 145 A H E
129 NA 146 A NA E
130 A 147 A E E
131 A 148 A E E
132 A 149 A E E
133 A 150 A
F E
134 A 151 A
E E
135 B 152 C
E G
136 A 153 A
E E 154 A 164 A E E
155 A 165 NA
E NA
156 A 166 A
E E
157 NA 167 A NA F
158 NA 168 A NA E
159 A 169 A
E E
160 A 170 A
E E
161 B 171 A H E
162 A 172 A E E
163 A 173 A E E
As demonstrated above, all of the compounds tested displayed inhibitory and anti-viral activity. Moreover, several of these compounds exhibited activity levels far greater than those of known HIV protease inhibitors. While we have described a number of embodiments of this invention, it is apparent that our basic constructions may be altered to provide other embodiments which utilize the products, processes and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims, rather than by the specific embodiments which have been presented by way of example.

Claims

Claims
We claim:
1. A compound of formula (i:
Figure imgf000331_0001
wherein:
A is selected from H; Ht; -Rx-Ht;
Figure imgf000331_0002
alkyl, which is optionally substituted with one or more groups independently selected from hydroxy, Cι-C4 alkoxy, Ht, -0- Ht, -NR2-CO-N(R2)2 or -CO-N(R2)2; -R^C∑-Ce alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, Ci-C4 alkoxy, Ht, -O-Ht, -NR2-CO- N(R2)2 or -CO-N(R2)2; or R7; each R1 is independently selected from -C(O)-, -S(0)2-, -C(0)-C(0)-, -O-C(O)-, -0-S(0)2, -NR2-S(0)2-, -NR2- C(O)- or -NR2-C(0)-C(0)-; each Ht is independently selected from C3-C7 cycloalkyl; C5-C cycloalkenyl; C6-Cι0 aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R2), 0, S and S(0)n; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR2, SR2, -R2, -N(R2) (R2), -R2-OH, -CN, -C02R2, -C(0)-N(R2)2, -S(0)2-N(R2)2, -N (R2) -C (0) -R2, -C(0)-R2, -S(0)n-R2, -OCF3, -S(0)n-Q, methylenedioxy, -N (R2) -S (0) 2 (R2) , halo, -CF3, -N02, Q, -0Q, -OR7, -SR7, -R7, -N(R2) (R7) or -N(R7)2; each R** is independently selected from H, Ht or
Cι-C6 alkyl optionally substituted with Q or R10;
B, when present, is -N (R2) -C (R3) 2-C (0) -; each x is independently 0 or 1; each R3 is independently selected from H, Ht, Cι-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl or C5-C6 cycloalkenyl; wherein any member of said R3, except H, is optionally substituted with one or more substituents selected from -OR2, -C(0)-NH-R2, -S (0)n-N(R2) (R2) , Ht, -CN, -SR2, -C02R2, NR2-C(0)-R2; each n is independently 1 or 2;
G, when present, is selected from H, R7 or Cι~C alkyl, or, when G is Cι~C alkyl, G and R7 are bound to one another either directly or through a Cι-C3 linker to form a heterocyclic ring; or when G is not present, the nitrogen to which G is attached is bound directly to the R7 group in -OR7 with the concomitant displacement of one -ZM group from R7;
D is selected from Q; Cι-C6 alkyl or C2-C4 alkenyl, which is optionally substituted with one or more groups selected from C3-C6 cycloalkyl, -OR2, -S-Ht, -R3, -O-Q or Q; C3-C6 cycloalkyl or C5-C6 cycloalkenyl, which is optionally substituted with or fused to Q; each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from 0, N, S, S(0)r. or N(R^); wherein Q is optionally substituted with one or more groups selected from oxo, -OR2, -R2, -N(R2)2, -N(R2)- C(0)-R2, -R2-OH, -CN, -C02R2, -C (0) -N (R2) 2, halo or -CF3;
D' is selected from -OR10, -N=R10 or -N (R10) -RX-R3;
E is selected from Ht; O-Ht; Ht-Ht; -O-R3; -N(R2) (R3) ; Cι-C6 alkyl, which is optionally substituted with one or more groups selected from R4 or Ht; C2-C6 alkenyl, which is optionally substituted with one or more groups selected from R4 or Ht; C3-C6 saturated carbocycle, which is optionally substituted with one or more groups selected from R4 or Ht; or C5-C6 unsaturated carbocycle, which is optionally substituted with one or more groups selected from R4 or Ht; each R4 is independently selected from -OR", -SR2, -C(0)-NHR2, -S(0)2-NHR2, halo, -NR2-C (0) -R2, -N(R2)2 or -CN; each Rn is independently selected from hydrogen,
Figure imgf000333_0001
wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, -N(R2)4, Cι-Cι2-alkyl, C2-C12- alkenyl, or -R6; wherein 1 to 4 -CH2 radicals of the alkyl or alkenyl group, other than the -CH2 that is bound to Z, is optionally replaced by a heteroatom group selected from 0, S, S (0) , S(02), or N(R2); and wherein any hydrogen in said alkyl, alkenyl or R6 is optionally replaced with a substituent selected from oxo, -OR2, -R2, N(R2)2, N(R2)3, ROH, -CN, -C02R2, -C (0) -N (R2) 2, S (0) 2-N (R2) 2, N (R2) -C (0) -R2, C(0)R, -S(0)r-R2, 0CF3, -S(0)n-R6, N(R2)-S(0)2(R2) , halo, -CF3, or -N02;
M' is H, Cι-Cι2-alkyl, C2-Cι2-alkenyl, or -R6; wherein 1 to 4 -CH2 radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from 0, S, S(0), S(02), or N(R2); and wherein any hydrogen in said alkyl, alkenyl or R6 is optionally replaced with a substituent selected from oxo, -OR2, -R2, -N(R2)2, N(R2)3, -R20H, -CN, -C02R2, -C(0)-N(R2)2, -S (0) 2-N (R2) 2, -N(R2)-C(0)-R2, -C(0)R2, -S(0)p-R2, -0CF3, -S(0)n-R6, -N(R2)-S (0)2(R2) , halo, -CF3, or -N02;
Z is 0, S, N(R2)2, or, when M is not present, H.
Y is P or S; X is 0 or S;
R9 is C(R2)2, 0 or N(R2); and wherein when Y is S, Z is not S;
R6 is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from 0, N, S, S(0)n or N(R2); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH, Cι-C4 alkyl, 0-Cι-C4 alkyl or 0-C(0)-Cι-C4 alkyl; p
R is selected from Ci-C8 alkyl, C3-C7 alkyl or cyano substituted C2-C6 alkenyl; and
R is selected from C:-C8 alkyl, C2_C6 alkenyl, C6-Cι aryl or Ht, wherein R10 optionally contains up to three substituents independently selected from -R3, -CN, -SR5, -SOR5, -S02R5, -SR-NR5-C(0)R5, -NR5- (S02) R5, -C(0)N(R5)2, -C(S)N(R5)2, -S(0)2N(R5)2, -C(0)R6, -C(S)R6, -N(R5)2, -NR5- C(0)R5, -NR5-C(0)0R5, -NR5-C(0)N(R)2, -NR5-C(S)R5, -NR5- C(S)0R5, -NR5-C(S)N(R5)2, -NR5-C [=N (R5) ] -N (R5) 2, -NH-C [=N-N02] - NH2, -NH-C[=N-N02]-OR5, -N (R8) 2-C (0) R8, -NH-C [=N-N02] -NH2, -NH- C[=N-N02]-OR5, -N(R8)2-C(0)R8, -0C(0)R6, -OC (0) N (R5) 2, -OC (S) N (R5) 2, wherein any one of the -CH2 groups of said alkyl or alkenyl chains of R10 may be optionally replaced by O, S, SO, S02, C(0) or NR5; wherein each R5 is independently selected from hydrogen, Cι-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or Ht, wherein each R5, except for hydrogen, is optionally substituted with -CF3, -P03R3, azido or halo; or a pharmaceutically acceptable derivative thereof.
2. The compound according to claim 1, wherein at least one R' is selected from:
Figure imgf000335_0001
O
.NH2
-P03(NH <U 2, -CH2-OP03Na2, H ' - (L) -serine,
-SO.Na2 N •N e2, -Sθ3 g, -S03(NH4)2, Me
-CH:-OS03Na2, -CH2-OS03(NH4)2, V
Figure imgf000335_0002
Figure imgf000335_0003
, _ (L) _valine
Figure imgf000335_0004
- (L) -glutamic acid, - (L) -aspartic acid,
- (L) -γ-t-butyl-aspartic acid, ^ c)-■«■ r--°»/> '
- (L) - (L) -3-pyridylalanine, - (L) -histidine, -CHO, ^""CF
Figure imgf000336_0001
O
II o
/ ,NMe3 +
*Ό'PYΌ- "Ό* o. o. P o. P03K2, P03Ca, P03-spermine, P03- (spermidine) 2 or P03- (meglamine) 2 •
A compound of formula (Ii:
Figure imgf000336_0002
wherein A, R , D' and E are as defined in claim 1; or a pharmaceutically acceptable derivative thereof,
A compound of formula (Hi:
Figure imgf000336_0003
wherein Ht, x, R 3, R7, D' and E are as defined in claim 1; or a pharmaceutically acceptable derivative thereof.
5. A compound of formula (IV) :
Figure imgf000337_0001
wherein A, R 3, R7, D' and E are as defined in claim 1; or a pharmaceutically acceptable derivative thereof.
6. The compound according to claim 3, wherein: A is -C(0)Ht;
D' is -O-R10; E is C6-Cιo aryl optionally substituted with one or more substituents selected from oxo, -OR2, SR2, -R2, -N(R2)2, -R2-OH, -CN, -C02R2, -C(O) -N(R2)2, -S (0) 2-N (R2) 2, -N(R2)-C(0)- R2, -C(0)-R2, -S(0)n-R2, -OCF3, -S(0)n-Q, methylenedioxy, -N(R2)-S (0)2(R2) , halo, -CF3, -N02, Q, -0Q, -OR7, -SR7, -R7, -N(R-) (R') or -N(R7)2; or a 5-membered heterocyclic ring containing one S and optionally containing N as an additional heteroatom, wherein said heterocyclic ring is optionally substituted with one to two groups independently selected from -CH3, R4, or Ht.
7. The compound according to claim 3, wherein: E is a 5-membered heterocyclic ring containing one S and optionally containing N as an additional heteroatom, wherein said heterocyclic ring is optionally substituted with one to two groups independently selected from -CH3, R4, or Ht.
8. The compound according to claim 3, wherein: R7 in -OR7 group shown in formula II is -PO(OM)2 or C(0)CH2OCH2CH2OCH2CH2OCH3 and both R7 in -N(R7)2 are H; or R7 in -OR7 group shown in formula II is C (0) CH2OCH2CH2OCH3, one R7 in -N(R7)2 is C (0) CH2OCH2CH2OCH3 and the other is H; and wherein M is H, Li, Na, K or Cι~C4 alkyl.
A compound according to claim 1, having formula (V)
Figure imgf000338_0001
wherein A, R 7, R10 and E are as defined in claim 1 ; or a pharmaceutically acceptable derivative thereof.
10. A compound of formula (VI) :
Figure imgf000338_0002
wherein;
R ° and R are as defined in claim 1; E is C6-Cι4 aryl, optionally substituted with one or more groups selected from the group consisting of nitro, oxo, alkoxy, amino, hydroxyamino; heterocyclcyl, optionally substituted with one or more groups selected from the group consisting of nitro, oxo, alkoxy, amino, hydroxyamino or N(CO)OCH3; or a pharmaceutically acceptable derivative thereof.
11. A compound of formula (VII) :
Figure imgf000339_0001
wherein A, E, R and R10 are as defined in claim, 1; or a pharmaceutically acceptable derivative thereof.
12. A compound of formula (VIII)
Figure imgf000339_0002
wherein A, R1, R3, R7 and E are as defined in claim 1; or a pharmaceutically acceptable salt thereof 13. A compound selected from:
Figure imgf000340_0001
Figure imgf000340_0002
Figure imgf000341_0001
wherein R is selected from isopropyl or cyclopentyl; R is selected from NHR7 or OR7; x, R7 and G are as defined in claim 1; and X" is a pharmaceutically acceptable counterion.
14. A compound selected from: (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) l-benzyl-3- (cyclopentyloxy) [ (3- [2- (dimethylamino) ethyl] aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate;
(35, 3a2?, 6aS) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?) l-benzyl-3- (cyclopentyloxy) [ (3- [2- (dimethylamino) ethyl] aminophenyl) sulfonyl] amino-2-hydroxypropyl) carbamate; (32?, 3aS, 6a2?) Hexahydrofuro [2, 3-b] furan-3-yl-N- ( (IS, 22?)- 1-benzyl-3- (cyclopentyloxy) (2- [ (methylsulfonyl) amino] benzimidazol-5-ylsulfonyl) amino-2-hydroxypropyl) carbamate;
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ [ (3-Ν-methylaminophenyl) sulfonyl] (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate;
1, 3-Dioxan-5-yl Ν- (IS, 2R) -l-benzyl-3- [ (cyclopentyloxy) (2-{ (methoxycarbonyl) amino] -lH-benzimidazol-5-ylsulfonyl) amino] -2-hydroxypropylcarbamate; (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -1- benzyl-2-hydroxy-3- [ [ (4-methoxyphenyl) sulfonyl] (tetrahydro- 22f-pyran-4-yloxy) amino] propylcarbamate ;
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ [ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate;
( 3R, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- [ (IS, 22?)- 1-benzyl-3- ( (cyclopentyloxy) [3- (2- [methoxy (methyl) amino] -2- oxoethylamino) phenyl] sulfonylamino) -2-hydroxypropyl] carbamate; (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- [ ( 1S, 22?)- l-benzyl-4- (cyclopentyloxy) -2-hydroxy-4- (6-quinoxalinyl sulfonyl) butyl] carbamate;
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- ( (IS, 22?)- 1-benzyl-3- (cyclopentyloxy) [ (4-methoxyphenyl) sulfonyl] amino- 2-hydroxypropyl) carbamate;
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- [ (IS, 22?)- l-benzyl-3- ( (cyclopentyloxy) [3- (2- [ (methylsulfonyl) amino] ethylamino) phenyl] sulfonylamino) -2-hydroxypropyl] carbamate;
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [[ (3-Ν-methylaminophenyl) sulfonyl] (cyclopentyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate, phosphate ester;
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 22?) -3- [ [ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -l-benzyl-2- hydroxypropylcarbamate phosphate ester; (3R, 3aS,6aR) hexahydrofuro [2, 3-b] furan-3-yl N- (IS, 2R) - 3- [ [ (4-aminophenyl) sulfonyl] (cyclopentyloxy) amino] -1-benzyl- 2-hydroxypropyl carbamate;
(3R,3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (1S,2R)-1- benzyl-3- { (1-ethylpropoxy) [ (4-hydroxyphenyl) sulfonyl] amino }- 2-hydroxypropylcarbamate;
(3R,3aS, 6aR) hexahydrofuro [2, 3-b] furan-3-yl (lS,2R)-3- [ (1, 3-benzodioxol-5-ylsulfonyl) (1-ethylpropoxy) amino] -1- benzyl-2-hydroxypropylcarbamate; (32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- [ ( 1S, 22?)- 3- [ (1, 3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2- (phosphonooxy) propyl] carbamate;
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl (lS,2R)-3- [ (1, 3-benzodioxol-5-ylsulfonyl) (cyclohexyloxy) amino] -1- benzyl-2-hydroxypropylcarbamate;
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl 3- [(1,3- benzodioxol-5-ylsulfonyl) (tetrahydro-2H-pyran-4- yloxy) amino] -l-benzyl-2-hydroxypropylcarbamate;
(32?, 3aS, 6a2?) hexahydrofuro [2, 3-b] furan-3-yl N- [ (IS, 22?)- 3- [ (1, 3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino] -1- benzyl-2- (phosphonooxy) propyl] carbamate; or a pharmaceutically acceptable derivative thereof.
15. The compound according to claim 1 wherein said compound has a molecular weight less than or equal to about 700 g/mol.
16. The compound according to claim 15 wherein said compound has a molecular weight less than or equal to about 600 g/mol.
17. A pharmaceutical composition comprising an effective antiviral amount of a compound according to any one of claims 1-14 or a pharmaceutically acceptable derivative thereof together with a pharmaceutically acceptable carrier therefore.
18. The pharmaceutical composition according to claim 17, further comprising an antiviral agent other than a compound according to claims 1-14.
19. A pharmaceutical composition according to claim 17 or 18 in the form of a tablet or capsule.
20. A method of treating a virus infection in a human comprising administering to said human an effective antiviral treatment amount of a compound according to any one of claims 1-13 or a pharmaceutically acceptable derivative thereof.
21. The method according to claim 20 wherein the virus infection is an HIV infection.
22. The method according to claim 20 or 21 wherein said step of administering comprises oral administration or administration by injection.
23. Use of a compound according to any of claims 1-14 for the manufacture of a medicament for the treatment or prophylaxis of a viral infection.
24. Use of a compound according to any of claims 1-14 or a formulation according to claim 17 for use in medical therapy.
PCT/US1999/013744 1998-06-19 1999-06-17 Sulfonamide inhibitors of aspartyl protease WO1999065870A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DK99928769T DK1086076T3 (en) 1998-06-19 1999-06-17 Sulfonamide inhibitors of aspartyl protease
BR9912169-7A BR9912169A (en) 1998-06-19 1999-06-17 Aspartyl protease sulfonamide inhibitors
APAP/P/2000/002023A AP1717A (en) 1998-06-19 1999-06-17 Sulfonamide inhibitors of aspartyl protease.
CA2335477A CA2335477C (en) 1998-06-19 1999-06-17 Sulfonamide inhibitors of aspartyl protease
DE69922807T DE69922807T2 (en) 1998-06-19 1999-06-17 SULPHONAMIDES AS ASPARTYL PROTEASE INHIBITORS
AU45760/99A AU767728B2 (en) 1998-06-19 1999-06-17 Sulfonamide inhibitors of aspartyl protease
NZ508855A NZ508855A (en) 1998-06-19 1999-06-17 Sulfonamide inhibitors of HIV aspartyl protease
EP99928769A EP1086076B1 (en) 1998-06-19 1999-06-17 Sulfonamide inhibitors of aspartyl protease
AT99928769T ATE285396T1 (en) 1998-06-19 1999-06-17 SULFONAMIDES AS ASPARTYL PROTEASE INHIBITORS
US09/731,129 US6613743B2 (en) 1998-06-19 2000-12-06 Sulfonamide inhibitors of aspartyl protease
NO20006405A NO20006405L (en) 1998-06-19 2000-12-15 Sulfonamide Inhibitors for Aspartyl Protease
HK01106764A HK1037605A1 (en) 1998-06-19 2001-09-25 Sulfonamide inhibitors of aspartyl protease.
US10/600,937 US20040097594A1 (en) 1998-06-19 2003-06-20 Sulfonamide inhibitors of aspartyl protease
AU2004200636A AU2004200636A1 (en) 1998-06-19 2004-02-19 Sulfonamide Inhibitors of Aspartyl Protease
US11/212,045 US7419967B2 (en) 1998-06-19 2005-08-25 Sulfonamide inhibitors of aspartyl protease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9009498P 1998-06-19 1998-06-19
US60/090,094 1998-06-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/731,129 Continuation US6613743B2 (en) 1998-06-19 2000-12-06 Sulfonamide inhibitors of aspartyl protease

Publications (2)

Publication Number Publication Date
WO1999065870A2 true WO1999065870A2 (en) 1999-12-23
WO1999065870A3 WO1999065870A3 (en) 2001-03-15

Family

ID=22221312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013744 WO1999065870A2 (en) 1998-06-19 1999-06-17 Sulfonamide inhibitors of aspartyl protease

Country Status (16)

Country Link
US (3) US6613743B2 (en)
EP (1) EP1086076B1 (en)
AP (1) AP1717A (en)
AT (1) ATE285396T1 (en)
AU (2) AU767728B2 (en)
BR (1) BR9912169A (en)
CA (1) CA2335477C (en)
DE (1) DE69922807T2 (en)
DK (1) DK1086076T3 (en)
ES (1) ES2235492T3 (en)
HK (1) HK1037605A1 (en)
NO (1) NO20006405L (en)
NZ (2) NZ508855A (en)
OA (1) OA11573A (en)
PT (1) PT1086076E (en)
WO (1) WO1999065870A2 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002506A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002083657A2 (en) * 2001-02-14 2002-10-24 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
WO2003076413A1 (en) * 2002-03-12 2003-09-18 Tibotec Pharmaceuticals Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
WO2003078438A1 (en) * 2002-03-12 2003-09-25 The Board Of Trustees Of The University Of Illinois Carbamates as hiv protease inhibitors
WO2004016619A1 (en) * 2002-08-14 2004-02-26 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
JP2005513102A (en) * 2001-12-21 2005-05-12 テイボテク・フアーマシユーチカルズ・リミテツド Heterocyclic substituted phenyl-containing sulfonamides are broad spectrum HIV protease inhibitors
EP1732891A1 (en) * 2004-03-11 2006-12-20 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
JP2007521277A (en) * 2003-06-27 2007-08-02 スミスクライン ビーチャム コーポレーション Compound production
JP2007536271A (en) * 2004-05-07 2007-12-13 セコイア、ファーマシューティカルズ、インコーポレイテッド Antiviral resistance retroviral protease inhibitors
JP2008543849A (en) * 2005-06-14 2008-12-04 シェーリング コーポレイション Aspartyl protease inhibitor
US7470506B1 (en) 1998-06-23 2008-12-30 The United States Of America As Represented By The Department Of Health And Human Services Fitness assay and associated methods
JP2009517370A (en) * 2005-11-28 2009-04-30 テイボテク・フアーマシユーチカルズ・リミテツド Aminophenylsulfonamide derivatives as HIV protease inhibitors
JP2009517371A (en) * 2005-11-28 2009-04-30 テイボテク・フアーマシユーチカルズ・リミテツド Substituted aminophenylsulfonamide compounds as HIV protease inhibitors
US7595408B2 (en) 2004-03-31 2009-09-29 Tibotec Pharmaceuticals, Ltd. Methods for the preparation of (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-ol
JP2009538876A (en) * 2006-05-30 2009-11-12 テイボテク・フアーマシユーチカルズ・リミテツド Lysine related derivatives as HIV aspartyl protease inhibitors
WO2010047819A1 (en) * 2008-10-24 2010-04-29 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
US8076513B2 (en) 2007-04-27 2011-12-13 Tibotec Pharmaceuticals Ltd. Methods for the preparation of N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide derivatives
US8153829B2 (en) 2006-11-09 2012-04-10 Janssen Pharmaceutica N.V. Methods for the preparation of hexahydrofuro[2,3-B]furan-3-ol
US8455497B2 (en) * 1999-06-11 2013-06-04 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1472536A4 (en) * 2002-01-07 2007-02-14 Sequoia Pharmaceuticals Broad spectrum inhibitors
US9403789B2 (en) * 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
EP2381786B1 (en) * 2009-01-29 2014-12-24 Mapi Pharma Limited Dimethylsulfoxide solvate of darunavir
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
CA2784398A1 (en) 2010-01-28 2011-08-04 Mapi Pharma Limited Process for the preparation of darunavir and darunavir intermediates
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2016069955A1 (en) * 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005639A1 (en) * 1992-09-08 1994-03-17 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of hiv-aspartyl protease
WO1996033187A1 (en) * 1995-04-19 1996-10-24 Vertex Pharmaceuticals Incorporated Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
WO1996033184A1 (en) * 1995-04-19 1996-10-24 Vertex Pharmaceuticals Incorporated Thf-containing sulfonamide inhibitors of aspartyl protease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (en) 1979-06-14 1981-01-09 Sanofi Sa NOVEL SULFONYL-ANILINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
JPS5946252A (en) 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc Fluorine-containing aminocarboxylate and its preparation
JPS5948449A (en) 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc Straight-chain fluorine-containing anionic compound and its preparation
JPS6171830A (en) 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc Cationic surfactant
US4616088A (en) 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (en) 1986-10-22 1988-04-28 Merck Patent Gmbh HYDROXY AMINO ACID DERIVATIVES
NL8800100A (en) 1987-01-21 1988-08-16 Sandoz Ag NEW PEPTIDE DERIVATIVES AND METHODS FOR PREPARING AND USING THESE DERIVATIVES.
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab Renin inhibiting hexanoic acid amide derivatives, process for their preparation and pharmaceutical compositions containing them
WO1990007330A1 (en) 1989-01-06 1990-07-12 The Regents Of The University Of California Selection method for specific useful pharmaceutical compounds
US5151438A (en) 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2032259A1 (en) 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
JPH07502970A (en) 1990-06-01 1995-03-30 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 1,4-diamino-2,3-dihydroxybutanes
TW225540B (en) 1990-06-28 1994-06-21 Shionogi & Co
US5475013A (en) 1990-11-19 1995-12-12 Monsanto Company Retroviral protease inhibitors
CA2096407C (en) 1990-11-19 2007-10-02 Kathryn Lea Reed Retroviral protease inhibitors
AU9053191A (en) 1990-11-19 1992-06-11 Monsanto Company Retroviral protease inhibitors
ATE196759T1 (en) 1990-11-19 2000-10-15 Monsanto Co INHIBITORS OF RETROVIRAL PROTEASES
ES2059289T3 (en) 1990-11-19 1997-10-16 Monsanto Co RETROVIRAL PROTEASE INHIBITORS.
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
IL103613A (en) 1991-11-08 1999-05-09 Merck & Co Inc Hiv protease inhibitors process and intermediats for their preparation and pharmaceutical compositions containing them
AU676479B2 (en) 1992-05-20 1997-03-13 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
EP1447398A1 (en) 1992-05-21 2004-08-18 Monsanto Company Retroviral protease inhibitors
PT810209E (en) 1992-08-25 2002-09-30 Searle & Co HYDROXYETHYLAMINO-SULFONAMIDES OF ALPHA- AND BETA-AMINOACIDOS UTEIS AS INHIBITORS OF RETROVIRAL PROTEASE
JP4091654B2 (en) 1992-08-25 2008-05-28 ジー．ディー．サール、リミテッド、ライアビリティ、カンパニー Sulfonylalkanoylaminohydroxyethylaminosulfonamides useful as retroviral protease inhibitors
ES2103488T3 (en) 1992-08-25 1997-09-16 Searle & Co N- (ALCANOYLAMINO-2-HYDROXYPROPIL) SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS.
WO1995006030A1 (en) 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
TW372972B (en) 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
EP0885880A3 (en) 1992-10-30 1999-10-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors
ATE211462T1 (en) 1992-10-30 2002-01-15 Searle & Co N-SUBSTITUTED HYDROXYETHYLAMINOSULFAMIC ACID DERIVATIVES USABLE AS INHIBITORS OF RETROVIRAL PROTEASES
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU6135294A (en) 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
TW281669B (en) 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
IL110898A0 (en) 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
IL111584A0 (en) 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AR031520A1 (en) * 1999-06-11 2003-09-24 Vertex Pharma AN INHIBITOR COMPOSITE OF ASPARTILO PROTEASA, A COMPOSITION THAT INCLUDES IT AND A METHOD TO TREAT A PATIENT WITH SUCH COMPOSITION

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005639A1 (en) * 1992-09-08 1994-03-17 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of hiv-aspartyl protease
WO1996033187A1 (en) * 1995-04-19 1996-10-24 Vertex Pharmaceuticals Incorporated Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
WO1996033184A1 (en) * 1995-04-19 1996-10-24 Vertex Pharmaceuticals Incorporated Thf-containing sulfonamide inhibitors of aspartyl protease

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470506B1 (en) 1998-06-23 2008-12-30 The United States Of America As Represented By The Department Of Health And Human Services Fitness assay and associated methods
US9889115B2 (en) 1998-06-23 2018-02-13 Board Of Trustees Of The University Of Illinois Fitness assay and associated methods
US8597876B2 (en) 1998-06-23 2013-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating HIV infection
US8455497B2 (en) * 1999-06-11 2013-06-04 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
WO2002002506A3 (en) * 2000-06-30 2002-08-29 Elan Pharm Inc Compounds to treat alzheimer's disease
US7034182B2 (en) * 2000-06-30 2006-04-25 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
WO2002002506A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
JP2004502665A (en) * 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド Compounds treating Alzheimer's disease
JP2004518767A (en) * 2001-02-14 2004-06-24 テイボテク・フアーマシユーチカルズ・リミテツド Broad spectrum 2- (substituted-amino) -benzothiazolesulfonamide HIV protease inhibitors
KR100870184B1 (en) 2001-02-14 2008-11-24 티보텍 파마슈티칼즈 리미티드 Broadspectrum 2-substituted-amino-benzothiazole sulfonamide HIV protease inhibitors
HRP20030735B1 (en) * 2001-02-14 2012-02-29 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
AP1504A (en) * 2001-02-14 2005-12-10 Tibotec Pharm Ltd Broadspectrum 2- (substituted-amino) -benzothiazole sulfonamide HIV protease inhibitors
CZ304273B6 (en) * 2001-02-14 2014-02-12 Tibotec Pharmaceuticals Ltd. 2-(Substituted-amino)-benzothiazole sulfonamide compound, process for its preparation and pharmaceutical composition containing thereof
WO2002083657A3 (en) * 2001-02-14 2003-02-13 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
CN101230067B (en) * 2001-02-14 2011-06-15 泰博特克药品有限公司 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
US7659404B2 (en) 2001-02-14 2010-02-09 Tibotec Pharmaceuticals Ltd. Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
WO2002083657A2 (en) * 2001-02-14 2002-10-24 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
JP2005513102A (en) * 2001-12-21 2005-05-12 テイボテク・フアーマシユーチカルズ・リミテツド Heterocyclic substituted phenyl-containing sulfonamides are broad spectrum HIV protease inhibitors
JP4808380B2 (en) * 2002-03-12 2011-11-02 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ Carbamate esters as HIV protease inhibitors
US8143421B2 (en) 2002-03-12 2012-03-27 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted benzimidazole sulfonamide HIV protease inhibitors
WO2003076413A1 (en) * 2002-03-12 2003-09-18 Tibotec Pharmaceuticals Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
WO2003078438A1 (en) * 2002-03-12 2003-09-25 The Board Of Trustees Of The University Of Illinois Carbamates as hiv protease inhibitors
KR101302421B1 (en) * 2002-03-12 2013-09-02 얀센 알 앤드 디 아일랜드 Broadspectrum substituted benzimidazole sulfonamide ＨＩＶ protease inhibitors
JP2005519952A (en) * 2002-03-12 2005-07-07 テイボテク・フアーマシユーチカルズ・リミテツド Broadly substituted benzimidazole sulfonamide HIV protease inhibitors
HRP20040936B1 (en) * 2002-03-12 2012-09-30 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
JP2006504621A (en) * 2002-03-12 2006-02-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ Carbamate esters as HIV protease inhibitors
US7897635B2 (en) 2002-03-12 2011-03-01 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
EA011946B1 (en) * 2002-03-12 2009-06-30 Тиботек Фармасьютикалз Лтд. Broad spectrum substituted benzimidazole sulfonamide hiv protease inhibitors
AP2111A (en) * 2002-03-12 2010-03-03 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide HIV protease inhibitors.
AU2003219159B2 (en) * 2002-03-12 2009-09-03 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted benzimidazole sulfonamide HIV protease inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
JP2005537305A (en) * 2002-08-14 2005-12-08 テイボテク・フアーマシユーチカルズ・リミテツド Broad spectrum substituted oxindolesulfonamide HIV protease inhibitors
EA010486B1 (en) * 2002-08-14 2008-10-30 Тиботек Фармасьютикалз Лтд. Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
AU2003262574B2 (en) * 2002-08-14 2009-07-09 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
HRP20050606B1 (en) * 2002-08-14 2014-04-25 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
AP2126A (en) * 2002-08-14 2010-06-03 Tibotec Pharm Ltd Broadspectrum substituted oxindole sulfonamide HIVprotease inhibitors
WO2004016619A1 (en) * 2002-08-14 2004-02-26 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
US7199148B2 (en) 2002-08-14 2007-04-03 Tibotec Pharmaceuticals Ltd Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
JP2007521277A (en) * 2003-06-27 2007-08-02 スミスクライン ビーチャム コーポレーション Compound production
US7807845B2 (en) 2004-03-11 2010-10-05 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
EP1732891A4 (en) * 2004-03-11 2009-05-06 Sequoia Pharmaceuticals Inc Resistance-repellent retroviral protease inhibitors
EP1732891A1 (en) * 2004-03-11 2006-12-20 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
US7595408B2 (en) 2004-03-31 2009-09-29 Tibotec Pharmaceuticals, Ltd. Methods for the preparation of (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-ol
JP2007536271A (en) * 2004-05-07 2007-12-13 セコイア、ファーマシューティカルズ、インコーポレイテッド Antiviral resistance retroviral protease inhibitors
JP2008543849A (en) * 2005-06-14 2008-12-04 シェーリング コーポレイション Aspartyl protease inhibitor
JP2009517370A (en) * 2005-11-28 2009-04-30 テイボテク・フアーマシユーチカルズ・リミテツド Aminophenylsulfonamide derivatives as HIV protease inhibitors
JP2009517371A (en) * 2005-11-28 2009-04-30 テイボテク・フアーマシユーチカルズ・リミテツド Substituted aminophenylsulfonamide compounds as HIV protease inhibitors
JP2009538876A (en) * 2006-05-30 2009-11-12 テイボテク・フアーマシユーチカルズ・リミテツド Lysine related derivatives as HIV aspartyl protease inhibitors
US8153829B2 (en) 2006-11-09 2012-04-10 Janssen Pharmaceutica N.V. Methods for the preparation of hexahydrofuro[2,3-B]furan-3-ol
US8076513B2 (en) 2007-04-27 2011-12-13 Tibotec Pharmaceuticals Ltd. Methods for the preparation of N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide derivatives
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
WO2010047819A1 (en) * 2008-10-24 2010-04-29 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors

Also Published As

Publication number Publication date
ES2235492T3 (en) 2005-07-01
AU2004200636A1 (en) 2004-03-11
US20040097594A1 (en) 2004-05-20
NZ508855A (en) 2003-10-31
OA11573A (en) 2004-07-01
US20020049201A1 (en) 2002-04-25
DK1086076T3 (en) 2005-03-29
ATE285396T1 (en) 2005-01-15
DE69922807T2 (en) 2005-12-08
PT1086076E (en) 2005-05-31
NO20006405D0 (en) 2000-12-15
CA2335477C (en) 2010-11-30
US7419967B2 (en) 2008-09-02
HK1037605A1 (en) 2002-02-15
WO1999065870A3 (en) 2001-03-15
NO20006405L (en) 2001-02-19
AP2000002023A0 (en) 2000-12-31
AU767728B2 (en) 2003-11-20
AU4576099A (en) 2000-01-05
AP1717A (en) 2007-01-30
EP1086076B1 (en) 2004-12-22
CA2335477A1 (en) 1999-12-23
US6613743B2 (en) 2003-09-02
BR9912169A (en) 2001-04-10
EP1086076A1 (en) 2001-03-28
DE69922807D1 (en) 2005-01-27
US20060172936A1 (en) 2006-08-03
NZ528074A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
US6613743B2 (en) Sulfonamide inhibitors of aspartyl protease
US6617350B2 (en) Inhibitors of aspartyl protease
DE60027722T2 (en) Aspartyl protease inhibitors
EP1159278B1 (en) Inhibitors of aspartyl protease
AU2007234578B2 (en) Sulfonamide Inhibitors of Aspartyl Protease
MXPA00012637A (en) Sulfonamide inhibitors of aspartyl protease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09731129

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 45760/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 508855

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2335477

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/012637

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999928769

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1999928769

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 45760/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999928769

Country of ref document: EP